---
document_datetime: 2023-09-21 19:25:24
document_pages: 151
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/lenvima-h-c-3727-ii-0011-g-epar-assessment-report-variation_en.pdf
document_name: lenvima-h-c-3727-ii-0011-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 223.1353365
conversion_datetime: 2025-12-20 01:25:25.459357
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

28 June 2018 EMA/582721/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lenvima

International non-proprietary name: lenvatinib

Procedure No. EMEA/H/C/003727/II/0011/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                 | 6                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ....................................................................................6   |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                       | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                 | 8                                                                                                         |
| 2.1. Introduction                                                                                                        | ........................................................................................................8 |
| 2.2. Non-clinical aspects............................................................................................    | 10                                                                                                        |
| 2.2.1. Introduction....................................................................................................  | 10                                                                                                        |
| 2.2.2. Pharmacology.................................................................................................     | 11                                                                                                        |
| 2.2.3. Pharmacokinetics                                                                                                  | ............................................................................................ 18           |
| 2.2.4. Toxicology......................................................................................................  | 18                                                                                                        |
| 2.2.5. Ecotoxicity/environmental risk assessment.........................................................                | 18                                                                                                        |
| 2.2.6. Discussion on non-clinical aspects                                                                                | ..................................................................... 19                                  |
| 2.2.7. Conclusion on the non-clinical aspects                                                                            | ............................................................... 20                                        |
| 2.3. Clinical aspects .................................................................................................. | 20                                                                                                        |
| 2.3.1. Introduction....................................................................................................  | 20                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                  | ............................................................................................ 21           |
| 2.3.3. Pharmacodynamics..........................................................................................        | 41                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                   | ............................................................................................. 41          |
| 2.3.5. Discussion on clinical pharmacology...................................................................            | 46                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................             | 47                                                                                                        |
| 2.4. Clinical efficacy                                                                                                   | .................................................................................................. 48     |
| 2.4.1. Dose response study(ies) .................................................................................        | 49                                                                                                        |
| 2.4.2. Main study                                                                                                        | ..................................................................................................... 50  |
| 2.4.3. Discussion on clinical efficacy............................................................................       | 90                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy                                                                              | .................................................................... 93                                   |
| 2.5. Clinical safety                                                                                                     | .................................................................................................... 93   |
| 2.5.1. Discussion on clinical safety............................................................................         | 130                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................         | 134                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                        | ................................................................................................... 134   |
| 2.6. Risk management plan                                                                                                | ..................................................................................... 135                 |
| 2.7. Update of the Product information......................................................................             | 146                                                                                                       |
| 2.7.1. User consultation                                                                                                 | .......................................................................................... 146            |
| 3. Benefit-Risk Balance...........................................................................                       | 147                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................       | 147                                                                                                       |
| 3.1.1. Disease or condition ......................................................................................       | 147                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                   | 147                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................      | 147                                                                                                       |
| 3.2. Favourable effects............................................................................................      | 147                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                   | 148                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................       | 148                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                            | ....................................... 148                                                               |
| 3.6. Effects Table....................................................................................................   | 148                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................               | 149                                                                                                       |

<div style=\"page-break-after: always\"></div>

| 3.7.1. Importance of favourable and unfavourable effects............................................                  |   149 |
|-----------------------------------------------------------------------------------------------------------------------|-------|
| 3.7.2. Balance of benefits and risks ..........................................................................       |   150 |
| 3.8. Conclusions..................................................................................................... |   150 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AASLDA

American Association for Study of Liver Disease Adverse drug reaction

AE

Adverse event

AESI

Adverse events of special safety interest

AF

Alpha-fetoprotein

AJCC

American Joint Committee on Cancer

ALT

Alanine aminotransferase (also known as SGPT)

AST

Aspartate aminotransferase (also known as SGOT)

BCLC

Barcelona Clinic Liver Cancer

BMI

Body mass index

BSC

Best supportive care

CI

Confidence interval

CNS

Central nervous system

CR

Complete response

CSR

Clinical Study Report

CT

Computed tomography

CTCAE

Common Terminology Criteria for Adverse Events

DCR

Disease control rate

DMC

Data Monitoring Committee

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

EQ-5D

EuroQoL-5 Dimensions questionnaire

EU

European Union

FACT-Hep

Functional Assessment of Cancer Therapy-Hepatobiliary

FAS

Full Analysis Set

FDA

Food and Drug Administration

FFPE

Formalin-fixed paraffin-embedded FWB Functional well-being

GCP

Good Clinical Practice

GFR

Glomerular filtration rate

GGT

Gamma glutamyl transferase

GMP

Good Manufacturing Practices

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

HCS

Hepatobiliary Cancer Subscale

HCV

Hepatitis C virus

HFSR

Hand foot skin reaction

HGF

Hepatocyte growth factor

HR

Hazard ratio

HRQoL

Health-related quality of life

ICH

International Conference on Harmonization

ITT

Intention to treat

IVRS

Interactive voice response system

KIT

Gene encodes the ligand of the tyrosine-kinase receptor

LDH

Lactic dehydrogenase

MedDRA

Medical Dictionary for Regulatory Activities

MEK

Mitogen activated protein kinase

MID

minimally important difference

mRECIST

modified Response Evaluation Criteria in Solid Tumours

MRI

Magnetic Resonance Imaging

NA

Not assessed

NASH

Non-Alcoholic steatohepatitis

NCI

National Cancer Institute

NRAS

Neuroblastoma RAS viral oncogene homolog New York Heart Association

OD

once daily

ORR

Objective tumour response rate

OS

Overall survival

PD

Progressive disease

PFS

Progression-free survival

PK

Pharmacokinetics

p.o.

per os (by mouth)

PR

Partial response

PRO

Patient reported outcome

PS

Performance status score

QoL

Quality of life

RECIST

Response Evaluation Criteria in Solid Tumours

ROW

Rest of the World

SAE

Serious adverse event

SAS

Safety analysis set

SAP

Statistical analysis plan

SD

Stable disease

SOC

System organ class

TACE

trans catheter arterial chemoembolization

TEAE

Treatment-emergent adverse event

TESAE

Treatment-emergent serious adverse event

TKI

Tyrosine kinase inhibitor

TNM

Tumour, node, metastasis

TOI

Trial Outcome Index

TTP

Time to progression

VAS

Visual analog scale

VEGF

Vascular endothelial growth factor

VEGFR

Vascular endothelial growth factor receptor

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, Eisai Europe Ltd. submitted to the European Medicines Agency on 24 July 2017 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |
| C.I.4                  | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I and IIIB         |

Extension of indication to include treatment of hepatocellular carcinoma (HCC) based on pivotal Study 304; consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are being updated and the package leaflet is updated accordingly. In addition, section 4.2 of the SmPC is being updated to add that the product can be administered as a suspension in water or apple juice. In addition, the labelling is updated to include the unique identifier. An updated RMP version 10 was provided a part of the application.

The requested group of variations proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

Lenvima was designated as an orphan medicinal product on 26 April 2013 in the following indications: Treatment of follicular thyroid cancer (EU/3/13/1119) and Treatment of papillary thyroid cancer (EU/3/13/1121).

The new indication, which is the subject of this application, falls within a separate orphan designation EU/3/15/1460 granted on 19 March 2015.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) will review the designation of Lenvima as an orphan medicinal product in the approved indication.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/345/2010 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with the authorised orphan medicinal product Nexavar. However, as the orphan market exclusivity of Nexavar expired on 1 November 2017, it was no longer necessary for the CHMP to conclude on possible similarity with Nexavar. At the time of adoption of the CHMP opinion, there were no authorised orphan medicinal products for the concerned indication.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The applicant did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur: Bart Van der                             | Schueren Co-Rapporteur:   | Robert James Hemmings   |
|------------------------------------------------------|---------------------------|-------------------------|
| Timetable                                            |                           | Actual dates            |
| Submission date                                      |                           | 24 July 2017            |
| Start of procedure:                                  |                           | 12 August 2017          |
| CHMP Co-Rapporteur Assessment                        | Report                    | 5 October 2017          |
| CHMP Rapporteur Assessment                           | Report                    | 10 October 2017         |
| PRAC Rapporteur Assessment                           | Report                    | 13 October 2017         |
| PRAC members comments                                |                           | 18 October 2017         |
| Updated PRAC Rapporteur Assessment Report            |                           | 23 October 2017         |
| PRAC Outcome                                         |                           | 26 October 2017         |
| CHMP members comments                                |                           | 30 October 2017         |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report |                           | 2 November 2017         |
| Request for supplementary information                | (RSI)                     | 9 November 2017         |
| CHMP Rapporteur (Joint) Assessment Report            |                           | 25 January 2018         |
| PRAC Rapporteur Assessment Report                    |                           | 25 January 2018         |
| PRAC members comments                                |                           | 31 January 2018         |
| PRAC Outcome                                         |                           | 8 February 2018         |
| CHMP members comments                                |                           | 12 February 2018        |
| Updated CHMP Rapporteur (Joint) Assessment Report    |                           | 15 February 2018        |
| Request for supplementary information (RSI)          |                           | 22 February 2018        |
| CHMP Rapporteur (Joint) Assessment Report            |                           | 9 May 2018              |
| CHMP members comments                                |                           | 22 May 2018             |
| Updated CHMP Rapporteur (Joint) Assessment Report    |                           | 25 May 2018             |
| Request for supplementary information (RSI)          |                           | 31 May 2018             |
| CHMP Rapporteur (Joint) Assessment Report            |                           | 18 June 2018            |
| CHMP members comments                                |                           | 20 June 2018            |
| Updated CHMP Rapporteur (Joint) Assessment Report    |                           | 22 June 2018            |
| CHMP opinion:                                        |                           | 28 June 2018            |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Disease or condition

Hepatocellular carcinoma (HCC) is an invasive carcinoma of the liver.

## Epidemiology

HCC is a cancer that usually occurs in the setting of liver cirrhosis,  because  of  chronic  infections  with hepatitis  B  virus  or  hepatitis  C  virus,  alcohol  consumption,  non-alcoholic  steatohepatitis,  or  diabetes (EASL&amp;EORTC 2012).

It is the third-leading cause of cancer-related death, and the global incidence is rising, with approximately 700,000 cases diagnosed worldwide in 2012 alone (Lozano et al. 2010, Torre et al. 2015).

In the US, the incidence of HCC is approximately 9.18 per 100,000 persons, in Southern Europe 9.8/3.2, in  Western  Europe  7.2/2.1,  and  in  Northern  Europe  3.8/1.6  (male/female,  respectively)  per  100,000 persons  (Jemal  et  al.  2011).  The  incidence  of  HCC  is  rising  in  the  last  decennia  and  it  varies geographically largely due to variations in the incidences of hepatitis B and C infection, with the majority of  the  cases  (&gt;  80%)  occurring  in  sub-Saharan  Africa  and  eastern  Asia.  One  country  alone,  China, accounts for 40% to 50% of worldwide cases. Chronic HBV infection is the predominant risk factor for HCC in Southeast Asia and Africa, whereas chronic infection with hepatitis C virus (HCV) is the risk factor for HCC in Western countries and Japan. Unlike the rest of Asia, HCV infection accounts for up to 70% of HCCs in Japan. Currently, there is a rising HCC trend in the West, where the incidence used to be low, such as in the United States and Canada; this rise is attributed in part to the HCV epidemic in the 1960s and the prevalence of obesity and diabetes mellitus, which are associated with the metabolic syndrome and  with  nonalcoholic  fatty  liver  disease  (NAFLD).  In  Southern  Europe,  HCV  and  alcohol  consumption account  for  the  factors  contributing  to  rising  HCC  incidence.  Recent  genomic  studies  have  highlighted differences in genetic mutations and signatures among different groups of patients who have HCC with various etiologies. HCC outcomes also differ between Asian and non-Asian patients because of variations in management practices between East and West (Choo et al, 2016).

## Management

Individual treatment decisions largely depend on the stage of disease, but not on its aetiology. Surgical resection,  transplantation,  and  ablation  are  potential  curative  options  for  early-stage  disease,  whereas chemoembolisation is recommended for patients with preserved liver function and disease confined to the liver  generally  without  vascular  invasion.  In  most  HCC  patients,  the  disease  is  diagnosed  at  advanced stages, when curative treatments, including resection, liver transplantation, and ablation, are no longer suitable.  For  patients  who  are  not  or  who  are  no  longer  candidates  for  loco  regional  therapy,  the  oral multikinase inhibitor sorafenib is the only systemic treatment currently approved in the EU. The approval was based on the results of a large Phase-3 clinical trial (Study 100554 SHARP) conducted in 602 HCC patients  (Llovet  et  al.  2008).  The  study  demonstrated  significantly  increased  survival  under  sorafenib (plus BSC) compared to placebo (plus BSC) (HR 0.69; p=0.0005), with a median survival rate for the sorafenib  arm  of  10.6  months,  compared  with  7.9  months  for  the  placebo  arm.  Another  trial  (Study 11849) similarly designed as SHARP and conducted in Asian subjects, confirmed the favourable SHARP results (Cheng et al. 2009). Subgroup analyses from studies conducted with sorafenib have demonstrated that  the  survival  benefit  of  sorafenib  is  independent  of  the  underlying  aetiology  of  liver  disease  and independent  of  prior  treatments  such  as  TACE  (transarterial  chemoembolization)  which  is  usually administered in intermediate-stage HCC. Other compounds (e.g., the anti-PD1 antibody nivolumab) are currently tested in clinical trials as first line treatment options in comparison with sorafenib.

<div style=\"page-break-after: always\"></div>

Currently, another oral multikinase inhibitor regorafenib (Stivarga) is indicated as monotherapy for the treatment of adult patients with HCC who have been previously treated with sorafenib.

## About the product

Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFRs) VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3  (FLT4),  in  addition  to  other  proangiogenic  and  oncogenic  pathway-related  RTKs  including fibroblast growth factor receptors (FGFRs) FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor α (PDGFRα); KIT; and RET.

It  is  currently  authorised  as  monotherapy  for  the  treatment  of  patients  with  radio-iodine  refractory differentiated  thyroid  cancer  (orphan  designation)  and  under  the  name  of  Kisplyx  in  combination  with everolimus for treatment of advanced renal cell carcinoma (RCC) following a prior anti-angiogenic therapy (non-orphan designation).

With this variation application, the marketing authorisation holder (MAH) would like to extend the indication to the treatment of adult patients with HCC supported by the results of a Phase 3 trial (REFLECT).

Lenvima was designated as an orphan medicinal product EU/3/15/1460 on 19 March 2015 in the following indication: 'Treatment of hepatocellular carcinoma (HCC)'. Orphan Designation for the treatment of HCC was granted on the grounds of prevalence (less than 5 in 10,000 patients) and an assumption of significant benefit of lenvatinib over the other medicinal product approved in the EU for treatment of hepatocellular carcinoma at that time (sorafenib).

CHMP scientific advice on the HCC clinical development programme was received on 15 Nov 2012 (EMA/CHMP/SAWP/698149/2012). For the Phase 3 study, the choice of comparator (sorafenib) and primary endpoint (overall survival) were endorsed. The CHMP preferred a blinded study to enhance the objectivity of the assessment of the secondary endpoints and safety. However, if the study were to be conducted open-label, measures should be implemented to ensure symmetric study conduct in both treatment arms.

An addendum to the non-clinical part of the dossier is submitted with this application and the Environmental Risk Assessment has been updated based on the expected wider use of Lenvima due to the new indication.

As part of the current grouped variation, to aid administration to patients who have difficulty swallowing, it is proposed to introduce alternative instructions to allow the capsule shells to be dissolved first in either water or apple juice, to produce a suspension prior to administration. Consequently, changes are proposed to Section 4.2 of the SmPC and the relevant section of the PL.

An RMP (version 10.0 dated 4 July) has been provided which covers the new indication with this variation. The adult indication of this extension is covered by a respective paediatric class waiver. Furthermore, the MAH has included a critical report addressing the possible similarity with authorised orphan medicinal products (Nexavar (INN: sorafenib tosylate) in the HCC condition.

The MAH applied for the following indication:

LENVIMA is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC).

The CHMP adopted a positive opinion for the following indication:

LENVIMA is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy (see section 5.1).

<div style=\"page-break-after: always\"></div>

The recommended daily dose of lenvatinib is 8 mg (two 4 mg capsules) once daily for patients with a body weight of &lt; 60 kg and 12 mg (three 4 mg capsules) once daily for patients with a body weight of ≥ 60 kg.  Dose adjustments are based only on toxicities observed and not on body weight changes during treatment. The daily dose is to be modified, as needed, according to the dose/toxicity management plan.

## Dose adjustment and Discontinuation

Management of some adverse reactions may require dose interruption, adjustment, or discontinuation of lenvatinib therapy. Mild to moderate adverse reactions (e.g., Grade 1 or 2) generally do not warrant interruption of lenvatinib, unless intolerable to the patient despite optimal management.  Details for monitoring, dose adjustment and discontinuation are provided in Table 2.

Table 1: Dose modifications from recommended lenvatinib daily dose in HCC patients

| Starting Dose                                              | Starting Dose                                              | ≥60 kg BW 12 mg (three 4 mg capsules orally once daily)    | <60 kg BW 8mg (two 4 mg capsules orally once daily)        |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Persistent and Intolerable Grade 2 or Grade 3 Toxicities a | Persistent and Intolerable Grade 2 or Grade 3 Toxicities a | Persistent and Intolerable Grade 2 or Grade 3 Toxicities a | Persistent and Intolerable Grade 2 or Grade 3 Toxicities a |
| Adverse Reaction                                           | Modification                                               | Adjusted Dose b (≥60 kg BW)                                | Adjusted Dose b (<60 kg BW)                                |
| First occurrence c                                         | Interrupt until resolved to Grade 0-1 or baseline d        | 8 mg (two 4 mg capsules) orally once daily                 | 4 mg (one 4 mg capsule) orally once daily                  |
| Second occurrence (same reaction or new reaction)          | Interrupt until resolved to Grade 0-1 or baseline d        | 4 mg (one 4 mg capsule) orally once daily                  | 4 mg (one 4 mg capsule) orally every other day             |
| Third occurrence (same reaction or new reaction)           | Interrupt until resolved to Grade 0-1 or baseline d        | 4 mg (one 4 mg capsule) orally every other day             | Discontinue                                                |

## Life-threatening toxicities (Grade 4): Discontinue e

- a. Initiate medical management for nausea, vomiting, or diarrhoea prior to interruption or dose reduction.
- b. Reduce dose in succession based on the previous dose level (12 mg, 8 mg, 4 mg or 4 mg every other day).
- c. Haematologic toxicity or proteinuria-no dose adjustment required for first occurrence.
- d. For haematologic toxicity, , dosing  can restart when resolved to Grade 2; proteinuria, resume when resolves to less than 2g/24 hours
- e. Excluding laboratory abnormalities judged to be nonlife-threatening, which should be managed as Grade 3.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

To evaluate the primary pharmacodynamic effects of lenvatinib against HCC, the following additional in vitro and in vivo studies were conducted (limited to those not previously submitted in the RCC or DTC marketing authorization applications).

## Primary PD, in vitro studies:

- Crystal structure of FGFR1-lenvatinib complex
- Inhibition of FGFR signaling in HCC cells
- Direct antiproliferative effects against HCC cells

## Primary PD, in vivo studies:

- Antitumour effects in human HCC xenograft models
- Immunostimulatory effect in an HCC isograft model

Unless otherwise noted, all doses or concentrations on a weight basis described for lenvatinib in the

<div style=\"page-break-after: always\"></div>

nonclinical studies are expressed in terms of the mesilate salt.

Four additional pharmacokinetics (PK) studies have been completed, and one study has been reanalysed. With the exception of the study conducted to evaluate substrate recognition and inhibition of multidrug and toxin extrusion (MATE) by lenvatinib, these studies were conducted to further address questions raised during the review of the original marketing application.

These studies include:

- Calculation of pharmacokinetic parameters of radioactive peaks in monkey plasma
- Protein binding in human liver microsomes (HLMs)
- Reversibility of covalently bound lenvatinib-related components to human plasma protein
- Reanalysis of modeling and simulation using Simcyp®
- Substrate recognition and inhibition of MATE

## 2.2.2. Pharmacology

## Primary pharmacodynamic studies

## In vitro studies

## • Crystal structure of FGFR1-lenvatinib complex

In the original Marketing Authorization Application (MAA) for radio-iodine refractory DTC, crystal structure analysis of VEGFR2-lenvatinib complex revealed that lenvatinib binds to both the ATP-binding site and a neighboring allosteric region of VEGFR2 with the DFG motif adopting a 'DFG-in' conformation, indicating a  novel  binding  mode termed type V, which is distinct from that for most other multikinase inhibitors (type I or type II) on market (Okamoto, et al., 2015). A new study was conducted to confirm whether lenvatinib binds to another major target kinase, FGFR1 with the same binding mode.

The  amino  acid  residues  in  the  FGFR1-lenvatinib  complex  located  in  the  vicinity  of  lenvatinib,  with  a maximum distance of 3.9 Å. They are identified as those belonging to the ATP-binding site. The result is comparable  to  that  obtained  from  VEGFR2-lenvatinib  complex,  where  the  same  analysis  results  in  13 residues for ATPbinding site, the Val916 residue for gate-keeper, and 5 residues for neighboring region.

As shown in0, in both the FGFR1-lenvatinib and VEGFR2-lenvatinib complexes, lenvatinib (colored green in the ball-and-stick model) binds to the ATP-binding site (amino acid residues are shown in red letters) at the common core from the urea group to the quinoline ring, and binds to the neighboring allosteric region (amino acid residues are shown in black letters) via the cyclopropane ring, which might have a strong hydrophobic interaction with the phenyl ring of Phe642 (FGFR1) or Phe1047 (VEGFR2).

These results indicated that the binding mode of lenvatinib to FGFR1 should be type V like the binding mode to VEGFR2, since the binding of lenvatinib to FGFR1 meets the 3 criteria that define a type V kinase inhibitor: 1) binds to the ATP-binding site, 2) binds to the neighboring allosteric region, and 3) fits to the kinase adopting the DFG-in conformation.

<div style=\"page-break-after: always\"></div>

## A FGFR1-Lenvatinib B VEGFR2-Lenvatinib

A: FGFR1-lenvatinib, B: VEGFR2-lenvatinib C: Schema for \"DFG-in\" and \"DFG-out\" Lenvatinib and the DFG-motif are shown as ball-and-stick models colored in green ) and pink (), respectively. Neighboring protein side chains are shown as ribbon models. Amino acid residues located less than 3.9 A from lenvatinib are shown in red letters (ATP-binding site), violet letters (gate-keeper), or blue letters (the neighboring region). ATP = adenosine triphosphate, DFG = aspartic acid- phenylalanine-glycine, FGFR = fibroblast growth factor.

<!-- image -->

Figure 1: X-ray Analysis for Crystal Structure of FGFR1-Lenvatinib and VEGFR2-Lenvatinib Complexes

## • Inhibition of FGFR signalling in HCC cells

The inhibitory effects of lenvatinib on the FGFR signal transduction in human HCC cell lines, Hep 3B2.1-7, HuH-7, and SNU-449 cells were studied by measuring the phosphorylation of FRS2, which is a pan-FGFR specific downstream signalling molecule. The effect of sorafenib, a multikinase inhibitor clinically used for the treatment of HCC, was also evaluated under the same study conditions (see 0).

Hep 3B2.1-7 and HuH-7 cells overexpress FGF19 and express its cognate receptor FGFR4. SNU-449 cells mainly express FGFR1.

Lenvatinib inhibited the phosphorylation of FRS2 in HuH-7 and Hep 3B2.1-7 human HCC cells at concentrations 0.03 to 3 μmol/L in a concentration-dependent manner and completely inhibited the phosphorylation of FRS2 at concentrations ≥1 μmol/L. In contrast, sorafenib showed incomplete inhibition of the phosphorylation of FRS2 at concentrations from 0.1 to 3 μmol/L. In SNU-449 cells lenvatinib inhibited the phosphorylation of FRS2 in a concentration-dependent manner at concentrations from 0.3 to 3 μmol/L and completely inhibited the phosphorylation of FRS2 at 3 μmol/L. In contrast, sorafenib showed incomplete inhibition of the phosphorylation of FRS2 at concentrations from 0.1 to 3 μmol/L.

<div style=\"page-break-after: always\"></div>

Table 2: Tabulated summary of new in vitro primary pharmacodynamics studies

| Type of Study                      | Methods                                                                                                                                                                                                        | Species/Strain                                       | Dose or Concentration                                                    | Observations                                                                                                                                                                                                                                                                                                           | Study/ Report No.   |
|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Crystal structure analysis         | Recombinantly expressed human FGFR1 including kinase domain (Ser461-Asp774) was crystalized with lenvatinib. The resulting crystals of kinase- inhibitor complexes were subjected to x-ray structural analysis | Human/ FGFR1 (recombinant)                           | NA                                                                       | Lenvatinib binds to the ATP- binding site and the neighboring allosteric region. The DFG motif adopts the DFG-in conformation in the FGFR1-lenvatinib complex.                                                                                                                                                         | W-20160357          |
| Effect on FGFR signaling           | Effect oftheFGFR signal transduction in HCC cells was evaluated by a westem blot analysis using antibodies against FRS2 and phosphorylated FRS2.                                                               | Human/ Hep 3B2.1-7 (HCC)                             | lenvatinib: 0.03,0.1, 0.3,1, 3 μmol/L sorafenib: 0.1, 0.3, 1, 3 μmol/L   | Lenvatinib inhibited FGF19- driven phosphorylation of FRS2 at concentrations from 0.03 to 3 μmol/L in a concentration-dependent manner and completely inhibited the phosphorylation of FRS2 at ≥1 μmol/L Sorafenibshowedincomplete inhibition at concentrations from 0.1 to 3 μmol/L                                   | M16014              |
| Effect on FGFR signaling           | Effect oftheFGFR signal transduction in HCC cells was evaluated by a westem blot analysis using antibodies against FRS2 and phosphorylated FRS2.                                                               | Human/ HuH-7 (HCC)                                   | lenvatinib: 0.03, 0.1, 0.3, 1, 3 μmol/L sorafenib: 0.1, 0.3, 1, 3 μmol/L | Lenvatinibinhibited the phosphorylation of FRS2 at concentrationsfrom0.03to 3 μmol/L in a concentration- dependent manner and completelyinhibited the phosphorylation ofFRS2 at ≥1 μmol/L. Sorafenib showed incompleteinhibition of the phosphorylation of FRS2 at concentrations from 0.1 to 3 μmol/L.                | M16019              |
| Effect on FGFR signaling           | Effect of the FGFR signal transduction in HCC cells was evaluated by a westem blot analysis using antibodies against FRS2 and phosphorylated FRS2.                                                             | Human/ SNU-449 (HCC)                                 | lenvatinib: 0.1, 0.3, 1, 3 μmol/L sorafenib: 0.1, 0.3, 1, 3 μmol/L       | Lenvatinibinhibited the bFGF-driven phosphorylation of FRS2 at concentrations from 0.3 to 3 μumol/L in a concentration- dependentmanner and completely inhibited the phosphorylation of FRS2 at 3 μmol/L.Sorafenib showed incomplete inhibition of the phosphorylation of FRS2 at concentrations from 0.1 to 3 μmol/L. | M16015              |
| Effect on tumor cell proliferation | Inhibition of the cell proliferation was measured by a colorimetric assay using WST-8.                                                                                                                         | Human/ Hep 3B2.1-7 (HCC) HuH-7 (HCC) PLC/PRF/5 (HCC) | Lenvatinib and sorafenib: 39.1 - 10.000 mmol/L                           | Lenvatinib: ICso = 230, 420, >10,000 mmol/L against Hep 3B2.1-7, HuH-7, PLC/PRF/5 cells, respectively. Sorafenib: ICso = 2300, 2200,5300 mmol/L against Hep 3B2.1-7, HuH-7, PLC/PRF/5 cells, respectively.                                                                                                             | M16007              |

Doses or concentrations described for lenvatinib and sorafenib are expressed as those of the salt form.

ATP = adenosine triphosphate, DFG = aspartic acid-phenylalanine-glycine, FGF = fibroblast growth factor, FGFR = fibroblast growth factor receptor, HCC = hepatocellular carcinoma, IC50 = half-maximal inhibitory concentration, WST8 = 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium.

## • Direct antiproliferative effects against HCC cell lines

This study examined the antiproliferative activity of lenvatinib against 3 human HCC cell lines, Hep 3B2.17, HuH-7, and PLC/PRF/5 in vitro (see 0). The cell proliferation of Hep 3B2.1-7 and HuH-7 is dependent on enhanced FGFR signaling involving an autocrine loop of overexpressing FGF19 and FGFR4. Serial

<div style=\"page-break-after: always\"></div>

dilutions of lenvatinib mesilate and sorafenib tosylate were added to the cells in culture wells, and the cells were cultured for 6 days to evaluate the antiproliferative effect of lenvatinib. As a blank control, the vehicle was added to wells without cells. The viable cell number was determined by colorimetric assay using WST-8 reagent. Percent inhibition was calculated. As shown in 0, lenvatinib showed stronger antiproliferative activity against Hep 3B2.1-7 and HuH-7 cells compared to PLC/PRF/5 cells. Sorafenib did not show remarkable selectivity against either of the cell systems. IC50 values are presented in 0

<!-- image -->

A:Lenvatinib.B:Sorafenib

Each point represents the mean ±SD of 3 independent experiments performed in triplicate.

Figure 2: Antiproliferative activities of lenvatinib and sorafenib against HCC cell lines

## In vivo studies

## • Antitumour effects in human HCC xenograft models

The antitumour effect of lenvatinib was evaluated in 5 human HCC xenograft models in athymic mice, and compared with the antitumour activity of sorafenib in the same models.

<div style=\"page-break-after: always\"></div>

Table 3: Tabulated summary of new in vivo primary pharmacodynamic xenograft studies

| Type of Study                                                   | Methods                                                                                                                                                                                 | Species/Strain                                                                                   | Number/ Gender    | Route                           | Dose or Concentration                               | Observations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study/ Report No.   |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------|---------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Antitumor effect in xenograft model in human cancer mice        | Xenografts were generated by SC inoculation of the cancer cells.Dosing was initiated after 12 days (Day 1). The TV and the body weight of mice were measured on Days 1, 3, 6, and 8.    | Mouse/ Foxn1\"/CrlCrlj CAnN.Cg- Human/ Hep 3B2.1-7 (HCC)                                          | 8 female / group  | lenvatinib, PO,QDx7 sorafenib:  | lenvatinib: 3, 10, 30 mg/kg sorafenib: 10, 30 mg/kg | Lenvatinib (3, 10, 30 mg/kg) showedsignificant TGI with T/C values of 56%, 51%, and 31%, respectively at Day 8. Sorafenib (10, 30 mg/kg) showed significant TGI with T/C values of 73% and 47%, respectively at Day 8. No remarkableBWLwas observed in all treated groups.                                                                                                                                                                                                                                                                                               | M16008              |
| Antiangiogenic activity in human cancer xenograft model in mice | Xenografts generated in Study No. M16008 were used. One day after the last dose (Day 8), tumor was isolated and the MVD was evaluated by IHC staining for CD31.                         | Mouse/ CAnN.Cg- Foxnl\"/Cr1Cr1 Human/ Hep 3B2.1-7 (HCC)                                           | 8 female / group  | lenvatinib, sorafenib: PO,QDx7  | lenvatinib: 3, 10, 30 mg/kg sorafenib: 10, 30 mg/kg | Lenvatinib (3, 10, 30 mg/kg) significantly reduced MVD in the tumor with T/C values of 77%, 62%, and 51%, respectively at Day 8. Sorafenib at 30 mg/kg but not 10mg/kg significantly reduced MVD with a T/C value of 72% at Day 8.                                                                                                                                                                                                                                                                                                                                       | M16011              |
| Antitumor effect in human cancer xenograft model in mice        | Xenografts were generated by SC inoculation of the cancer cells. Dosing was initiated after 11 days (Day 1). The TV (3 times a week) and the body weight of mice (daily) were measured. | Mouse/ Crl:NU-Foxn/\"u Human/ LIXC-012 (HCC cell line generated from a patient-derived xenograft) | 8 female / group  | lenvatinib, sorafenib: PO,QDx14 | lenvatinib: 3, 10, 30 mg/kg sorafenib: 10, 30 mg/kg | Lenvatinib (3, 10, 30 mg/kg) showedsignificantTGIwith T/C values of 61%, 43%, and 25%, respectively at Day 11. Sorafenib at 30 mg/kg but not 10mg/kgshowedsignificant TGI with a T/C value of 55% at Day 11. BWL was observed in the vehicle controls accompanied by cachexia, resulting in RBW values of0.85 to 0.87 at Day 11. This BWL was less in the lenvatinib (10,30 mg/kg) groups with RBW values of 0.93 and 0.96, respectively. TheBWLin sorafenib(10, 30 mg/kg) groups was similar to thatin thevehiclecontrol with RBW values of0.87 and 0.85, respectively. | CPB-P16-5670        |
| Antitumor effect in human cancer xenograft model in mice        | Xenografts were generated by SC inoculation of the tumor fragment. Dosing was initiated after 19 days (Day 1). The TV and the body weight of mice were measured twice a week.           | Mouse/ CAnN.Cg- Foxn\"/CrlChfk Human/ HuPrime*L10050 (HCC, patient derived)                       | 15 female / group | lenvatinib, sorafenib: PO,QDx28 | lenvatinib: 10, 30 mg/kg sorafenib: 30 mg/kg        | Lenvatinib (10, 30 mg/kg) showed significant TGI with T/C values of 46% and 33%, respectively without severe BWLatDay29.Sorafenib was not tolerated; multiple dosing suspensions were necessaryduringthetreatment and5of15micediedby Day 19. A maximum mean BWLof13% (RBW=0.87) was noted on Day 18.                                                                                                                                                                                                                                                                     | E0606-U1602. LI0050 |
| Antitumor effect in human cancer xenograft model in mice        | Xenografts were generated by SC inoculationof thetumor fragment. Dosing was initiated after 46 days (Day 1). The TV and the body weight of mice were measured twice a week.             | Mouse/ STOCK-FoxmI\"/JNju Human/ HuPrimeL10334 (HCC, patient derived)                             | 15 female / group | lenvatinib, sorafenib: PO,QDx28 | lenvatinib: 10, 30 mg/kg sorafenib: 30 mg/kg        | Lenvatinib (10, 30 mg/kg) showed significant TGI with T/C values of 25% and 14%, respectively without severe BWL atDay29.Sorafenib did not show significant TGI.                                                                                                                                                                                                                                                                                                                                                                                                         | E0606-U1602. LI0334 |

Doses or concentrations described for lenvatinib and sorafenib are expressed as those of the salt form. BWL = body weight loss, HCC = hepatocellular carcinoma, MVD = microvessel density, PO = oral, QD×X = once daily for X days, RBW = relative body weight, SC = subcutaneous, T/C = treatment/control, TGI = tumour growth inhibition, TV= tumour volume

In the Hep 3B2.1-7 human HCC xenograft model, lenvatinib (3, 10, and 30 mg/kg) showed dosedependent and significant tumour growth inhibition (TGI) compared to the vehicle control with treatment/control (T/C) values of 56%, 51%, and 31%, respectively on Day 8. Sorafenib (10 and 30 mg/kg) also showed dose-dependent and significant TGI with T/C values of 73% and 47%, respectively. Body weight loss was similar in vehicle, lenvatinib- and sorafenib-treated groups with relative body weights (RBW) of 0.93, 0.87 and 0.89 respectively, at Day 8.

The antiangiogenic activity of lenvatinib and sorafenib was evaluated in the same Hep 3B2.1-7 xenograft model. Lenvatinib (3, 10, and 30 mg/kg) showed dose-dependent and significant decrease of microvessel density (MVD) compared to Vehicle 1 at Day 8 with T/C values of 77%, 62%, and 51%, respectively.

<div style=\"page-break-after: always\"></div>

Sorafenib at 30 mg/kg showed significant decreases of MVD compared to Vehicle 2 with a T/C value of 72%; however, the effect on MVD at 10 mg/kg was not significant in this model. The good correlation of the TGI with the decrease of tumour MVD for lenvatinib suggests that the antiangiogenic activity contributes to the antitumour activity of lenvatinib.

In the PDX-derived LIXC-012 HCC xenograft model, lenvatinib (3, 10, and 30 mg/kg) showed dosedependent and significant TGI with T/C values of 61%, 43%, and 25%, respectively at Day 11. Sorafenib at a dose of 30 mg/kg also showed significant TGI with T/C values of 55% at Day 11; but sorafenib at a dose of 10 mg/kg resulted in no TGI.

BWL was observed in the vehicle control groups due to cachexia, resulting in RBW values at Day 11 of 0.87 and 0.85, respectively. The BWL in the mid- and high-dose (10 and 30 mg/kg) lenvatinib groups was small with RBW values of 0.93 and 0.96 at Day 11, respectively, indicating that the TGI also alleviated cachexia-induced BWL. All mice survived in these groups.

In the HCC PDX model using HuPrime® LI0050 tumour derived from a HCC patient, lenvatinib (10 and 30 mg/kg) showed significant TGI against the LI0050 xenografts compared to vehicle control on Day 29 with T/C values of 46% and 33%, respectively. In the group treated with lenvatinib (30 mg/kg), dosing to 1/15 mice was suspended from Day 15 to Day 27 due to a transient BWL (the individual RBW = 0.79) at Day 15. Statistical analysis for TGI in the sorafenib-treated group was not performed since dosing was stopped several times during the course of the study and 5/15 mice died by Day 19.

No remarkable BWL was observed in lenvatinib treated groups (10 and 30 mg/kg) throughout the dosing period although 1/15 mice in the lenvatinib (30 mg/kg) group showed transient BWL (the individual RBW = 0.79) at Day 15 as described above. Sorafenib (30 mg/kg) was poorly tolerated in this HCC PDX model.

In another HCC PDX model using HuPrime® LI0334 tumour derived from an HCC patient, lenvatinib (10 and 30 mg/kg) showed significant TGI against the LI0334 xenografts compared to vehicle control on Day 29 with T/C values of 25% and 14%, respectively. Sorafenib (30 mg/kg) did not show significant TGI with a T/C value of 70%.

No remarkable BWL was observed in the treated mice.

## • Immunostimulatory effect in an HCC isograft model

This study examined the antitumour effect of lenvatinib as well as the effect of lenvatinib on immune cell populations in the BNL 1ME A.7R.1 murine HCC isograft models (See 0).

As shown in 0, lenvatinib (3, 10 mg/kg) showed significant TGI on Day 8 in the BNL 1ME A.7R.1 murine HCC isograft model in immunocompetent mice with T/C values of -31% and -41%, respectively. The minus values indicate tumour regression compared with prior treatments (TV on Day 1). TGI for both doses of lenvatinib (3, 10 mg/kg) in the immunocompetent mice was significantly greater than those in the respective athymic mice. No remarkable BWL was noted in all treated groups.

<div style=\"page-break-after: always\"></div>

Figure 3: Antitumour Effects of Lenvatinib in the BNL 1ME A.7R.1 Murine HCC Isografts in Athymic Mice and Immunocompetent Mice

<!-- image -->

The  effect  of  lenvatinib  on  the  population  of  immune  cells  in  tumours  and  draining  lymph  nodes  was evaluated in the same model. Flow cytometric analysis of immune cells in the immunocompetent mice revealed  that  lenvatinib  (10  mg/kg)  decreased  the  population  of  TAM  (defined  CD45+CD11b+Ly6GF4/80+Ly6C low). Lenvatinib (10 mg/kg) also increased activated-cytotoxic T cells in the draining lymph node. These results suggested that tumour immunity was enhanced in these tumour bearing mice treated with lenvatinib, since TAM acts as a suppressor, and activated-cytotoxic T cells as an effector for tumour immunity.

Therefore, the immune stimulatory effect of lenvatinib in the tumour microenvironment may contribute to the greater antitumour activity observed in the immunocompetent mice compared to that in athymic mice in this murine HCC isograft model.

Table 4: Tabulated summary of new in vivo primary pharmacodynamic isograft study

| Type of Studly                                               | Methods                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Species/ Strain                                                                                                  | Number/ Gender                                    | Route               | Dose or Concentration                            | Observations                                                                                                                                                                                                                                                                                                                                                                                                                                  | Study/ Report No.   |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|---------------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Immunostimulatory Effectin murine cancer isograftmodelinmice | Isografts were generated by SCinoculation ofthe murine cancer cells to BALB/c immunocompetentmice or corresponding athymic mice. Dosing withlenvatinibwas initiated after 50 days. The TV and bodyweight of mice were measured onDays 1,3,6,and 8 (Exp. 1). Tumors and draining lymph nodes were isolatedfromthe immunocompetentmice 1 day after the end of dosing,and macrophages and cytotoxicT-cells were analyzed, respectivelybyflow cytometry (Exp. 2). | Mouse/ CAnN.Cg- Foxn\"/CrlCrlj (athymic) BALB/cAnNCrlCrlj. immunocompetent) (wild type, Mouse/ BNL1MEA.7R.1 (HCC) | 5 female/ group (Exp.1) 10 female / group (Exp.2) | lenvatinib: PO,QDx7 | lenvatinib: 3, 10 mg/kg (Exp.1) 10 mg/kg (Exp.2) | (Exp. 1) Lenvatinib (3, 10 mg/kg) showed significant TGI with tumor regression in the immunocompetent mice with T/Cvalues of-31%and -41%,respectively,but not in the athymic mice. No remarkableBWL was observed. (Exp. 2) Lenvatinibsignificantly decreased TAM population (CD45+CD11b*Ly6G- F4/80°Ly6Clow in the tumors andincreased the activated CD8+T cell population (IFN-y+CD3*CD8+)in the draining lymph node of immunocompetentmice. | W-20140959          |

Doses or concentrations described for lenvatinib and sorafenib are expressed as those of the salt form.

BWL = body weight loss, Exp. = experiment, PO = oral, QD×X = once daily for X days, SC = subcutaneous, TAM = tumour associated macrophage, T/C = treatment/control, TGI = tumour growth inhibition, TV= tumour volume

<div style=\"page-break-after: always\"></div>

## 2.2.3. Pharmacokinetics

## 2.2.3.1. Metabolism

## 2.2.3.1.1. Analysis of In Vivo Metabolites

## Calculation of pharmacokinetic parameters of radioactive peaks in monkey plasma

Lenvatinib was the main fraction of total radioactivity in plasma after administration of a single 3 mg/kg dose  of  either  [14C]lenvatinib  mesilate  (radiolabeled  on  the  quinoline  ring)  (maximum  observed concentration [Cmax]: 89.9%, area under the concentration-time curve from zero time extrapolated to infinite  time  [AUC(0-inf)]:  69.7%)  or  [14C]CB-lenvatinib  mesilate  (radiolabeled  on  the  chlorobenzene moiety)  (Cmax:  78.4%,  AUC(0-inf):  60.4%)  to  monkeys.  After  administration  of  [14C]lenvatinib mesilate, Cmax and AUC(0-inf) of all radioactive metabolite peaks did not individually exceed 1.9% of the total radioactivity.

After dosing of [14C]CB-lenvatinib mesilate, mCB9a was the major radioactive metabolite, with Cmax and AUC(0-inf)  values  of  12.1%  and  17.0%  of  the  total  radioactivity,  respectively.  With  the  exception  of mCB9a,  Cmax  and  AUC(0-inf)  of  all  radioactive  metabolite  peaks  detected  after  dosing  of  [14C]CBlenvatinib mesilate did not exceed 4.7% of total radioactivity.

## 2.2.4. Toxicology

No new toxicology data have been submitted in this application.

## 2.2.5. Ecotoxicity/environmental risk assessment

The maximum daily dose of lenvatinib in HCC patients is 12 mg/day to be administered during the entire disease period.

The log octanol-water partition coefficient (Kow) of lenvatinib is 3.30.

An Fpen default value of 0.01 (1%) is proposed in the guideline. The MAH however proposed to estimate a more accurate Fpen. Therefore, information based on epidemiological data is provided to support the prevalence of HCC for refinement of Fpen.

The public summary of opinion on ODD - Lenvatinib for the treatment of hepatocellular carcinoma (EMA/COMP/132959/2015, 06 May 2015) indicates that at the time of designation, HCC affected approximately 0.6 in 10,000 people in the European Union (EU). From a re-examination of prevalence of HCC the prevalence is concluded to have increased slightly over the past years (less than one decimal). However, a worst-case prevalence of 1.5 per 10,000 making the extreme assumption that every reported case of primary liver cancer was in fact a case of HCC and that liver cancer is underreported by 45%.

<div style=\"page-break-after: always\"></div>

Table 5: Calculation of the Phase I PECSURFACEWATER of Lenvatinib (for HCC)

<!-- image -->

| Input Parameter                              | Abbreviation    | Value                   | Value                            | Unit              |
|----------------------------------------------|-----------------|-------------------------|----------------------------------|-------------------|
|                                              |                 | Based on ODD prevalence | Basedoni wor'st- case prevalence |                   |
| Maximum daily dose                           | DOSEai          | 12                      | 12                               | mg/inh/day        |
| Market penietration factor                   | Fpen            | 0.00006                 | 0.00015                          | [refined value]   |
| Amount of waste water per inhabitant per day | WASTEmab        | 200                     | 200                              | L [default value] |
| Dilution from STP                            | DILUTION        | 10                      | 10                               | [default value]   |
| PECsURFACEWATER                              | PECsURFACEWATER | 0.00000036              | 0.00000090                       | mg/L              |
|                                              |                 | 0.00036                 | 0.00090                          | μg/L              |

ODD = orphan dnug designation, PEC = Predicted Environmental Concentration, STP = sewage treatment plant..

The PECSURFACEWATER is 0.00036 μg/L, or using the worst-case prevalence data 0.0009 μg/L. Both values are lower than the action limit of 0.01 μg/L. Hence, a phase II environmental fate and effects analysis is not applicable.

In addition, The PECSURFACEWATER for RR-DTC and RCC were calculated previously to be 0.00012 μg/L and 0.00396 μg/L, respectively. The combined PECSURFACEWATER for lenvatinib used in the treatment of RCC, RR-DTC and HCC patients was 0.0044 μg/L (based on ODD prevalence for HCC) and 0.0050 μg/L (based on worst-case prevalence for HCC). This combined value is lower than the action limit of 0.01 μg/L.  Therefore,  it  is  assumed  that  the  medicinal  product  is  unlikely  to  represent  a  risk  for  the environment following its prescribed usage in patients.

## 2.2.6. Discussion on non-clinical aspects

Several new in vitro and in vivo primary pharmacodynamics studies have been submitted to support the new proposed indication for Lenvima.

The new crystal structure analysis indicates that the binding mode of lenvatinib to FGFR1 is also type V, similar to the binding mode to VEGFR2.

The inhibition of FGFR by lenvatinib was further demonstrated in signal transduction assays where lenvatinib appeared to be a stronger inhibitor than sorafenib of phosphorylation of FRS2, a FGFR specific downstream signalling molecule, in several human HCC cell lines. The difference in potency in these assays was 10-fold.

Lenvatinib showed significant antiproliferative activity against HCC cell lines Hep 3B2.1-7 and HuH-7 but very weak antiproliferative activity against PLC/PRF/5 cells. Sorafenib did not show remarkable selectivity against either of the cell systems. When comparing lenvatinib and sorafenib, the difference in IC50 values for antiproliferative activity against the Hep 3B2.1-7 and HuH-7 cell lines was in the order of 10, which matches with the results of the FGFR signal transduction assays.

The weak in vitro antiproliferative activity which has been observed against PLC/PRF/5 cells but nevertheless the significant antitumour activity observed in the respective xenograft model suggest that the primary antitumour activity of lenvatinib is related to its antiangiogenic activity resulting from the

<div style=\"page-break-after: always\"></div>

inhibition of VEGFR and FGFR, and not to a direct antiproliferative activity against a particular tumour cell line.

The results of 5 new murine HCC xenograft models demonstrated that lenvatinib showed significant tumour growth inhibition at doses from 3 or 10 to 30 mg/kg without severe BWL (more or less 10% body weight loss compared to the body weight at the initiation of dosing). The activity of lenvatinib was generally greater than the activity of sorafenib at the same dose level (factor 1.5 to 2 greater tumour volume reduction for lenvatinib compared to sorafenib, depending on the model used). Also the tolerability of lenvatinib in terms of BWL was overall slightly better compared to sorafenib in these models.

In a murine HCC isograft model, tumour inhibition by lenvatinib (doses of 3 and 10 mg/kg) was significantly greater in immunocompetent mice, compared to athymic mice. In addition, lenvatinib (10 mg/kg) decreased the population of tumour associated macrophages (TAM) and increased activatedcytotoxic T cells in the draining lymph node. These results suggest an immune stimulatory effect of lenvatinib, since TAM act as a suppressor, and T cells as an effector for tumour immunity.

A new analysis of previously submitted monkey plasma PK data was submitted but does not impact previous conclusions.

No new clinical toxicology data have been submitted in this application, which is considered acceptable.

The data submitted to support the DTC and RCC indications was in line with ICH S9. Although a first line indication is currently being proposed for HCC, the survival of these patients is short (~1 year) and there are no effective therapies available.

The applicant provided data regarding the prevalence of the disease population targeted by the HCC indication and this was used to refine Fpen. The PEC surfacewater value is below the action limit of 0.01 µg/L and it is not a PBT substance as log Kow does not exceed 4.5.

Therefore lenvatinib is not expected to pose a risk to the environment.

## 2.2.7. Conclusion on the non-clinical aspects

The non-clinical data submitted as part of this application support the use of lenvatinib in HCC.

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of lenvatinib.

Considering the above data, lenvatinib is not expected to pose a risk to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

The proposed indication for lenvatinib is 'for the treatment of patients with hepatocellular carcinoma'. The pivotal study in support of this application is Study E7080-G000-304 (Study 304), a randomized,

<div style=\"page-break-after: always\"></div>

controlled, open label multicentre, Phase 3 trial. Supportive evidence is provided by Phase 1/2 study E7080-J081-202 (Study 202), a proof of concept, dose-finding study.

| Study ID              | Nunber of Study Centers (Locations)                                                                                                                     | Study Start/ Clinical Cutoff Date                                                                                                     | Study Design/ Indication                                                                                                                                                                           | Study Treatment(s): Dose, Route & Regimen                                                            | No. Subjects Planned/ Treated/ Ongoing?                                                                                                                               | Treated Subjects Sex (M/F); Median age, y (Range)                       | Efficacy Endpoints                                                                      |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Pivotal Phase 3 Study | Pivotal Phase 3 Study                                                                                                                                   | Pivotal Phase 3 Study                                                                                                                 | Pivotal Phase 3 Study                                                                                                                                                                              | Pivotal Phase 3 Study                                                                                | Pivotal Phase 3 Study                                                                                                                                                 | Pivotal Phase 3 Study                                                   | Pivotal Phase 3 Study                                                                   |
| E7080-G000-304        | 183 sites: Asia (China, Japan, Republic of Korea, Singapore, Hong Kong, Thailand, Taiwan, Philippines, Malaysia), North America, the EU, Russia, Israel | 01 Mar 2013 (1st subject signed ICF) 13 Nov 2016 (clinical cutoff for primary analysis)                                               | Randomized (1:1), open-label, noninferiority of lenvatinib vs unresectable, BCLC subjects with sorafenib in stage B or C HCC and CP class A                                                        | Lenvatinib QD: 8 mg (BW <60 kg) or 12 mg (BW ≥60 kg) oral capsules Sorafenib 400 mg BID oral tablets | Planned: Total N = 940 Treated/Ongoing: Lenvatinib: Sorafenib: 478/27 476/25                                                                                          | Lenvatinib: 405M/73F 63.0 y (20, 88) Sorafenib: 401M/75F 62.0y (22, 88) | Primary: OS Secondary (sequential analysis): PFS, TTP, ORR Exploratory: DCR, CBR, HRQoL |
| Supportive Study      | Supportive Study                                                                                                                                        | Supportive Study                                                                                                                      | Supportive Study                                                                                                                                                                                   | Supportive Study                                                                                     | Supportive Study                                                                                                                                                      | Supportive Study                                                        | Supportive Study                                                                        |
| E7080-J081-202        | Phase 1:  Japan (2 sites) Phase 2: Korea (2 sites) Japan (12 sites),                                                                                    | 24 Jul 2009 (1st subject signed ICF) (clinical cutoff 15 Jun 2014 for primary analysis) (cutoff date for 13 Aug 2015: final analysis) | Phase 1/2, nonrandomized, multicenter, multidose, open- label study with a dose-escalation component (Phase 1) and an  expansion RP2 dose (Phase 2) component at the in subjects with advanced HCC | Lenvatinib QD: Phase 1: 8, 12, or 16 mg Phase 2: 12 mg oral tablets (RP2 dose)                       | Phase 1: Group 1 (CP score 5-6): Group 2 Planned: 12-18/ Actual: 9; (CP score 7-8): Planned: 6-18/ Actual: 11 Ongoing: 0 (Groups 1+2) Phase 2: (CP score 5-6) 46/46/0 | Phase 1: 17M/3F 63.5 y Phase 2: (47, 74) 33M/13F (37, 80) 66.5y         | Phase 1: Primary: NAc Secondary: BOR Phase 2: Primary: TTP Secondary: BOR, ORR, DCR, OS |

BCLC = Barcelona Clinic Liver Cancer; BID = twice daily; BOR = best overall response; BW = body weight; CBR = clinical benefit rate; CP = Child-Pugh; DCR = disease control rate; HCC =hepatocellular carcinoma; HRQoL = health-related quality of life; ICF = informed consent form; NA = not applicable; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; QD = once daily; RP2 = recommended Phase 2 (dose); TTP = time to progression.

a: The number ongoing is the number of subjects still receiving study drug as of the clinical cut-off date for the study.

b: Three subjects (2 lenvatinib, 1 sorafenib) in Study 304 did not receive treatment and were included in the Full Analysis Set but not the Safety Analysis Set.

c: The primary endpoint in Phase 1 of Study 202 was safety.

## 2.3.2. Pharmacokinetics

## Introduction

Data from 21 studies were used to characterize the pharmacokinetics (PK) of lenvatinib. These included a Phase 1/2 dose finding study for subjects with HCC (Study E7080-J081-202) and an HCC Phase 3 safety and efficacy study (Study E7080-G000-304).

From a non-clinical and clinical perspective, 4 additional pharmacokinetics studies have been completed, and 1 study has been re-analysed. These studies include:

- Calculation of pharmacokinetic parameters of radioactive peaks in monkey plasma (see NC)
- Protein binding in human liver microsomes (HLMs)
- Reversibility of covalently bound lenvatinib-related components to human plasma protein
- Reanalysis of modeling and simulation using Simcyp®
- Substrate recognition and inhibition of MATE.

## Bioanalytical methods

The additional data regarding bioanalytical methods are summarised in the table below.

<div style=\"page-break-after: always\"></div>

Table 6: Additional bioanalytical method submitted as part of this application

| Analyte    | Human Matrix   | Lab                | Validation Reference   | Assay Range (ng/mL)   |   Assay Volume (mL) | Clinical Study No.            |
|------------|----------------|--------------------|------------------------|-----------------------|---------------------|-------------------------------|
| Lenvatinib | Plasma         | Wuxi-China         | 11BAS0295A2            | 0.250 - 250           |                 0.1 | E7080-G000-304 E7080-G000-209 |
| Lenvatinib | Plasma         | Wuxi- Philadelphia | P12BAS0005             | 0.250 -250            |                 0.1 | E7080-703                     |

Plasma lenvatinib was analysed using a validated LC-MS/MS method at Wuxi-China and Wuxi-Philadelphia in  support  of  clinical  studies  E7080-G000-304  (11BAS0295A2),  E7080-G000-209  (11BAS0295A2)  and E7080-703 (P12BAS0005). Incurred sample reanalyses (ISR) were performed in 6 to 15 % of human plasma samples depending on the study.

All ISR samples met the regulatory guidance acceptance criteria; at least 2/3 of the ISR samples were no more  than  ±20%  of  the  original  measured  values  (FDA  Guidance  for  Industry  'Bioanalytical  Methods Validation', May 2001, and EMA 'Guideline on bioanalytical method validation', July 2011).

## Bioequivalence

Study  E7080-A001-009  has  been  submitted  in  the  context  of  the  Kisplyx  marketing  authorisation (EMEA/H/C/004224)  evaluating  the  relative  bioavailability  and  palatability  of  a  lenvatinib  suspension compared to the capsule formulation in adult healthy volunteers.

Subjects were asked to take either lenvatinib capsules with 240 mL of water or the lenvatinib suspension in water or apple juice.

Table 7: Analysis of Pharmacokinetic Parameters of Lenvatinib - Suspension vs Capsule (Pharmacokinetic Analysis Set)

| Group Contrast (Test:Reference)   | Parameter           |   Geometric LeastSquareMeanRatio | (90%ConfidenceInter'va   |
|-----------------------------------|---------------------|----------------------------------|--------------------------|
| Suspension vs Capsule             | Cmax (ng/mL)        |                            1.025 | (0.8868, 1.1837)         |
|                                   | AUC(o-t) (h*ng/mL)  |                            0.997 | (0.9347, 1.0635)         |
|                                   | AUC(o-ins (h*ng/mL) |                            0.999 | (0.9379,1.0641)          |

Log-transformed PK parameters were fitted using a linear model including formulation group. period and sequence as a fixed effects and subject as a randomeffect.Backtransformedratios of geometricmeans and associated 2-sided 9o%confidence intervals

## Absorption

No new data regarding absorption, influence of food, influence of vehicle, bioequivalence was submitted.

## Distribution

Two additional studies related to the protein binding have been submitted in this application.

Study DMPKT2013-020 - Protein binding of E7080 in human liver microsomes

In  this  study,  protein  binding  of  E7080  (lenvatinib)  in  human  liver  microsomes  (HLM)  solution  was examined in an equilibrium dialysis method using RED Device (Thermo Scientific). Quantification of E7080 in PBS sample and HLM sample was performed by HPLC-UV, which was validated from 0.03 to 100 μg/mL of E7080 mesylate.

Protein binding of E7080 in HLM sample was calculated as follows:

<!-- formula-not-decoded -->

The results are summarised in the following table:

<div style=\"page-break-after: always\"></div>

|   Added Concentration (μg/mL as mesylate) |   11 | Protein Binding (%) Human Liver: Microsomes   |
|-------------------------------------------|------|-----------------------------------------------|
|                                       0.3 |    3 | 29.24±0.91                                    |
|                                       1   |    3 | 26.93±1.26                                    |
|                                       3   |    3 | 25.49±0.21                                    |
|                                      10   |    3 | 24.53±0.52                                    |
|                                      30   |    9 | 23.85±1.06                                    |

Each value represents the mean ±SEM.

a:Combination of1stexperiment（n=3)and 2ndexperiment（n=6).

Study  W-20140601  -  formation  of  covalent  binding  of  E7080  with  human  plasma  protein  and  its reversibility

This study investigated the mechanism for the formation of covalent binding of E7080 with human plasma protein and its reversibility. E7080-related components which covalently bound to human plasma protein were substituted by endogenous nucleophiles such as glutathione (GSH) and cysteine, and their chemical structures were analysed.

This study suggested that E7080 and its metabolite, N-cysteine conjugate of quinolone moiety in E7080, could form covalent binding with human plasma protein via thioether and di-sulfide bonds, respectively. Nucleophiles such as GSH and cysteine successfully released E7080-related components which covalently bound to human plasma protein as the corresponding conjugates via substitution  reaction,  suggesting that  the  covalent  binding  would  be  reversible  in  humans  in  vivo  since  abundant  amounts  of  GSH  and cysteine exist.

## Elimination

No additional data regarding elimination has been submitted with this application.

## Inter- and intra-individual variability

In the population analysis of study 202, the %CV of apparent total clearance is 32.6 %.

Table 8: final population pharmacokinetic parameter estimates of lenvatinib - Study 202

|                                    | NONMEM Estimates   | NONMEM Estimates   | NONMEM Estimates        |
|------------------------------------|--------------------|--------------------|-------------------------|
| Parameter                          | Point Estinate     | %RSE               | 95%Confidence Inter'val |
| Inter-individual variability (%CV) |                    |                    |                         |
| CL/F                               | 32.6               | 6.99               |                         |
| V1/F                               | 49.5               | 7.39               |                         |

In the population analysis of study 304, inter-individual variability (IIV) in the model parameters was moderate ranging between 25.4% for CL/F and 93.6% for D1. IIV was well estimated with good precision for all the parameters (%RSE ≤ 14.0%). The residual variability in lenvatinib concentrations for TAD ≤ 2 h was high (%CV 49.0), moderate for cancer patient studies (%CV 36.3), and low for Phase 1 clinical pharmacology studies (%CV 17.0).

## Dose proportionality and time dependencies

## Dose proportionality

In  the  new  study  E7080-J081-202,  exposure,  as  measured  by  Cmax,  AUC(0-24h),  AUC(0-t),  Css,max,  and AUC(0-τ), for lenvatinib appeared to increase with increasing doses.

<div style=\"page-break-after: always\"></div>

## Time-dependency

In  the  new  study  E7080-J081-202,  plasma  lenvatinib  concentration  accumulated  after  repeated  dosing with a mean accumulation index (Rac) of AUC(0-24h) and Cmax ranging from 1.23 to 2.11.

## Special populations

## Elderly

No new data have been submitted in elderly patients

## Impaired renal function

No specific study investigating patients with impaired renal function was submitted.

## Impaired hepatic function

No specific study investigating patients with impaired hepatic function was submitted.

## ●Study E7080-J081-202

The primary objective of the study was to determine the maximum tolerated dose (MTD) as defined by the dose limiting toxicity (DLT) of lenvatinib administered continuously once a day (QD) as 4 weeks cycle in subjects with advanced HCC and hepatic function of Child-Pugh (CP) scores of 5-6 or 7-8 (groups 1 and 2 respectively). One of the secondary objectives is to determine the PK profiles of lenvatinib.

In the Dose Escalation Component (Phase 1), PK parameters were determined after single (Cycle 1/Day1) and multiple doses (Cycle 1/Day 15), using non-compartmental analysis. The PK profile of lenvatinib was evaluated  by  concentration-time  plots.  PK  results  were  summarized  descriptively  by  dose  level  and hepatic  function  (Group  1  and  Group  2).  If  possible,  the  relationships  between  pharmacokinetics, pharmacodynamics, and efficacy/safety were to be evaluated by plots.

In the Expansion Component (Phase 2), summary statistics of lenvatinib plasma concentration at each time point were calculated. If necessary, pooled data combining this component and the Dose Escalation Component (Phase 1)  and  other  clinical  studies  (eg,  E7080-J081-103)  were  to  be  analyzed  using  the population approach.

Table 9: Analysis Sets - Enrolled Subjects (Dose Escalation Component [Phase 1])

|                       | Group 1 (Child-Pugh Score 5or 6)   | Group 1 (Child-Pugh Score 5or 6)   | Group 1 (Child-Pugh Score 5or 6)   | Group 2 (Child-Pugh Score 7 or 8)   | Group 2 (Child-Pugh Score 7 or 8)   | Group 2 (Child-Pugh Score 7 or 8)   |                      |
|-----------------------|------------------------------------|------------------------------------|------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------|
| Analysis Set          | 12 mg QD (N=6) n (%)               | 16 mg QD (N=3) n (%)               | Total (N=9) n (%)                  | 8 mg QD (N=6) (%) uI                | 12 mg QD (N=5) n (%)                | Total (N=11) n (%)                  | Overall (N=20) n (%) |
| Enrolled Set          | 6                                  | 3                                  | 9                                  | 6                                   | 5                                   | 11                                  | 20                   |
| Efficacy Analysis Set | 6 (100.0)                          | 3 (100.0)                          | 9 (100.0)                          | 6 (100.0)                           | 5 (100.0)                           | 11 (100.0)                          | 20 (100.0)           |
| PK Analysis Set       | 6 (100.0)                          | 3 (100.0)                          | 9 (100.0)                          | 6 (100.0)                           | 5 (100.0)                           | 11 (100.0)                          | 20 (100.0)           |
| PD Analysis Set       | 6 (100.0)                          | 3 (100.0)                          | 9 (100.0)                          | 6 (100.0)                           | 5 (100.0)                           | 11 (100.0)                          | 20 (100.0)           |
| Safety Analysis Set   | 6 (100.0)                          | 3 (100.0)                          | 9 (100.0)                          | 6 (100.0)                           | 5 (100.0)                           | 11 (100.0)                          | 20 (100.0)           |

Percentages are based on the number of enrolled subjects in the relevant dose group.

PD = pharmacodynamic, PK = pharmacokinetic, QD = once a day.

<div style=\"page-break-after: always\"></div>

Table  10:  Summary  of  Pharmacokinetic  Parameters  of  Lenvatinib  in  Group  1  (Child-Pugh  Score  5,  6)  Cycle 1 Day 1 - Pharmacokinetic Analysis Set (study 202)

|                          | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|--------------------------|-------------------------|-------------------------|
| PharmacokineticParameter | 12 mg QD (n=6)          | 16 mg QD (n=3)          |
| Cmax (ng/mL)             | 212 ± 70.8              | 344 ± 166               |
| tmax (h)                 | 2.000 (0.97 - 5.95)     | 1.970 (0.97 - 4.00)     |
| AUC(0-24h) (ng h/mL)     | 2020 ± 170              | 3280 ± 961              |

AUC(o-24h) = area under the concentration-time curve from zero time to 24h, Cmax * = maximum observed concentration, tmax = time at which the highest drug concentration occurs.

Data is shown as mean ± SD except tmax; for tmax, median (minimum - maximum) is shown.

Table 11: Summary of Pharmacokinetic Parameters of Lenvatinib in Group 2 (Child-Pugh Score 7, 8)- Cycle 1 Day 1 - Pharmacokinetic Analysis Set

|                           | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|---------------------------|-------------------------|-------------------------|
| Pharmacokinetic Parameter | 8 mg QD (9=)            | 12 mg QD (n=5)          |
| C x (ng/mL)               | 146 ± 56.9              | 254 ±169                |
| (max (h)                  | 2.015 (0.50 - 3.93)     | 2.000 (1.00 - 3.98)     |
| AUC(0-24h) (ng-h/mL)      | 1250 ± 399              | 2140 ± 1030             |

AUC(o-24h) = area under the concentration-time curve from zero time to 24h, Cmax = maximum observed concentration, tmax = time at which the highest drug concentration occurs. Data is shown as mean ± SD except tmax for tmax median (minimum - maximum) is shown.

Table 12: Summary of Pharmacokinetic Parameters of Lenvatinib in Group 1 (Child-Pugh Score 5,6) - Cycle 1 Day 15 - Pharmacokinetic Analysis Set

|                          | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|--------------------------|-------------------------|-------------------------|
| PharmacokineticParameter | 12 mg QD (n=5)          | 16 mg QD (m=2)          |
| Css.max (ng/mL)          | 346 ± 75.4              | 402                     |
| Css.min (ng/mL)          | 43.1 ± 21.7             | 84.6                    |
| Css.av (ng/mL)           | 130 ± 23.5              | 213                     |
| (h) Iss,max              | 1.950 (1.00- 3.98)      | 3.915 (3.83 - 4.00)     |
| AUC(o-t) (ng h/mL)       | 3120 ± 566              | 5110                    |
| Rac(Cmax)                | 1.67± 0.645             | 1.64                    |
| Rac(AUC)                 | 1.54± 0.290             | 1.73                    |

AUC(o-t)= area under the concentration-time curve over the dosing interval on multiple dosing, C Css,av = average steady-state concentration, Css,max x = maximum observed concentration at steady-state, Css,min = minimum observed concentration at steady-state, Rac = accumulation index, ts,max = time at which the highest drug concentration occurs at steady-state.

Rac(Cmax) = Css,max/Cmax: Rac(AUC) = AUC(0-t/AUC(0-24h).

Data are shown as mean ± SD except tss,max; for tss.max, median (minimum - maximum) is shown. Last sampling time point is 24 hours after administration.

<div style=\"page-break-after: always\"></div>

Table 13: Summary of Pharmacokinetic Parameters of Lenvatinib in Group 2 (Child-Pugh Score 7,8) - Cycle 1 Day 15 - Pharmacokinetic Analysis Set

|                          | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|--------------------------|-------------------------|-------------------------|
| PharmacokineticParameter | 8 mg QD (m=6)           | 12 mg QD (n=2)          |
| (ng/mL)                  | 167 ± 40.4              | 349                     |
| (ng/mL)                  | 29.9 ± 13.4             | 64.0                    |
| Css.av (ng/mL)           | 73.8± 14.2              | 165                     |
| (h) ss.max               | 2.025 (1.98 - 4.02)     | 1.995 (1.97 - 2.02)     |
| AUC(o-t) (ng h/mL)       | 1770 ± 340              | 3960                    |
| Rac(Cmax)                | 1.23 ± 0.315            | 1.91                    |
| Rac(AUC)                 | 1.49 ± 0.385            | 2.11                    |

AUC(o-t)= area under the concentration-time curve over the dosing interval on multiple dosing, Cs.av = average steady-state concentration, Cs.max x = maximum observed concentration at steady-state, Css,min n=minimum observed concentration at steady-state, Rac = accumulation index, tss.max = time at which the highest drug concentration occurs at steady-state.

Rac(Cmax) = Css,max/Cmax; Rac(AUC) = AUC(0-t)/AUC(0-24h)- mous si (unxi - uuu) up *xur'ss iy xtr'ss pdoxa as +  se umous die eea Last sampling time point is 24 hours after administration.

No relationship between CP score and the PK of lenvatinib was observed in Study 202. This finding is similar to results from the hepatic impairment study for lenvatinib, E7080-A001-006.

Sparse PK sampling was performed for all subjects. A total of up to 6 samples per subject were to be obtained pre-dose on Days 1, 8, 15, 22 of Cycle 1 and on Day 1 of Cycle 2 and Cycle 3. These data are pooled for population PK analysis and are reported in a separate report (see population PK analysis below)

## ● Study 304

Based on the results of the initial Phase 1/2 lenvatinib trial, study 304 was designed and conducted to compare  the  safety  and  efficacy  of  lenvatinib  versus  sorafenib  in  subjects  with  Child-Pugh  class  A, unresectable/advanced  HCC.main  criteria  for  inclusion,  adult  subjects  ( ≥ 18  years  of  age)  with  a histologically or cytologically confirmed diagnosis of unresectable HCC, or a clinically confirmed diagnosis of HCC according to the American Association for the Study of Liver Diseases criteria, including cirrhosis of any etiology, or with chronic hepatitis B or C infection were eligible. In the other key inclusion criteria included, child-pugh score A was mentioned.

Pharmacokinetic samples were collected from all subjects who took lenvatinib. Exposure parameters such as  maximum  concentration  and  area  under  the  concentration  ×  time  curve  (AUC)  were  derived  from posterior estimates of the PK parameters from the final population PK model.

In  general,  the  incidence  of  TEAEs  was  similar  for  subjects  with  a  baseline  CP  score  of  5  or  of  6  in lenvatinib  treated  subjects  in  HCC  Study  304.The  incidences  of  severe  (Grade ≥ 3)  TEAEs,  SAEs,  and TEAEs leading to study drug withdrawal were higher in subjects with baseline CP score of 6 than of 5. Subjects  with  baseline  CP  score  of  6  compared  with  those  with  baseline  CP  score  of  5  had  a  higher incidence of nonfatal SAEs. Subjects with a baseline CP score of 6 also had a higher incidence of TEAEs leading to study drug interruption or to study drug reduction or interruption.

Overall, the rate of major protocol deviations was low (2.5%; 24 of 954 subjects), and the incidence and nature of the protocol deviations were balanced across the treatment arms. Most of the major protocol deviations  in  both  the  lenvatinib  and  sorafenib  arms  were  eligibility  criteria  not  met,  mostly  due  to laboratory levels outside the acceptable range or Child-Pugh score of 7 or 8 (Class B).

<div style=\"page-break-after: always\"></div>

## Gender

The effect of gender on the pharmacokinetics of lenvatinib was evaluated in the population PK analysis. No significant differences between sexes were found in lenvatinib exposure.

## Race

The  effect  of  race  on  the  pharmacokinetics  of  lenvatinib  was  evaluated  in  the  population  PK  analysis. According to the POP PK analysis, the PK of lenvatinib was unaffected by race.

In the new study 304, individual lenvatinib oral clearance and AUC at steady state for Western, Asian, Chinese and Japanese populations are summarized by starting dose group. The median value and range of AUC values are each comparable between the 8 mg group and 12 mg group. There were no differences of  lenvatinib  oral  clearance  and  AUC  at  steady  state  among  Western,  Asian,  Chinese  and  Japanese populations.

## Weight

The effect of weight on the pharmacokinetics of lenvatinib was evaluated in the original population PK analysis (DTC). In this POP PK analysis, weight (37.8 - 178 kg) added as an allometric constant on CL/F and volume parameters showed a statistically significant effect, but only explained 1.2 % of the interindividual variability on CL/F. PK simulations showed a major overlap in the steady-state exposure in the presence  and  absence of this  covariate.  Subjects  with  body  weight  &lt;60  kg  had  36%  higher  exposure compared with subjects &gt;60 kg.

## Study E7080-J081-202

The (POP) PK analysis for Study 202 (CPMS-E7080-005R-v1) showed that included statistically significant and clinically relevant effects of bodyweight on both clearance and volume increased with increasing body weight. Allometric functions were used to characterize these effects. As a consequence, fixed dosing as initially  implemented  in  Study  202  led  to  high  difference  in  exposures  (AUC)  across  the  range  of bodyweight.  Observed  data  and  predictions  from  the  final  model  showed  that  compared  with  subjects weighing ≥ 60 kg, subjects with a low body weight ([BW] &lt;60 kg) had a higher lenvatinib area under the plasma concentration-time curve (AUC) and a high rate of dose reductions and discontinuations at the 12-mg starting dose.

In  phase  2  part  of  study  202,  the  dose  reduction  occurred  frequently  and  early  in  the  course  of treatment.  Twenty-one  patients  (46.7  %)  of  PK/PD  population  experienced  TEAEs  leading  to  dose reduction or discontinuation during Cycle 1. The median body weight of these patients with early dose withdrawal or reduction was 54.3 kg, whereas the median body weight of patients without early dose modification was 67.6 kg. The final PK model for lenvatinib included body weight effect on oral clearance, whereby the relationship between the AUC and body weight shows an increase in AUC as the body weight decreases.  The  median  AUC  based  on  the  starting  dose  of  patients  with  early  dose  withdrawal  or reduction was 2950 ng*h/mL, whereas the median AUC based on the starting dose of patients without early dose modification was 2050 ng*h/mL (see figure below).

The  median  steady  state  Cmin  of  patients  with  early  dose  withdrawal  or  reduction  was  46.8  ng/mL, whereas the median steady state Cmin of patients without early dose modification was 30.6 ng/mL.

<div style=\"page-break-after: always\"></div>

Figure 4: Boxplot of body weight, lenvatinib AUC and Cmin for patients with vs without TEAEs that lead to dose reduction or study drug withdrawal during Cycle 1

<!-- image -->

Patients with low body weight experienced the early dose reduction or discontinuation, and this can be explained by the higher lenvatinib AUC for patients with low body weight.

The  MAH  explored  the  cut-off  value  of  lenvatinib  AUC  to  predict  high  risk  group  of  the  early  dose reduction or discontinuation. To investigate the best cut-off value of lenvatinib exposure and body weight to predict high risk group of the occurrence of TEAEs leading to study drug withdrawal or dose reduction during Cycle 1, a receiver operating characteristics (ROC) curve was used. The classification table crossclassifies the binary response with prediction of whether the subject experiences TEAEs leading to study drug withdrawal/reduction during Cycle 1 or not for some cut-off value based on the final PK/PD logistic model.

ROC curve which was predicted from the developed logistic regression model indicates that the best cutoff value of lenvatinib AUC is 2430 ng*h/mL with 0.71 sensitivity and 0.71 specificity.

Based on the final PK model, simulated body weight (range: 40 - 120 kg) vs. lenvatinib AUC curve in 12 and 8 mg dose groups is shown in figure below. Based on the 2430 ng*h/mL of AUC as threshold to predict high risk group of the early dose reduction or discontinuation, the figure suggested that a simple body weight adjusted dosing regimen, namely 12 mg dose in subjects whose body weight are 60kg and over,  and  8  mg  dose  in  subjects  whose  body  weight  are  less  than  60kg,  was  recommended  to  avoid TEAEs leading the early dose reduction or discontinuation. Within the range between 40 kg and 120 kg of body  weight,  the  predicted  AUC  of  subjects  whose  body  weight  were  less  than  60kg,  are  calculated between 1540 and 2050 ng·h/mL, and the predicted AUC of subjects whose body weight are 60kg and over,  are  calculated  between  1410  and  2310  ng·h/mL.  The  AUC  range  between  two  dose  groups  was similar, which supports the adequacy of the proposed dosing regimens based on a body weight cut-off at 60kg.Because of the reduced tolerability of the 12-mg dose observed in subjects with low body weight and the results of PK modelling, a 2-tier dosing strategy based on body weight was proposed for future clinical studies with lenvatinib in patients with advanced HCC: 12 mg for subjects weighing ≥ 60 kg and 8 mg for subjects weighing &lt;60 kg.

<div style=\"page-break-after: always\"></div>

Figure 5 : simulated body weight vs lenvatinib AUC curve for 12 and 8 mg dose groups

<!-- image -->

## Study E7080-G000-304 and POP PK report CPMS-E7080-011R

While bodyweight effects on CL/F and V/F was fixed in model development when data from study 304 were used.  The fitting performances from final PopPK model including data from Study 304 confirmed that lenvatinib PK was affected by body weight in subjects with HCC (Report CPMS-E7080-011R). Both CL/F and volume increase with increasing body weight. The lower CL/F in subjects with low body weight results in an increase in lenvatinib AUC. Based on individual lenvatinib AUC values for subjects with HCC in  Study  304,  however,  the  median  value  and  range  of  individual  AUC  values  at  steady  state  were comparable  between  the  8-mg  starting  dose  for  subjects  weighing  &lt;60  kg  and  the  12-mg  dose  for subjects weighing ≥ 60 kg. The effect of changes in body weight was more pronounced in HCC than in previously  studied  tumour  types  (RR-DTC,  RCC).  In  other  tumour  types,  the  effect  of  body  weight  on lenvatinib PK was small, not clinically relevant, and did not warrant any dose adjustment (CPMS-E7080 007R; CPMS-E7080-008R). These data confirm the use of the 2-tier dosing strategy based on bodyweight in HCC in study 304.

Table 14: Summary of Individual Predicted Pharmacokinetic Parameters for Lenvatinib in Study 304 by Starting Dose Group (All)

| Starting Dose   | Parameter (unit)          |   N | Mean (SD)      |   Median | Range (Min-Max)   |
|-----------------|---------------------------|-----|----------------|----------|-------------------|
| 8 mg            | Oral clearance (L/h)      | 150 | 4.14 (0.98)    |     4.06 | 1.93 - 6.96       |
| 8 mg            | AUC (ng·h/mL)             | 150 | 1969.6 (743.0) |  1820.2  | 704.8 - 4980.7    |
| 8 mg            | Baseline body weight (kg) | 150 | 52.6 (4.9)     |    53    | 39.4 - 59.9       |
| 12 mg           | Oral clearance (L/h)      | 318 | 5.64 (1.20)    |     5.64 | 2.66 - 8.97       |
| 12 mg           | AUC (ng h/mL)             | 318 | 2120.9 (685.6) |  1996    | 925.5-5427.9      |
| 12 mg           | Baseline body weight (kg) | 318 | 75.9 (14.4)    |    72    | 59.6 - 142.2      |

<div style=\"page-break-after: always\"></div>

Table 15: Summary of Individual Predicted Pharmacokinetic Parameters for Lenvatinib in Study 304 by Starting Dose Group (Western Population)

| Starting Dose   | Parameter (unit)          |   N | Mean (SD)      |   Median | Range (Min-Max)   |
|-----------------|---------------------------|-----|----------------|----------|-------------------|
| 8 mg            | Oral clearance (L/h)      |  20 | 3.71 (0.92)    |     3.66 | 2.03 -6.21        |
| 8 mg            | AUC (ng·h/mL)             |  20 | 2322.3 (855.4) |  2179.9  | 889.4 - 4980.7    |
| 8 mg            | Baseline body weight (kg) |  20 | 52.1 (5.2)     |    51.5  | 40.0 - 59.0       |
| 12 mg           | Oral clearance (L/h)      | 127 | 5.91 (1.20)    |     5.85 | 2.96 - 8.97       |
| 12 mg           | AUC (ng-h/mL)             | 127 | 2010.2 (631.1) |  1935.4  | 925.5 -4337.2     |
| 12 mg           | Baseline body weight (kg) | 127 | 84.4 (17.3)    |    82    | 60.0 - 142.2      |

Western consists of North America and Europe including Russia and Israel.

Table 16: Summary of Individual Predicted Pharmacokinetic Parameters for Lenvatinib in Study 304 by Starting Dose Group (Asian Population)

| Starting Dose   | Parameter (unit)          |   N | Mean (SD)      |   Median | Range (Min-Max)   |
|-----------------|---------------------------|-----|----------------|----------|-------------------|
| 8 mg            | Oral clearance (L/h)      | 130 | 4.20 (0.97)    |     4.18 | 1.93 - 6.96       |
| 8 mg            | AUC (ng h/mL)             | 130 | 1915.4 (712.5) |  1737.6  | 704.8 - 4937.8    |
| 8 mg            | Baseline body weight (kg) | 130 | 52.7 (4.9)     |    53.3  | 39.4 - 59.9       |
| 12 mg           | Oral clearance (L/h)      | 191 | 5.47 (1.17)    |     5.39 | 2.66 - 8.61       |
| 12 mg           | AUC (ng h/mL)             | 191 | 2194.5 (711.6) |  2064.7  | 945.5 - 5427.9    |
| 12 mg           | Baseline body weight (kg) | 191 | 70.3 (8.1)     |    68    | 59.6 - 102.0      |

Asian consists of China, Japan, Korea, Hong Kong, Malaysia, Philippines, Singapore, Taiwan and Thailand.

## Pharmacokinetic interaction studies

No new PK interaction studies were submitted in this application.

## Pharmacokinetics using human biomaterials

With the exception of Study GE-1399-G, this section is unchanged from the DTC and RCC information.

## Study GE-1399-G

This study was conducted to assess the potential of E7080 as a substrate or an inhibitor for MATE1 and MATE2-K using cells expressing respective transporters. Cells transfected with each control vector were used as the control cells.

The  transports  of  [ 14 C]E7080 by each transporter at  a  concentration  of  1  µmol/L  in  the  presence  and absence of each typical inhibitor were assessed. The inhibitory effects of E7080 on each transporter were determined at concentrations of 0.1, 0.3, 1, 3, 10, and 30 µmol/L using radiolabelled typical substrates. Assay system, and typical substrates and inhibitors used in this study are summarized below:

<div style=\"page-break-after: always\"></div>

| Transporter   | Assay system   | Typical substrate (concentration used)   | Typical inhibitor (concentration used)   |
|---------------|----------------|------------------------------------------|------------------------------------------|
| MATE1         | HEK293 cells   | Metformin (10 μmol/L)                    | Cimetidine (10 μmol/L)                   |
| MATE2-K       | HEK293 cells   | Metformin (10 μmol/L)                    | Cimetidine (100 μmol/L)                  |

In all preparations of transporter-expressing cells and their control cells used in this study, the transport activities of typical substrates and inhibitory effects by typical inhibitors were retained normally, indicated that the test systems used in this study were adequate to evaluate the potentials of E7080 as a substrate and an inhibitor of MATE1 and MATE2-K.

## Substrate recognition

Study  GE-1399-G  showed  that  lenvatinib  was  not  a  substrate  of  either  multidrug  and  toxin  extrusion (MATE)  1  or  MATE2-K.  No  MATE1-  and  MATE2-K-mediated  transports  of  [ 14 C]E7080  were  detected, indicating that E7080 was not a substrate of either MATE1 or MATE2-K.

## -MATE 1

In the absence of cimetidine, the uptakes of [ 14 C]E7080 in the MATE1-expressinc cells after incubation for 1, 2, and 5 minutes were 38.1, 44.1, and 53.8 μL/mg protein, respectively; those in the control cells were 41.1, 48.8, and 53.2 μL/mg protein, respectively. In the presence of cimetidine (10 μmol/L), the uptakes of [ 14 C]E7080 in the MATE1-expressing cells after incubation for 1, 2, and 5 minutes were 36.2, 43.4, and 46.2 μL/mg protein, respectively; those in the control cells were 39.7, 49.0, and 52.0 μL/mg protein, respectively.

The uptakes of [ 14 C]E7080 in the MATE1-expressing cells after incubation for 1, 2, and 5 minutes were comparable to those in the control cells. In addition, cimetidine, a typical MATE1 inhibitor, did not inhibit the uptake of [ 14 C]E7080 in the MATE1-expressing cells. These results indicated that E7080 was not a substrate of MATE1.

## -MATE 2

In the absence of cimetidine, the uptakes of [ 14 C]E7080 in the MATE2-K-expressing cells  after incubation for 1, 2, and 5 minutes were 38.8, 41.4, and 50.5 μL/mg protein, respectively; those in the control cells were 41.1, 43.1, and 55.9 μL/mg protein, respectively. In the presence of cimetidine (100 μmol/L), the uptakes  of  [ 14 C]E7080 in  the  MATE2-K-expressing  cells  after  incubation  for  1,  2,  and  5  minutes  were 40.4, 43.2, and 52.2 μL/mg protein, respectively; those in the control cells were 40.6, 42.4, and 55.8 μL/mg protein, respectively.

The uptakes of [ 14 C]E7080 in the MATE2-K-expressing cells after incubation for 1, 2, and 5 minutes were comparable  to  those  in  the  control  cells.  In  addition,  cimetidine,  a  typical  MATE2-K  inhibitor,  did  not inhibit the uptake of [ 14 C]E7080 in the MATE2-K-expressing cells. These results indicated that E7080 was not a substrate of MATE2-K.

<div style=\"page-break-after: always\"></div>

Table 17: [ 14 C]E7080 and [ 14 C]Metformin Uptake into MATE2-K-expressing HEK293 Cells and Control Cells

| Compound       | Typical    | Concentration of typical inhibitor   | Incubation time (min)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | % of control (%)   |
|----------------|------------|--------------------------------------|-------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------|
|                | inhibitor  | (μmol/L)                             |                         | Control                          | Control                          | MATE2-K                          | MATE2-K                          |                    |
| [4C]E7080      | Cimetidine | 0                                    | 1                       |                                  | 41.1 ± 2.0                       | 38.8 ± 3.1                       |                                  |                    |
| (1 μmol/L)     |            |                                      | 2                       | 43.1                             | ± 1.9                            | 41.4                             | ±3.7                             |                    |
|                |            |                                      | 5                       | 55.9                             | ± 8.4                            | 50.5                             | ±5.0                             |                    |
|                | Cimetidine | 100                                  | 1                       | 40.6                             | ±0.4                             | 40.4                             | 4±1.7                            |                    |
|                |            |                                      | 2                       | 42.4                             | ±3.8                             | 43.2                             | ±4.4                             |                    |
|                |            |                                      | 5                       | 55.8                             | ±8.2                             | 52.2                             | ± 4.9                            |                    |
| [14C]Metformin | Cimetidine | 0                                    | 5                       | 0.952                            | ± 0.126                          | 13.2                             | ±0.8                             | 100.0              |
| (10 μmol/L)    |            | 100                                  | 5                       |                                  | 0.442±0.048                      | 3.88                             | 3±0.22                           | 28.1               |

Each value represents the mean ± SD of three samples.

-: % of control was not evaluated because E7080 was judged not to be a substrate for MATE2-K.

## Inhibitory effect

Inhibitory  effects  of  E7080  on  MATE1  and  MATE2-K  were  also  assessed  using  the  each  transporterexpressing cells and their control cells. The uptake volumes of [14C]metformin in MATE1- or MATE2-Kexpressing cells in the absence of inhibitors were higher than those in the control cells. In the presence of the  typical  inhibitors,  cimetidine  (10  μmol/L  and  100  μmol/L  for  MATE1  and  MATE2-K),  the  uptake volumes of [14C]metformin into MATE1- or MATE2-K-expressing cells decreased to 13.1% and 28.1% of control, respectively.

E7080 inhibited MATE1 with the IC50 value of 6.31 μmol/L. For MATE2-K, E7080 showed slight inhibition (87.3% or more of control, IC50 &gt; 30 μmol/L).

Table 18: Inhibitory Effect of E7080 on MATE1 mediated Uptake of [14C]Metformin into HEK293 Cells

| Compound       | Additive   | Concentration of   | Uptake volume (μL/mg protein)   | Uptake volume (μL/mg protein)   | Uptake volume (μL/mg protein)   | Uptake volume (μL/mg protein)   | Uptake volume (μL/mg protein)   | Uptake volume (μL/mg protein)   | % of        |
|----------------|------------|--------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------|
|                |            | additive (μumol/L) | Control                         | Control                         | Control                         | MATE1                           | MATE1                           | MATE1                           | control (%) |
| [14C]Metformin | E7080      | 0                  | 1.19                            | 士                               | 0.06                            | 37.3                            | 干                               | 1.8                             | 100.0       |
| (10 μmol/L)    |            | 0.1                | 0.804                           | 干                               | 0.069                           | 32.5                            | 士                               | 1.6                             | 87.8        |
|                |            | 0.3                | 1.21                            | 士                               | 0.08                            | 36.8                            | ±                               | 1.7                             | 98.6        |
|                |            | 1                  | 0.745                           | 士                               | 0.155                           | 29.9                            | ±                               | 2.0                             | 80.7        |
|                |            | 3                  | 0.980                           | 干                               | 0.010                           | 26.8                            | 士                               | 1.0                             | 71.5        |
|                |            | 10                 | 0.550                           | 干                               | 0.011                           | 12.4                            | 士                               | 0.5                             | 32.8        |
|                |            | 30                 | 0.603                           | 干                               | 0.031                           | 10.1                            | 干                               | 0.2                             | 26.3        |
|                | Cimetidine | 10                 | 0.466                           | 干                               | 0.044                           | 4.95                            | 干                               | 0.03                            | 12.4        |

Each uptake volume represents the mean ± SD of three samples.

Incubation time was 5 minutes

<div style=\"page-break-after: always\"></div>

Table 19: Inhibitory Effect of E7080 on MATE2-K mediated Uptake of [14C]Metformin into HEK293 Cells

| Compound       | Additive   | Concentration of   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | Uptake volume (μuL/mg protein)   | % of        |
|----------------|------------|--------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|-------------|
|                |            | additive (μumol/L) | Control                          | Control                          | Control                          | MATE2-K                          | MATE2-K                          | control (%) |
| [14C]Metformin | E7080      | 0                  | 1.20                             | 干                                | 0.09                             | 17.3                             | 干 0.3                            | 100.0       |
| (10 μmol/L)    |            | 0.1                | 0.968                            | 士                                | 0.089                            | 18.6                             | 干 0.9                            | 109.5       |
|                |            | 0.3                | 1.22                             | 士                                | 0.15                             | 17.1                             | 0.8                              | 98.6        |
|                |            | 1                  | 0.890                            | 士                                | 0.062                            | 20.0                             | 士 1.1                            | 118.7       |
|                |            | 3                  | 0.960                            | 干                                | 0.063                            | 18.6                             | 士 1.2                            | 109.6       |
|                |            | 10                 | 0.658                            | 士                                | 0.023                            | 17.7                             | 士 1.4                            | 105.9       |
|                |            | 30                 | 0.549                            | 干                                | 0.037                            | 14.6                             | 干 2.2                            | 87.3        |
|                | Cimetidine | 100                | 0.488                            | 干                                | 0.054                            | 5.04                             | 干 0.26                           | 28.3        |

Each uptake volume represents the mean ± SD of three samples.

Incubation time was 5 minutes

## Target population

## Study E7080-J081-202 - Phase 1/2 Study of E7080 in Patients with Advanced Hepatocellular Carcinoma (HCC)

Primary  objective:  To  determine  the  MTD  as  defined  by  the  dose  limiting  toxicity  (DLT)  of  lenvatinib administered continuously once a day (QD) as 4 week cycles in subjects with advanced HCC and hepatic function of CP scores of 5-6 or 7-8. Secondary objectives included evaluating the safety and tolerability of lenvatinib, determining the PK profile of lenvatinib as well as determining the recommended dose for future studies, evaluating the antitumour efficacy and exploring the pharmacodynamic (PD) markers of lenvatinib.

Serial blood samples were collected at predose and 0.5, 1, 2, 4, 6, 8, and 24 hours after the first dose on Day 1 of Cycle 1, at predose and 0.5, 1, 2, 4, 6, 8, and 24 hours after repeated dose on Day 15 of Cycle 1, and at predose on Days 8 and Days 22 of Cycle 1.

Lenvatinib was administered on an empty stomach or at least 1 hour after eating. Otherwise, lenvatinib was administered under fasting conditions on Day 1 and Day 15 of Cycle 1 to avoid a possible food effect on PK analysis.

Mean ± standard deviation (SD) plasma concentration-time curves of lenvatinib after first dose (Cycle 1 Day 1) in Group 1 (Child-Pugh score 5, 6) and Group 2 (Child-Pugh score 7, 8) are presented on a semilog scale in the figures below. Analogous mean ± SD plasma concentration-time curves of lenvatinib after multiple doses (Cycle 1 Day 15) in group 1 and Group 2 are presented on a semi-log scale in the figures below as well.

<div style=\"page-break-after: always\"></div>

<!-- image -->

PK analysis set: (N=9). Data for 12 mg (n=6), and for 16 mg (n=5) is shown.

Figure 6: Mean ± standard deviation (SD) plasma concentration-time curves of lenvatinib after first dose (Cycle 1 Day 1) in Group 1 (Child-Pugh score 5,6)

<!-- image -->

PK analysis set: (N=9). Data for 12 mg (n=6), and for 16 mg (n=5) is shown.

Figure 7: Mean ± standard deviation (SD) plasma concentration-time curves of lenvatinib after first dose (Cycle 1 Day 1) in Group 2 (Child-Pugh score 7,8)

<!-- image -->

PK analysis set: (N=8). Data for 12 mg (n=6), and for 16mg (n=2) is shown.

Figure 8: Mean ± standard deviation (SD) plasma concentration-time curves of lenvatinib after first dose (Cycle 1 Day 15) in Group 1 (Child-Pugh score 5,6)

<div style=\"page-break-after: always\"></div>

<!-- image -->

PK analysis set: (N=8). Data for 12 mg (n=6), and for 16mg (n=2) is shown.

Figure 9: Mean ± standard deviation (SD) plasma concentration-time curves of lenvatinib after first dose (Cycle 1 Day 15) in Group 2 (Child-Pugh score 7,8)

Table 20: Summary of PK parameters of lenvatinib in Group 1 (Child-Pugh score 5,6) - Cycle 1 Day 1 - PK analysis set

|                           | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|---------------------------|-------------------------|-------------------------|
| Pharmacokinetie Parameter | 11mg QD (n=6)           | 16mgQD (n-)             |
| Cm(ngmL)                  | 212± 70.8               | 344 ±166                |
| ()                        | 2.000 (0.97-5.95)       | 1.970 (0.97-4.00)       |
| AUCpan (nglh/mL)          | 2020 ± 170              | 3280± 961               |

Data ane shown as moan ± standard deviation except ti for a, medinn (minimim - maximum) is shown.

AUCoun=anea underthe concenhation-time cuve fom zero time to 24h, Cm= maximum obseved concenhation, (n = tine at which the highest dng coneenhation cccun, QD = once daily.

Table 21: Summary of PK parameters of lenvatinib in Group 2 (Child-Pugh score 7,8) - Cycle 1 Day 1 - PK analysis set

|                           | Lenvatinib Dose Group   | Lenvatinib Dose Group   |
|---------------------------|-------------------------|-------------------------|
| Pharmacokinetie Parameter | 8mgQD (μ=6)             | 1mgQD (n=5)             |
| Cn (ng/mL)                | 146 ± 56.9              | 254 ± 169               |
| (b)                       | 2.015 (0.50-3.93)       | 2.000 (1.00 -3.98)      |
| AUCqu (ngh/mL)            | 1250 ± 399              | 2140 ± 1030             |

Data ae shown as mean ±standard deviation except t: for tm, median (minimum  maximum) is shown.

AUCoxny = area under the coneenhation-time cwve fom zero time to 24h, Cm = maximum obsered eoncentation, lon

time at which the highest drug concentation occus, QD = once daily.

<div style=\"page-break-after: always\"></div>

Table 22: Summary of PK parameters of lenvatinib in Group 1 (Child-Pugh score 5,6) - Cycle 1 Day 15 - PK analysis set

|                           | LenvatinibDote Group   | LenvatinibDote Group   |
|---------------------------|------------------------|------------------------|
| Pharmacokinetie Parameter | 11QD (n=5)             | 16 mg QD (n=2)         |
| Cumn (ng/mL)              | 346 ± 75.4             | 402                    |
| (ng/mL)                   | 43.1± 21.7             | 84.6                   |
| Cun(ng/mL)                | 130± 23.5              | 213                    |
| mn (b)                    | 1.950 (1.00 - 3.98)    | 3.915 (3.83 - 4.00)    |
| AUC (ngh/mL)              | 3120 ± 566             | 5110                   |
| R(C-)                     | 1.67±0.645             | 1.64                   |
| R_(AUO)                   | 1.54±0.290             | 1.73                   |

Data are shown as mean ± sthndard deviation except tumn: for tamn, median (minimum = maximum) is shown Last sampling time point is 24 hours aher adminishation. AUC,oa- anma under the concenhation-timn curve ower the dosing interval on multple dosing. Can = average steady. stale concentration, Cun maximum observed concentation at steady-shate, Cauh  mininum obsarved concentation at steady-state, R = accumulation index, taumn = time at which the highest drug concentration occus at steady-state. R\\_(C) =Cm/C R(AUC)=AUC-/AUCpm QD =one daily.

Table 23: Summary of PK parameters of lenvatinib in Group 2 (Child-Pugh score 7,8) - Cycle 1 Day 15 - PK analysis set

|                           | LenvatinibDote Group   | LenvatinibDote Group   |
|---------------------------|------------------------|------------------------|
| Pharmncokinetie Parameter | $mgQD (n=6)            | 1mgQD (n=2)            |
| m (ng/mL)                 | 167 ± 40.4             | 349                    |
| Ca (ng/mL)                | 29.9 ± 13.4            | 64.0                   |
| Ca(ng/mL)                 | 73.8 ± 14.2            | 165                    |
| un (h)                    | 2.025 (1.98 - 4.02)    | 1.995 (1.97 - 2.02)    |
| AUC(ngh/mL)               | 1770 ±340              | 3960                   |
| R(C)                      | 1.23±0.315             | 1.91                   |
| R(AUQ)                    | 1.49±0.385             | 2.11                   |

AUCn area under the concentration-time curve over the dosing interval on multiple dosing. Cuu  average steady stbte coneenhation, Cumrmaximum observed coneenhation at steady-state, Cuml minimum observnd coneenbation al sleady-stale, R,  accuoulation index, Lumn  tiwe at which the highest dug concentation ocewrs at steadyshte.R(C...)= Cnmn/C: R\\_(AUC) =AUCmu/AUCa. OD=onee daily.

Data ane sbown as mean ±standard deviation excepttur: for tuen, median (minimum - maximum) is shown. Lasl ampling time point is 24 boun afer adminishation.

## Summary of the relevant PK information from study 202:

- -Maximum  plasma  concentration  of  lenvatinib  was  typically  observed  2  hours  after  single  and multiple doses.
- -In general, exposure, as measured by Cmax, AUC(0-24h), AUC(0-t), Css,max, and AUC(0-τ), for lenvatinib appeared to increase with increasing doses.
- -Plasma  lenvatinib  concentration  accumulated  after  repeated  dosing  with  a  mean  accumulation index  (Rac)  of  AUC(0-24h)  and  Cmax  ranging  from  1.23  to  2.11.The  pharmacokinetics  of lenvatinib did not appear to change when evaluated by Child-Pugh score in subjects with HCC.

## Study E7080-G000-304

In  study  304,  pharmacokinetic samples were collected from all subjects who took lenvatinib. Exposure parameters such as maximum concentration and area under the concentration × time curve (AUC) were derived from posterior estimates of the PK parameters from the final population PK model.

- Subjects with HCC had a 13.2% lower lenvatinib oral clearance than subjects with other cancer types, including DTC.
- Lenvatinib PK parameters were affected by body weight with both clearance and volume parameters increasing with increasing body weight. This was associated with an increase in lenvatinib exposure in

<div style=\"page-break-after: always\"></div>

subjects with low body weight.

● Lenvatinib exposure was comparable between the 8-mg starting dose group with body weight &lt;60 kg and the 12-mg dose group with body weight ≥ 60 kg. This supports the 8-mg and 12-mg starting doses used in the lower and higher weight groups in Study 304.

● There were no differences in lenvatinib oral clearance or in AUC at steady-state values among Western, Asian, Chinese, and Japanese HCC populations in Study 304.

## POP PK modelling

Two popPK analysis analyses supporting the HCC submission was performed and two different reports submitted: POP PK and PK/PD CPMS-E7080-005R-V1 (including data from study 202) and POP PK report CPMS-E7080-011R-V1 (including data from study 202 and from study 304).

## Report CPMS-E7080-005R-V1

The primary objectives of the population PK analysis were:

- To describe the PK profile of lenvatinib in subjects with hepatocellular carcinoma and compare the PK with other cancer sub-types

- To identify covariates that explain between subject variability in lenvatinib PK.

The population PK analysis for lenvatinib was based on pooled data collected from 8 Phase 1 studies in healthy subjects (001-008), 4 Phase 1 MTD studies in subjects with solid tumours (101,102, 103 and 105), and study 202 in subjects with HCC.

Model-based analyses consisted of a population PK model for lenvatinib. The models was developed in NONMEM 7.2. Model building and covariate assessments were conducted using standard methods.

The final population PK model was used to derive individual PK parameters and lenvatinib exposures (AUC based on the starting dose and steady state Cmin), which were then incorporated into the PK/PD datasets to be used in the subsequent PK/PD analyses.

The PK population for lenvatinib from study 202 consisted of 65 HCC subjects, while the PK population from 4 Phase 1 MTD studies (101,102, 103 and 105) consisted of 155 subjects with solid tumours. HCC subjects in study 202 had lower body weights and lower liver function values (eg. higher ALP) than subjects with other tumour types.

The PK of lenvatinib was best described by a 3-compartment model with elimination from the central compartment.

The parameter estimates of the final PK model for lenvatinib are presented below:

<div style=\"page-break-after: always\"></div>

Table 24: final population pharmacokinetic parameter estimates of lenvatinib

<!-- image -->

Report CPMS-E7080-011R-V1

The objectives of the population pharmacokinetics (PK) analysis of lenvatinib monotherapy on pooled data from multiple studies, including studies 304 and 202 were:

- -To characterize the PK of lenvatinib in subjects with hepatocellular carcinoma (HCC) and compare to that in healthy subjects and subjects with other types of cancer
- -Identify covariates that explain between-subject variability in lenvatinib PK.Population PK analysis of lenvatinib was based on PK data pooled from the 13 studies. Brief descriptions of the studies included are presented in the table below:

<div style=\"page-break-after: always\"></div>

Table 25: brief description of studies with Pk sampling included in population PK analysis

<!-- image -->

| Study                                                                                                                    | Dose Range and Regimen                                                                                                   | N                                                                                                                        | Fornulation                                                                                                              | Subjeets                                                                                                                 | Pharmacolinetie sampling                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| E70S0-G000-304                                                                                                           | 12 mg (if baseline body weight 2 60 kg)or 8 mg (if baseline body                                                         | 468                                                                                                                      | Capsule                                                                                                                  | HCC                                                                                                                      | Day I of Cycle 1 and 2: Pre-dose, and post- dose on 0.5-4 h and 6-10 h, Cycle 1 Day 15: Pre-dose and 2-12 h post dose Cmun: Cycle 3-Cvcle 6/Davl          |
|                                                                                                                          | weight ≤ 60 kg) QD                                                                                                       |                                                                                                                          |                                                                                                                          |                                                                                                                          |                                                                                                                                                           |
| E7080-J081-202                                                                                                           | Phav 1: 8 - 16 mg QD conlinuous Phare 2: 12 mg QD continuous                                                             | 20 46                                                                                                                    | Tablet                                                                                                                   | HCC                                                                                                                      | Day 1 amd15 ofCyele 1:0.5, 1.2.4. 6.8 and 24 h post dose Cuoyh: Days 1, 8, 15 and 22 of Cyele 1 C: Days 1, 8, 15 and 22 ofCycle 1 Dhys 1 of Cycle 2 and 3 |
| E70S0-G000-303                                                                                                           | 24 mg QD continuous                                                                                                      | 260                                                                                                                      | Capsule                                                                                                                  | DTC                                                                                                                      | Day 1 and 15 of Cycle 1: Pre-dose, and post- dose on 0.5-4 h and 6-10 h, Cycle 2 Day 1: Pre-dose and 2-12 h post dose Cuoagb: Cycle 3-Cycle 6/Dnyl        |
| E7080-E014-101                                                                                                           | 0.2-32mg QD continuous                                                                                                   | 66                                                                                                                       | Tablet                                                                                                                   | Tumors Solid                                                                                                             | Day 1 of Cycle 1 and Cycle 2: 0.25, 0.5, 1, 1.5,2, 2.5,3,4, 6, and 24 h post dose Cuoh: Days 1. 8. and 15 of Cyele 1                                      |
| E7080-A001-102                                                                                                           | Schedule I:0.1- 3.2mgBIDx 7d/14d Sehedule 2: 3.2- 12 mg BD continuous:                                                   | 62                                                                                                                       | Tablet                                                                                                                   | Solid Tumors                                                                                                             | Day 1 of Cycle 1 nnd Cycle 2: 0.25,0.5, 1, 1.5,2,2.5,3,4, 6, nd 24 h post dosc Cu∞h: Days 8, 15 and 22 ofCycle 1                                          |
| E7080-A001-102                                                                                                           | 10 mg BD continuous                                                                                                      | 62                                                                                                                       | Tablet                                                                                                                   | Melanoma                                                                                                                 | Day 1 of Cycle 1 nnd Cycle 2: 0.25,0.5, 1, 1.5,2,2.5,3,4, 6, nd 24 h post dosc Cu∞h: Days 8, 15 and 22 ofCycle 1                                          |
| E7080-J081-103                                                                                                           | 0.5 -20 mg BID x14d/2ld                                                                                                  | 18                                                                                                                       | Tablet                                                                                                                   | Tumors Solid                                                                                                             | 1,2,3,5,6,8,12,24,48,96,nnd 168 hpost dose on Dnyl of Cycle 0 nnd Day 14 of Cuut: Days 5, 8and 11 of Cyele 1, Day 8 Cyclel ofCycle 2                      |
| E7080-J081-105                                                                                                           | 20 and 24 mg QD continuous                                                                                               | 6                                                                                                                        | Capsule                                                                                                                  | Solid                                                                                                                    | Day 1 and 15 of Cyele 1: 1, 2. 4, 8, and 24 h post dose Cmyh: Dayua 8, 15 of Cyele 1, Day 15 of Cyele 2                                                   |
| E7080-A001-001                                                                                                           | 10 mg                                                                                                                    | 20                                                                                                                       | capsule Thbletl/                                                                                                         | volunteer Healthy                                                                                                        | Pre-dose mnd at 1, 2.3,4. 8, 16, 24,48, 72. 96,120, 144, md 168 h post-dose                                                                               |
| E7080-A001-002                                                                                                           | 32 mg                                                                                                                    | 51                                                                                                                       | Capsule                                                                                                                  | Healthy volunteers                                                                                                       | Prc-dowe mmdmt 0.5, 1.2,3.4,5.6,8, 12, 24, 48, 72, and96 h post-dose                                                                                      |
| E7080-A001-003                                                                                                           | 10 mg                                                                                                                    | 16                                                                                                                       | Capsule                                                                                                                  | volunteers Henlthy                                                                                                       | Pre-dose mnd nt 1, 2.3, 4, 8, 12, 16, 24,48, 72, 96, 120, 144, mnd 168 h post-dose                                                                        |
| E7080-A001-005                                                                                                           | 24 mg                                                                                                                    | 26                                                                                                                       | Capsule                                                                                                                  | Healthy volunteers nnd renal impnime nt                                                                                  | Pre-dose mnd nt 0.5, 1.2,3,4, 8, 12, 16, 24, 48, 72, 96, 120, 144, mmd 168 h post-dose                                                                    |
| E7080-A001-006                                                                                                           | 5 and 10 mg                                                                                                              | 26                                                                                                                       | Capsule                                                                                                                  | Healthy volunteers and hepatic impairme nt                                                                               | Pre-dose mndnt 0.5,1.2,3,4,8,12,16,24 48,72,96,120, 144, 168,240,288,mnd336 h post-dose                                                                   |
| E70S0-A001-008                                                                                                           | 10mg                                                                                                                     | 60                                                                                                                       | Capsule                                                                                                                  | Healthy volmteers                                                                                                        | Pre-dove and at 1, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, and 120 h post-dose                                                                                |
| DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset | DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset | DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset | DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset | DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset | DTC: differentiated thyroid cancer Subjects who received a starting dose of3.2 mg and higher Were included in PK dataset                                  |

Differences in the PK of lenvatinib in subjects with HCC and subjects with other tumour type were tested.

The final population PK model for lenvatinib was a 3-compartment model with simultaneous first and zero order absorption and linear elimination from the central compartment parameterized for CL/F, V1/F, Q2/F, V2/F, Q3/F, V3/F, Ka, D1 and F1. Inter-individual variability (IIV) was estimated on all parameters except Q2/F and Q3/F. A combined additive and proportional error for time after dose (TAD) ≤2 h and separate proportional errors for Phase 1 clinical pharmacology studies and cancer patient studies was used for estimation of residual variability. The final PK model for lenvatinib included body weight effect as an allometric constant on both clearance and volume parameters, whereby both parameters increased with increasing body weight. Lenvatinib CL/F decreased by 10.2% with albumin levels below 30 g/L and decreased by 8.6% with ALP above upper limit of normal (ULN). The HCC population was found to have a

<div style=\"page-break-after: always\"></div>

13.2% lower lenvatinib CL/F compared to patients with other cancer types, and a 24.5% lower lenvatinib CL/F compared to healthy subjects. Population PK parameter estimates are presented in the table below.

Table 26: population pharmacokinetic parameter estimates of lenvatinib - final model

|                                                                                     | NONNIEM Esdmates                                                                    | NONNIEM Esdmates                                                                    | NONNIEM Esdmates                                                                    |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Parameter                                                                           | Point Estimate                                                                      | %RSE                                                                                | 95% Confidence Interval                                                             |
| CL/F [L/h]=*(WGT/70)7+ DDU-O INHB*O ALB+O AP+O HV*O, PPH INDU IMHIB ALLB ALP HV SOH | CL/F [L/h]=*(WGT/70)7+ DDU-O INHB*O ALB+O AP+O HV*O, PPH INDU IMHIB ALLB ALP HV SOH | CL/F [L/h]=*(WGT/70)7+ DDU-O INHB*O ALB+O AP+O HV*O, PPH INDU IMHIB ALLB ALP HV SOH | CL/F [L/h]=*(WGT/70)7+ DDU-O INHB*O ALB+O AP+O HV*O, PPH INDU IMHIB ALLB ALP HV SOH |
| Basal CL/F in L/h [o]                                                               | 6.25                                                                                | 1.81                                                                                | 6.03-6.47                                                                           |
| Effect of inducer on CL/F [O MDul                                                   | 1.30 FIX                                                                            |                                                                                     |                                                                                     |
| Effect of inhibitor on CL/F [N]                                                     | 0.922 FIX                                                                           |                                                                                     |                                                                                     |
| Effect of ALB(<30) on CL/F []                                                       | 0.898                                                                               | 1.85                                                                                | 0.865-0.931                                                                         |
| Effect of ALP (>ULN) on CLF [Ap]                                                    | 0.914                                                                               | 0.0941                                                                              | 0.912-0.916                                                                         |
| Effect of Healthy population on CL F [9v]                                           | 1.15                                                                                | 3.07                                                                                | 1.08- 1.22                                                                          |
| Enfect of HCC population on CL/F [Ogcc]                                             | 0.868                                                                               | 2.15                                                                                | 0.831-0.905                                                                         |
| VI/F [L]=O*WGT/70                                                                   |                                                                                     |                                                                                     |                                                                                     |
| Basal Vi/F in L [O]                                                                 | 48.7                                                                                | 0.232                                                                               | 48.5-48.9                                                                           |
| V2/F[L]-O*WGT/70                                                                    |                                                                                     |                                                                                     |                                                                                     |
| Basal V2/F in L [0]                                                                 | 25.4                                                                                | 4.33                                                                                | 23.2-27.6                                                                           |
| V3/F[L]-O*WGT/70                                                                    |                                                                                     |                                                                                     |                                                                                     |
| Basai V3/F in L [Oy]                                                                | 37.1 FIX                                                                            |                                                                                     |                                                                                     |
| Q1/F[L/h]-O*(WGT/70) 520                                                            |                                                                                     |                                                                                     |                                                                                     |
| Basai Qi/F in Lh [0]                                                                | 3.25                                                                                | 3.51                                                                                | 3.03-3.47                                                                           |
| Q2/F [L/h]-O*(WGT/70)                                                               |                                                                                     |                                                                                     |                                                                                     |
| Basal Q2/F in L/h [0]                                                               | 0.798                                                                               | 876                                                                                 | 0.747-0.849                                                                         |
| Ka [1/h] -Og                                                                        |                                                                                     |                                                                                     |                                                                                     |
| Basal Ka in 1/h [Om]                                                                | 1.02 FIX                                                                            |                                                                                     |                                                                                     |
| D1[b]=0                                                                             |                                                                                     |                                                                                     |                                                                                     |
| Basal Dl inh [0oi]                                                                  | 1.22 FIX                                                                            |                                                                                     |                                                                                     |
| F1=01                                                                               |                                                                                     |                                                                                     |                                                                                     |
| Relative bioavailability of capsule vs tablet formulation [O]                       | 0.9FIX                                                                              |                                                                                     |                                                                                     |
| Inter-individual variability (%CV)                                                  |                                                                                     |                                                                                     |                                                                                     |
| CL/F                                                                                | 25.4                                                                                | 5.53                                                                                |                                                                                     |
| V1/F                                                                                | 28.3                                                                                | 10.2                                                                                | 一                                                                                   |
| V2/F                                                                                | 43.0                                                                                | 14.0                                                                                |                                                                                     |
| V3/F                                                                                | 32.4                                                                                | 11.3                                                                                |                                                                                     |
| Ka                                                                                  | 51.7                                                                                | 13.4                                                                                |                                                                                     |
| D1                                                                                  | 93.6                                                                                | 6.34                                                                                | 一                                                                                   |
| F1                                                                                  | 26.2                                                                                | 7.19                                                                                |                                                                                     |
| Residual variability                                                                |                                                                                     |                                                                                     |                                                                                     |
| Proportional (%CV) (Clin pharm studies)                                             | 17.0                                                                                | 0.817                                                                               |                                                                                     |
| Proportional (%CV) (Patients studies)                                               | 36.3                                                                                | 1.40                                                                                |                                                                                     |
| Proportional (%CV) (TAD≤2 h)                                                        | 49.0                                                                                | 3.57                                                                                |                                                                                     |
| Additional (ng/mL) (TAD ≤ 2 h)                                                      | 6.65                                                                                | 16.8                                                                                |                                                                                     |

<!-- image -->

<div style=\"page-break-after: always\"></div>

The final PK model for lenvatinib included body-weight effect as an allometric constant on both clearance and volume parameters, whereby both parameters increased with increasing body weight. The decrease in CL/F in subjects with low body weight results in an increase in lenvatinib AUC. Based on the individual lenvatinib AUC at steady state for subjects with HCC in study 304, the median value and range of AUC are comparable between the group of starting dose of 8 mg for body weight &lt; 60 kg and 12 mg for body weight ≥ 60 kg in study 304, which supports the starting dose of 8 mg for body weight &lt; 60 kg.

The final PK model for lenvatinib also included covariates related to liver function; CL/F decreased by 8.6% with ALP &gt; the upper limit of normal, and by 10.2% with albumin levels below 30 g/L. HCC subjects had a 13.2% lower lenvatinib CL/F than subjects with other cancer types, including DTC.

## 2.3.3. Pharmacodynamics

## Mechanism of action

No new data regarding mechanism of action has been submitted with this application.

## Primary and secondary pharmacology

## Biomarker analysis

Exploratory biomarker analyses were performed on blood and tumour tissue samples in the Biomarker Analysis Set from Study 304.

Archival tumour tissue and blood samples were collected pretreatment and at specified time points. The BM analysis set (BAS; n = 119) included pts who provided both archival tissue and serum samples. Serum samples from 114 pts were analyzed at baseline and over time with ELISA or chemiluminescence for VEGF, ANG2, FGF21, FGF23, and PIVKA-II. Gene-expression profiling was performed on tissue samples with nCounter® (NanoString). Results from BM analyses were correlated with OS.

Gene-expression analysis was performed in 58 pts (34 lenvatinib, 24 sorafenib).

Serum BM and gene expression levels appear to correlate with outcomes in the BAS. The correlation analyses for serum biomarkers and gene expression were limited by the small number of samples, as well as the observed imbalances between the Full Analysis Set (FAS) and the biomarker analysis subset. Therefore, no valid conclusion is possible to correlate the results of the biomarker analyses with the clinical outcomes of the overall study population as well as between treatment arms at this point.

## 2.3.4. PK/PD modelling

## Report CPMS-E7080-005R-V1

In addition to the population PK analysis performed (described above) , a PK/PD analysis for safety for Study 202 was included in this report. The objectives of this analysis were:

- -To  describe  the  relationship  between  lenvatinib  exposure  and  longitudinal  platelet  profile  in patients with hepatocellular carcinoma
- -To  explore  the  relationship  between  lenvatinib  exposure  and  the  occurrence  of  treatment emergent adverse events (TEAE) leading to study drug withdrawal or dose reduction for Phase 2 part of Study 202.
- -To explore the relationship between lenvatinib exposure and occurrence of the following TEAE for Phase  2 part of Study  202:  Hypertension (During Cycle 1), proteinuria, palmar-plantar

<div style=\"page-break-after: always\"></div>

erythrodysaesthesia  syndrome  (PPES),  Fatigue,  decreased  appetite,  diarrhoea,  nausea  and hepatic encephalopathy

The objectives of the population PK/PD analysis for efficacy for Phase 2 part of Study 202 were:

- -To  explore  the  relationship  between  lenvatinib  exposure  and  efficacy  endpoints  (objective response rate (ORR), disease control rate (DCR), time to progression (TTP), overall survival (OS), progression free survival (PFS) and maximum tumour shrinkage in subjects with hepatocellular carcinoma

The objectives of the PK/PD analyses for biomarkers of Study 202 were:

## Phase 1 part

- -To  explore  the  relationship  between  lenvatinib  exposure  and  the  change  from  baseline  in  the following serum biomarkers: VEGF, SDF-1α, SCF, IL-6, IL-8, IL-10, total CEP, total CEC, c-kit (-) CEP, c-kit (+) CEP, c-kit (-) CEC and c-kit (+) CEP

## Phase 2 part

- -To  explore  the  relationship  between  lenvatinib  exposure  and  the  change  from  baseline  in  the following  serum  biomarkers:  soluble  VEGFR1,  soluble  VEGFR2,  soluble  VEGFR3,  VEGFA,  PGF, angiopoietin-2, soluble Tie-2, eotaxin, SDF-1α, G-CSF, IP-10, IL-8, RANTES and soluble CD40L.

The final population PK model was used to derive individual PK parameters and lenvatinib exposures (AUC based on the starting dose and steady state Cmin), which were then incorporated into the PK/PD datasets to be used in the subsequent PK/PD analyses.

Graphical analyses were performed to assess the relationship between AE and lenvatinib exposure for the occurrence of CTCAE grade ≥2 hypertension (During Cycle 1), proteinuria, palmar-plantar erythrodysaesthesia syndrome (PPES), fatigue, decreased appetite, diarrhoea, CTCAE grade ≥1 nausea and hepatic encephalopathy.

The population used for the PK/PD analysis of the platelet count consisted of a total of 65 subjects from study  202  only.  The  platelet  count  data  were  best  described  by  an  eight-compartment  PK/PD  lifespan model  including  four  PK  compartments  and  four  PD  compartments  parameterized  for  a  zero-order production rate constant (Kin), first-order transition rate constant (KT), and slope coefficient of lenvatinib plasma  concentration  (SLOP)  where  model  predicted  lenvatinib  concentrations  reduced  the  platelet proliferation  rate or  induced  cell  loss.  The  elimination  rate  constant  (Kdeg) was  defined  using  baseline platelet count (BASE) as Kdeg = Kin/BASE. Exponential IIV was estimated for BASE, KT and SLOP. The results from the covariate analysis indicated that the relationship between lenvatinib plasma concentration  and  platelet  count  change  in  study  202  was  independent  of  gender,  age,  body  weight, hepatic function markers, performance status, factor of carcinogenesis, portal vein involvement, previous systemic chemotherapy and surgery history.

: Parameter estimates of the PK/PD model for platelet count

<div style=\"page-break-after: always\"></div>

|                                                                | NONMIEM Estimates                  | NONMIEM Estimates                  | NONMIEM Estimates                  |
|----------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| Parameter                                                      | Point Estimate                     | 9RSE                               | 95% Confidence Interval            |
| Kin (*10/Lh)                                                   | 1.51                               | 19.5                               | 0.934- 2.09                        |
| SLOP of lenvatinib concentration effect (per 1 μg /mL) (mL/ug) | 3.50                               | 6.03                               | 3.09 -3.91                         |
| KT (h)                                                         | 0.0335                             | 6.03                               | 0.0295-0.0375                      |
| Inter-individual variability (%CV)                             | Inter-individual variability (%CV) | Inter-individual variability (%CV) | Inter-individual variability (%CV) |
| Kin                                                            | 0 Fix                              |                                    |                                    |
| BASE                                                           | 19.9                               | 22.9                               |                                    |
| SLOP                                                           | 33.5                               | 24.9                               |                                    |
| KT                                                             | 84.4                               | 23.4                               |                                    |
| Residual variability                                           | Residual variability               | Residual variability               | Residual variability               |
| Proportional (%C V)                                            | 19.0                               | 9.42                               |                                    |

<!-- image -->

In the phase 2 part of study 202, 21 patients (46.7 %) of PK/PD population experienced any treatment emergent adverse events (TEAE) leading to dose reduction or discontinuation during Cycle 1. The median AUC based on the starting dose of patients with early dose withdrawal or reduction was 2950 ng*h/mL, whereas the median AUC based on the starting dose of patients without early dose modification was 2050 ng*h/mL. The occurrence of TEAE leading to study drug withdrawal or dose reduction during Cycle 1 as a function of lenvatinib exposure was modeled with the logit function. The exposure parameters, AUC based on the starting dose and steady state Cmin, were tested for linear relationship. Adding lenvatinib AUC based on the starting dose as a linear function resulted in higher drop in OFV than that of Cmin. Adding lenvatinib  AUC  as  log-linear  and  Emax  functions  resulted  in  the  worse  OFV,  thus  adding  lenvatinib exposure as linear AUC was selected as the base model.

The effects of the following covariates were tested in the univariate analysis, separately both on intercept of experiencing TEAE leading to study drug withdrawal or dose reduction as well as for the effect each covariate on slope of lenvatinib effect: demographics (sex, body weight and age), liver function markers, ECOG performance status, Child-Pugh score, factor  of  carcinogenesis  (HBV  or  HCV  vs.  Others),  portal vein involvement, previous systemic chemotherapy, prior antihypertensives, and with/without surgery at the baseline.

The model parameters estimated for the final model are represented below.

Table 27: Final model parameter estimates for the logistic model for occurrence of TEAE leading to study drug withdrawal or dose reduction during cycle 1

| Parameter                                             | NONMEM Estimates   | NONMEM Estimates   | NONMEM Estimates   |
|-------------------------------------------------------|--------------------|--------------------|--------------------|
|                                                       | Point Estimate     | %RSE               | 95% CI             |
| f(x) =INT+SLP*AUC                                     |                    |                    |                    |
| INT: Intercept                                        | -4.71              | 29.3               | -7.41 - -2.01      |
| SLP: Slope of lenvatinib AUC effect (per 1000 ngh/mL) | 1.82               | 28.8               | 0.793 -2.85        |
| Odds ratio (per 1000 ngh /mL of AUC)                  | 6.17               |                    |                    |

The model predicted probability of TEAE leading to study drug withdrawal or dose reduction during Cycle 1 for HCC patients is shown in the figure below. The observed probability of TEAE leading to study drug withdrawal or dose reduction during Cycle 1 for lenvatinib AUC group are also plotted using median AUC

<div style=\"page-break-after: always\"></div>

of  each  quantile  AUC  group  (Q1:  1700,  Q2:  2120,  Q3:  2690,  Q4:  3550  ng∙h/mL).  The  probability increased with higher AUC.

PlotofModel-Predicted ProbabilityofTEAE LeadingtoStudyDrugWithdrawalorDoseReduction During Cycle 1 vs. Lenratinib AUC

Figure 10: Graphical relationship of lenvatinib exposure with time to TEAE leading to study drug withdrawal or dose reduction (study 202 Phase 2 part)

<!-- image -->

Graphical analysis suggested that lenvatinib exposures are higher in subjects experiencing CTCAE grade ≥2  palmar-plantar  erythrodysaesthesia  syndrome,  fatigue,  decreased  appetite,  diarrhoea  and  CTCAE grade ≥1 hepatic encephalopathy than those in subjects not experiencing these AEs.

Clear relationship was seen between the occurrence of TEAEs leading to dose reduction or discontinuation during Cycle 1 and body weight, whereby patients with low body weight experienced early dose reduction or  discontinuation,  and  this  can  be  explained  by  the  higher  lenvatinib  AUC  of  patients  with  low  body weight.

Therefore,  the  exploratory  assessment  for  the  adjustment  of  the  starting  dose  of  lenvatinib  by  body weight was performed in further clinical study for HCC.

ROC curve which was predicted from the developed logistic regression model indicated that the best cutoff value of lenvatinib AUC is 2430 ng*h/mL with 0.71 sensitivity and 0.71 specificity.

Within the range between 40 kg and 120 kg of body weight, the predicted AUC of subjects whose body weight were less than 60kg, are calculated between 1540 and 2050 ng·h/mL, and the predicted AUC of subjects whose body weight are 60kg and over, are calculated between

No  clear  relationship  between  the  efficacy  endpoints  (TTP,  PFS,  OS,  BOR,  ORR,  DCR  and  maximum tumour shrinkage) with lenvatinib AUC based on starting dose could be detected. Thus use of a lower starting dose (8 mg) in patients with body weights less than 60 mg is not expected to impact efficacy.

Clear trend of ratio change in each of the following serum biomarkers with lenvatinib concentration was observed: PGF and VEGFA increased with lenvatinib concentration and angiopoietin-2 and soluble VEGFR2 decreased with lenvatinib concentration, as shown in the figures below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## : Plot of ratio change (post dose/baseline) of PGF and VEGFA verus lenvatinib concentration (cycle 1 day 8 and day 15)

<!-- image -->

## : Plot of ratio change (post dose/baseline) of angiopoietin-2 and soluble VEGFR-2 verus lenvatinib concentration (cycle 1 day 8 and day 15)

No clear exposure relationships were found for soluble VEGFR1, soluble VEGFR3, soluble Tie-2, eotaxin, SDF-1α, G-CSF, IP-10, IL-8, RANTES and soluble CD40L.

## CPMS-E7080-011R-V1

The same approach as described above was implemented for exposure-response analysis with only data from study 304 been used.

<div style=\"page-break-after: always\"></div>

Exposure-Response Analysis for Overall Survival and Other Efficacy Variables

· After accounting for effects of baseline albumin, bilirubin, tumour size, Alpha-fetoprotein (AFP), ChildPugh  score,  macroscopic  portal  vein  invasion,  extrahepatic  spread  or  both,  no  exposure-response relationship for OS was observed in the multivariate Cox regression analysis within the exposure range of study 304.

· No exposure-response relationship for PFS and ORR was observed within the exposure range of study 304.

· In the absence of a relationship between % change in tumour size and lenvatinib exposure as well as the absence of data following placebo in Eisai-sponsored studies to accurately estimate tumour growth rate constant in HCC, or a published value, a PK/PD model for tumour size could not established.

Exposure-Response Analysis for Adverse Event

· Lenvatinib AUC at steady state based on the starting dose was a significant predictor for the occurrence of any grade of decreased appetite. The occurrence of any grade of decreased appetite increased with higher lenvatinib AUC. No covariates tested in this analysis affected the exposure-response relationship for the occurrence of decreased appetite.

·  For  hypertension,  proteinuria,  weight  decreased,  fatigue,  vomiting,  thrombocytopenia,  platelet  count decreased,  diarrhoea,  palmar-plantar  erythrodysaesthesia  syndrome  and  hepatic  encephalopathy,  no significant  relationship  between  lenvatinib  exposure  and  these  AEs  was  detected  within  the  exposure range of study 304.

· Lenvatinib AUC at steady state based on the starting dose was a significant predictor for the occurrence of AEs leading to lenvatinib dose reduction or interruption. The occurrence of AEs leading to lenvatinib dose reduction or interruption increased with higher lenvatinib AUC.

· Lower baseline AFP level was a significant predictor for the occurrence of AEs leading to lenvatinib dose reduction or interruption. Lower baseline AFP level was also associated with longer treatment duration confounding any interpretation of AFP levels and dose reductions or interruptions.

·  For  AEs  leading  to  lenvatinib  treatment  withdrawal,  no  significant  relationship  between  lenvatinib exposure and these AEs was detected within the exposure range of study 304.

Exposure-Response Analysis for Blood Pressure

· Systolic and diastolic blood pressure (BP) data were best described by an indirect response model with lenvatinib AUC at BP assessment affecting input rate constant for BP resulting in increased BP.

- No covariates tested in this analysis affected the exposure-response relationship for blood pressure.

· The model predicted increase in BP was small and not considered clinically important in the therapeutic exposure range for subjects with HCC.

## 2.3.5. Discussion on clinical pharmacology

Data from 21 studies were used to characterize the pharmacokinetics (PK) of lenvatinib. These included a Phase 1/2 dose finding study for subjects with HCC (Study E7080-J081-202) and an HCC Phase 3 safety and efficacy study (Study E7080-G000-304). The understanding of the pharmacokinetics of lenvatinib is broadened by the secondary objectives defined in the clinical studies 202 and 304, especially by means of the accompanying POP PK analysis provided.

From study 304, it was observed that subjects with HCC had a 13.2% lower lenvatinib oral clearance than subjects with other cancer types, including DTC. Lenvatinib PK parameters were affected by body weight

<div style=\"page-break-after: always\"></div>

with both clearance and volume parameters increasing with increasing body weight. This was associated with  an  increase  in  lenvatinib  exposure  in  subjects  with  low  body  weight.  Lenvatinib  exposure  was comparable between the 8-mg starting dose group with body weight &lt;60 kg and the 12-mg dose group with  body  weight  ≥60  kg.  The  8-mg  and  12-mg  starting  doses  used  in  the  lower  and  higher  weight groups in Study 304 are supported from a PK perspective.

In  HCC  studies  202  and  304,  subjects  with  Child-Pugh  class  A  and  B  were  included.  In  study  202,  no relationship  between  CP  score  and  the  PK  of  lenvatinib  was  observed  and  the  exposure  is  significantly decreased in moderate impaired patients with 8 mg QD compared to the exposure of mild and moderate impaired patients with 12 mg QD. In study 304, no PK analysis has been made with the subjects with child-Pugh B (score 7 or 8) since the enrolment of these subject was in fact a protocol deviation (n=3).

Patients ≥ 75 years,  of  white  race  or  female  sex  or  those  with  worse  baseline  hepatic  impairment (Child-Pugh A score of 6 compared to score of 5) appear to have reduced tolerability to lenvatinib.

The available data are insufficient to allow for a dosing recommendation for HCC patients with moderate hepatic  impairment  (Child-Pugh  B).  Lenvatinib  has  not  been  studied  in  patients  with  severe  hepatic imparement (Child-Pugh C) and is not recommended for use in these patients.

From  a  non-clinical/clinical  perspective,  the  4  additional  pharmacokinetics  studies  that  have  been completed (peaks in monkey plasma, protein binding in HLMs, reversibility of covalently bound lenvatinibrelated components and MATE inhibition and substrate) are adequately performed and address questions raised during the review of the original marketing application. Lenvatinib is not a substrate for MATE1 and MATE2-K and showed minimal or no inhibitory effect on MATE2-K and weakly inhibits MATE1.

In  addition  to  the  population  PK  (PopPK)  and  PK/PD  analyses  performed  for  the  original  lenvatinib submissions (reported in CPMS-E7080-007R) and the population PK and PK/PD analyses performed for the RCC submission (reported in CPMS-E7080- 008R), an analysis supporting the HCC submission was performed.

No dose adjustments are required on the basis of renal function in patients with mild or moderate renal impairment.  The available data do not allow for a dosing recommendation for patients with HCC and severe renal impairment (see SmPC section 4.2).

The level of lenvatinib protein binding is yet not considered to be known while the assessment of severe renal and hepatic impairment should be based on free fraction. To reply to this question, study 010 entitled \"A Multicenter Phase 0 Study In Healthy Subjects As Well As Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma To Assess In Vitro Lenvatinib Protein Binding\" will be submitted according to the timeline and is included in the RMP. Study 109 entitled 'drug-drug interaction to investigate the potential of lenvatinib for CYP3A4 inhibition/induction' is included in the RMP and should be submitted according to the timelines.

Based on the results of study E7080-A001-009, the lenvatinib capsules may be added without breaking or crushing them to a tablespoon of water or apple juice in a small glass to produce a suspension.  The capsules must be left in the liquid for at least 10 minutes and stirred for at least 3 minutes to dissolve the capsule shells.  The suspension is to be swallowed.  After drinking, the same amount of water or apple juice (one tablespoon) must be added to the glass and swirled a few times.  The additional liquid must be swallowed (see section 4.2 of the SmPC).

## 2.3.6. Conclusions on clinical pharmacology

Overall,  the  pharmacokinetics  of  lenvatinib  is  appropriately  described.  No  major  issues  have  been identified. However, for the time being, it is not clearly demonstrated that the exposure in patients with moderate hepatic impairment is sufficiently high with a starting dose of 8 mg, especially for patients with &gt; 60 kg. The SmPc should be adapted accordingly.

<div style=\"page-break-after: always\"></div>

Lenvatinib  is  not  a  substrate  for  MATE1  and  MATE2-K  and  showed  minimal  or  no  inhibitory  effect  on MATE2-K and weakly inhibits MATE1.

Study 010 entitled \"A Multicenter Phase 0 Study In Healthy Subjects As Well As Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma To Assess In Vitro Lenvatinib Protein Binding\" and study 109 entitled 'drug-drug interaction to investigate the potential of lenvatinib for CYP3A4 inhibition/induction' are included in the RMP and should be submitted according to the timelines.

The analyses of biomarkers in a subset of patients enrolled in the study did allow to make definitive conclusion or indicate a particular biomarker for selection of patients.

&lt;The CHMP considers the following measures necessary to address the issues related to pharmacology:&gt;

## 2.4. Clinical efficacy

Initial evidence for the efficacy and safety of lenvatinib in HCC was obtained from Study E7080-J081-202 (hereafter  referred  as  Study  202),  which  was  a  multicenter,  open-label,  Phase  1/2  study  of  lenvatinib consisting of a Dose Escalation Component (Phase 1) and an Expansion Component (Phase 2) in subjects with advanced HCC for whom standard therapy or other appropriate therapy was not available. This study was conducted with tablet formulation of lenvatinib.

The  primary  basis  for  establishing  the  efficacy  and  safety  of  lenvatinib  in  HCC  is  the  Phase  3  Study E7080-G000-304 (hereafter referred as Study 304), a randomized, controlled, open-label, multi-center, non-inferiority trial versus sorafenib. This study was conducted with an approved capsule formulation of lenvatinib.

A tabular listing of the lenvatinib studies contributing efficacy data in HCC is provided in table below.

Table 28 : Clinical efficacy studies contributing to the evaluation of efficacy in hepatocellular carcinoma

| Study ID           | Number of Study Centers (Locations)                                                                                                                     | Study Start/ Clinical Cutoff Date                                                                                                    | Study Design/ Indication                                                                                                                                                                          | StudyTreatment(s): Dose,Route & Regimen                                                             | No. Subjects Planned/ Treated/ Ongoinga                                                                                                                              | Treated Subjects Sex (IF); Median age, y (Range)                       | Efficacy Endpoints                                                                      |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| PivotalPhase3Study | PivotalPhase3Study                                                                                                                                      | PivotalPhase3Study                                                                                                                   | PivotalPhase3Study                                                                                                                                                                                | PivotalPhase3Study                                                                                  | PivotalPhase3Study                                                                                                                                                   | PivotalPhase3Study                                                     | PivotalPhase3Study                                                                      |
| E7080-G000-304     | 183 sites: Asia (China, Japan, Republic of Hong Kong. Korea, Singapore, Taiwan, Thailand, Philippines, Malaysia), North America, the EU, Russia, Israel | 01 Mar 2013 (1st subject signed ICF) (clinical cutoff 13 Nov 2016 for primary analysis)                                              | Randomized (1:1), open-label, noninferiority of unresectable, BCLC stage B or C HCC lenvatinib vs subjects with sorafenib in and CP class A                                                       | Lenvatinib QD: 8 mg (BW<60 kg) or 12 mg (BW ≥60 kg) Sorafenib 400 mg BID oral capsules oral tablets | Planned: TotalN=940 Treated/Ongoing: Lenvatinib: Sorafenib: 478/27 476/25                                                                                            | Lenvatinib: 405M/73F 63.0y Sorafenib: 401M/75F (20, 88) 62.0y (22, 88) | Primary: OS Secondary (sequential analysis):PFS,TTP, ORR Exploratory: DCR, CBR, HRQoL   |
| Supportive Study   | Supportive Study                                                                                                                                        | Supportive Study                                                                                                                     | Supportive Study                                                                                                                                                                                  | Supportive Study                                                                                    | Supportive Study                                                                                                                                                     | Supportive Study                                                       | Supportive Study                                                                        |
| E7080-J081-202     | Phase 1: Japan (2 sites) Japan (12 sites). Phase 2: Korea (2 sites)                                                                                     | 24 Ju12009 (1st subject (clinical cutoff signed ICF) 15 Jun 2014 for primary analysis) (cutoff date for 13 Aug 2015: final analysis) | Phase 1/2, nonrandomized, label study with a multidose, open- dose-escalation multicenter, component (Phase 1) and an expansion RP2 dose (Phase 2) component at the in subjects with advanced HCC | Lenvatinib QD: Phase 1: 8, 12, or 16 mg Phase 2: 12 mg oral tablets (RP2 dose)                      | Phase 1: Group 1 Group 2 (CP score 5-6): Planned: 12-18/ Achual: 9; (CP score 7-8): Actual: 11 Planned: 6-18/ Ongoing:0 (Groups 1+2) Phase 2: (CP score 5-6) 46/46/0 | Phase 1: 17M/3F Phase 2: (47, 74) 63.5y 33M/13F (37, 80) 66.5 y        | Phase 1: Primary: NA* Phase 2: Secondary: BOR Primary: TTP Secondary: BOR, ORR, DCR, OS |

BCLC=Barcelona Clinic Liver Cancer; BID=twice daily;BOR=best overall response;BW =body weight; CBR=clinical benefitrate; CP=Child-Pugh; CSR=Clinical Study Report; DCR = disease control rate; EU = European Union; F = female; HCC = hepatocellular carcinoma; HRQoL = health-related quality of life; ICF = informed consent form;M=male;NA =not applicable; ORR=objective response rate; OS =overall survival; PFS=progression-free survival; QD= once daily,RP2 =recommended Phase 2 (dose);TTP=timetoprogression.

<div style=\"page-break-after: always\"></div>

## 2.4.1. Dose response study(ies)

## Study E7080-J081-202: A Phase 1/2 Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)

This study was a multicenter, open-label, Phase 1/2, dose-finding study of lenvatinib that evaluated the safety, activity, and pharmacokinetic (PK)/pharmacodynamic relationships of lenvatinib in subjects with advanced HCC for whom standard therapy or other appropriate therapy was not available. Lenvatinib was given as tablet formulation once daily (QD) for 4 weeks per cycle with no break. The study was conducted in Japan and Korea. The first patient enrolled 24 July 2009 and the data cut-off date for the primary analysis was 15 June 2014. The study completed 13 August 2015. The data cut-off for the interim analysis occurred on 23 Dec 2011 when all subjects completed at least 6 months of study therapy or discontinued study treatment.

Study 202 consisted of (1) a Dose-escalation component (Phase 1) designed to determine the maximum tolerated dose of lenvatinib in HCC based on dose-limiting toxicity (DLT) and identify a dose for Phase 2 of the study, and (2) an Expansion component (Phase 2) designed to evaluate the efficacy and safety of lenvatinib at the recommended Phase 2 dose (12 mg QD).

Figure 11: Study design of Phase1/2 study 202

<!-- image -->

In  the  dose-escalation  component  (Phase1),  lenvatinib  doses  of  12  mg  (6  subjects)  and  16  mg  (3 subjects) QD were tested in subjects with advanced HCC and hepatic function of Child-Pugh (CP) scores of 5-6 (Group 1) and lenvatinib dose of 8 mg (6 subjects) and 12 mg (5 subjects) QD in subjects with advanced  HCC  and  hepatic  function  of  Child-Pugh  (CP)  scores  of  7-8  (Group  2).  The  dose-escalation component was designed primarily to determine the maximum tolerated dose based on DLT. The MTD was defined as the highest dose at which no more than 1 of 6 patients had a DLT. The Enrolled Analysis Set comprised 20 subjects (9 in Group 1 and 11 in Group 2) that received study treatment and completed the study (i.e. experienced DLT or completed tolerability assessment without DLT until Day 28 of Cycle 1).

In Group 1 (CP scores of 5-6), 1 DLT (fever and vomiting, resulting in less than 75% of the prescribed number of doses) was observed in the 6 subjects dosed at 12-mg QD and 2 DLTs (liver dysfunction and hepatic encephalopathy; proteinuria) were observed in the 3 subjects dosed at 16-mg QD, establishing 12 mg QD as the MTD for Group 1.

In Group 2 (CP scores of 7-8), 2 DLTs (hepatic encephalopathy; AST increased, hyperbilirubinaemia, creatinine increased resulting in less than 75% of the prescribed number of doses) were observed in the 5 subjects dosed at 12-mg QD and no DLT was observed in 6 subjects dosed at 8-mg QD, establishing 8 mg QD as the MTD for Group 2.

The 12-mg QD dose, determined to be the MTD in subjects with a Child-Pugh score of 5 or 6 (Class A

<div style=\"page-break-after: always\"></div>

[CP-A]), was the recommended dose for the Phase 2 portion of the study.

Tumour assessments were performed using RECIST 1.1. Based on investigator assessment, the ORR was 15.0% (95% CI: 3.2, 37.9) and the DCR was 65.0% (95% CI: 40.8, 84.6). Three subjects (15.0%) had a BOR of PR, and 10 subjects (50.0%) had a BOR of SD, while 6 subjects (30.0%) had PD. One subject was declared NE. No subject had a BOR of CR. Median TTP was 3.60 months (95% CI: 1.90, 7.50).

However,  approximately  74%  of  subjects  with  HCC  treated  with  lenvatinib  12  mg  QD  required  dose reduction  to  8  mg.  A  PopPK  analysis  including  Study  202  showed  that  both  clearance  and  volume increased  with  increasing  body  weight  (please  refer  to  the  PK  section).  Consequently,  lenvatinib  AUC increased as body weight decreased in subjects with HCC. Subjects with a low body weight (&lt;60 kg) had a  higher  lenvatinib  AUC,  which  appears  to  have  led  to  the  high  rate  of  dose  reductions  and discontinuations in these subjects in Cycle 1 in Study 202.

Based on these results, a 2-tier dosing strategy based on body weight was proposed in future HCC trials both to achieve comparable lenvatinib exposures and to manage toxicity: 12 mg QD for subjects weighing 60 kg and over, and 8 mg QD for subjects weighing less than 60 kg. This 2-tier dosing strategy was used in HCC Study 304. The final PopPK model including data from Study 304 confirmed that lenvatinib PK was affected by body weight in subjects with HCC (Report CPMS-E7080-011R). The effect of changes in body weight was more pronounced in HCC than in previously studied tumour types (RR-DTC, RCC). In other tumour types, the effect of body weight on lenvatinib PK was small, not clinically relevant, and did not warrant any dose adjustment (CPMS-E7080-007R; CPMS-E7080-008R). These data supported the use of the 2-tier dosing strategy based on body weight in HCC. (see relevant clinical pharmacology sections)

## 2.4.2. Main study

Study E7080-G000-304: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

## Methods

Study E7080-G000-304 (Study 304) was a multi-center, randomized, open-label, non-inferiority Phase 3 study of lenvatinib versus sorafenib.

The study consisted of 3 phases, the Pre-randomization, the Randomization, and the Extension Phase. The Pre-randomization phase comprised 2 periods, Screening and Baseline. The Randomization and the Extension phases each comprised 2 periods, the Treatment Period and Follow-up Period.

The Randomization Phase of the study ended at the date of data cut-off for the primary analysis of OS (13 Nov 2016), which occurred when the target number of events (700 deaths) among the 2 treatment groups was observed. All subjects who were still on study treatment or in follow-up at that time entered the Extension Phase. Ongoing subjects continued to be followed for survival and all subsequent anticancer treatments received were recorded.

<div style=\"page-break-after: always\"></div>

Figure 12: Flow-chart of study design for Phase 3 Study 304

<!-- image -->

a: Extension Phase also included a Treatment Period and Follow-up Period. All subjects still on treatment at the end of the Randomization Phase entered the Extension Phase and continued the same study treatment they received in the Randomization Phase.

## Study participants

## Main inclusion criteria

-  Adult  subjects  ( ≥ 18  years  of  age)  with  a  histologically  or  cytologically  confirmed  diagnosis  of unresectable  HCC,  or  a  clinically  confirmed  diagnosis  of  HCC  according  to  the  American Association  for  the  Study  of  Liver  Diseases  criteria,  including  cirrhosis  of  any  etiology,  or  with chronic hepatitis B or C infection were eligible.

<div style=\"page-break-after: always\"></div>

-  Subjects had at least 1 measureable target hepatic or non-hepatic lesion according to mRECIST, and adequate liver, bone marrow, blood coagulation, renal, and pancreatic function as defined in the protocol.
-  Female subjects of childbearing potential could not be pregnant or lactating.
-  Subjects categorized to stage B (not applicable for transarterial chemoembolization) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system.
-  Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP ≤ 150/90 mm Hg at Screening and no change in antihypertensive agents within 1 week prior to Cycle 1/Day 1.
-  Child-Pugh score A (score 5 or 6).
-  ECOG PS 0 or 1.
-  Survival expectation of 12 weeks or longer after starting study drug.

## Main exclusion criteria

-  Subjects were not eligible to participate in the study if they had any previous systemic anticancer therapy or any systemic investigational anticancer agents, including lenvatinib, for advanced/unresectable HCC.
-  Subjects  were  excluded  if  they  had  imaging  findings  that  indicated  HCC  with ≥ 50%  liver occupation, clear invasion into the bile duct or main portal branch invasion (Vp4), or any bloodenhancing treatment within 28 days of randomization.
-  Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart  Association  (NYHA)  Class  II,  unstable  angina,  myocardial  infarction  or  stroke  within  6 months  of  the  first  dose  of  study  drug,  or  cardiac  arrhythmia  requiring  medical  treatment  at Screening
-  Prolongation of QTc interval to &gt;480 ms
-  Bleeding  or  thrombotic  disorders  or  use  of  anticoagulants  requiring  therapeutic  international normalized ratio (INR) monitoring, eg, warfarin or similar agents. Treatment with low molecular weight  heparin  and  factor  X  inhibitors  which  did  not  require  INR  monitoring  was  permitted. Antiplatelet agents were prohibited throughout the study.
-  Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 28 days prior to randomization
-  Gastric or esophageal varices that required active interventional treatment within 28 days prior to randomization.  Prophylaxis  with  pharmacologic  therapy  (eg,  nonselective  beta-blocker)  was permitted.
-  Subjects whose only target lesion was in bone.
-  Subjects with a urine protein ≥ 1 g/24 hours
-  Female subjects of childbearing potential could not be pregnant or lactating.

Subjects who were taking herbal or Traditional Chinese Medicines (TCMs) approved for use in advanced HCC in  China  were  eligible  for  enrolment  although  a  letter  was  sent  to  investigators  on  21  Nov  2014 instructing them to consider TCMs as prohibited concomitant medications; use of concomitant TCMs was classified as a minor protocol deviation.

<div style=\"page-break-after: always\"></div>

## Treatments

Lenvatinib capsules were taken orally, QD in continuous 28-day cycles. The lenvatinib dose was based on the subject's baseline body weight (BW):

- Lenvatinib 12 mg QD for subjects with baseline BW ≥ 60 kg
- Lenvatinib 8 mg QD for subjects with baseline BW &lt;60 kg

Capsules were taken in a fasting state or after a meal.

No dose adjustments were required on the basis of hepatic function in those patients who had mild hepatic impairment (Child-Pugh A).

Sorafenib tablets were taken orally at the approved dose for HCC (400 mg BID, Nexavar SmPC).

Table 29 : Treatments administered

| Drug Name   | BaselineBody Weight   | Strength   | OralDose Form   | NumberDispensed andFrequency                            |
|-------------|-----------------------|------------|-----------------|---------------------------------------------------------|
| Lenvatinib  | ≥60 kg                | 12 mg      | capsule         | 3 × 4-mg capsules,once daily at the same time each day  |
|             | <60 kg                | 8 mg       | capsule         | 2 × 4-mg capsules, once daily at the same time each day |
| Sorafenib   | N/A                   | 400 mg     | tablet          | 2 × 200-mg tablets, twice daily                         |

N/A = not applicable.

Sorafenib was selected as comparator as this is the only approved systemic therapy for advanced HCC in the first-line setting and is regarded as standard of care.

Toxicity  for  both  treatment  arms  was  managed  by  a  combination  of  treatment  interruption,  dose reduction,  or  treatment  discontinuation.  Dose  modifications  for  sorafenib  related  toxicity  followed  the approved prescribing information for each country/region.

## Objectives

## Primary objective

- to  compare  OS  in  subjects  treated  with  lenvatinib  versus  sorafenib  as  a  first-line  treatment  in subjects with unresectable HCC.

## Secondary objectives

- To compare progression-free survival (PFS), time-to progression (TTP), and  objective response rate  (ORR)  of  subjects  treated  with  lenvatinib  versus  sorafenib  using  modified  Response Evaluation Criteria in Solid Tumours (mRECIST)
- To compare the impact of treatment on generic Health Related Quality of Life (HRQoL) of subjects treated  with  lenvatinib  versus  sorafenib  using  the  European  Organisation  for  Research  and Treatment of Cancer (EORTC) QLQ-C30 and HCC-specific EORTC QLQ-HCC18 questionnaire
- To compare safety and tolerability of subjects treated with lenvatinib versus sorafenib
- To characterize the pharmacokinetics (PK) of lenvatinib using the population approach
- To assess the PK/pharmacodynamic (PD) relationship between exposure and efficacy/safety.

## Exploratory objectives

- To compare disease control rate (DCR) of subjects treated with lenvatinib versus sorafenib using mRECIST
- To compare the clinical benefit rate (CBR) of subjects treated with lenvatinib versus sorafenib

<div style=\"page-break-after: always\"></div>

- To compare the impact of treatment on generic HRQoL factors for subjects treated with lenvatinib versus sorafenib using the European Quality of Life questionnaire
- To  explore  blood  and  tumour  biomarkers  which  may  correlate  with  clinical  outcomes-related endpoints.

## Outcomes/endpoints

## Primary Efficacy Endpoint

- Overall survival (OS), measured from the date of randomization until the date of death from any cause. Subjects who were lost to follow-up were censored at the last date the subject was known to be alive, and subjects who remained alive were censored at the time of data cut-off.

## Secondary Efficacy Endpoints

- Progression-free survival, defined as the time from the date of randomization to the date of first documentation of disease progression, or the date of death, whichever occurred first. Progression-free survival censoring rules were defined in the statistical analysis plan (SAP) and followed United States Food and Drug Administration (US FDA) guidance.
- Time to progression (TTP), defined as the time from the date of randomization to the date of the first documentation of disease progression. Time to progression censoring rules were defined in the SAP.
- Objective response rate, defined as the proportion of subjects who had a best overall response (BOR) of complete response (CR) or partial response (PR).
- HRQoL assessed using EORTC QLQ-C30, the HCC-specific questionnaire (HCC-18), and a generic instrument EQ-5D-3L.
- Plasma PK lenvatinib exposure parameters.

## Exploratory endpoints

- Disease  control  rate,  defined  as  the  proportion  of  subjects  with  a  BOR  of  CR  or  PR,  or  stable disease  (SD).  Best  overall  response  of  SD  must  have  occurred  at  least  7  weeks  after randomization (within a 1-week window of the protocol-specified 8-week time point for the first post-baseline tumour scan).
- Clinical benefit rate, defined as the proportion of subjects who had a BOR of CR or PR or durable SD (duration of SD ≥ 23 weeks after randomization).
- Exploratory biomarker analysis, defined as baseline and/or change from Baseline of exploratory soluble,  tissue  and/or  genetic  biomarkers  and  their  correlations  with  clinical  outcomes  were assessed. Correlative data will be presented in a separate Biomarker Analysis Report.

## Assessments

Tumour  assessments  were  performed  every  8  weeks  from  the  date  of  randomization,  or  as  clinically indicated,  until  disease  progression.  Subjects  discontinued  study  treatment  at  the  time  of  objectively documented disease progression, development of unacceptable toxicity, subject request or withdrawal of consent. Subjects were followed every 12 weeks for survival.

Time-to-event  efficacy  endpoints  were  based  on  investigator  assessment  of  tumour  response  as determined using the mRECIST for hepatic lesions and RECIST v1.1 for non-hepatic lesions.

<div style=\"page-break-after: always\"></div>

Investigators  were  trained  in  the  application  of  mRECIST  and  early  feedback  on  quality  of  tumour assessment was provided to sites by an independent mRECIST expert. All tumour assessment scans were sent to PAREXEL for quality assessment and archiving. A blinded, retrospective IIR of tumour assessment scans was performed by experienced radiologists using both mRECIST and RECIST 1.1.

## Sample size

Sample size determination was based primarily on the required number of target events to detect the noninferiority and superiority of lenvatinib to sorafenib in the comparison of the OS. The required number of target events was estimated based on the following assumptions:

- Exponential  distribution  was  assumed  for  OS.  The  estimated  median  OS  of  sorafenib  is approximately 10 months, and an improvement of 2.5 months was derived from the underlying objective of achieving a hazard ratio (HR) of 0.8, which would be of marked clinical benefit.
- Using a noninferiority test by the 95% confidence interval (CI) lower limit method on log HR for OS  with  assumed  true  HR  of  0.80  and  noninferiority  margin  of  1.08  (corresponding  to  60% retention of sorafenib effect versus placebo), the power of the study to declare noninferiority was approximately 97%.
- The power of the study to declare superiority of lenvatinib to sorafenib was approximately 82% using the superiority test with assumed true HR of 0.80. The overall false positive rate was set at 2-sided 0.05.

Based on these assumptions, the required number of events was estimated to be approximately 666 events (deaths) based on PPS. Assuming approximately 5% of subjects with major protocol deviations would be excluded from PPS, approximately 700 events (deaths) based on the FAS would be required at the time of primary analysis. Two interim analyses for futility (1 at approximately 30%, and a second at approximately 70% of the target number of events) were taken into account for the estimation. It was estimated that approximately 940 subjects were to be randomized to observe this number of events, which for a randomization ratio of 1:1 is a minimum of 470 per treatment group.

## Randomisation

After the Baseline period, subjects were randomised 1:1 to lenvatinib (12mg if baseline BW ≥60kg or 8mg if baseline BW &lt;60kg) QD oral dosing or sorafenib 400mg BID oral dosing. Allocation of randomization numbers was performed using an interactive voice/web response system (IxRS®) based on the following stratification factors:

- Region: Region 1 (Asia-Pacific); Region 2 (Western - EU, North America, other)
- Macroscopic portal vein invasion (MPVI) or extrahepatic spread or both: Yes; No
- Eastern Cooperative Oncology Group performance status (ECOG PS): PS = 0; PS = 1
- BW: &lt;60 kg; ≥ 60 kg

## Blinding (masking)

The study was open-label.

## Statistical methods

## Definition of Analysis Sets

<div style=\"page-break-after: always\"></div>

Full Analysis Set (Intent to Treat Analysis Set) included all subjects who were randomized. This was the primary analysis set for all efficacy evaluations. Subjects were analysed according to their randomized treatment group.

Per Protocol Analysis Set (PPS) included subjects who were randomized and received at least 1 dose of the  assigned  study  drug  and  had  no  major  protocol  deviations.  Criteria  for  exclusion  from  the  PPS analysis set were determined before the data lock for the primary analysis of OS. This was the secondary analysis set for all efficacy evaluations.

Safety Analysis Set included subjects who received at least 1 dose of the study treatment. Subjects who  received  any  dose  of  lenvatinib  during  the  treatment  period  were  grouped  into  the  lenvatinib treatment group. Subjects who received sorafenib only during the treatment period were grouped into the sorafenib treatment group. This was the analysis set for all safety evaluations.

Pharmacokinetic  Analysis  Set included  subjects  who  received  at  least  1  dose  of  lenvatinib,  had evaluable dose data, and had at least 1 quantifiable lenvatinib concentration.

Pharmacodynamic Analysis Set included subjects who received at least 1 dose of study drug and had evaluable PD data.

## Statistical Methodology

## Primary efficacy analysis

The primary endpoint for this study was overall survival (OS).

A non-inferiority test of OS between lenvatinib and sorafenib was performed based on the FAS as the primary analysis set and the PPS as the secondary analysis set. Noninferiority of OS between lenvatinib and sorafenib was tested using a 2-sided 95% CI of HR (lenvatinib: sorafenib) estimated using a Cox proportional hazard model with treatment group as a factor, stratified by the randomization (IxRS) stratification factors (region, presence or absence MPVI or extrahepatic spread or both, ECOG PS, and BW). Noninferiority was declared if the upper limit of the 2-sided 95% CI for HR was &lt;1.08 at the final analysis.The non-inferiority margin of 1.08 was calculated based on the sorafenib SHARP trial and AsiaPacific trial data. Using the 95% CI lower limit method on log HR as described in Rothmann etal. (2003), the non-inferiority margin corresponding to lenvatinib preserving at least 60% of sorafenib effect versus placebo was calculated as 1.08. If at the final analysis the upper limit of the 2-sided 95% CI for the HR (lenvatinib/sorafenib) was less than 1.08, non-inferiority of lenvatinib to sorafenib would be inferred and &gt;60% retention of sorafenib treatment effect by lenvatinib would be demonstrated. Using a margin of 1.08 and an assumed true HR of 0.8, the power of the study to declare NI was approximately 97%.

If noninferiority was declared for OS, then superiority (corresponding to δ = 1) was to be tested for OS using a stratified log-rank test with the randomization (IxRS) stratification factors. Superiority would be declared if the 2-sided P value was &lt;0.05 using the stratified log-rank test at the final analysis. No multiplicity adjustments were needed for testing of the noninferiority and superiority of OS due to the closed testing principle.

In the SAP, all primary efficacy analyses were changed to be based on randomisation stratification factors per IxRS rather than per the CRF data (as stated in the protocol). The analysis with stratification factors based on CRF data were used for sensitivity analyses. Other sensitivity analyses were an unstratified log rank test and an unstratified Cox proportional hazards model.

The median OS and the cumulative probability of OS at selected time points were calculated for each treatment group and presented with 2-sided 95% CIs. The selected time points depended on the OS times that were observed during the study and were specified in the SAP. Kaplan-Meier estimates of OS for each treatment group were plotted over time.

<div style=\"page-break-after: always\"></div>

## Secondary efficacy analyses

For  the  secondary  endpoints,  PFS,  TTP,  ORR  using  mRECIST  and  impact  on  health-related  Qol,  the objective was to show superiority of lenvatinib to sorafenib.

The  fixed  sequence  procedure  was  used  to  control  the  overall  type  I  error  rate  of  analyses  for  the secondary endpoints at α = 0.05 (2-sided) after the non-inferiority for primary efficacy endpoint, OS, was declared. The order of testing for secondary endpoints followed the order: PFS, TTP, ORR, and healthrealted QoL. In the ordered sequence, each secondary endpoint was tested at the 5% level until the first nonsignificant outcome occurred. If a nonsignificant outcome occurred, then the results of the inferential analyses of the subsequent endpoints were presented for descriptive purposes only.

PFS : The test for a difference in PFS between lenvatinib and sorafenib was performed using a stratified log-rank test stratified by the randomization stratification factors. The corresponding estimate of HR was calculated from the Cox proportional hazard model with treatment group as a factor and stratified by the randomization stratification factors. Median PFS and the cumulative probability of PFS at selected time points was calculated for each treatment group, and presented with corresponding 2-sided 95% CIs. The selected time points depended on the PFS times that were observed during the study and were specified in the SAP. Kaplan-Meier estimates of PFS for each treatment group were plotted over time.

TTP : The difference in TTP between lenvatinib and sorafenib was evaluated using the same procedure as used for PFS, with the exception that death was censored.

ORR :  Objective  response  rate  was  estimated  by  treatment  group.  The  statistical  significance  of  the difference  in  ORR  between  treatment  groups  was  evaluated  using  the  Cochran-Mantel-Haenszel  chisquare test with the stratification factors as strata, tested at an alpha level of 0.05 (2-sided). The 2-sided 95% CIs for the odds ratio and the difference in ORR were calculated as well as 2-sided 95% CIs for the rate within treatment group.

HRQoL :  For  HRQoL,  a  simple,  comparative,  cross-sectional  analysis  was  performed  for  each  available PRO variable using the cross-sectional population (CSP). The EORTC QLQ-HCC18 and QLQ-C30 domains were tested  hierarchically,  guided  by  their  relative  importance  to  the  condition  being  studied,  with  all EORTC  QLQ-HCC18  domains  tested  prior  to  the  EORTC  QLQ-C30  domains.  To  estimate  the  effect  of treatment assignment on change in domain scores from Baseline, mixed models were constructed among patients included in the longitudinal period population (LPP)-based on the Full Analysis Set. Sensitivity analyses were conducted on the LPP-based on the per protocol analysis set. If the sample size of LPP permitted, longitudinal modelling of the EQ-5D Health Utility Index (HUI), EQ-5D Visual Analogue Scale (VAS), EORTC QLQ-C30 summary scores, and the QoL/global health status were conducted to estimate the effect of treatment assignment (lenvatinib versus sorafenib) on change from Baseline. A two-sided test with p-value ≤ 0.05 (unadjusted for multiplicity) was considered statistically significant.

## Interim analyses

Two interim analyses were planned with early stopping rules for futility based on non-inferiority. The first interim  analysis  was  planned  for  when  ~210  deaths  (30%  of  the  target)  were  observed,  estimated around 16 months. The second interim analysis was planned for when ~ 490 deaths (70% of the target) were observed, estimated around 26 months.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 13: Subjects disposition in the randomization phase (Full Analysis Set)

<!-- image -->

Data cutoff date: 13 Nov 2016.

a: Other reasons for screening failure varied, with the most common reasons being expiration of the 21-day screening window (n=4) and worsening of the subject's condition (n=3).

b: Two subjects randomized to lenvatinib were not treated as they were randomized in error, and 1 subject randomized to sorafenib chose not to receive treatment; therefore the Safety Analysis Set includes 476 subjects in the lenvatinib arm and 475 subjects in the sorafenib arm.

c: 'Other' reasons for discontinuation in the lenvatinib arm included randomization in error (n=2; not treated); subject required surgery (n=2) and investigator choice (n=1). In the sorafenib arm, 'other' reasons included investigator choice (n=5); need for a prohibited medication (warfarin; 1 subject); and discontinuation to undergo liver transplantation (n=1).

<div style=\"page-break-after: always\"></div>

Table 30: Status at the end of randomization phase (Full Analysis Set)

|                                              | Lenvatinib (N=478) n (%)      | Sorafenib (N=476) n (%)        | Total (N=954) n (%)            |
|----------------------------------------------|-------------------------------|--------------------------------|--------------------------------|
| On Study a Treatment ongoing at data cut-off | 109 (22.8) 27 (5.6)           | 107 (22.5) 25 (5.3)            | 216 (22.6) 52 (5.5)            |
| Off Study b - reason Death Lost to follow-up | 369 (77.2) 351 (73.4) 5 (1.0) | 369 (77.5) 350 (73.5) 11 (2.3) | 738 (77.4) 701 (73.5) 16 (1.7) |
| Withdrawal of consent                        | 13 (2.7)                      | 8 (1.7)                        | 21 (2.2)                       |

Data cut-off date: 13 Nov 2016.

Percentages are based on the total number of subjects in FAS within the relevant treatment group.

a: On study refers to subjects who were still receiving study drug or who were in survival follow-up as of the cut-off date.

b: Off study refers to subjects who were no longer being followed for survival as of the cut-off date.

As of the 13 Nov 2016 data cut-off, median duration of treatment was 5.7 months in the lenvatinib arm and 3.7 months in the sorafenib arm.

## Recruitment

Enrolment in Study 304 occurred between 01 March 2013 (first subject gave informed consent) and 30 July 2015 (last subject enrolled) . A total of 954 subjects were enrolled and assigned to treatment at 183 study sites (number of sites initiated) in Asia, North America, the European Union, Russia, and Israel. Per protocol, the planned number of subjects enrolled in China was limited to 200; in actuality, 213 subjects were randomly assigned to study treatment in China.

## Conduct of the study

The data cut-off date for the primary analysis of OS was 13 November 2016, which occurred when the target number of events (700 deaths) was observed across the 2 treatment arms. All subjects who were still receiving study drug or who were in follow-up as of the cut-off date entered the Extension Phase of the study, whereby subjects continued to receive study drug at their assigned dose. Ongoing subjects continued to be followed for survival and all subsequent anticancer treatments received were recorded.

## Interim Analyses and Data Monitoring

An independent DMC conducted 2 unblinded interim analyses. The interim analyses were performed by an independent statistical team and the study team was not given access to the summary of aggregated data by treatment group. Early stopping boundaries for futility at the interim analyses and success criteria at the final analyses are shown in Table below.

Table 31: Early Stopping Boundaries for Futility at the Interim Analyses and Noninferiority and Superior Efficacy Success Criteria at the Final Analysis

| Analysis      | No of Events: Planned/Actual   | SuperiorEfficacy 2-sided P-value   | Futility for Noninferiority         | Noninferiority CI for HR (lenvatinib:sorafenib)   |
|---------------|--------------------------------|------------------------------------|-------------------------------------|---------------------------------------------------|
|               |                                | Stratified Log-Rank Test           | Bayesian Predictive Probability (%) | Upper Limit of 2-sided                            |
| First Interim | 210/249                        | NA                                 | 5                                   | NA                                                |
| SecondInterim | 490/521                        | NA                                 |                                     | NA                                                |
| Final         | 700/700                        | <0.05                              | NA                                  | <1.08                                             |

CI = confidence interval, HR = hazard ratio, NA = not applicable.

<div style=\"page-break-after: always\"></div>

The first interim analysis was performed when 249 deaths were reported, and the efficacy and key safety results were reviewed by the DMC on 13 May 2015. The second interim analysis was performed when 521 deaths were reported, and the results were reviewed on 3 Feb 2016. Both times, the DMC recommended continuation of the trial with no modifications.

## Protocol amendments

The original protocol (v1.0) was approved on 16 Nov 2012. Three protocol amendments were made throughout the period covered by this study report.

## Changes to planned analysis (SAP)s

A change to the planned analysed in the SAP before treatment unblinding was that all efficacy analyses had  to  be  based  on  randomization  factors  per  IxRS  rather  than  per  the  CRF  data  (as  stated  in  the protocol). The randomization factors based on CRF data were used for sensitivity analyses.

## Protocol deviations

Overall, the rate of major protocol deviations was low (2.5%; 24 of 954 subjects; lenvatinib - 11 [2.3%] subjects; sorafenib- 13 [2.7%] subjects), and the incidence and nature of the protocol deviations were balanced across the treatment arms. (table below)

Most of the major protocol deviations in both the lenvatinib and sorafenib arms were eligibility criteria not met, mostly due to laboratory levels outside the acceptable range or Child-Pugh score of 7 or 8 (Class B).

Fifteen subjects, 8 (1.7%) in the lenvatinib and 7 (1.5%) in the sorafenib arm, were enrolled and did not meet eligibility criteria and 4 subjects, 2 (0.4%) in each arm, had a prohibited procedure. These prohibited procedures were:

Lenvatinib: TACE on Study Day 253 then discontinued study treatment 1 month later (subject 24151008) and radiotherapy of 1 target and 3 non-target lymph nodes on C1D1 plus baseline Child-Pugh of 8 [Class B], (subject 30031005).

Sorafenib: radiotherapy of lymph node target lesion on C1D7 (subject 30051009) and on C2D1 (subject 30051014).

One subject (14061009) in the lenvatinib arm took an overdose of study medication (single 120-mg dose on Study Day 1 rather than the assigned 12 mg).

<div style=\"page-break-after: always\"></div>

Table 32: Major protocol deviations during the randomization phase  (Full Analysis Set)

|                                                          | Lenvatinib (N=478) n (%)   | Sorafenib (N=476) n (%)   | Total (N=954) n (%)   |
|----------------------------------------------------------|----------------------------|---------------------------|-----------------------|
| No. of subjects with at least 1 major protocol deviation | 11 (2.3)                   | 13 (2.7)                  | 24 (2.5)              |
| Discontinuation criteria                                 | 0 (0.0)                    | 1 (0.2)                   | 1 (0.1)               |
| Eligibility criteria not met                             | 8 (1.7)                    | 7 (1.5)                   | 15 (1.6)              |
| Prohibited concomitant medication (warfarin)             | 0 (0.0)                    | 1 (0.2)                   | 1 (0.1)               |
| Improper procedureb                                      | 0 (0.0)                    | 1 (0.2)                   | 1 (0.1)               |
| Prohibited procedure                                     | 2 (0.4)                    | 2 (0.4)                   | 4 (0.4)               |
| Screening/baseline assessment not done                   | 0 (0.0)                    | 1 (0.2)                   | 1 (0.1)               |
| Study drug dosing error/noncompliance                    | 1 (0.2)                    | 0 (0.0)                   | 1 (0.1)               |

Data cutoff date: 13 Nov 2016.

Percentages are based on the total number of subjects within the relevant treatment group in the Full Analysis Set.

One sorafenib subject (Subject 17021001) had 2 major protocol deviations.

- Subject developed a Grade 4 hemorrhage on study, but was not discontinued from study treatment by the investigator.
- b: Subject's protocol deviation was mistakenly classified as \"improper procedure\" in the database. The subject did not meet Inclusion criterion #10 as the baseline Child-Pugh was 8 (Class B).

## Baseline data

## Demographic and Baseline Disease characteristics

Demographic  and  baseline  characteristics  of  patients  from  the  Study  304  in  overall  population  are presented in the table below.

Table 33: Selected demographic and baseline characteristics, including some disease characteristics  (Full Analysis set)

|                         | Lenvatinib       | Lenvatinib        | Lenvatinib      | Sorafenib    | Total        |
|-------------------------|------------------|-------------------|-----------------|--------------|--------------|
|                         | 8 mg a (N = 151) | 12 mg a (N = 327) | Total (N = 478) | (N = 476)    | (N = 954)    |
| Age (years)             |                  |                   |                 |              |              |
| Mean (SD)               | 63.1 (12.30)     | 60.4 (11.32)      | 61.3 (11.69)    | 61.2 (12.01) | 61.3 (11.84) |
| Median                  | 65.0             | 62.0              | 63.0            | 62.0         | 62.0         |
| Min, Max                | 20, 86           | 24, 88            | 20, 88          | 22, 88       | 20, 88       |
| Age group (yrs), n (%)  |                  |                   |                 |              |              |
| <65                     | 69 (45.7)        | 201 (61.5)        | 270 (56.5)      | 283 (59.5)   | 553 (58.0)   |
| ≥65 to <75              | 56 (37.1)        | 94 (28.7)         | 150 (31.4) 58   | 126 (26.5)   | 276 (28.9)   |
| ≥75                     | 26 (17.2)        | 32 (9.8)          | (12.1)          | 67 (14.1)    | 125 (13.1)   |
| Sex, n (%)              |                  |                   |                 |              |              |
| Male                    | 106 (70.2)       | 299 (91.4)        | 405 (84.7)      | 401 (84.2)   | 806 (84.5)   |
| Female                  | 45 (29.8)        | 28 (8.6)          | 73 (15.3)       | 75 (15.8)    | 148 (15.5)   |
| Region, n (%)           |                  |                   |                 |              |              |
| Western b               | 21 (13.9)        | 136 (41.6)        | 157 (32.8)      | 157 (33.0)   | 314 (32.9)   |
| Asia-Pacific b          | 130 (86.1)       | 191 (58.4)        | 321 (67.2)      | 319 (67.0)   | 640 (67.1)   |
| Race, n (%)             |                  |                   |                 |              |              |
| White                   | 17 (11.3)        | 118 (36.1)        | 135 (28.2)      | 141 (29.6)   | 276 (28.9)   |
| Black/Afr. American     | 0 (0.0)          | 7 (2.1)           | 7 (1.5)         | 6 (1.3)      | 13 (1.4)     |
| Asian                   | 134 (88.7)       | 200 (61.2)        | 334 (69.9)      | 326 (68.5)   | 660 (69.2)   |
| Weight (kg)             |                  |                   |                 |              |              |
| Mean (SD)               | 52.7 (4.90)      | 75.9 (14.40)      | 68.6 (16.32)    | 68.1 (13.90) | 68.3 (15.16) |
| Median                  | 53.0             | 72.0              | 66.2            | 67.0         | 66.9         |
| Min, Max                | 39, 60           | 60, 142           | 39, 142         | 39, 123      | 39, 142      |
| Body Weight Group       |                  |                   |                 |              |              |
| <60 kg                  | 151 (100.0)      | 2 (0.6)           | 153 (32.0)      | 146 (30.7)   | 299 (31.3)   |
| ≥60 kg                  | 0 (0.0)          | 325 (99.4)        | 325 (68.0)      | 330 (69.3)   | 655 (68.7)   |
| ECOG PS, n (%)          |                  |                   |                 |              |              |
| 0                       | 93 (61.6)        | 211 (64.5)        | 304 (63.6)      | 301 (63.2)   | 605 (63.4)   |
| 1                       | 58 (38.4)        | 116 (35.5)        | 174 (36.4)      | 175 (36.8)   | 349 (36.6)   |
| Child-Pugh Score, n (%) |                  |                   |                 |              |              |

<div style=\"page-break-after: always\"></div>

| 5                                            | 111 (73.5)   | 257 (78.6)   | 368 (77.0)   | 357 (75.0)   | 725 (76.0)   |
|----------------------------------------------|--------------|--------------|--------------|--------------|--------------|
| 6                                            | 40 (26.5)    | 67 (20.5)    | 107 (22.4)   | 114 (23.9)   | 221 (23.2)   |
| 7                                            | 0 (0.0)      | 3 (0.9)      | 3 (0.6)      | 4 (0.8)      | 7 (0.7)      |
| 8                                            | 0 (0.0)      | 0 (0.0)      | 0 (0.0)      | 1 (0.2)      | 1 (0.1)      |
| MPVI, n (%) Yes                              | 38 (25.2)    | 71 (21.7)    | 109 (22.8)   | 90 (18.9)    | 199 (20.9)   |
| Extrahepatic spread, n (%) Yes               | 91 (60.3)    | 200 (61.2)   | 291 (60.9)   | 295 (62.0)   | 586 (61.4)   |
| MPVI, extrahepatic spread or both, n (%) Yes | 105 (69.5)   | 224 (68.5)   | 329 (68.8)   | 336 (70.6)   | 665 (69.7)   |
| Cirrhosis, n (%) c Yes                       | 75 (49.7)    | 168 (51.4)   | 243 (50.8)   | 231 (48.5)   | 474 (49.7)   |

Percentages based on the total number of subjects in the Full Analysis Set in the relevant treatment group.

ECOG = Eastern Cooperative Oncology Group; MPVI = Macroscopic Portal Vein Invasion a: 8 mg and 12 mg were the lenvatinib starting doses based on body weight (&lt;60 kg, ≥60 kg) at Baseline.

b: Western region consists of North America and Europe including Russia and Israel; Asia-Pacific region consists of China, Hong Kong, Japan, Korea, Malaysia, Philippines, Singapore, Taiwan, and Thailand.

c: The proportion of subjects with underlying cirrhosis at Baseline was likely underestimated, as this information was collected on the CRF under medical history, and the presence or absence of cirrhosis was verified only if needed to confirm the clinical diagnosis of HCC.

Disease  history  and  characteristics  of  patients  from  the  Study  304  at  study  entry  in  the  overall  are presented in the table below.

Table 34: S elected disease history and characteristics at study entry  (Full Analysis Set)

|                                            | Lenvatinib (N=478)    | Sorafenib (N=476)     | Total (N=954)       |
|--------------------------------------------|-----------------------|-----------------------|---------------------|
| Time since First Diagnosis (months)        |                       |                       |                     |
| Mean (SD)                                  | 21.1 (30.17)          | 23.3 (34.66)          | 22.2 (32.49)        |
| Median                                     | 8.2                   | 9.0                   | 8.5                 |
| Q1, Q3                                     | 1.6, 27.3             | 2.0, 27.2             | 1.8, 27.2           |
| Min, Max                                   | 0, 180                | 0, 250                | 0, 250              |
| Barcelona Clinic Liver Cancer Stage, n (%) |                       |                       |                     |
| B: Intermediate stage                      | 104 (21.8)            | 92 (19.3)             | 196 (20.5)          |
| C: Advanced stage                          | 374 (78.2)            | 384 (80.7)            | 758 (79.5)          |
| Involved disease sites a , n (%)           |                       |                       |                     |
| Liver                                      | 441 (92.3)            | 430 (90.3)            | 871 (91.3)          |
| Lung                                       | 163 (34.1)            | 144 (30.3)            | 307 (32.2)          |
| Lymph nodes                                | 127 (26.6)            | 141 (29.6)            | 268 (28.1)          |
| Bone                                       | 51 (10.7)             | 43 (9.0)              | 94 (9.9)            |
| Other                                      | 82 (17.2)             | 97 (20.4)             | 179 (18.8)          |
| Involved disease sites per subject, n (%)  |                       |                       |                     |
| 1                                          | 207 (43.3)            | 207 (43.5)            | 414 (43.4)          |
| 2                                          | 167 (34.9)            | 183 (38.4)            | 350 (36.7)          |
| ≥3                                         | 103 (21.5)            | 86 (18.1)             | 189 (19.8)          |
| Factor of carcinogenesis b , n (%)         |                       |                       |                     |
| Hepatitis B                                | 251 (52.5)            | 228 (47.9)            | 479 (50.2)          |
| Hepatitis C                                | 91 (19.0)             | 126 (26.5)            | 217 (22.7)          |
| Alcohol                                    | 36 (7.5)              | 21 (4.4)              | 57 (6.0)            |
| Other                                      | 38 (7.9)              | 32 (6.7)              | 70 (7.3)            |
| Unknown                                    | 62 (13.0)             | 69 (14.5)             | 131 (13.7)          |
| Baseline Alpha-fetoprotein Level (ng/mL)   |                       |                       |                     |
| Mean (SD)                                  | 17507.5 (105137.39)   | 16678.5 (94789.46)    | 17096.5 (100088.76) |
| Median                                     | 133.1                 | 71.2                  | 89.0                |
| Q1, Q3                                     | 8.0, 3730.6           | 5.2, 1081.8           | 6.3, 2120.2         |
| Min, Max                                   | 0, 1567470            | 0, 1446396            | 0, 1567470          |
| Baseline Alpha-fetoprotein Group, n (%)    |                       |                       |                     |
| <200 ng/mL                                 | 255 (53.3)            | 286 (60.1)            | 541 (56.7)          |
| ≥200 ng/mL                                 | 222 (46.4)            | 187 (39.3)            | 409 (42.9)          |
| Missing                                    | 1 (0.2)               | 3 (0.6)               | 4 (0.4)             |
| Ammonia level (μg/dL)                      |                       |                       |                     |
| Mean (SD)                                  | 38.2 (29.98) 31.8     | 36.7 (32.90) 30.0     | 37.5 (31.46) 31.0   |
| Median                                     |                       |                       |                     |
| Min, Max                                   | 4, 246                | 4, 473                | 4, 473              |
| Systemic Hepatitis B or C therapy, n (%)   | 163 (34.1) 327 (68.4) | 149 (31.3) 344 (72.3) | 312 (32.7)          |
| Prior anticancer procedures, n (%)         |                       |                       | 671 (70.3)          |
| Hepatic intra-arterial chemotherapy        | 22 (4.6)              | 35 (7.4)              |                     |
| Transarterial [chemo] embolization         | 246 (51.5)            | 245 (51.5)            |                     |
| Radiofrequency ablation                    | 90 (18.8)             | 110 (23.1)            |                     |

<div style=\"page-break-after: always\"></div>

| Cryoablation Percutaneous ethanol injection Hepatectomy Other c End Recent Procedure to Randomization (months) Mean (SD) Median Q1, Q3   | 1 (0.2) 15 (3.1) 124 (25.9) 85 (17.8) 6.5 3.8 2.0, 6.7 0, 108   | 1 (0.2) 19 (4.0) 144 (30.3) 72 (15.1) 6.7 (11.26) 3.7 2.1, 5.9 1, 106   |            |
|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|------------|
| Time Radiotherapy to Randomization                                                                                                       | 49 (10.3)                                                       | 60 (12.6)                                                               | 109 (11.4) |
|                                                                                                                                          | 22 (4.6)                                                        | 28                                                                      |            |
| Min, Max Radiotherapy, n (%)                                                                                                             | (9.99)                                                          | 20 (4.2)                                                                |            |
| (months) <3 3 - 6                                                                                                                        |                                                                 | (5.9)                                                                   |            |
|                                                                                                                                          | 14 (2.9)                                                        | 8 (1.7)                                                                 |            |
| >6                                                                                                                                       | 13 (2.7)                                                        | 24 (5.0)                                                                |            |
| Lesion Progressed Since Most Recent Radiotherapy Yes                                                                                     | 18 (3.8)                                                        |                                                                         |            |
| No                                                                                                                                       | 13 (2.7)                                                        | 25 (5.3)                                                                |            |

Percentages based on the total number of subjects within the relevant treatment group in the FAS

a: Subjects may be counted in more than 1 disease site.

b: Based on the combined data from HCC diagnosis and medical history. Subjects may be counted in more than 1 factor.

c: 'Other' reported on the CRF by the investigator were varied, but were primarily hepatectomy, microwave therapy, biopsies or pulmonary resections.

## Table 35: Demographic and Baseline Characteristics, disease history and characteristics at study entry by Region (Full Analysis Set)

|                                                                                                                                                               | Lenvatinib                                                       | Lenvatinib                                                        | Sorafenib                                                           | Sorafenib                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|
|                                                                                                                                                               | Asia-Pacific (N=321)                                             | Western (N=157)                                                   | Asia-Pacific (N=319)                                                | Western (N=157)                                                 |
| Time since First Diagnosis (months) Mean (SD) Median                                                                                                          | 23.9 (31.70) 10.3                                                | 15.4 (25.93) 5.6                                                  | 26.8 (37.61) 11.4                                                   | 16.1 (26.40) 5.3                                                |
| Age at First Diagnosis (years) Mean (SD) Median                                                                                                               | 58.1 (11.45) 59.0                                                | 62.6 (11.26) 63.0                                                 | 58.0 (11.23) 59.0                                                   | 62.0 (11.72) 63.0                                               |
| HCC type, n (%) Trabecular Moderately Differentiated Poorly Differentiated Well Differentiated Biopsy Performed - HCC Type Unknown Biopsy not Performed Other | 31 (9.7) 27 (8.4) 14 (4.4) 5 (1.6) 61 (19.0) 160 (49.8) 23 (7.2) | 13 (8.3) 23 (14.6) 7 (4.5) 10 (6.4) 50 (31.8) 35 (22.3) 19 (12.1) | 36 (11.3) 35 (11.0) 16 (5.0) 10 (3.1) 57 (17.9) 140 (43.9) 15 (4.7) | 7 (4.5) 14 (8.9) 5 (3.2) 16 (10.2) 42 (26.8) 49 (31.2) 12 (7.6) |
| Barcelona Clinic Liver Cancer Stage, n(%) B: Intermediate stage C: Advanced stage                                                                             | 70 (21.8) 251 (78.2)                                             | 34 (21.7) 123 (78.3)                                              | 65 (20.4) 254 (79.6)                                                | 27 (17.2) 130 (82.8)                                            |
| Factor of carcinogenesis, n (%) Hepatitis B Hepatitis C Alcohol                                                                                               | 212 (66.0) 50 (15.6) 17 (5.3) 17 (5.3) 25 (7.8)                  | 39 (24.8) 41 (26.1) 19 (12.1) 21 (13.4) 37 (23.6)                 | 197 (61.8) 70 (21.9) 8 (2.5) 11 (3.4) 33 (10.3)                     | 31 (19.7) 56 (35.7) 13 (8.3) 21 (13.4)                          |
| (%) Yes Baseline Alpha-fetoprotein Level                                                                                                                      | 180 (56.1)                                                       | 63 (40.1)                                                         | 169 (53.0)                                                          | 62 (39.5)                                                       |
| (ng/mL) Mean (SD) Median Q1, Q3                                                                                                                               | 10078.5 (39198.91) 168.0 11.1,                                   | 32508.2 (173397.79) 78.9 5.2, 3102.1                              | 16460.6 (77052.08) 100.6 7.5,                                       | 17115.6 (123204.55) 27.0 3.6, 622.0                             |
| Baseline Serum Alpha-fetoprotein Level Group, n (%) <200ng/mL ≥200ng/mL                                                                                       | 164 (51.1) 157 (48.9) 0                                          | 91 (58.0) 65 (41.4)                                               | 182 (57.1) 137 (42.9)                                               | 104 (66.2) 50 (31.8)                                            |
| Missing Concomitant systemic antiviral therapy for                                                                                                            |                                                                  | 26 (16.6)                                                         | 129 (40.4)                                                          | 3 (1.9)                                                         |
| Hep                                                                                                                                                           | 137                                                              | 1 (0.6)                                                           |                                                                     | 20                                                              |
| B or Hep C, n (%) Prior Anticancer procedures n (%)                                                                                                           | 235 (73.2)                                                       |                                                                   | 252                                                                 |                                                                 |
|                                                                                                                                                               |                                                                  |                                                                   | (79.0)                                                              |                                                                 |
|                                                                                                                                                               |                                                                  |                                                                   | 0                                                                   |                                                                 |
| Cirrhosis                                                                                                                                                     |                                                                  |                                                                   |                                                                     | 36 (22.9)                                                       |
| Other Unknown                                                                                                                                                 |                                                                  |                                                                   |                                                                     |                                                                 |
| Present,                                                                                                                                                      |                                                                  |                                                                   |                                                                     |                                                                 |
| n                                                                                                                                                             |                                                                  |                                                                   | 1416.0                                                              |                                                                 |
|                                                                                                                                                               | 4186.8                                                           |                                                                   |                                                                     |                                                                 |
|                                                                                                                                                               |                                                                  |                                                                   |                                                                     | (12.7)                                                          |
|                                                                                                                                                               | (42.7)                                                           | 92 (58.6)                                                         |                                                                     | 92 (58.6)                                                       |
| Prior Radiotherapy n (%)                                                                                                                                      | 42 (13.1)                                                        | 7 (4.5)                                                           | 55 (17.2)                                                           | 5 (3.2)                                                         |

<div style=\"page-break-after: always\"></div>

Percentages are based on the total number of subjects in FAS within the relevant treatment group.

## Prior therapy

## Prior medication

Overall, 86.2% of lenvatinib subjects and 87.4% of sorafenib subjects received at least 1 prior medication (excluding anticancer therapies). The type and frequency of prior medications in the 2 treatment arms were comparable.

Table 36 : Antiviral therapy

| Anatomical class (ATC Level 1) Pharmacological class (ATC Level 3) WHO Drug Name (Preferred Term)   | Lenvatinib (N=478) n (%)   | Sorafenib (N=476) n (%)   |
|-----------------------------------------------------------------------------------------------------|----------------------------|---------------------------|
| DIRECT ACTING ANTIVIRALS                                                                            | 163 (34.1)                 | 149 (31.3)                |
| ADEFOVIR                                                                                            | 21 (4.4)                   | 17 (3.6)                  |
| CLEVUDINE                                                                                           | 1 (0.2)                    | 1 (0.2)                   |
| DACLATASVIR                                                                                         | 0 (0.0)                    | 1 (0.2)                   |
| ENTECAVIR                                                                                           | 93 (19.5)                  | 89 (18.7)                 |
| LAMIVUDINE                                                                                          | 23 (4.8)                   | 21 (4.4)                  |
| SOFOSBUVIR                                                                                          | 0 (0.0)                    | 1 (0.2)                   |
| TELBIVUDINE                                                                                         | 5 (1.0)                    | 9 (1.9)                   |
| TENOFOVIR                                                                                           | 33 (6.9)                   | 25 (5.3)                  |
| THYMALFASIN                                                                                         | 0 (0.0)                    | 1 (0.2)                   |

## Prior anticancer therapy

Since Study 304 was designed to evaluate lenvatinib and sorafenib as first-line systemic treatment of subjects with advanced/unresectable HCC, prior anticancer therapy for this disease was not allowed, with  two  exceptions.  Prior  anticancer  therapy  was  allowed  only  if  given  in  the  adjuvant  setting  or  if administered locally, concurrently with a liver-directed procedure.

Three subjects in the lenvatinib arm received a prior anticancer medication; 2 as adjuvant HCC treatment (human telomerase reverse transcriptase peptide vaccine, approximately 30 months prior to randomization, and combination chemotherapy, approximately 3.5 years prior to randomization).  The third subject received thalidomide for advanced HCC approximately 1.5 months prior to randomization; this was considered a major protocol deviation.

In the sorafenib arm, 2 subjects received adjuvant anticancer medication (an investigational drug, PI-88, sulfonated monophosphorylated mannose oligosaccharides) 3.9 months and 2.4 months, prior to randomization in this study.

## Prior anticancer procedures

<div style=\"page-break-after: always\"></div>

Table 37: Previous Anticancer Procedures and Radiotherapy - Full Analysis Set

| Subjects with Any Previous Anticancer Procedure, n (%o)          | Lenvatinib (N=478) n (%) 327 (68.4)   | Sorafenib (N=476) n (%) 344 (72.3)   |
|------------------------------------------------------------------|---------------------------------------|--------------------------------------|
| Number of Previous Procedures, n (%)                             |                                       |                                      |
| 1                                                                | 144 (30.1)                            | 149 (31.3)                           |
| 2                                                                | 118 (24.7)                            | 119 (25.0)                           |
| 3                                                                | 44 (9.2)                              | 56 (11.8)                            |
| 4                                                                | 14 (2.9)                              | 15 (3.2)                             |
| ≥5                                                               | 7 (1.5)                               | 5 (1.1)                              |
| Previous Procedure Name                                          |                                       |                                      |
| Hepatic intra-arterial chemotherapy                              | 22 (4.6)                              | 35 (7.4)                             |
| Transarterial[chemo]embolization                                 | 246 (51.5)                            | 245 (51.5)                           |
| Radiofrequency ablation                                          | 90 (18.8)                             | 110 (23.1)                           |
| Cryoablation                                                     | 1 (0.2)                               | 1 (0.2)                              |
| Percutaneous ethanol injection                                   | 15 (3.1)                              | 19 (4.0)                             |
| Hepatectomy                                                      | 124 (25.9)                            | 144 (30.3)                           |
| Otherb                                                           | 85 (17.8)                             | 72 (15.1)                            |
| Time from End of Most Recent Procedure to Randomization (months) |                                       |                                      |
| N                                                                | 327                                   | 344                                  |
| Mean (SD)                                                        | 6.5 (9.99)                            | 6.7 (11.26)                          |
| Median                                                           | 3.8                                   | 3.7                                  |
| Q1, Q3                                                           | 2.0, 6.7                              | 2.1, 5.9                             |
| Min, Max                                                         | 0.108                                 | 1. 106                               |
| No. of Subjects with any Previous Radiotherapy Treatment         | 49 (10.3)                             | 60 (12.6)                            |
| Time from Most Recent Radiotherapy to Randomization (months)     |                                       |                                      |
| <3                                                               | 22 (4.6)                              | 28 (5.9)                             |
| 3-6                                                              | 14 (2.9)                              | 8 (1.7)                              |
| >6                                                               | 13 (2.7)                              | 24 (5.0)                             |

Percentages are based on the total number of subjects within the relevant treatment group in the Full Analysis Set. a: A subject may be counted in multiple categories. b: Previous anticancer procedures that were reported on the case report form by the investigator in the 'other' category were varied, but were primarily hepatectomy, microwave therapy, biopsies, or pulmonary resections.

## Concomitant therapy

Concomitant Medication : The proportion of subjects who received at least 1 concomitant medication was similar in the 2 treatment arms (&gt;95%). A high proportion of patients took concomitant anti-hypertensive agents  (72.8%  and  67.6%,  in  the  lenvatinib  and  sorafenib  arms,  respectively).  Other  concomitant medications were generally balanced between the 2 arms. Thyroid preparations were administered more often in the lenvatinib arm (levothyroxine 13.6% vs 4.6%, respectively). Loperamide was used by more sorafenib-treated  subjects  (15.9%  of  lenvatinib  vs.  24.4%  of  sorafenib)  and  dermatological  agents/ emollients were more common with sorafenib.

Concomitant  Palliative  Radiotherapy :  A  few  subjects  in  both  treatment  arms  received  low  dose,  short duration,  palliative  radiotherapy  during  the  study  (15  patients,  3.1%,  lenvatinib;  11  patients,  2.3%,

<div style=\"page-break-after: always\"></div>

sorafenib). Most radiotherapy was to bone (13, 2.7% lenvatinib; 9 (1.9%) sorafenib) and was directed at a non-target lesion.

Anticancer Medications and Procedures during Survival Follow-up: In the overall population, slight imbalance between the treatment arms was seen in the proportion of subjects who received any posttreatment anticancer therapy (anticancer medications and procedures): 51.1% (243/476) in the sorafenib versus 43.1% (206/478) in the lenvatinib arm.

Posttreatment anticancer medication (not for a procedure), was given to 38.7% in the sorafenib 32.6% in the lenvatinib arm.

Table 38: Anticancer Medications (Not Given for Any Procedure) During Survival Follow-up - FAS

|                                                                      | Lenvatinib (N=478) n (%)   | Sorafenib (N=476) n (%)   |
|----------------------------------------------------------------------|----------------------------|---------------------------|
| Subjects with Anticancer Medication during Survival Follow-up, n (%) | 156 (32.6)                 | 184 (38.7)                |
| Number of Medications, n (%)                                         |                            |                           |
| 1                                                                    | 100 (20.9)                 | 98 (20.6)                 |
| 2                                                                    | 20 (4.2)                   | 50 (10.5)                 |
| 3                                                                    | 19 (4.0)                   | 22 (4.6)                  |
| 4                                                                    | 9 (1.9)                    | 8 (1.7)                   |
| ≥5                                                                   | 8 (1.7)                    | 6 (1.3)                   |
| Duration of First Posttreatment Anticancer Medication (Months)       |                            |                           |
| n                                                                    | 115                        | 132                       |
| Mean (SD)                                                            | 3.1 (4.90)                 | 2.8 (2.95)                |
| Median                                                               | 1.6                        | 1.7                       |
| Q1, Q3                                                               | 0.5, 3.3                   | 0.9, 3.6                  |
| Min, Max                                                             | 0, 30                      | 0, 16                     |

Percentages are based on the total number of subjects within the relevant treatment group in the Full Analysis Set. Source: Table 14.1.6.10. (and Table 20 of CSR)

Sorafenib was the most common anti-cancer agent, given to 121 (25.3%) of lenvatinib treated subjects, whilst 56 (11.8%) of patients in the sorafenib arm restarted or continued sorafenib during survival followup. A higher proportion of subjects in the sorafenib arm (9.5% [45] vs 3.1% [15]) received posttreatment anticancer therapy with investigational drugs, as many second-line trials targeted sorafenib failures and/or sorafenib-intolerant subjects.

Anticancer procedures were performed during survival follow-up in comparable proportions of subjects in the 2 treatment arms: 25.5%, lenvatinib and 27.3%, sorafenib. Transcatheter arterial chemoembolization (TACE) was most common (14.4% vs. 17.0% of subjects in the lenvatinib and sorafenib arm, respectively). Regional chemotherapy was given to 4.8% of lenvatinib and 5.3% of sorafenib patients. The figures for radiotherapy to bone were 5.0%, lenvatinib and 4.8%, sorafenib.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The analysis sets and number and percentage of subjects in each analysis set is summarised in table below.

Table 39: Analysis sets (Randomization Phase)

|                                | Lenvatinib   | Sorafenib   | Total       |
|--------------------------------|--------------|-------------|-------------|
| Full Analysis Set a            | 478 (100.0)  | 476 (100.0) | 954 (100.0) |
| Safety Analysis Set b          | 476 (99.6)   | 475 (99.8)  | 951 (99.7)  |
| Per Protocol Analysis Set c    | 467 (97.7)   | 462 (97.1)  | 929 (97.4)  |
| Pharmacokinetic Analysis Set d | 468 (97.9)   | 0 (0.0)     | 468 (49.1)  |
| Pharmacodynamic Analysis Set   | 66 (13.8)    | 48 (10.1)   | 114 (11.9)  |

Data cutoff date:13 Nov 2016.

Percentages are based on the number of subjects within the relevant treatment group in the Full Analysis Set.

- a: Full Analysis Set includes all subjects who were randomized.
- b: Safety Analysis Set includes all subjects who received at least 1 dose of study drug.
- C: Per Protocol Analysis Set includes all subjects who were randomized, received at least 1 dose of the assigned study drug, and had no major protocol deviations. Eleven subjects in the lenvatinib arm had a major protocol deviation; 2 of these subjects did not receive study drug. Thirteen subjects in the sorafenib arm had a major protocol deviation, and 1 additional subject chose not to receive study treatment.
- d: PKAnalysis Set includes all subjects whohave received at least 1 dose oflenvatinib and have at least 1 quantifiable lenvatinib concentration.
- e: Pharmacodynamic Set includes all subjects who received at least 1 dose of study drug and have evaluable Pharmacodynamic data.

## Outcomes and estimation

## Primary efficacy endpoint of Overall Survival (OS)

## Primary analysis

Table 40: Overall Survival based on randomization stratification factors recorded in the IxRS  (Full Analysis Set) - Cut-off date: 13 November 2016

|                                                                        | Lenvatinib (N=478) n (%)                              | Sorafenib (N=476) n (%)                |
|------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------|
| Deaths, n (%)                                                          | 351 (73.4)                                            | 350 (73.5)                             |
| Censored Subjects, n (%) Lost to follow-up Withdrawal of consent Alive | 127 (26.6) 5 (1.0) 13 (2.7) 109 (22.8)                | 126 (26.5) 11 (2.3) 8 (1.7) 107 (22.5) |
| Median Overall Survival (months) a (95% CI)                            | 13.6 (12.1, 14.9)                                     | 12.3 (10.4, 13.9)                      |
| Overall Survival Rate (%) (95% CI) b at 6 Months 12 Months 24 Months   | 80.8 (76.9, 84.1) 55.0 (50.4, 59.4) 29.9 (25.6, 34.2) | 75.2 (71.0, 78.8) 50.0 (45.4, 54.5)    |
|                                                                        |                                                       | 30.5)                                  |
|                                                                        |                                                       | 26.2 (22.1,                            |
| Stratified Cox Model Hazard Ratio (95% CI)                             | 0.92 (0.79, 1.06)                                     |                                        |
| c,d                                                                    |                                                       |                                        |

Data cutoff date: 13 Nov 2016.

Noninferiority margin for the HR of lenvatinib versus sorafenib is 1.08.

a: 95% CIs are estimated with a generalized Brookmeyer and Crowley method.

b: OS rate &amp; 95% CI calculated using Kaplan-Meier product-limit method and Greenwood Formula.

c: Hazard ratio is for lenvatinib vs. sorafenib, based on a Cox model including treatment group as a factor. Efron method was used for ties.

d: Stratified by region (Region 1: Asia-Pacific; Region 2: Western), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (&lt;60 kg, ≥60 kg).

Median duration of survival follow-up was 27.7 months (95% CI 26.4, 29.4) in the lenvatinib arm and 27.2 months (95% CI 25.9, 28.4) in the sorafenib arm.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data cutoff date = 13 Nov 2016.

Noninferiority margin for hazard ratio (Lenvatinib vs. Sorafenib) is 1.08.

Median was estimated with the Kaplan-Meier method and the 95% confidence interval was constructed with a generalized Brookmeyer and Crowley method.

HR was estimated from the Cox proportional hazard model with treatment as independent variable and stratified by IxRS stratification factors. The Efron method was used for ties.

+ = censored observations.

Figure 14: Kaplan-Meier curve and analysis of Overall Survival with stratification factors recorded in the IxRS - Full Analysis Set

## Supportive analyses Per Protocol Population

Table 41: Overall Survival based on randomization stratification factors recorded in the IxRS (Per Protocol Analysis Set)

|                                              | Lenvatinib (N=467) n (%)   | Sorafenib (N=462) n (%)   |
|----------------------------------------------|----------------------------|---------------------------|
| Deaths, n (%)                                | 342 (73.2)                 | 339 (73.4)                |
| Censored Subjects, n (%)                     | 125 (26.8)                 | 123 (26.6)                |
| Lost to follow-up                            | 5 (1.1)                    | 11 (2.4)                  |
| Withdrawal of consent                        | 12 (2.6)                   | 7 (1.5)                   |
| Alive                                        | 108 (23.1)                 | 105 (22.7)                |
| Overall Survival (months)a                   |                            |                           |
| Median (95% CI)                              | 13.7 (12.2, 15.1)          | 12.3 (10.6, 14.2)         |
| Q1 (95% CI)                                  | 7.1 (6.3, 8.0)             | 6.2 (5.4, 7.0)            |
| Q3 (95% CI)                                  | 27.2 (24.5, 30.1)          | 25.4 (22.3, 30.2)         |
| Overall Survival Rate (%) (95% CI)b at       |                            |                           |
| 6 Months                                     | 81.4 (77.5, 84.7)          | 75.5 (71.3, 79.2)         |
| 12 Months                                    | 55.3 (50.6, 59.8)          | 50.3 (45.6, 54.8)         |
| 18 Months                                    | 41.2 (36.7, 45.7)          | 36.8 (32.3, 41.3)         |
| 24 Months                                    | 30.3 (26.0, 34.7)          | 26.3 (22.1, 30.7)         |
| Stratified Cox Model Hazard Ratio (95% CI)&d | 0.91 (0.78, 1.06)          | 0.91 (0.78, 1.06)         |
| Duration of Survival Follow-up (months)ae    |                            |                           |
| Median (95% CI)                              | 27.7 (26.4, 29.3)          | 27.1 (25.9, 27.7)         |
| Q1 (95% CI)                                  | 23.3 (22.3, 24.3)          | 22.6 (20.7, 23.8)         |
| Q3 (95% CI)                                  | 33.1 (31.2, 34.2)          | 31.1 (29.4, 33.1)         |

<div style=\"page-break-after: always\"></div>

## Secondary efficacy endpoints

## Progression-free Survival

Full Analysis Set

Table 42: Progression-free Survival based on randomization stratification factors recorded in IxRS  (Full Analysis Set)

|                                                           | Lenvatinib (N=478) (%) u   | Sorafenib (N=476) n (%)   |
|-----------------------------------------------------------|----------------------------|---------------------------|
| Subjects with Events, n (%)                               | 349 (73.0)                 | 367 (77.1)                |
| Progressive Disease                                       | 308 (64.4)                 | 343 (72.1)                |
| Death                                                     | 41 (8.6)                   | 24 (5.0)                  |
| Censored Subjects, n (%)                                  | 129 (27.0)                 | 109 (22.9)                |
| No postbaseline tumor assessment                          | 23 (4.8)                   | 21 (4.4)                  |
| Death or Progression after more than 1 missing assessment | 4 (0.8)                    | 1 (0.2)                   |
| New anticancer treatment started                          | 10 (2.1)                   | 14 (2.9)                  |
| No progression at the time of data cutoff                 | 26 (5.4)                   | 24 (5.0)                  |
| No progression at the time of treatment discontinuation   | 66 (13.8)                  | 49 (10.3)                 |
| Progression-free Survival (months) a                      |                            |                           |
| Median (95% CI)                                           | 7.4 (6.9, 8.8)             | 3.7 (3.6, 4.6)            |
| Q1 (95% CI)                                               | 3.6 (3.5, 3.7)             | 1.9 (1.8, 1.9)            |
| Q3 (95% CI)                                               | 14.3 (12.8, 16.4)          | 9.1 (7.4, 9.4)            |
| Progression-free Survival Rate (%) (95% C1) b at 6 Months | 56.8 (51.9, 61.4)          | 35.9 (31.3, 40.5)         |
| 12 Months                                                 | 30.8 (26.3, 35.5)          | 16.7 (13.2, 20.7)         |
| 18 Months                                                 | 15.7 (12.0, 19.7)          | 13.1 (9.9, 16.9)          |
| 24 Months                                                 | 8.5 (5.5, 12.2)            | 9.3 (6.3, 12.9)           |
| Stratified Cox Model Hazard Ratio (95% CI) cd             | 0.66 (0.57, 0.77)          | 0.66 (0.57, 0.77)         |
| Stratified Log-rank Test P-value d                        | <0.00001                   | <0.00001                  |
| Follow-up Time for Progression-free Survival (months) ae  |                            |                           |
| Median (95% CI)                                           | 20.3 (18.4, 23.9)          | 19.2 (15.2, 23.3)         |
| Q1 (95% CI)                                               | 11.0 (9.1, 14.3)           | 10.8 (7.4, 14.6)          |
| Q3 (95% CI)                                               | 25.9 (23.9, 29.5)          | 25.8 (23.3, 31.2)         |

P -value is for the superiority test of lenvatinib versus sorafenib a: Quartiles are estimated by Kaplan-Meier method, and the 95% confidence intervals are estimated with a generalized Brookmeyer and Crowley method.

b: PFS rate and 95% CI were calculated using the Kaplan-Meier product-limit method and the Greenwood Formula.

c: Hazard ratio is for lenvatinib vs sorafenib, based on a Cox model including treatment group as a factor.

d: Stratified by region (Region 1: Asia-Pacific; Region 2: Western regions), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (&lt;60 kg, ≥60 kg).

e: Follow-up time for PFS was measured from date of randomization to date of the subject's last PFS follow-up, and it has same numeric value but opposite censoring indicator as compared to PFS.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Data cutoff date = 13 Nov 2016.

Median was estimated with the Kaplan-Meier method and the 95% CI was constructed with a generalized Brookmeyer and Crowley method.

Hazard ratio is expressed as lenvatinib:sorafenib and was estimated from the Cox proportional hazard model with treatment as independent variable and stratified by IxRS stratification factors.The Efron method used for correction of tied events.

P-value was for superiority test (lenvatinib vs. sorafenib) and was calculated using logrank test stratified by IxRS stratification factors.

+ = censored observations.

CI = confidence interval; HR = hazard ratio; IxRS = interactive voice/web response system.

Figure 15: Kaplan-Meier Curves and Analysis of Progression-free Survival With Stratification Factors Recorded in the IxRS (Full Analysis Set)

Per Protocol Analysis Set

Results of the PFS in the PFFs were consistent; the median PFS was 7.4 months for lenvatinib versus 3.7 months for sorafenib (HR = 0.66; 95% CI of 0.57, 0.77; P&lt;0.00001).

<div style=\"page-break-after: always\"></div>

## Time to Progression

Table 43: Time to Progression based on randomization stratification factors recorded in IxRS  (Full Analysis Set)

|                                                         | Lenvatinib (N=478) n (%)   | Sorafenib (N=476) n (%)   |
|---------------------------------------------------------|----------------------------|---------------------------|
| Subjects with Disease Progression, n (%)                | 308 (64.4)                 | 343 (72.1)                |
| Censored Subjects, n (%)                                | 170 (35.6)                 | 133 (27.9)                |
| No postbaseline tumor assessment                        | 33 (6.9)                   | 34 (7.1)                  |
| Progression after more than 1 missing assessment        | 4 (0.8)                    | 1 (0.2)                   |
| New anticancer treatment started                        | 10 (2.1)                   | 14 (2.9)                  |
| No progression at the time of data cutoff               | 26 (5.4)                   | 24 (5.0)                  |
| No progression at the time of treatment discontinuation | 97 (20.3)                  | 60 (12.6)                 |
| Time to Progression (months) b                          |                            |                           |
| Median (95% CI)                                         | 8.9 (7.4, 9.2)             | 3.7 (3.6, 5.4)            |
| Q1 (95% CI)                                             | 3.7 (3.6, 3.7)             | 1.9 (1.8, 1.9)            |
| Q3 (95% CI)                                             | 15.8 (13.7, 16.6)          | 9.2 (7.4, 11.0)           |
| Cumulative Progression Rate (%) (95% C1) ^ at           |                            |                           |
| 6 Months                                                | 39.7 (35.0, 44.7)          | 61.9 (57.2, 66.7)         |
| 12 Months                                               | 65.2 (60.2, 70.1)          | 82.0 (77.9, 85.8)         |
| 18 Months                                               | 81.6 (76.9, 85.8)          | 85.6 (81.6, 89.1)         |
| 24 Months                                               | 89.5 (85.0, 93.1)          | 89.9 (86.0, 93.1)         |
| Stratified Cox Model Hazard Ratio (95% C1 d e           | 0.63 (0.53, 0.73)          | 0.63 (0.53, 0.73)         |
| Stratified Log-rank Test P-value d                      | <0.00001                   | <0.00001                  |
| Follow-up time for time to progression (months) b,f     |                            |                           |
| Median (95% CI)                                         | 16.7 (14.7, 20.3)          | 17.5 (14.7, 22.0)         |
| Q1 (95% CI)                                             | 7.3 (5.5, 9.1)             | 7.3 (5.5, 10.8)           |
| Q3 (95% CI)                                             | 25.7 (23.8, 27.7)          | 25.8 (22.1, 29.4)         |

P -value is for the superiority test of lenvatinib vs sorafenib.

Percentages are based on the total number of subjects within the relevant treatment group in the FAS.

a: Deaths were not counted as progression events in this analysis.

b: Quartiles are estimated by Kaplan-Meier method, and the 95% confidence intervals are estimated with a generalized Brookmeyer and Crowley method.

c: Cumulative progression rate was calculated using the Kaplan-Meier product-limit method and Greenwood Formula.

d: Hazard ratio is for lenvatinib vs sorafenib, based on a Cox model including treatment group as a factor. Efron method was used for ties.

e: Stratified by region (Region 1: Asia-Pacific; Region 2: Western regions), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (&lt;60 kg, ≥60 kg).

f: Follow-up time for TTP was measured from the date of randomization to the date of the subject's last follow-up, and it has same numeric value but opposite censoring indicator as compared to TTP.

Results for the TTP analysis based on the PPS were supportive: median TTP was 9.0 months for lenvatinib versus 3.7 months for sorafenib (HR = 0.63; 95% CI 0.53, 0.74; P&lt; 0.00001).

## Objective Response Rate

A summary of the ORR for the FAS is presented in the table below.

<div style=\"page-break-after: always\"></div>

Table 44: Summary of investigator assessment of Objective Response using mRECIST (Full Analysis Set)

|                                                                                                                                                                                                                                                                         | Lenvatinib (N=478) n (%)                                                                     | Sorafenib (N=476) n (%)                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Best Overall Response, n (%)                                                                                                                                                                                                                                            |                                                                                              |                                                                                             |
| Complete Response (CR) Partial Response (PR) Stable Disease (SD) Durable Stable Disease (SD) Progressive Disease (PD) Unknown/Not Evaluable No baseline tumour assessment No postbaseline tumour assessment 1 or more lesions were not evaluable Early SD (SD <7 Weeks) | 6 (1.3) 109 (22.8) 246 (51.5) 167 (34.9) 71 (14.9) 46 (9.6) 1 (0.2) 39 (8.2) 2 (0.4) 4 (0.8) | 2 (0.4) 42 (8.8) 244 (51.3) 139 (29.2) 147 (30.9) 41 (8.6) 0 (0.0) 34 (7.1) 1 (0.2) 6 (1.3) |
| Objective Response Rate (CR + PR), n (%) 95% CI a                                                                                                                                                                                                                       | 115 (24.1) (20.2, 27.9)                                                                      | 44 (9.2) (6.6, 11.8)                                                                        |
| Difference (%) (95% CI) a Odds ratio (95% CI) b with stratification factors in IxRS P -value b Odds ratio (95% CI) b with stratification factors in CRF P -value b                                                                                                      | 14.8 (10.2, 19.4) 3.13 (2.15, 4.56) <0.00001 3.08 (2.12, 4.48) <0.00001                      | 14.8 (10.2, 19.4) 3.13 (2.15, 4.56) <0.00001 3.08 (2.12, 4.48) <0.00001                     |
| Time to First Objective Response (months)                                                                                                                                                                                                                               |                                                                                              |                                                                                             |
| Subjects with objective response Mean (standard deviation) Median Q1, Q3 Min, Max Duration of Objective                                                                                                                                                                 | n=115 3.6 (3.45) 1.9 2, 4 1, 28                                                              | n=44 4.8 (4.95) 1.9 2, 6 2, 26                                                              |
| Response (months)                                                                                                                                                                                                                                                       |                                                                                              |                                                                                             |
| Subjects with objective response Median (95% CI) c Q1 (95% CI) Q3 (95% CI)                                                                                                                                                                                              | n=115 7.3 (5.6, 7.7) 3.7 (2.2, 3.7) 12.9 (9.6, 16.6)                                         | n=44 11.2 (5.6, 16.6) 3.8 (1.9, 7.3) 20.5 (14.8, NE)                                        |

Data cut-off: 13 Nov 2016. Percentages are based on the total number of subjects within the relevant treatment group in the Full Analysis Set. Tumour assessment based on mRECIST

a: 95% CI was calculated using asymptotic normal approximation.

b: Odds ratio and P -value (for superiority test) were calculated using the Cochran-Mantel-Haenszel method, stratified by IxRS or CRF stratification factors.

c: Median was estimated using the Kaplan-Meier product-limit method and 95% CI was estimated using a generalized Brookmeyer and Crowley method. SD must have occurred ≥7 weeks after randomization. Durable stable disease is a subset of SD, and is defined as SD with a duration of ≥23 weeks after randomization.

Time to first objective response (months) = (Date of first objective response - Date of Randomization + 1) *12/365.25, for subjects with a best overall response of CR or PR. Subjects without a best overall response of CR or PR were censored.

Duration of objective response (months) = (Date of progressive disease/Death - Date of first objective response) *12/365.25, for subjects with objective response.

The  ORR  analysis  in  the  PPS  was  supportive;  24.4%  in  the  lenvatinib  compared  with  9.3%  in  the sorafenib arm.  The difference between the treatment arms was 15.1% (95% CI: 10.4, 19.8). The odds ratio  was  3.19  (95%  CI:  2.18,  4.66),  which  was  statistically  significant  (P&lt;0.00001)  in  favour  of lenvatinib treatment.

## Quality of Life

Assessments of HRQoL scores were performed using the generic cancer HRQoL instrument (EORTC QLQC30), the HCC-specific module (EORTC QLQ-HCC18), and the generic HRQoL instrument, EQ-5D.

During the Randomization Phase, the EORTC  QLQ-C30, EORTC  QLQ-HCC18,  and EQ-5D were administered at Baseline, Day 1 of each cycle after Cycle 1, and at the OTV. During the Extension Phase, the EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D were administered on Day 1 of each treatment and during the OTV.

Missing data were evaluated at the score level for each patient at each cycle to assess the patterns of missing  data  within  and  between  treatment  arms  for  potential  evaluation  in  subsequent  statistical analyses if required or deemed to be appropriate. Patients missing baseline data were excluded from the longitudinal analyses. No imputation for missing PRO data were conducted.

Study compliance was high (&gt;90%) for the patient outcome measures at baseline and throughout the Randomisation Phase, but interpretation was limited in later cycles due to the decline in patient numbers.

<div style=\"page-break-after: always\"></div>

Under  half  of  the  total  population  was  observed  at  Cycle  6  (48.6%  and  48.1%  in  the  CSP  and  LPP, respectively) and one quarter at Cycle 12 (23.2% and 22.6% in the CSP and LPP, respectively). Baseline scores for all domains in the EORTC QLQ-HCC18, EORTC QLQ-C30 and EQ-5D were similar between the lenvatinib and sorafenib treatment arms. The QoL scores declined with both treatments and there was no significant difference between the 2 arms for most domains.

Figure 16: Hazard ratio of time to clinically meaningful worsening of EQ-5D, EORTC QLQ-C30 and EORTC QLQ-HCC18 domains

<!-- image -->

## Ancillary analyses

## Overall Survival

## Sensitivity Analyses for OS based on stratification data in the CRF and without stratification factors

Data used for stratification for the primary analysis were obtained by the IxRS. Stratification factors were region  (Asia-Pacific;  Western),  MPVI  or  extrahepatic  spread  or  both,  ECOG  PS  (PS  =  0;  1),  and  body weight  (&lt;60  kg;  ≥60  kg).  When  comparing  the  stratification  -  factors  based  on  CRF-reported  data  to those based on the IxRS data, the factor 'MPVI, extrahepatic spread or both' had a discrepancy of 87 subjects, and the rest of the factors had no or few discrepancies (15 subjects for ECOG PS and 2 for body weight).

Results of a sensitivity analysis of OS for the FAS based on the stratification data recorded on the CRF [median OS 13.6 vs. 12.3 months, stratified HR 0.91 (0.79, 1.06)] were highly consistent with the results obtained  with  the  primary  analysis  of  OS.  An  analysis  of  OS  without  stratification  factors  for  the  FAS

<div style=\"page-break-after: always\"></div>

confirmed the results based on the primary OS analysis [median OS 13.6 months (95% CI 12.1, 14.9) vs. 12.3 months (95% CI 10.4, 13.9), unstratified Cox Model HR 0.928 (95% CI 0.801, 1.077)].

## OS Adjusted by Baseline Characteristics that may have impacted OS

Table 45 : Overall Survival with Stratification Factors in IxRS, Adjusted by Baseline Characteristics (Full Analysis Set)

| BaselineCharacteristics Overall Sex (Male, Female)                      | HazardRatio(Lenvatinib:Sorafenib)(95%CI) 0.916 (0.789, 1.064) 0.919 (0.791, 1.067)   |
|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Age (<65, ≥65 to <75, ≥75 yrs.)                                         |                                                                                      |
|                                                                         | 0.916 (0.789, 1.064)                                                                 |
| Region (Asia-Pacific, Western Region)                                   | 0.915 (0.789,1.062)                                                                  |
| Macroscopic Portal Vein Invasion (Yes, No)                              | 0.910 (0.784, 1.057)                                                                 |
| Extrahepatic Spread (Yes, No)                                           | 0.915 (0.788, 1.062)                                                                 |
| Macroscopic Portal Vein Invasion, Extrahepatic Spread or Both (Yes, No) | 0.908 (0.783, 1.054)                                                                 |
| ECOG PS (0, ≥1)                                                         | 0.923 (0.795,1.071)                                                                  |
| Body Weight (<60 kg, ≥60 kg)                                            | 0.923 (0.796,1.071)                                                                  |
| Alpha-fetoprotein level at Baseline (<200 ng/mL, ≥200 ng/mL)            | 0.856 (0.736, 0.995)                                                                 |
| Ammonia level (≤ULN, >ULN)                                              | 0.920 (0.788, 1.073)                                                                 |
| Antiviral Therapy for Hepatitis B or Hepatitis C (Yes, No)              | 0.912 (0.785, 1.059)                                                                 |
| Child-Pugh Score (5, ≥6)                                                | 0.932 (0.802, 1.082)                                                                 |
| No. of Disease Sites at Baseline (1, 2, ≥3)                             | 0.878 (0.755, 1.020)                                                                 |
| Etiology (HBV, HCV, Alcohol)                                            | 0.855 (0.721,1.013)                                                                  |
| Underlying Cirrhosis (Yes, No)                                          | 0.916 (0.789, 1.063)                                                                 |
| BCLC Staging (Stage B, Stage C)                                         | 0.918 (0.791, 1.067)                                                                 |
| Prior Procedure (Yes, No)                                               | 0.902 (0.777, 1.048)                                                                 |

If a stratification factor was same as the respective baseline characteristics, this stratification factor was excluded from stratified analysis. Aetiology was based on data from medical history. Prior procedure excluded prior radiotherapy.

a: Hazard ratio was based on a Cox regression model including treatment group and the respective baseline characteristics (not included for overall population) as factors. Efron method was used for ties.

For  baseline  AFP,  the  HR  for  lenvatinib:  sorafenib  was  0.856  (95%  CI:  0.736,  0.995).  Analysis  of  OS adjusted for baseline AFP category (&lt;200 ng/mL, ≥200 ng/mL) was consistent with the primary analysis (4 subjects without baseline AFP values were excluded, 1 in the lenvatinib and 3 in the sorafenib arm). Median OS with baseline AFP as a factor was 13.6 months (12.2, 14.9) vs. 12.3 months (10.6, 14.1) for lenvatinib and sorafenib respectively.

## Subgroup Analysis of OS

<div style=\"page-break-after: always\"></div>

|                                                           | Events / Subjects                                         | Events / Subjects                                         | HR (95% CI)                        | Median (months)                    | Median (months)                    |                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                           | Lenvatinib                                                | Sorafenib                                                 | LenvatinibvsSorafenib              | LenvatinibSorafenib                |                                    |                                    |
| Overall                                                   | 351/478                                                   | 350/476                                                   | 0.92 (0.79, 1.06)                  | 13.6                               | 12.3                               |                                    |
| Age                                                       |                                                           |                                                           |                                    |                                    |                                    |                                    |
| <65 years                                                 | 203/270                                                   | 204/283                                                   | 0.94 (0.77, 1.15)                  | 12.4                               | 11.4                               |                                    |
| >=65 to <75 years                                         | 107/150                                                   | 94/126                                                    | 0.84 (0.63, 1.12)                  | 15.3                               | 12.3                               |                                    |
| >=75 years                                                | 41/58                                                     | 52/67                                                     | 0.84 (0.53, 1.33)                  | 13.4                               | 17.8                               |                                    |
| Sex                                                       |                                                           |                                                           |                                    |                                    |                                    |                                    |
| Male                                                      | 293/405                                                   | 293/401                                                   | 0.91 (0.77, 1.07)                  | 13.4                               | 12.4                               |                                    |
| Female                                                    | 58/73                                                     | 57/75                                                     | 0.84 (0.56, 1.26)                  | 15.3                               | 11.4                               |                                    |
| Region                                                    |                                                           |                                                           |                                    |                                    |                                    |                                    |
| Asia-Pacific                                              | 243/321                                                   | 248/319                                                   | 0.86 (0.72, 1.02)                  | 13.5                               | 11.0                               |                                    |
| Westermregions                                            | 108/157                                                   | 102/157                                                   | 1.08 (0.82, 1.42)                  | 13.6                               | 14.2                               |                                    |
| China                                                     | 79/112                                                    | 68/101                                                    | 0.82 (0.59, 1.14)                  | 14.7                               | 10.5                               |                                    |
| RestofWorld (Excluding China)                             | 272/366                                                   | 282/375                                                   | 0.95 (0.81, 1.13)                  | 13.1                               | 12.7                               |                                    |
| MacroscopicPortal VeinInvasion                            | MacroscopicPortal VeinInvasion                            |                                                           |                                    |                                    |                                    |                                    |
| Yes                                                       | 88/109                                                    | 73/90                                                     | 0.99 (0.71, 1.36)                  | 8.5                                | 9.4                                |                                    |
| No                                                        | 263/369                                                   | 277/386                                                   | 0.88 (0.74, 1.05)                  | 14.9                               | 13.6                               |                                    |
| ExtrahepaticSpread                                        | ExtrahepaticSpread                                        |                                                           |                                    |                                    |                                    |                                    |
| Yes                                                       | 223/291                                                   | 226/295                                                   | 0.89 (0.74, 1.07)                  | 11.6                               | 9.7                                |                                    |
| No                                                        | 128/187                                                   | 124/181                                                   | 1.01 (0.78,1.30)                   | 16.2                               | 15.9                               |                                    |
| MacroscopicPortal VeinInvasion,Extrahepatic Spread orBoth | MacroscopicPortal VeinInvasion,Extrahepatic Spread orBoth | MacroscopicPortal VeinInvasion,Extrahepatic Spread orBoth |                                    |                                    |                                    |                                    |
| Yes                                                       | 250/329                                                   | 259/336                                                   | 0.87 (0.73,1.04)                   | 11.5                               | 9.8                                |                                    |
| No                                                        | 101/149                                                   | 91/140                                                    | 1.05 (0.79, 1.40)                  | 18.0                               | 18.0                               |                                    |
| ECOG-PS                                                   |                                                           |                                                           |                                    |                                    |                                    |                                    |
| PS=0                                                      | 221/304                                                   | 223/301                                                   | 0.88 (0.73,1.06)                   | 14.6                               | 12.8                               |                                    |
| PS=1                                                      | 130/174                                                   | 127/175                                                   | 0.97 (0.76, 1.25)                  | 10.7                               | 10.3                               |                                    |
| Body Weight                                               |                                                           |                                                           |                                    |                                    |                                    |                                    |
| <60 kg                                                    | 110/153                                                   | 113/146                                                   | 0.85 (0.65, 1.11)                  | 13.4                               | 10.3                               |                                    |
| >=60 kg                                                   | 241/325                                                   | 237/330                                                   |                                    |                                    | 12.5                               |                                    |
| Favors Lenvatinib Favors Sorafenib                        | Favors Lenvatinib Favors Sorafenib                        | Favors Lenvatinib Favors Sorafenib                        | Favors Lenvatinib Favors Sorafenib | Favors Lenvatinib Favors Sorafenib | Favors Lenvatinib Favors Sorafenib | Favors Lenvatinib Favors Sorafenib |
|                                                           |                                                           |                                                           | 0.95 (0.79, 1.14)                  | 13.7                               |                                    |                                    |

0.1

1

HazardRatioand95%ConfidenceInterval

10

<div style=\"page-break-after: always\"></div>

|                                     | Events / Subjects                   | Events / Subjects                   |                   | HR (95% CI)             | Median (months)   | Median (months)      |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------|-------------------------|-------------------|----------------------|
|                                     | Lenvatinib                          | Sorafenib                           |                   | Lenvatinib vs Sorafenib |                   | Lenvatinib Sorafenib |
| AFP at Baseline                     |                                     |                                     |                   |                         |                   |                      |
| <200 ng/mL                          | 167/255                             | 193/286                             |                   | 0.91 (0.74, 1.12)       | 19.5              | 16.3                 |
| >=200 ng/mL                         | 183/222                             | 154/187                             |                   | 0.78 (0.63, 0.98)       | 10.4              | 8.2                  |
| Etiology                            |                                     |                                     |                   |                         |                   |                      |
| HBV                                 | 196/259                             | 186/244                             |                   | 0.83 (0.68, 1.02)       | 13.4              | 10.2                 |
| HCV                                 | 75/103                              | 97/135                              |                   | 0.91 (0.66, 1.26)       | 15.3              | 14.1                 |
| Alcohol                             | 22/33                               | 15/23                               |                   | 1.03 (0.47,2.28)        | 14.1              | 11.9                 |
| BCLC Staging                        |                                     |                                     |                   |                         |                   |                      |
| Stage B                             | 71/104                              | 65/92                               |                   | 0.91 (0.65, 1.28)       | 18.5              | 17.3                 |
| Stage C                             | 280/374                             | 285/384                             |                   | 0.92 (0.77, 1.08)       | 11.8              | 10.3                 |
| Post-treatmentAnti-cancerTherapy    | Post-treatmentAnti-cancerTherapy    | Post-treatmentAnti-cancerTherapy    |                   |                         |                   |                      |
| Yes                                 | 143/206                             | 175/243                             |                   | 0.84 (0.67, 1.06)       | 19.5              | 17.0                 |
| No                                  | 208/272                             | 175/233                             | T                 | 0.91 (0.74, 1.11)       | 10.5              | 7.9                  |
| Post-treatmentAnti-cancerProcedures | Post-treatmentAnti-cancerProcedures | Post-treatmentAnti-cancerProcedures |                   |                         |                   |                      |
| Yes                                 | 63/99                               | 82/112                              |                   | 0.71 (0.51, 1.01)       | 23.0              | 19.6                 |
| No                                  | 288/379                             | 268/364                             |                   | 0.94 (0.79, 1.11)       | 11.6              | 10.1                 |
| Post-treatmentAnti-cancerMedication | Post-treatmentAnti-cancerMedication | Post-treatmentAnti-cancerMedication |                   |                         |                   |                      |
| Yes                                 | 110/156                             | 132/184                             |                   | 0.87 (0.67, 1.14)       | 20.8              | 17.0                 |
| No                                  | 241/322                             | 218/292                             |                   | 0.90 (0.75, 1.09)       | 11.5              | 9.1                  |
| Favors Lenvatinib                   | Favors Lenvatinib                   | Favors Lenvatinib                   | Favors Lenvatinib | FavorsSorafenib         | FavorsSorafenib   | FavorsSorafenib      |
| 0.1                                 | 0.1                                 | 0.1                                 | 1                 | 10                      |                   |                      |

HazardRatioand95%ConfidenceInterval

Figure 17: Forest Plot of Hazard Ratio for Lenvatinib vs Sorafenib in Overall Survival with Stratification Factors in IxRS (Full Analysis Set)

## OS by Region and Subsequent Anti-Cancer Therapy (medication and procedures)

Analysis  of  OS  by  subgroup  (see  figure  above)  revealed  that  within  each  treatment,  subjects  who received posttreatment anticancer therapy during survival follow-up had longer median OS than those who did not.

Table 46: Post-treatment Anticancer Therapy during Survival Follow-up by Region (Full Analysis Set)

|                                                                                                 | Lenvatinib           | Lenvatinib      | Sorafenib            | Sorafenib       |
|-------------------------------------------------------------------------------------------------|----------------------|-----------------|----------------------|-----------------|
|                                                                                                 | Asia-Pacific (N=321) | Western (N=157) | Asia-Pacific (N=319) | Western (N=157) |
| Received any anticancer therapy a during survival follow-up, n (%)                              | 162 (50.5)           | 44 (28.0)       | 172 (53.9)           | 71 (45.2)       |
| Underwent any anticancer procedure b during survival follow-up, n (%)                           | 111 (34.6)           | 11 (7.0)        | 112 (35.1)           | 18 (11.5)       |
| Received any anticancer medication c (not given for procedure) during survival follow-up, n (%) | 115 (35.8)           | 41 (26.1)       | 123 (38.6)           | 61 (38.9)       |
| Fluorouracil                                                                                    | 18 (5.6)             | 2 (1.3)         | 25 (7.8)             | 1 (0.6)         |
| Doxorubicin                                                                                     | 5 (1.6)              | 2 (1.3)         | 8 (2.5)              | 11 (7.0)        |
| Cisplatin                                                                                       | 17 (5.3)             | 1 (0.6)         | 21 (6.6)             | 2 (1.3)         |
| Sorafenib                                                                                       | 84 (26.2)            | 37 (23.6)       | 43 (13.5)            | 13 (8.3)        |
| Investigational drug                                                                            | 11 (3.4)             | 4 (2.5)         | 25 (7.8)             | 20 (12.7)       |

Percentages are based on the total number of subjects in the Full Analysis Set within relevant treatment group.

a: Posttreatment anticancer therapy includes both posttreatment anticancer procedures and posttreatment anticancer medications during survival follow-up.

b: Subject with 2 or more procedures reported in the same system organ class or preferred term were only counted once. Anticancer procedures were coded using MedDRA version 19.1.

<div style=\"page-break-after: always\"></div>

c: Subjects with 2 or more medications within a class level and drug name were counted only once within that class level and drug name. WHODD MAR2016 HD B2 was used to code posttreatment anticancer medications not given for any procedure. Selected anticancer medications presented when frequency in any region &gt;5%

Subject health status, including hepatic function, at the end of treatment visit was comparable between the lenvatinib and sorafenib arms in the Western region except for an imbalance in AFP concentration (median AFP: 124.6 ng/mL [Q1, Q3: 7.7, 3848 ng/mL] in the lenvatinib arm vs 45.9 ng/mL [Q1, Q3: 4.7, 986.2 ng/mL] in the sorafenib arm). This reflected the imbalance between the arms at Baseline and the change from Baseline in AFP concentration was similar in both arms.

Median OS was approximately 9 months longer in subjects who received post-treatment anticancer therapy than in those who did not.  In the lenvatinib arm, median OS was 19.5 months (95% CI: 15.7, 23.0) for subjects who received post-treatment anticancer therapy (43%) and 10.5 months (95% CI: 8.6, 12.2) for those who did not.  In the sorafenib arm, median OS was 17.0 months (95% CI: 14.2, 18.8) for subjects who received posttreatment anticancer therapy (51%) and 7.9 months (95% CI: 6.6, 9.7) for those who did not.  Median OS was longer by approximately 2.5 months in the lenvatinib compared with the sorafenib arm in both subsets of subjects (with or without post-treatment anticancer therapy).

When adjusted for post-treatment anticancer therapy, the HR for OS favoured lenvatinib in both regions (table below).

Table 47: Overall Survival adjusted by use of post-treatment anticancer treatment, overall and by region (Full Analysis Set)

|              | Stratified Cox Model Hazard Ratio (95% CI)   | Stratified Cox Model Hazard Ratio (95% CI)   |
|--------------|----------------------------------------------|----------------------------------------------|
|              | WithoutAdjustment                            | With Adjustment                              |
| Overall      | 0.92 (0.79, 1.06)                            | 0.87 (0.75, 1.01)                            |
| Region       |                                              |                                              |
| Asia-Pacific | 0.86 (0.72, 1.02)                            | 0.83 (0.70, 1.00)                            |
| Western      | 1.08 (0.82, 1.42)                            | 0.93 (0.70, 1.23)                            |

For the Asia-Pacific and Western regions, the stratification factor of 'region' was not included.

a: Hazard ratio is for lenvatinib: sorafenib, based on a Cox model including treatment group as a factor. The Efron method used for correction  of  tied  events.  Stratified  by  region  (Region  1:  Asia-Pacific;  Region  2:  Western),  macroscopic  portal  vein  invasion  or extrahepatic spread or both (yes, no), ECOG PS (0, 1), and body weight (&lt;60 kg, ≥60 kg).

b: Status of posttreatment anticancer therapy (yes/no) was used as an additional covariate factor.

## Progression-free Survival

## Sensitivity Analysis for PFS

A  stratified  analysis  of  PFS  using  all  disease  progression  and  death  events  was  done  as  a  sensitivity analysis using the FAS.

## PFS by subgroup

Forest  plots  of  the  HRs  (lenvatinib:sorafenib)  in  PFS  for  selected  stratification  factors  in  the  IxRS  is presented in the figure below.

<div style=\"page-break-after: always\"></div>

|                                              | Events / Subjects                 | Events / Subjects                 | HR (95% CI)                       | Median (months)                   | Median (months)                   |                                   |
|----------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                              | Lenvatinib                        | Sorafenib                         | LenvatinibvsSorafenib             | Lenvatinib Sorafenib              |                                   |                                   |
| Overall                                      | 349/478                           | 367/476                           | 0.66 (0.57,0.77)                  | 7.4                               | 3.7                               |                                   |
| Age                                          |                                   |                                   |                                   |                                   |                                   |                                   |
| <65 years                                    | 201/270                           | 223/283                           | 0.67 (0.55, 0.82)                 | 7.3                               | 3.6                               |                                   |
| >=65 to <75 years                            | 113/150                           | 100/126                           | 0.61 (0.46,0.82)                  | 7.4                               | 5.3                               |                                   |
| >=75 years                                   | 35/58                             | 44/67                             | 0.59 (0.34, 1.02)                 | 7.8                               | 5.5                               |                                   |
| Sex                                          |                                   |                                   |                                   |                                   |                                   |                                   |
| Male                                         | 298/405                           | 308/401                           | 0.66 (0.56, 0.77)                 | 7.4                               | 3.7                               |                                   |
| Female                                       | 51/73                             | 59/75                             | 0.75 (0.49, 1.13)                 | 7.4                               | 4.6                               |                                   |
| Region                                       |                                   |                                   |                                   |                                   |                                   |                                   |
| Asia-Pacific                                 | 249/321                           | 264/319                           | 0.61 (0.51,0.73)                  | 7.3                               | 3.6                               |                                   |
| Westemregions                                | 100/157                           | 103/157                           | 0.81 (0.61, 1.08)                 | 7.4                               | 5.5                               |                                   |
| China                                        | 83/112                            | 80/101                            | 0.59 (0.43, 0.81)                 | 11.0                              | 3.7                               |                                   |
| Restof World                                 | 266/366                           | 287/375                           | 0.70 (0.59,0.83)                  | 7.2                               | 3.7                               |                                   |
| (Excluding China)                            |                                   |                                   |                                   |                                   |                                   |                                   |
| MacroscopicPortal Vein Invasion Yes          | 78/109                            | 72/90                             | 0.64 (0.46, 0.91)                 | 5.5                               | 2.2                               |                                   |
| No                                           | 271/369                           | 295/386                           | 0.65 (0.55, 0.77)                 | 8.4                               | 3.7                               |                                   |
| ExtrahepaticSpread                           |                                   |                                   |                                   |                                   |                                   |                                   |
| Yes                                          | 218/291                           | 233/295                           | 0.60 (0.50,0.73)                  | 7.4                               | 3.6                               |                                   |
| No                                           | 131/187                           | 134/181                           | 0.72 (0.56, 0.93)                 | 8.0                               | 5.6                               |                                   |
| MacroscopicPortal Vein Invasion,Extrahepatic |                                   |                                   |                                   |                                   |                                   |                                   |
| Spread or Both                               |                                   |                                   |                                   |                                   |                                   |                                   |
| Yes                                          | 246/329                           | 265/336                           | 0.64 (0.54, 0.77)                 | 7.3                               | 3.6                               |                                   |
| No                                           | 103/149                           | 102/140                           | 0.73 (0.55, 0.97)                 | 9.2                               | 5.6                               |                                   |
| ECOG-PS                                      |                                   |                                   |                                   |                                   |                                   |                                   |
| PS=0                                         | 220/304                           | 233/301                           | 0.63 (0.52, 0.76)                 | 7.4                               | 3.7                               |                                   |
| PS=1                                         | 129/174                           | 134/175                           | 0.70 (0.55, 0.90)                 | 7.3                               | 3.7                               |                                   |
| Body Weight                                  |                                   |                                   |                                   |                                   |                                   |                                   |
| <60 kg                                       | 111/153                           | 121/146                           | 0.61 (0.46, 0.79)                 | 7.4                               | 3.6                               |                                   |
| >=60 kg                                      | 238/325                           | 246/330                           | 0.69 (0.58, 0.83)                 | 7.4                               | 3.7                               |                                   |
| Extrahepatic Spread                          |                                   |                                   |                                   |                                   |                                   |                                   |
| Yes                                          | 218/291                           | 233/295                           | 0.60 (0.50, 0.73)                 | 7.4                               | 3.6                               |                                   |
| No                                           | 131/187                           | 134/181                           | 0.72 (0.56, 0.93)                 | 8.0                               | 5.6                               |                                   |
| MacroscopicPortal Vein Invasion,Extrahepatic |                                   |                                   |                                   |                                   |                                   |                                   |
| Yes                                          | 246/329                           | 265/336                           | 0.64 (0.54, 0.77)                 | 7.3                               | 3.6                               |                                   |
| No                                           | 103/149                           | 102/140                           | 0.73 (0.55, 0.97)                 | 9.2                               | 5.6                               |                                   |
| PS=0                                         | 220/304                           | 233/301                           | 0.63 (0.52, 0.76)                 | 7.4                               | 3.7                               |                                   |
| PS=1                                         | 129/174                           | 134/175                           | 0.70 (0.55, 0.90)                 | 7.3                               | 3.7                               |                                   |
| ECOG-PS                                      |                                   |                                   |                                   |                                   |                                   |                                   |
|                                              | 111/153                           |                                   | 0.61 (0.46, 0.79)                 | 7.4                               |                                   |                                   |
| Body Weight                                  |                                   |                                   |                                   |                                   |                                   |                                   |
| <60 kg                                       |                                   | 121/146                           |                                   |                                   | 3.6                               |                                   |
| >=60 kg                                      | 238/325                           | 246/330                           | 0.69 (0.58, 0.83)                 | 7.4                               | 3.7                               |                                   |
| FavorsLenvatinib Favors Sorafenib            | FavorsLenvatinib Favors Sorafenib | FavorsLenvatinib Favors Sorafenib | FavorsLenvatinib Favors Sorafenib | FavorsLenvatinib Favors Sorafenib | FavorsLenvatinib Favors Sorafenib | FavorsLenvatinib Favors Sorafenib |

0.1

1

10

Figure 18: Forest Plot of Hazard Ratio for Lenvatinib vs Sorafenib in Progression Free Survival with Stratification Factors in IxRS Full Analysis Set

## Time to Progression

## Sensitivity Analyses for TTP

A stratified analysis of TTP using all disease progression events (subjects were not censored for missing assessments,  new  anticancer  therapy  or  treatment  discontinuation  for  reasons  other  than  PD)  was consistent with the initial results. Median TTP was 7.6 months for lenvatinib compared with 3.7 months for sorafenib with an HR = 0.62, 95% CI of 0.54, 0.73, and P&lt; 0.00001.

## Subgroup analysis of TTP

<div style=\"page-break-after: always\"></div>

As seen in the overall population, median TTP with stratification factors in the IxRS was longer with lenvatinib than sorafenib, with HR &lt;1 in each of the subgroups tested.

## Objective Response Rate

## Subgroup analysis of ORR

The ORR was consistently higher in the lenvatinib arm than in the sorafenib arm in each of the subgroups tested, with the exception of alcohol use, for which the number of subjects was small.

The ORR with lenvatinib in the Western region (21.0%, 95% CI: 14.6, 27.4) was consistent with that observed for the Asia-Pacific region (25.5%, (95% CI: 20.8, 30.3) and for the overall population (24.1%, 95% CI: 20.2, 27.9). The odds ratios were 2.18 (1.15, 4.11) for the Western region, 3.77 (95% CI: 2.36, 6.04) for the Asia-Pacific region, and 3.13 (95% CI: 2.15, 4.56) for the overall population.

## Post-hoc retrospective independent imaging review

A post hoc, blinded IIR was conducted per an Independent Review Charter (IRC).

At screening all but 5 subjects (4 lenvatinib, 1 sorafenib) had disease as identified by the IIR. In regard to target lesions at baseline, 33 patients by mRECIST (18 lenvatinib, 15 sorafenib) and 21 patients by RECIST 1.1 (12 lenvatinib, 9 sorafenib) did not have lesions meeting requirement for a target lesion at baseline.

Although the proportion of subjects with cirrhosis was underreported based on CRF data (49.7%), further post-hoc analysis of screening scans using non-invasive imaging confirmed diagnosis of HCC in 74.5% for lenvatinib arm and 76.5% for sorafenib arm.

A side-by-side summary of key efficacy results for both treatment arms, obtained using the investigator assessment (primary comparison) and the confirmatory blinded IIR using mRECIST, is presented in table below.

<div style=\"page-break-after: always\"></div>

Table 48: Summary of key efficacy results obtained with the investigator or blinded independent review using mRECIST - Randomization Phase (Full Analysis Set)

|                                                                      | Investigator Assessment                           | Investigator Assessment                           | Independent Imaging Assessment                    | Independent Imaging Assessment                    |
|----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                      | Lenvatinib                                        | Sorafenib                                         | Lenvatinib                                        | Sorafenib                                         |
| Progression-free Survival -Primary Analysis                          | Progression-free Survival -Primary Analysis       | Progression-free Survival -Primary Analysis       | Progression-free Survival -Primary Analysis       | Progression-free Survival -Primary Analysis       |
| Median (mo) (95% CI) “                                               | 7.4 (6.9, 8.8)                                    | 3.7 (3.6, 4.6)                                    | 7.3 (5.6, 7.5)                                    | 3.6 (3.6, 3.7)                                    |
| Hazard Ratio (95% CI) b,c                                            | 0.66 (90.57, 0.77) P<0.00001                      | 0.66 (90.57, 0.77) P<0.00001                      | 0.64 (0.55, 0.75) P<0.00001                       | 0.64 (0.55, 0.75) P<0.00001                       |
| Progression-free Survival -- Sensitivity Analysis                    | Progression-free Survival -- Sensitivity Analysis | Progression-free Survival -- Sensitivity Analysis | Progression-free Survival -- Sensitivity Analysis | Progression-free Survival -- Sensitivity Analysis |
| Median (mo) (95% CI)a                                                | 7.3 (5.8, 7.5)                                    | 3.7 (3.6, 4.7)                                    | 6.6 (5.5, 7.4)                                    | 3.7 (3.6, 5.1)                                    |
| Hazard Ratio (95% CI) P value b,c                                    | 0.72 (0.63, 0.83) P<0.00001                       | 0.72 (0.63, 0.83) P<0.00001                       | 0.82 (0.71, 0.94) P=0.0047                        | 0.82 (0.71, 0.94) P=0.0047                        |
| Time to Progression                                                  | Time to Progression                               | Time to Progression                               | Time to Progression                               | Time to Progression                               |
| Median (mo) (95% CI) a                                               | 8.9 (7.4, 9.2)                                    | 3.7 (3.6, 5.4)                                    | 7.4 (7.2, 9.1)                                    | 3.7 (3.6, 3.9)                                    |
| Hazard Ratio (95% CI) P value b,c                                    | 0.63 (0.53, 0.73) P<0.00001                       | 0.63 (0.53, 0.73) P<0.00001                       | 0.60 (0.51, 0.71) P<0.00001                       | 0.60 (0.51, 0.71) P<0.00001                       |
| Objective Response Rate                                              | Objective Response Rate                           | Objective Response Rate                           | Objective Response Rate                           | Objective Response Rate                           |
| ORR (CR+ PR), %d (95% CI)                                            | 24.1% (20.2, 27.9)                                | 9.2% (6.6, 11.8)                                  | 40.6% (36.2, 45.0)                                | 12.4% (9.4, 15.4)                                 |
| Difference (%) (95% CI)                                              | 14.8 (10.2, 19.4)                                 | 14.8 (10.2, 19.4)                                 | 28.2 (22.9, 33.5)                                 | 28.2 (22.9, 33.5)                                 |
| Odds Ratio (95% C1) with stratification factors from IxRS; P value f | 3.13 (2.15, 4.56) P<0.00001                       | 3.13 (2.15, 4.56) P<0.00001                       | 5.01 (3.59, 7.01) P<0.00001                       | 5.01 (3.59, 7.01) P<0.00001                       |

CI = confidence interval; CMH = Cochran-Mantel-Haenszel CR = complete response; CRF = case report form; ECOG PS = Eastern Cooperative Oncology Group Performance Status; IxRS = Interactive Voice/Web Response

System; ORR -- objective response rate; PR = partial response.

- a: 95% CIs were estimated with a generalized Brookmeyer and Crowley method.
- b: Hazard ratio is for lenvatinib vs sorafenib, based on a Cox model including treatment group as a factor. Efron method is used for ties.
- c: Stratified by region (Region 1: Asia-Pacific; Region 2: Western regions), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (&lt;60 kg, ≥60 kg).
- d: Percentages are based on the total number of subjects in the Full Analysis Set within the relevant treatment group.
- e: 95% CI was calculated using asymptotic normal approximation.
- f: Odds ratio and P-value (for superiority test) were calculated using the CMH method, stratified by IxRS or CRF stratification factors.

<div style=\"page-break-after: always\"></div>

## PFS

Table 49: Progression-Free Survival Based on Randomization Stratification Factors Recorded in the IxRS Independent Imaging Review Using mRECIST (Full Analysis Set)

|                                                          | Lenvatinib (N=478) n (%)   | Sorafenib (N=476) n (%)   |
|----------------------------------------------------------|----------------------------|---------------------------|
| Subjects with Events, n (%)                              | 311 (65.1)                 | 323 (67.9)                |
| Progressive Disease                                      | 278 (58.2)                 | 307 (64.5)                |
| Death                                                    | 33 (6.9)                   | 16 (3.4)                  |
| Censored Subjects, n (%)                                 | 167 (34.9)                 | 153 (32.1)                |
| No baseline tumor assessment                             | 3 (0.6)                    | 1 (0.2)                   |
| No postbaseline tumor assessment                         | 23 (4.8)                   | 22 (4.6)                  |
| New anticancer treatment started                         | 43 (9.0)                   | 31 (6.5)                  |
| No progression at the time of data cutoff                | 16 (3.3)                   | 13 (2.7)                  |
| No progression at the time of treatment discontinuation  | 82 (17.2)                  | 86 (18.1)                 |
| Progression-Free Survival (months)                       |                            |                           |
| Median (95% CI)                                          | 7.3 (5.6, 7.5)             | 3.6 (3.6, 3.7)            |
| Q1 (95% CI)                                              | 3.5 (2.3, 3.6)             | 1.9 (1.8, 1.9)            |
| Q3 (95% CI)                                              | 11.2 (11.0, 12.9)          | 7.3 (5.6, 9.2)            |
| Progression-Free Survival Rate (%) (95% C1)b at          |                            |                           |
| 6 Months                                                 | 53.7 (48.6, 58.5)          | 27.4 (22.8, 32.2)         |
| 12 Months                                                | 24.4 (19.8, 29.2)          | 15.4 (11.5, 19.8)         |
| 18 Months                                                | 12.6 (8.9, 16.9)           | 11.7 (8.1, 16.0)          |
| 24 Months                                                | 8.4 (5.1, 12.6)            | 8.5 (5.1, 13.0)           |
| Stratified Cox Model Hazard Ratio (95% C1)&d             | 0.64 (0.55, 0.75)          | 0.64 (0.55, 0.75)         |
| Stratified Log-Rank Test P valued                        | <0.00001                   | <0.00001                  |
| Follow-Up Time for Progression-Free Survival (months)a,e |                            |                           |
| Median (95% CI)                                          | 14.7 (11.3, 17.5)          | 11.0 (7.6, 14.7)          |
| Q1 (95% CI)                                              | 5.5 (3.7, 7.3)             | 3.6 (2.1, 5.4)            |
| Q3 (95% CI)                                              | 23.8 (21.7, 26.6)          | 23.9 (18.4, 27.6)         |

Data cutoff date: 13 Nov 2016. P value is for the superiority test of lenvatinib versus sorafenib. Percentages are based on the total number of subjects in the Full Analysis Set within the relevant treatment arm.

a: Quartiles estimated by Kaplan-Meier method; 95% CIs estimated with a generalized Brookmeyer and Crowley method

b: PFS rate and 95% CI calculated using Kaplan-Meier product-limit method and Greenwood Formula.

c: Hazard ratio is for lenvatinib vs sorafenib, based on a Cox model including treatment arm as a factor. Efron method was used for ties.

d: Stratified by region (Region 1: Asia-Pacific; Region 2: Western regions), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1), and body weight (&lt;60 kg, ≥60 kg).

e: Follow-up time for PFS measured from the date of randomization to the date of the subject's last PFS follow-up, and had same numeric value but opposite censoring indicator as compared to PFS.

A sensitivity analysis using all PD and deaths as events was consistent with the primary PFS analysis; median PFS was 6.6 months for lenvatinib compared with 3.7 months for sorafenib with an HR of 0.82 (95% CI: 0.71, 0.94) and P =0.0047.

TTP - Similarly, median TTP as assessed by blinded IIR using mRECIST was consistent with the median TTP obtained using the investigator assessment.

<div style=\"page-break-after: always\"></div>

Table 50: Time to Progression Based on Randomization Stratification Factors Recorded in the IxRS Independent Imaging Review Using mRECIST (Full Analysis Set)

| Subjects with Disease Progression, n (%) Censored Subjects, n (%)   | Lenvatinib (N=478) n (%) 278 (58.2) 200 (41.8)   | Sorafenib (N=476) n (%) 307 (64.5) 169 (35.5)   |
|---------------------------------------------------------------------|--------------------------------------------------|-------------------------------------------------|
| No baseline tumor assessment                                        | 3 (0.6)                                          | 1 (0.2)                                         |
| No postbaseline tumor assessment                                    | 33 (6.9)                                         | 34 (7.1)                                        |
| New anticancer treatment started                                    | 43 (9.0)                                         | 31 (6.5)                                        |
| No progression at the time of data cutoff                           | 16 (3.3)                                         | 13 (2.7)                                        |
| No progression at the time of treatment discontinuation             | 105 (22.0)                                       | 90 (18.9)                                       |
| Time to Progression (months)a                                       |                                                  |                                                 |
| Median (95% CI)                                                     | 7.4 (7.2, 9.1)                                   | 3.7 (3.6, 3.9)                                  |
| Q1 (95% CI)                                                         | 3.6 (3.5, 3.7)                                   | 1.9 (1.8, 1.9)                                  |
| Q3 (95% CI)                                                         | 12.9 (11.0, 14.7)                                | 7.4 (5.7, 9.2)                                  |
| Cumulative Progression Rate (%) (95% C1)b at                        |                                                  |                                                 |
| 6 Months                                                            | 42.9 (38.1, 48.1)                                | 71.4 (66.5, 76.1)                               |
| 12 Months                                                           | 72.5 (67.2, 77.6)                                | 83.9 (79.4, 88.0)                               |
| 18 Months                                                           | 85.5 (80.7, 89.7)                                | 87.8 (83.3, 91.6)                               |
| 24 Months                                                           | 90.0 (85.0, 93.8)                                | 91.1 (86.4, 94.7)                               |
| Stratified Cox Model Hazard Ratio (95% CI)&d                        | 0.60 (0.51, 0.71)                                | 0.60 (0.51, 0.71)                               |
| Stratified Log-rank Test P valued                                   | <0.00001                                         | <0.00001                                        |
| Follow-Up Time for TTP (months)a,e                                  |                                                  |                                                 |
| Median (95% CI)                                                     | 11.3 (9.2, 14.7)                                 | 11.0 (7.4, 13.0)                                |
| Q1 (95% CI)                                                         | 3.7 (3.6, 5.5)                                   | 3.4 (1.9, 3.7)                                  |
| Q3 (95% CI)                                                         | 22.2 (20.1, 25.9)                                | 23.3 (16.7, 25.8)                               |

Results of a TTP sensitivity analysis using all PD events were consistent with the results obtained with the primary TTP analysis.

## ORR

Table 51: Summary of Tumour Response per Investigator Assessment and Independent Imaging Review per mRECIST (Full Analysis Set)

|                                | Investigator Assessment   | Investigator Assessment   | Independent Review       | Independent Review      |
|--------------------------------|---------------------------|---------------------------|--------------------------|-------------------------|
|                                | Lenvatinib (N=478) n (%)  | Sorafenib (N=476) n (%)   | Lenvatinib (N=478) n (%) | Sorafenib (N=476) n (%) |
| Complete Response (CR) Partial | 6 (1.3)                   | 2 (0.4)                   | 10 (2.1)                 | 4 (0.8)                 |
| Response (PR) Stable Disease   | 109 (22.8)                | 42 (8.8)                  | 184 (38.5)               | 55 (11.6)               |
| (SD) Durable SD                | 246 (51.5)                | 244 (51.3)                | 159 (33.3)               | 219 (46.0)              |
| Progressive Disease (PD) Not   | 167 (34.9)                | 139 (29.2)                | 84 (17.6)                | 90 (18.9)               |
| Evaluable/Unknown              | 71 (14.9)                 | 147 (30.9)                | 79 (16.5)                | 152 (31.9)              |
| Evaluable/Unknown              | 46 (9.6)                  | 41 (8.6)                  | 46 (9.6)                 | 46 (9.7)                |

Mean time to first objective response for responders was shorter by IIR than Ix assessment (2.7 months for lenvatinib and 3.4 months for sorafenib by IIR vs. 3.6 and 4.8 months by Ix). For responders, median duration of response was 7.3 months for lenvatinib-treated subjects (n=194) and 6.2 months for sorafenib-treated subjects (n=59) by IIR compared to 7.3 months (n=115) and 11.2 months (n=44) by Ix assessment.

Overall, agreement on best overall response (BOR) between the independent and investigator assessments was 62.6%. Agreement was higher for sorafenib (70.0%; 333/476) than lenvatinib (55.2%; 264/478), driven by the high agreement on BOR of SD and PD in the sorafenib arm. Independent

<div style=\"page-break-after: always\"></div>

reviewers assessed more instances of PR when investigators assessed SD, especially for subjects treated with lenvatinib (103 [21.5%]) as compared with sorafenib (29 [6.1%]).

Table 52: Summary of Progression Assessed by Investigator and Independent Review Using mRECIST (Full Analysis Set)

|                    |                     | Independent Review   | Independent Review   |
|--------------------|---------------------|----------------------|----------------------|
|                    | Investigator Review | PD n (%)             | Non PD n (%)         |
| Overall (N=954)    | PD                  | 538 (56.4)           | 165 (17.3)           |
|                    | Non PD              | 77 (8.1)             | 174 (18.2)           |
| Lenvatinib (N=478) | PD                  | 249 (52.1)           | 80 (16.7)            |
|                    | Non PD              | 45 (9.4)             | 104 (21.8)           |
| Sorafenib (N=476)  | PD                  | 289 (60.7)           | 85 (17.9)            |
|                    | Non PD              | 32 (6.7)             | 70 (14.7)            |

Table 53: Agreement on timing of progression assessed by investigator and IRR using mRECIST

|                                                 | Agreement on Timing of PDa   | Agreement on Timing of PDa   |
|-------------------------------------------------|------------------------------|------------------------------|
| SubjectsWithPDbyBothInvestigator Review and IIR | Yes n (%)                    | No n (%)                     |
| Overall (N=538)                                 | 274 (50.9)                   | 264 (49.1)                   |
| Lenvatinib (N=249)                              | 115 (46.2)                   | 134 (53.8)                   |
| Sorafenib (N=289)                               | 159 (55.0)                   | 130 (45.0)                   |

IIR = Independent Imaging Review, mRECIST = modified Response Evaluation Criteria in Solid Tumors; PD = progressive disease.

Percentages are based on the total number of randomized subjects with PD by both Investigator and Independent Reviewer in the relevanttreatmentarm.

a: If both Investigator and Independent Reviewer identified PD for a subject on the same date, they were considered as agreed on timing of PD; if the PDs of the subject were on different dates, they were considered as not agreed on timing. Source:IIR Summary Table 7.

Table 54 : Comparison of Timing of Progression Assessed per mRECIST by Investigator and Independent Review (Full Analysis Set)

|                                 |   Lenvatinib (N=478) |   Sorafenib (N=476) |   DifferentialDiscordance for LenvatinibvsSorafenib |   Overall (N=954) |
|---------------------------------|----------------------|---------------------|-----------------------------------------------------|-------------------|
| Early Discordance Rate (EDR, %) |                 28.3 |                26.2 |                                                 2.1 |              27.2 |
| Late Discordance Rate (LDR, %)  |                 64.1 |                60.3 |                                                 3.8 |              62.3 |

EDR (Early Discordance Rate) = (number of subjects with INV PD earlier than IIR PD + number of subjects with INV PD and without IIR PD) / number of subjects with INV PD.

LDR (Late Discordance Rate) = (number of subjects with INV PD later than IIR PD + number of subjects without INV PD but with IIR PD)/ (number of subjects with INV PD earlier than IIR PD + number of subjects with INV PD later than IIR PD + number of subjects without INV PD but with IIR PD + number of subjects with INV PD and without IIR PD).

Differential discordance for EDR = Difference among EDR between 2 treatment arms.

Differential discordance for LDR = Difference among LDR between 2 treatment arms.

Discordance rates on timing of progression (EDR and LDR) were similar in the 2 arms (EDR: 28.3% in the lenvatinib arm vs 26.2% in the sorafenib arm; LDR: 64.1% in the lenvatinib arm vs 60.3% in the sorafenib arm), showing that there was no meaningful bias in the investigator results.

## IRR using RECIST 1.1

Independent review of tumour assessments using RECIST 1.1 yielded similar results for both PFS (median 7.3 months lenvatinib vs 3.6 months sorafenib; HR=0.65 [95% CI: 0.56, 0.77; p&lt;0.00001] ) and TTP (median 7.4 months vs. 3.7 months; HR=0.61 [95% CI: 0.51, 0.72; p&lt;0.00001]) as with mRECIST. As expected, the response rates for both arms were lower when using RECIST 1.1 (18.8% for lenvatinib vs

<div style=\"page-break-after: always\"></div>

6.5% for sorafenib) than with mRECIST, but the relative benefit of lenvatinib treatment compared with sorafenib by mRECIST was maintained (Odds ratio 3.34; 95% CI: 2.17, 5.14; p&lt;0.00001).

The duration of objective response was longer in sorafenib arm than in lenvatinib arm: 15.8 (5.9, NE) months vs 7.4 (5.6, 9.2) months, respectively.

## Efficacy results by dose of lenvatinib

## Efficacy by Lenvatinib Starting Dose (Body Weight Category)

At the request of the CHMP, the MAH reviewed the efficacy data by starting dose of lenvatinib.

Starting  dose  was  based  on  body  weight.  The  number  of  subjects  who  received  lenvatinib  by  starting dose (8 mg, n=151; 12 mg, n=327) was nearly identical to the number of subjects in the body weight subgroups (&lt;60 kg, n=153; ≥60 kg, n=325). The efficacy of lenvatinib by starting dose was based on the analysis by body weight category, as already presented in the subgroup analyses. Body weight was not a randomization factor; these were not planned analyses.

Table 55 : Efficacy by Lenvatinib starting dose (BW category)

| Lenvatinib results                                  | BW<60kg (8mg starting dose)         | BW ≥60kg (12mg starting dose)       |
|-----------------------------------------------------|-------------------------------------|-------------------------------------|
| Median OS months (95% CI) HR lenvatinib: sorafenib  | 13.4 (10.5, 15.7) 0.85 (0.65, 1.11) | 13.7 (12.0, 15.6) 0.95 (0.79, 1.14) |
| Median PFS months (95% CI) HR lenvatinib: sorafenib | 7.4 (5.4, 9.2) 0.61 (0.46, 0.79)    | 7.4 (6.9, 9.0) 0.69 (0.58, 0.83)    |
| Median TTP months (95% CI) HR lenvatinib: sorafenib | 9.0 (5.6, 9.2) 0.61 (0.46, 0.80)    | 8.8 (7.3, 9.2) 0.64 (0.53, 0.77)    |
| ORR% (95% CI) Odds ratio lenvatinib: sorafenib      | 22.2 (15.6, 28.8) 3.16 (1.56, 6.41) | 24.9 (20.2, 29.6) 3.11 (2.00, 4.85) |

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 56: Summary of Efficacy for trial 304

| Title: A Multicenter, Randomised, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma   | Title: A Multicenter, Randomised, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma   | Title: A Multicenter, Randomised, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                       | E7080-G000-304                                                                                                                                                                                                         | E7080-G000-304                                                                                                                                                                                                         |
| Design                                                                                                                                                                                                                 | - Phase III - randomised (1:1), open-label, multi-centre, non-inferiority study - comparator-controlled (sorafenib)                                                                                                    | - Phase III - randomised (1:1), open-label, multi-centre, non-inferiority study - comparator-controlled (sorafenib)                                                                                                    |
| Design                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                         | Until target 700 deaths (~3 years 8 months) 01 March 2013 - 13 November 2016 ~21 days (screening + baseline) ongoing                                                                                                   |
| Hypothesis                                                                                                                                                                                                             | Non-inferiority (NI margin for HR lenvatinib vs sorafenib = 1.08)                                                                                                                                                      | Non-inferiority (NI margin for HR lenvatinib vs sorafenib = 1.08)                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                      | lenvatinib                                                                                                                                                                                                             | 8 mg QD (BW<60kg), N=151 12 mg AQD (BW≥60kg), N=327 TOTAL N=478                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                      | sorafenib                                                                                                                                                                                                              | 400 mg BID, N=476                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Overall Survival (OS)                                                                                                                                                        | Primary endpoint The time from the date of randomisation until death due to any cause                    | Progression -free Survival (PFS)                                                                                                                             | Progression -free Survival (PFS)                                                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| The time from the date of randomisation to the date of first documentation of radiologic disease progression (investigator assessed by mRECIST), or date of death, whichever | Secondary endpoints Time-to- Progression (TPP)                                                           | occurs first The time from the date of randomisation to the date of first documentation of radiologic disease progression (investigator assessed by mRECIST) | occurs first The time from the date of randomisation to the date of first documentation of radiologic disease progression (investigator assessed by mRECIST) |
| subjects complete (PR).                                                                                                                                                      | Objective Response The proportion of who have best overall response of response (CR) or partial response | Rate (ORR) HRQoL                                                                                                                                             | Rate (ORR) HRQoL                                                                                                                                             |
| EORTC QLQ-C30, HC-18 and EQ-5D-3L.                                                                                                                                           | Data cut-off date for primary analysis: 13 November 2016                                                 | Primary Analysis                                                                                                                                             | Primary Analysis                                                                                                                                             |
| Set (FAS) i.e. ITT - all randomised subjects analysed per their treatment, based on randomisation stratification factors per                                                 |                                                                                                          |                                                                                                                                                              |                                                                                                                                                              |
| Treatment group Lenvatinib Sorafenib Number of subjects Number of 478 351 (73.4%) 476 350 (73.5%)                                                                            | Treatment group Lenvatinib Sorafenib Number of subjects Number of 478 351 (73.4%) 476 350 (73.5%)        | Treatment group Lenvatinib Sorafenib Number of subjects Number of 478 351 (73.4%) 476 350 (73.5%)                                                            | Treatment group Lenvatinib Sorafenib Number of subjects Number of 478 351 (73.4%) 476 350 (73.5%)                                                            |
| 95% CI (6.9;8.8) (3.6;4.6)                                                                                                                                                   | 95% CI (6.9;8.8) (3.6;4.6)                                                                               | 95% CI (6.9;8.8) (3.6;4.6)                                                                                                                                   | 95% CI (6.9;8.8) (3.6;4.6)                                                                                                                                   |
| TTP (months) median 8.9 3.7                                                                                                                                                  | TTP (months) median 8.9 3.7                                                                              | TTP (months) median 8.9 3.7                                                                                                                                  | TTP (months) median 8.9 3.7                                                                                                                                  |
| 95% CI (7.4;9.2) (3.6;5.4) ORR (%) 24.1 9.2                                                                                                                                  | 95% CI (7.4;9.2) (3.6;5.4) ORR (%) 24.1 9.2                                                              | 95% CI (7.4;9.2) (3.6;5.4) ORR (%) 24.1 9.2                                                                                                                  | 95% CI (7.4;9.2) (3.6;5.4) ORR (%) 24.1 9.2                                                                                                                  |
| 95% CI (20.2;27.9) (6.6;11.8)                                                                                                                                                | 95% CI (20.2;27.9) (6.6;11.8)                                                                            | 95% CI (20.2;27.9) (6.6;11.8)                                                                                                                                | 95% CI (20.2;27.9) (6.6;11.8)                                                                                                                                |
| Primary endpoint Comparison groups Lenvatinib - Sorafenib                                                                                                                    | Primary endpoint Comparison groups Lenvatinib - Sorafenib                                                | Primary endpoint Comparison groups Lenvatinib - Sorafenib                                                                                                    | Primary endpoint Comparison groups Lenvatinib - Sorafenib                                                                                                    |
| OS Stratified HR 0.92 95% CI (0.79;1.06)                                                                                                                                     | OS Stratified HR 0.92 95% CI (0.79;1.06)                                                                 | OS Stratified HR 0.92 95% CI (0.79;1.06)                                                                                                                     | OS Stratified HR 0.92 95% CI (0.79;1.06)                                                                                                                     |
| P-value - Secondary Comparison groups Lenvatinib - Sorafenib                                                                                                                 | P-value - Secondary Comparison groups Lenvatinib - Sorafenib                                             | P-value - Secondary Comparison groups Lenvatinib - Sorafenib                                                                                                 | P-value - Secondary Comparison groups Lenvatinib - Sorafenib                                                                                                 |
| endpoint Stratified HR 0.66                                                                                                                                                  | endpoint Stratified HR 0.66                                                                              | endpoint Stratified HR 0.66                                                                                                                                  | endpoint Stratified HR 0.66                                                                                                                                  |
| PFS 95% CI (0.57;077)                                                                                                                                                        | PFS 95% CI (0.57;077)                                                                                    | PFS 95% CI (0.57;077)                                                                                                                                        | PFS 95% CI (0.57;077)                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Secondary endpoint TTP                                                                                                                        | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Stratified HR                                                                                                                                 | 0.63                                                                                                                                          |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (0.53;0.73)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |
|                                                 | Secondary endpoint ORR                                                                                                                        | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Odds ratio (IxRS stratified)                                                                                                                  | 3.13                                                                                                                                          |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (2.15;4.56)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |
| Analysis description                            | Secondary analysis                                                                                                                            | Secondary analysis                                                                                                                            | Secondary analysis                                                                                                                            |
| Analysis population and time point              | Per Protocol Analysis Set (PPS) consisted of subjects who were randomised and received at least 1 dose of the assigned drug, and had no major | Per Protocol Analysis Set (PPS) consisted of subjects who were randomised and received at least 1 dose of the assigned drug, and had no major | Per Protocol Analysis Set (PPS) consisted of subjects who were randomised and received at least 1 dose of the assigned drug, and had no major |
| description Descriptive statistics and estimate | protocol deviations Treatment group                                                                                                           | Lenvatinib                                                                                                                                    | Sorafenib                                                                                                                                     |
| variability                                     | Number of subjects                                                                                                                            | 467                                                                                                                                           | 462                                                                                                                                           |
|                                                 | OS (months) median                                                                                                                            | 13.7                                                                                                                                          | 12.3                                                                                                                                          |
|                                                 | 95% CI                                                                                                                                        | (12.2;15.1)                                                                                                                                   | (10.6;14.2)                                                                                                                                   |
|                                                 | PFS (months) median                                                                                                                           | 7.4                                                                                                                                           | 3.7                                                                                                                                           |
|                                                 | 95% CI                                                                                                                                        | (7.2;8.9)                                                                                                                                     | (3.6;4.6)                                                                                                                                     |
|                                                 | TTP (months) median                                                                                                                           | 9.0                                                                                                                                           | 3.7                                                                                                                                           |
|                                                 | 95% CI                                                                                                                                        | (7.4;9.2)                                                                                                                                     | (3.6;5.4)                                                                                                                                     |
|                                                 | ORR (%)                                                                                                                                       | 24.4                                                                                                                                          | 9.3                                                                                                                                           |
|                                                 | 95% CI                                                                                                                                        | (20.5;28.3)                                                                                                                                   | (6.7;12.0)                                                                                                                                    |
| sEffect estimate per comparison                 | Primary endpoint OS                                                                                                                           | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Stratified HR                                                                                                                                 | 0.91                                                                                                                                          |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (0.78;1.06)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | -                                                                                                                                             |
|                                                 | Secondary endpoint PFS                                                                                                                        | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Stratified HR                                                                                                                                 | 0.66                                                                                                                                          |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (0.57;0.77)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |
|                                                 | Secondary endpoint TTP                                                                                                                        | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Stratified HR                                                                                                                                 | 0.63                                                                                                                                          |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (0.53;0.74)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |
|                                                 | Secondary endpoint                                                                                                                            | Comparison groups                                                                                                                             | Lenvatinib - Sorafenib                                                                                                                        |
|                                                 |                                                                                                                                               | Odds ratio (IxRS                                                                                                                              | 3.19                                                                                                                                          |
|                                                 | ORR                                                                                                                                           | stratified)                                                                                                                                   |                                                                                                                                               |
|                                                 |                                                                                                                                               | 95% CI                                                                                                                                        | (2.18;4.66)                                                                                                                                   |
|                                                 |                                                                                                                                               | P-value                                                                                                                                       | <0.00001                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Ancillary analysis: Retrospective analysis of key secondary endpoints using mRECIST and per blinded independent review                                     | Ancillary analysis: Retrospective analysis of key secondary endpoints using mRECIST and per blinded independent review                                     | Ancillary analysis: Retrospective analysis of key secondary endpoints using mRECIST and per blinded independent review                                     |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Full Analysis Set (FAS) i.e. ITT - all randomised subjects analysed per their randomised treatment, based on randomisation stratification factors per IxRS | Full Analysis Set (FAS) i.e. ITT - all randomised subjects analysed per their randomised treatment, based on randomisation stratification factors per IxRS | Full Analysis Set (FAS) i.e. ITT - all randomised subjects analysed per their randomised treatment, based on randomisation stratification factors per IxRS |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                            | Lenvatinib                                                                                                                                                 | Sorafenib                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                          | 478                                                                                                                                                        | 476                                                                                                                                                        |
| Descriptive statistics and estimate variability | PFS (months) median                                                                                                                                        | 7.3                                                                                                                                                        | 3.6                                                                                                                                                        |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                     | (5.6;7.5)                                                                                                                                                  | (3.6;3.7)                                                                                                                                                  |
| Descriptive statistics and estimate variability | TTP (months) median                                                                                                                                        | 7.4                                                                                                                                                        | 3.7                                                                                                                                                        |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                     | (7.2;9.1)                                                                                                                                                  | (3.6;3.9)                                                                                                                                                  |
| Descriptive statistics and estimate variability | ORR (%)                                                                                                                                                    | 40.6                                                                                                                                                       | 12.4                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                     | (36.2;45.0)                                                                                                                                                | (9.4;15.4)                                                                                                                                                 |
| Effect estimate per comparison                  | Secondary endpoint PFS                                                                                                                                     | Comparison groups                                                                                                                                          | Lenvatinib - Sorafenib                                                                                                                                     |
| Effect estimate per comparison                  | Secondary endpoint PFS                                                                                                                                     | Stratified HR                                                                                                                                              | 0.64                                                                                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint PFS                                                                                                                                     | 95% CI                                                                                                                                                     | (0.55;0.75)                                                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint PFS                                                                                                                                     | P-value                                                                                                                                                    | <0.00001                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint TTP                                                                                                                                     | Comparison groups                                                                                                                                          | Lenvatinib - Sorafenib                                                                                                                                     |
| Effect estimate per comparison                  | Secondary endpoint TTP                                                                                                                                     | HR                                                                                                                                                         | 0.60                                                                                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint TTP                                                                                                                                     | 95% CI                                                                                                                                                     | (0.51;0.71)                                                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint TTP                                                                                                                                     | P-value                                                                                                                                                    | <0.00001                                                                                                                                                   |
| Effect estimate per comparison                  | Secondary endpoint ORR                                                                                                                                     | Comparison groups                                                                                                                                          | Lenvatinib - Sorafenib                                                                                                                                     |
| Effect estimate per comparison                  | Secondary endpoint ORR                                                                                                                                     | Odds ratio (IxRS stratified)                                                                                                                               | 5.01                                                                                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint ORR                                                                                                                                     | 95% CI                                                                                                                                                     | (3.59;7.01)                                                                                                                                                |
| Effect estimate per comparison                  | Secondary endpoint ORR                                                                                                                                     | P-value                                                                                                                                                    | <0.00001                                                                                                                                                   |

## Analysis performed across trials (pooled analyses and meta-analysis)

## Comparison with historical studies of sorafenib (SHARP &amp; Asia -Pacific)

The MAH provided Study E7080-G000-304 Constancy Report (10 July 2017). To evaluate the validity of the  constancy  assumption,  key  study  features  were  compared  among  Study  304  and  the  2  previous sorafenib  studies  (SHARP  and  Asia-Pacific).  These  features  included  characteristics  of  the  patient population,  inclusion/exclusion  (entry)  criteria,  concomitant  treatments  allowed,  sorafenib  dose,  and analytic  approach  for  determination  of  treatment  effect  (study  endpoints).  In  addition,  the  use  of posttreatment anticancer therapy among the 3 studies was also considered.

<div style=\"page-break-after: always\"></div>

Table : Baseline Disease Characteristics - Study 304 and Previous Sorafenib Trials

<!-- image -->

|                                 | SHARP Sorafenib (N=299)   | Asia- Pacific Sorafenib (N=150)   | Study 304 Sorafenib (N=476)   | Study 304 Sorafenib WesternRegion (N=157)   | Study304 Sorafenib Asia-Pacific Region (N=319)   |
|---------------------------------|---------------------------|-----------------------------------|-------------------------------|---------------------------------------------|--------------------------------------------------|
| Disease Etiology                |                           |                                   |                               |                                             |                                                  |
| Hepatitis B virus               | 56 (19)                   | 106 (70.7)                        | 228 (47.9)                    | 31 (19.7)                                   | 197 (61.8)                                       |
| Hepatitis C virus               | 87 (29)                   | 16 (10.7)                         | 126 (26.5)                    | 56 (35.7)                                   | 70 (21.9)                                        |
| Alcohol                         | 79 (26)                   | NA                                | 21 (4.4)                      | 13 (8.3)                                    | 8 (2.5)                                          |
| Other                           | 28 (9)                    | NA                                | 32 (6.7)                      | 21 (13.4)                                   | 11 (3.4)                                         |
| Unknown                         | 49 (16)                   | NA                                | 69 (14.5)                     | 36 (22.9)                                   | 33 (10.3)                                        |
| ECOG PS                         |                           |                                   |                               |                                             |                                                  |
| 0                               | 161 (54)                  | 38 (25.3)                         | 301 (63.2)                    | 97 (61.8)                                   | 204 (63.9)                                       |
|                                 | 114 (38)                  | 104 (69.3)                        | 175 (36.8)                    | 60 (38.2)                                   | 115 (36.1)                                       |
| 2                               | 24 (8)                    | 8 (5.3)                           | 0                             | 0                                           | 0                                                |
| BCLC stage                      |                           |                                   |                               |                                             |                                                  |
| B (intermediate)                | 54 (18)                   | NA                                | 92 (19.3)                     | 27 (17.2)                                   | 65 (20.4)                                        |
| C (advanced)                    | 244 (82)                  | 143 (95.3)                        | 384 (80.7)                    | 130 (82.8)                                  | 254 (79.6)                                       |
| MPVI, EHS, or Both              |                           |                                   |                               |                                             |                                                  |
| Present                         | 209 (70)                  | 118 (79.7)                        | 336 (70.6)                    | 115 (73.2)                                  | 221 (69.3)                                       |
| Absent                          | 90 (30)                   | 32 (20.3)                         | 140 (29.4)                    | 42 (26.8)                                   | 98 (30.7)                                        |
| MPVI                            | 108 (36)                  | 54 (36.0)                         | 90 (18.9)                     | 26 (16.6)                                   | 64 (20.1)                                        |
| Extrahepaticspread              | 159 (53)                  | 103 (68.7)                        | 295 (62.0)                    | 102 (65.0)                                  | 193 (60.5)                                       |
| Lynph nodes                     | 89 (30)                   | 46 (30.7)                         | 141 (29.6)                    | 58 (36.9)                                   | 83 (26.0)                                        |
| Lung                            | 67 (22)                   | 78 (52.0)                         | 144 (30.3)                    | 34 (21.7)                                   | 110 (34.5)                                       |
| Child-Pugh                      |                           |                                   |                               |                                             |                                                  |
| A                               | 284 (95)                  | 146 (97.3)                        | 471 (98.9)                    | 152 (96.8)                                  | 319 (100.0)                                      |
| B                               | 14 (5)                    | 4 (2.7)                           | 5 (1.1)                       | 5 (3.2)                                     | 0                                                |
| Alpha-fetoprotein (ng/mL)       |                           |                                   |                               |                                             |                                                  |
| Median                          | 44.3                      | NA                                | 71.2                          | 27.0                                        | 100.6                                            |
| Min-Max                         | 0-208×104                 | NA                                | 0-145×104                     | 0-145×104                                   | 1-93×104                                         |
| < 40 ng/mL                      | NA                        | 28 (18.7)                         | 215 (45.2)                    | 86 (54.8)                                   | 129 (40.4)                                       |
| ≥ 40 ng/mL                      | NA                        | 114 (76.0)                        | 258 (54.2)                    | 68 (43.3)                                   | 190 (59.6)                                       |
| < 200 ng/mL                     | NA                        | NA                                | 286 (60.1)                    | 104 (66.2)                                  | 182 (57.1)                                       |
| ≥200 ng/mL                      | NA                        | NA                                | 187 (39.3)                    | 50 (31.8)                                   | 137 (42.9)                                       |
| ≤ULN                            | 111 (37.1)                | NA                                | 124 (26.1)                    | 55 (35.0)                                   | 69 (21.6)                                        |
| ULN-≤ 400 ng/mL                 | 78 (26.1)                 | NA                                | 184 (38.7)                    | 58 (36.9)                                   | 126 (39.5)                                       |
| > 400 ng/mL                     | 93 (31.1)                 | NA                                | 165 (34.7)                    | 41 (26.1)                                   | 124 (38.9)                                       |
| Previous therapy                |                           |                                   |                               |                                             |                                                  |
| Surgical resection              | 57 (19)                   | 49 (32.7)                         | 144 (30.3)                    | 24 (15.3)                                   | 120 (37.6)                                       |
| Transarterial chemoembolization | 86 (29)                   | 61 (40.7)                         | 245 (51.5)                    | 60 (38.2)                                   | 185 (58.0)                                       |
| Percutaneous ethanol injection  | 28 (9)                    | NA                                | 19 (4.0)                      | 4 (2.5)                                     | 15 (4.7)                                         |
| Radiofrequency ablation         | 17 (6)                    | NA                                | 110 (23.1)                    | 20 (12.7)                                   | 90 (28.2)                                        |
| Radiotherapy                    | 13 (4)                    | NA                                | 60 (12.6)                     | 5 (3.2)                                     | 55 (17.2)                                        |

BCLC = Barcelona Clinic Liver Cancer; ECOG PS = Eastern Cooperative Oncology Group performance status;

EHS = extrahepatic spread; MPVI = macroscopic portal invasion; ULN = upper limit of normal.

<div style=\"page-break-after: always\"></div>

Table : Outcomes in Historical Sorafenib Studies and Study 304

<!-- image -->

| Parameter          | SHARP Sorafenib (N=299)                                                                          | Asia-Pacific Sorafenib (N=150)   | Study 304 Sorafenib (N=476)   | Study 304 Sorafenib Western Region (N=157)   | Study 304 Sorafenib Asia-Pacific Region (N=319)   |
|--------------------|--------------------------------------------------------------------------------------------------|----------------------------------|-------------------------------|----------------------------------------------|---------------------------------------------------|
| OS (nonths)        |                                                                                                  |                                  |                               |                                              |                                                   |
| Median             | 10.7                                                                                             | 6.5                              | 12.3                          | 14.2                                         | 11.0                                              |
| 95% CI             | 9.4-13.3                                                                                         | 5.56-7.56                        | 10.4-13.9                     | 11.9-18.0                                    | 9.6-12.5                                          |
| 9  % months        | NA                                                                                               | 53.5                             | 75.2                          | 78.8                                         | 73.3                                              |
| % at 12 months     | 44                                                                                               | NA                               | 50.0                          | 57.6                                         | 46.2                                              |
| P value vs Placebo | <0.001                                                                                           | 0.014                            | NA                            | NA                                           | NA                                                |
| HR (95% CI)        | 0.69 (0.55-0.87) (sorafenib:placebo) sorafenib:placebollenvatinib:sorafenib|lenvatinib:sorafenib | 0.68 (0.50-0.93)                 | 0.92 (0.79, 1.06)             | 1.08 (0.82, 1.42)                            | 0.86 (0.72, 1.02) lenvatinib: sorafenib           |
| TTP (months)       |                                                                                                  |                                  |                               |                                              |                                                   |
| Median             | 5.5                                                                                              | 2.8                              | 3.7                           | 5.6                                          | 3.6                                               |
| 95% CI             | 4.1-6.9                                                                                          | 2.63-3.58                        | 3.6-5.4                       | 3.9-7.9                                      | 3.5-3.8                                           |
| ORR (%)            |                                                                                                  |                                  | 9.2                           | 10.8                                         | 8.5                                               |
| CR                 | 0                                                                                                | 0                                | 0.4                           | 0.6                                          | 0.3                                               |
| PR                 | 2                                                                                                | 3.3                              | 8.8                           | 10.2                                         | 8.2                                               |
| SD                 | 71                                                                                               | 54.0                             | 51.3                          | 56.7                                         | 48.6                                              |
| PD                 | NA                                                                                               | 30.7                             | 30.9                          | 22.3                                         | 35.1                                              |

## Clinical studies in special populations

N/A

## Supportive study

## Study E7080-J081-202: A Phase 1/2 Study of E7080 in patients with advanced hepatocellular carcinoma (HCC)

In  the  expansion  component  (Phase  2),  the  lenvatinib  12  mg dose  (recommended  Phase  2  dose)  was tested in subjects with advanced HCC and hepatic function of CP scores of 5-6.

In total 46 subjects were enrolled. Subjects were permitted to receive up to 1 prior systemic therapy, including targeted therapy or transarterial infusion chemotherapy.

The expansion component was primarily designed to evaluate the efficacy (TTP based on independent review  assessments  using  mRECIST  in  Per  Protocol  Population)  and  safety  of  lenvatinib  at  the recommended dose. Secondary efficacy endpoints included ORR, DCR, OS, and PFS based on mRECIST.

The Safety Analysis Set, FAS, PK Analysis Set and the PD Analysis Set were identical (N= 46). The PPS (N=41) excluded 5 subjects; 1 subject did not meet inclusion criterion #3 (baseline haematology and renal laboratory values), 3 subjects discontinued during the 2 cycles and 1 subject did not show ≥ 75%

<div style=\"page-break-after: always\"></div>

cumulative treatment compliance without regard to study drug interruption due to toxicity.

Table 57: Efficacy Results for Study 202 Phase 2 - Child Pugh Score 5 or 6, lenvatinib 12mg OD

| Efficacy endpoint                                                   | Independent review   | 95% CI                | Investigator assessment   | 95% CI               |
|---------------------------------------------------------------------|----------------------|-----------------------|---------------------------|----------------------|
| Median TTP by mRECIST in PPS Probability of progression at 6 months | 7.4 months 44%       | 5.5, 9.4 30, 61       | 12.8 months 30.9%         | 7.2, 14.7 18.8, 48.0 |
| Median TTP by mRECIST in FAS Probability of progression at 6 months | 7.4 months 45.2%     | 5.5, 9.4 31.3, 61.9   | 12.8 months 32.2%         | 7.2, 14.7 20.1, 49.0 |
| ORR in FAS DCR in FAS (CR, PR + SD≥8 weeks)                         | 37.7% 78.3%          | 23.2, 52.5 63.6, 89.1 | 37.7% 82.6%               | 23.2,52.5 68.6,92.2  |
| Median PFS for FAS                                                  | 7.4 months           | 5.5, 9.4              | 12.8 months               | 7.2,14.0             |
| Median OS for PPS 12-month OS rate                                  | 18.3 months 68.3%    | 12.7, 25.1 51.7, 80.2 |                           |                      |
| Median OS for FAS 12-month OS rate                                  | 18.65 months 67.4%   | 12.7, 25.1 51.9, 78.9 |                           |                      |

PPS, N=41; FAS, N=46

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The main study E7080-G000-304 (REFLECT or Study 304) was a multi-centre, randomized, open-label, non-inferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a firstline systemic treatment in subjects with unresectable HCC.

For the main Study 304, sorafenib as comparator is acceptable in the first line treatment for advanced disease since it is the only medicine approved in this setting for systemic treatment and is considered as a standard of care.

The primary endpoint of OS is supported as the most relevant and unbiased measure of efficacy.

In view of non-inferiority design, several critical aspects were highlighted at the time of CHMP scientific advice, like internal validity, internal consistency and external validity. The enrolment of an adequate number of patients from EU population was advised.

The trial was well-conducted. Very few randomised subjects were not treated (3 in total) and the rate of major protocol deviations was low (2.5%) and balanced across the treatment arms.

Still,  the  trial  was  open-label,  which  always  introduces  the  possibility  of  investigator  bias  in  terms  of adjudication  of  progression.  Most  subjects  in  both  treatment  arms  received  study  drug  until  PD  as stipulated in the protocol, but more had no progression at the time of treatment discontinuation in the lenvatinib than the sorafenib arm (97 vs. 60 in the TTP analysis, 66 vs 49 in the PFS analysis). This may be due to safety concerns as discussed later.

Patients  were  to  have  advanced/unresectable  HCC  suitable  for  palliative  treatment  but  very  advanced disease  was  excluded.  Patients  had  stage  BCLC  B  (multiple  liver  tumours)  or  BCLC  C  (portal  vein invasion/ extrahepatic spread) HCC but with liver function adequately maintained - CP A (score of 5 or 6) and PS 0-1. Patients with very heavy liver involvement (≥50% occupation), clear invasion into the main

<div style=\"page-break-after: always\"></div>

portal  vein  or  bile  duct,  or  any  blood-enhancing  treatment  within  28  days  of  randomization  were excluded. Patients could have received prior local therapy but not systemic therapy alone for advanced disease.

The comparability of the patient populations among Study 304 and the historical trials was evaluated. The geographical patient pool of the SHARP and the Asia-Pacific trials are comparable to the Western and the Asia-Pacific regions of the Study 304, respectively.

The overall patient populations of Study 304 and the historical SHARP and Asia Pacific trials were similar with regard to demographic and key disease characteristics.

The  baseline  demographics  and  disease  characteristics  of  Study  304  were  reasonably  well  matched between the 2 treatment groups for the overall population, except a greater proportion with baseline AFP &gt;200 ng/ml in the lenvatinib arm and more subjects with underlying hepatitis C in the sorafenib arm.

With a higher threshold, the proportion of subjects with a baseline AFP concentration of ≥ 400 ng/mL was 40.8%  (195  subjects)  in  the  lenvatinib  arm  and  34.7%  (165  subjects)  in  the  sorafenib  arm.    Both imbalances might favour the sorafenib arm.

The  aetiology,  course  and  prognosis  of  HCC  differ  by  regions,  with  epidemiologic  risk  factors  varying greatly. At the time of scientific advice the Applicant was requested to enrol at least one third of patients in the Western region.

In both the Asia-Pacific and Western regions, the proportion of subjects with baseline AFP levels ≥ 200 ng/mL was greater in the lenvatinib than in the sorafenib arm, although the difference was greatest in the Western region: 48.9% vs 42.9%, respectively, for the Asia-Pacific, and 41.4% vs 31.8% for the Western region. Regarding the proportion of subjects with baseline hepatitis C, for lenvatinib vs. sorafenib this was 26.1% vs. 35.7% in the West (15.6% vs 21.9% Asia Pacific).

Still,  other  factors  such  as  BCLC  stage  of  disease  were  well  balanced  between  the  regions;  BCLC  C (advanced stage) was 78.3% vs. 82.8% for lenvatinib vs. sorafenib in the West and 78.2% vs. 79.6% for lenvatinib  vs.  sorafenib  in  the  Asia-Pacific.  The  proportion  with  MVPI/  extrahepatic  spread,  one  of  the stratification factors, was requested by treatment group by region.  MPVI/ EHS were shown to be well balanced between the treatment arms although a lower proportion of sorafenib compared with lenvatinib treated subjects had MPVI alone in the Western region. Subjects with MVPI/ EHS had a shorter median OS regardless  of  the  treatment  arm.  Non-inferiority  of  lenvatinib  vs.  sorafenib  was  maintained  for  all subgroups of MVPI/ EHS.

The  baseline  characteristics  of  patients  in  the  sorafenib  arm  were  sufficiently  similar  to  those  of  the historical  sorafenib  trials  to  allow  cross-study  comparison  in  terms  of  sorafenib  efficacy  to  support  the evaluation of non-inferiority in the current study.

## Efficacy data and additional analyses

## Efficacy results - primary endpoint

Non-inferiority of lenvatinib to sorafenib for OS, the primary endpoint of the study, has been convincingly demonstrated.  The  OS  data  are  sufficiently  mature  (about  75%).  However,  superiority  could  not  be shown  (median  OS  13.6  vs.  12.3  months  for  lenvatinib  vs.  sorafenib).  The  per  protocol  analysis  was similar  to  the  FAS,  as  were  sensitivity  analyses  based  on  stratification  factors  in  the  CRF  (rather  than IxRS) and without stratification factors.

Subjects who were lost to follow-up were censored at the last date the subject was known to be alive, and subjects who remained alive were censored at the time of data cut-off.

<div style=\"page-break-after: always\"></div>

The MAH indicated imbalances in the use of posttreatment anticancer therapy, as well as imbalances in some baseline factors (ie, AFP, HCV aetiology) in the sorafenib arm overall, appeared to have favoured sorafenib for OS, which resulted in a higher hazard ratio in the Western region.

At the end of study treatment, subjects on the sorafenib arm were naturally eligible for potential secondline trials specifically requiring enrollment of sorafenib failures and/or sorafenib-intolerant patients, while lenvatinib  patients  would  be  typically  ineligible  for  such  trials.  Consequently,  a  higher  proportion  of subjects received post-study treatment with investigational anticancer drugs in the sorafenib arm (9.5%) vs lenvatinib (3.1%). These factors might favour the sorafenib arm, but no definitive conclusions can be made to this regard. Subgroup analyses for OS revealed that the effect of lenvatinib and sorafenib on OS was generally consistent across subgroups. Amongst the subgroup analyses, the only exception was the Western  Region  where  the  median  OS  for  lenvatinib  was  13.6  months  compared  to  14.2  months  for sorafenib, resulting in an HR of 1.08 (95% CI: 0.82, 1.42). Still, this HR does not deviate far from 1.00 and the median OS difference is only 0.6 months.

Median OS for sorafenib in the Western region in Study 304 was higher than that in the full sorafenib trial population  (12.3  months)  and  higher  than  the  median  OS  in  the  historic  SHARP  trial  (10.7  months), which was conducted in Western countries. Furthermore, the median OS of sorafenib in the Asia-Pacific region (11.0 months) in Study 304 was higher than the median OS of sorafenib in the historic Asia-Pacific trial (6.5 months; 95% CI: 5.6, 7.6).  The possible reason for the higher OS of sorafenib in Study 304 compared to historical sorafenib studies may be the greater use of posttreatment anticancer therapies, as explained by the MAH.

Overall,  the  KM  curves  and  HR  are  consistent  with  non-inferiority  in  OS  for  lenvatinib  vs  sorafenib  in patients ≥ 75 years. The secondary efficacy endpoints favoured lenvatinib in this subgroup.

## Efficacy results - secondary endpoints

The  results  of  secondary  analyses  support  those  reported  for  primary  analyses,  however  statistically significant  differences  in  secondary  endpoints  do  not  appear  to  translate  into  the  OS  benefit,  with potential underlying reasons discussed above.

Lenvatinib treatment resulted in improvement over sorafenib for PFS (median PFS, 7.4 vs 3.7 months, respectively; HR=0.66; 95% CI of 0.57, 0.77, P&lt;0.00001) for this population of patients. Median followup time was 20.3 and 19.2 months for the lenvatinib and sorafenib arms, respectively. Median TTP with lenvatinib was longer than that of sorafenib: 8.9 months for lenvatinib versus 3.7 months for sorafenib (HR = 0.63; P&lt;0.00001).

Taken together, PFS and TTP were the same for sorafenib but the benefit on progression was greater for lenvatinib in the TTP analysis (8.9 vs 3.7 months) where deaths before progression were not considered as an event compared to the PFS results (7.4 vs. 3.7 months).

Lenvatinib treatment significantly prolonged TTP compared to sorafenib. However, neither PFS benefit nor TTP benefit translated to OS improvement. The observed TTP in the lenvatinib arm was longer than the duration of treatment (5.7 months), while it was similar to the duration of treatment in the sorafenib arm (3.7 months).

The ORR by investigator assessment was increased for lenvatinib compared with sorafenib (24.1% vs. 9.2%) mainly due to an increase in the proportion of lenvatinib patients with PR (22.8 vs. 8.8%). This result included all responses; there was no consideration of confirmed responses, as tumour assessments were conducted every 8 weeks. The duration of response in responders was longer for sorafenib (11.2 vs. 7.3 months), albeit with overlapping 95% confidence intervals, whilst the proportion with durable stable disease  (≥23  weeks)  was  higher  for  lenvatinib  (34.9%  vs.  29.2%).  By  IRR,  the  duration  of  objective response was 7.4 (5.6, 9.2) months in the lenvatinib arm and 15.8 (5.9, NE) months in the sorafenib

<div style=\"page-break-after: always\"></div>

arm.

The ORR with lenvatinib in the Western region (21.0%, 95% CI: 14.6, 27.4) was consistent with that observed for the Asia-Pacific region (25.5%, (95% CI: 20.8, 30.3) and for the overall population (24.1%, 95% CI: 20.2, 27.9). The odds ratios were 2.18 (1.15, 4.11) for the Western region, 3.77 (95% CI: 2.36, 6.04) for the Asia-Pacific region, and 3.13 (95% CI: 2.15, 4.56) for the overall population.

The  results  of  IIR  using  mRECIST  or  RECIST  1.1  both  supported  the  results  of  the  investigator-based assessments.

The  PFS  and  TTP  subgroup  analysis  consistently  favoured  lenvatinib.  The  only  ORR  subgroup  that favoured  sorafenib  was  alcohol  but  this  involved  a  small  number  of  patients  with  wide  confidence intervals and PFS/ TTP still favoured lenvatinib.

The primary endpoint and key secondary endpoint results were similar in the lenvatinib arm per the 2 starting doses, as assessed based on body weight category (&lt;60kg vs. ≥60kg). Lenvatinib dose was not adjusted based on change in body weight during treatment. Lenvatinib dose adjustments were performed only  for  individual  subjects  who  experienced  lenvatinib-related  toxicity  as  pre-specified  in  the  dosemodification section of the protocol.

PFS on sorafenib post lenvatinib in comparison to the other post lenvatinib therapies was investigated to assess whether sorafenib remains a useful option in this patient population (data not shown). There was no  difference  in  PFS2  (based  on  the  surrogate  duration  of  next  line  therapy)  between  patients  who received sorafenib compared with another therapy post progression on lenvatinib.

## 2.4.4. Conclusions on the clinical efficacy

The  non-inferiority  in  terms  of  OS  over  sorafenib  has  been  demonstrated  for  lenvatinib  monotherapy. Secondary endpoints support the primary analysis.

## 2.5. Clinical safety

## Introduction

The safety data for the new HCC indication are taken from Study 304 and from Study 202. Two sets are defined: The HCC randomized safety data coming from study 304, a randomized, sorafenib controlled trial and the All HCC Lenvatinib Safety Set that contain the data of 20 additional patients (4% of this last database). In absence of a placebo control arm, a third set of non HCC patients (monotherapy) is also used to contrast safety issues more likely linked to the disease and/or the patient condition.

## The 'HCC Randomized Safety Set' (N = 476)

This set corresponds to the study 304 safety data. In this study subjects with advanced/unresectable HCC were randomized and treated with either lenvatinib (476 patients; 12 mg or 8 mg QD by oral dosing) or sorafenib (475 patients; 400 mg BID by oral dosing) in a 1:1 ratio. The starting dose of lenvatinib was based on baseline BW: 12 mg QD for subjects with a BW of ≥ 60 kg (325 pts) and 8 mg QD for subjects with a BW of &lt;60 kg (151 pts). The cutoff date for the study 304 safety data was 13 Nov 2016.

## The 'All HCC Lenvatinib Safety Set' (N = 496)

This set corresponds to the data of study 304 (HCC Randomized Safety Set) to which have been added the safety data of 20 patients of study 202.

In Study 202, the maximum tolerated (MTD) was determined in subjects with Child-Pugh (CP) Class A (CP score of 5 to 6) and CP Class B. The MTD found for subjects with Child-Pugh Class A was 12 mg QD

<div style=\"page-break-after: always\"></div>

and in an extension Phase 2, all subjects (CP Class A) were treated with this 12 mg dose of lenvatinib. However, only the safety data for the 20 subjects in Phase 2 who had baseline BW ≥ 60 kg and received at  least  1  dose  of  lenvatinib  12  mg  QD  (ie  the  dosing  matching  the  recommendations  for  the  sough indication) were included in the 'All HCC Lenvatinib Safety Set'. Safety information for the additional 26 subjects in Study 202 who took lenvatinib 12 mg QD but weighed &lt;60 kg is presented in the Study 202 CSR.

## The 'Non-HCC Lenvatinib Monotherapy Safety Set' (N=1327)

This set includes all subjects who received at least 1 dose of lenvatinib monotherapy in the following 14 studies that evaluated various tumour types (including DTC and RCC): E7080-G000-201, -203, -204, 205  (only  monotherapy  arm),  -206,  209,  -303  (both  Randomized  and  optional  open-label)  and  -398; E7080-J081-105 and - 208;  E7080-A001-102; E7080-E044-101 and -104; E7080-703.

In  this  safety  set,  1130/1327  (85%) subjects received a lenvatinib starting dose of 24 mg QD and an additional  7  subjects  received  a  total  daily  dose  of  24  mg  (12  mg  BID);  the  remaining  subjects  were enrolled in dose-finding studies and received a range of lenvatinib starting doses of 0.2 to 32 mg daily (Appendix 1). The safety data cutoff date was 01 Sep 2016 for ongoing studies; for studies completed before 01 Sep 2016, their respective completion dates were used.

Table 58: Number of HCC patients exposed

|                                            | HCC Patients enrolled   | HCC Patients exposed   | HCC Patients exposed to 8 - 12 mg lenvatinib   | HCC Patients with ≥ 1 year safety data   |
|--------------------------------------------|-------------------------|------------------------|------------------------------------------------|------------------------------------------|
| Placebo-controlled                         | -                       | -                      | -                                              | -                                        |
| Active -controlled                         | 478                     | 476                    | 476                                            | 109                                      |
| (\"HCC randomized safety set\") Open studies | ND                      | 66                     | 20 (*)                                         | 7 (*)                                    |
| Post marketing                             |                         | 2208                   |                                                |                                          |
| Compassionate use                          |                         | ND                     |                                                |                                          |
| total (\"All HCC Lenvatinib Safety Set\")    |                         |                        | 496                                            | 116 (**)                                 |

(*) overall 63 HCC patients were exposed to 8 or 12 mg in study 20. However only 20 fitted the inclusion criterions for body weight and Child-Plough score of A and were included in the safety analysis. Sources: table 2.7.4-4 of SCS.

## Patient exposure

In  the  Study  304,  51% of the subjects on the 8  mg lenvatinib dose and 36% of those on the 12 mg lenvatinib dose received 100% of their planned starting dosage (overall 41% of subjects in the lenvatinib arm).  In addition 24% of patients on the 8 mg lenvatinib dose and 30% of patients on the 12 dose received at least 80% of the planned dosing (overall 27.7% for the lenvatinib arm). Thus 75% (8 mg group) and 66% (12 mg group) of patients received at least 80% of the planned dose. Three subjects received accidentally higher than planned doses (2 patients received once 24 mg of lenvatinib and one patient received one dose of 120 mg).

In  the  sorafenib  arm,  33.9% of subjects received 100% of their planned dosage; an additional 31.2% received at least 80% of the planned dosage. Overall 65 % of the patients received at least 80% of the planned dosage but more patients received less than 60% of the planned dosage than in the lenvatinib arm.

Regarding dose intensity, the patients received on 'average' 87.5% of the planned dose in the lenvatinib arm  and  83%  of  the  planned  dose  in  the  sorafenib  arm.  In  both  treatment  arms,  exposure  (ie,  dose intensity)  versus  planned  dose  was  high,  and  the  percentage  of  planned  dose  received  was  similar between the 2 arms or slightly higher for lenvatinib.

<div style=\"page-break-after: always\"></div>

Table 59: Study Drug Extent of Exposure - HCC Randomized, All HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Sets

|                                                      | HCC Randomized Safety                                | Set                                                  | All HCC Lenvatinib Safety Set                        | Non-HCC Lenvatinib Monotherapy Safety Set            |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                      | Lenvatinib 8 or 12 mg (N=476) n (%)                  | Sorafenib 800 mg (N=475) n (%)                       | Lenvatinib 8 or 12 mg (N=496) n (%)                  | (N=1327) n (%)                                       |
| Duration of Treatment a (months)                     | Duration of Treatment a (months)                     | Duration of Treatment a (months)                     | Duration of Treatment a (months)                     | Duration of Treatment a (months)                     |
| n                                                    | 476                                                  | 475                                                  | 496                                                  | 1327                                                 |
| Mean (SD)                                            | 8.2 (7.04)                                           | 6.0 (6.47)                                           | 8.2 (6.99)                                           | 11.3 (14.10)                                         |
| Median                                               | 5.7                                                  | 3.7                                                  | 5.9                                                  | 5.5                                                  |
| Q1, Q3                                               | 2.9, 11.1                                            | 1.8, 7.4                                             | 3.0, 11.2                                            | 1.9, 14.5                                            |
| Min, Max                                             | 0.0, 35.0                                            | 0.1, 38.7                                            | 0.0, 35.0                                            | 0.0, 125.1                                           |
| Duration of Treatment (months), n (%)                | Duration of Treatment (months), n (%)                | Duration of Treatment (months), n (%)                | Duration of Treatment (months), n (%)                | Duration of Treatment (months), n (%)                |
| 0 - <1                                               | 39 (8.2)                                             | 31 (6.5)                                             | 41 (8.3)                                             | 163 (12.3)                                           |
| 1 - <2                                               | 50 (10.5)                                            | 124 (26.1)                                           | 51 (10.3)                                            | 208 (15.7)                                           |
| 2 - <4                                               | 94 (19.7)                                            | 114 (24.0)                                           | 95 (19.2)                                            | 206 (15.5)                                           |
| 4 - <6                                               | 59 (12.4)                                            | 53 (11.2)                                            | 62 (12.5)                                            | 153 (11.5)                                           |
| 6 - <8                                               | 46 (9.7)                                             | 47 (9.9)                                             | 47 (9.5)                                             | 81 (6.1)                                             |
| 8 - <12                                              | 79 (16.6)                                            | 45 (9.5)                                             | 84 (16.9)                                            | 140 (10.6)                                           |
| 12 - <18                                             | 58 (12.2)                                            | 28 (5.9)                                             | 64 (12.9)                                            | 96 (7.2)                                             |
| >=18                                                 | 51 (10.7)                                            | 33 (6.9)                                             | 52 (10.5)                                            | 280 (21.1)                                           |
| No. of Subject-Years b                               | 324.2                                                | 239.1                                                | 340.0                                                | 1244.7                                               |
| Total Dose (mg) Per Subject                          | Total Dose (mg) Per Subject                          | Total Dose (mg) Per Subject                          | Total Dose (mg) Per Subject                          | Total Dose (mg) Per Subject                          |
| n                                                    | 476                                                  | 475                                                  | 496                                                  | 1327                                                 |
| Mean (SD)                                            | 2282.5 (2167.04)                                     | 121396.0 (142550.76)                                 | 2305.6 (2167.92)                                     | 5301.9 (6541.03)                                     |
| Median                                               | 1578.0                                               | 66200.0                                              | 1616.0                                               | 2764.0                                               |
| Q1, Q3                                               | 679.0, 3254.0                                        | 42000, 148000                                        | 680.0, 3303.0                                        | 1128, 6672                                           |
| Min, Max                                             | 24.0, 11964.0                                        | 1400, 916800                                         | 24, 11964                                            | 1.6, 44905.5                                         |
| Dose Intensity (mg/day/Subject)                      | Dose Intensity (mg/day/Subject)                      | Dose Intensity (mg/day/Subject)                      | Dose Intensity (mg/day/Subject)                      | Dose Intensity (mg/day/Subject)                      |
| n                                                    | 476                                                  | 475                                                  | 496                                                  | 1327                                                 |
| Mean (SD)                                            | 9.4 (5.71)                                           | 663.8 (173.15)                                       | 9.4 (5.62)                                           | 17.9 (5.76)                                          |
| Median                                               | 8.9                                                  | 771.4                                                | 8.9                                                  | 19.1                                                 |
| Q1, Q3                                               | 7.9, 12.0                                            | 514.6, 800.0                                         | 7.9, 12.0                                            | 13.5, 24.0                                           |
| Min, Max                                             | 1.7, 120.0                                           | 126.3, 800.0                                         | 1.7, 120.0                                           | 0.2, 32.0                                            |
| Received Dose as Percentage of Planned Starting Dose | Received Dose as Percentage of Planned Starting Dose | Received Dose as Percentage of Planned Starting Dose | Received Dose as Percentage of Planned Starting Dose | Received Dose as Percentage of Planned Starting Dose |
| n                                                    | 476                                                  | 475                                                  | 496                                                  | 1327                                                 |
| Mean (SD)                                            | 87.5 (46.40)                                         | 83.0 (21.64)                                         | 87.2 (45.64)                                         | 78.3 (21.77)                                         |
| Median                                               | 98.2                                                 | 96.4                                                 | 97.7                                                 | 84.1                                                 |
| Q1, Q3                                               | 73.5, 100                                            | 64.3, 100.0                                          | 72.8, 100.0                                          | 60.5, 100.0                                          |
| Min, Max                                             | 14.4, 1000                                           | 15.8, 100.0                                          | 14.4, 1000                                           | 2.8, 106.2                                           |
| <60%                                                 | 59 (12.4)                                            | 106 (22.3)                                           | 62 (12.5)                                            | 320 (24.1)                                           |
| 60% - <70%                                           | 42 (8.8)                                             | 24 (5.1)                                             | 47 (9.5)                                             | 141 (10.6)                                           |
| 70% - <80%                                           | 45 (9.5)                                             | 36 (7.6)                                             | 48 (9.7)                                             | 127 (9.6)                                            |
| 80% - <90%                                           | 41 (8.6)                                             | 30 (6.3)                                             | 42 (8.5)                                             | 185 (13.9)                                           |
| 90% - <100%                                          | 91 (19.1)                                            | 118 (24.8)                                           | 94 (19.0)                                            | 172 (13.0)                                           |
| =100%                                                | 195 (41.0)                                           | 161 (33.9)                                           | 200 (40.3)                                           | 374 (28.2)                                           |
| >100%                                                | 3 (0.6)                                              | 0 (0.0)                                              | 3 (0.6)                                              | 8 (0.6)                                              |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies).

HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; max = maximum; min = minimum; Q1, Q3 = first, third quartiles; QD = once daily; SD = standard deviation.

a: Duration of treatment (months) = (Date of last dose of study drug -Date of first dose of study drug + 1)/30.4375.

b: Number of subject-years = Sum of all years received by all subjects based on treatment duration.

<div style=\"page-break-after: always\"></div>

Table 60: Subject Exposure by Subgroup - HCC Randomized, All HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Set

|                                           | HCC Randomized Safety Set           | HCC Randomized Safety Set           | HCC Randomized Safety Set      | HCC Randomized Safety Set       | All HCC Lenvatinib Safety Set       | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy       | Non-HCC Lenvatinib Monotherapy       |
|-------------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|---------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|
|                                           | Lenvatinib 8 or 12 mg (N=476) n (%) | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Sorafenib 800 mg (N=475) n (%)  | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Safety Set Lenvatinib (N=1327) n (%) | Safety Set Lenvatinib (N=1327) n (%) |
| Subgroup Total, n (%)                     | Number of Subjects n 476            | Median Duration Months (a*) 5.7     | Number of Subjects n 475       | Median Duration Months (a*) 3.7 | Number of Subjects n (%) 496        | Median Duration Months (a*) 5.9     | Number of Subjects n (%) 1327        | Median Duration Months (a*) 5.5      |
| Sex                                       |                                     |                                     |                                |                                 |                                     |                                     |                                      |                                      |
| Male                                      | 403                                 | 6.0                                 | 400                            | 3.7                             | 423 (85%)                           | 6.4                                 | 666 (50%)                            | 5.5                                  |
| Female                                    | 73                                  | 5.6                                 | 75                             | 3.9                             | 73 (15%)                            | 5.6                                 | 661 (50%)                            | 5.4                                  |
| Age                                       |                                     |                                     |                                |                                 |                                     |                                     |                                      |                                      |
| <65 years                                 | 269                                 | 6.0                                 | 282                            | 3.6                             | 283 (57%)                           | 6.5                                 | 833 (63%)                            | 5.6                                  |
| ≥65 -<75 years                            | 150                                 | 5.7                                 | 126                            | 4.0                             | 155 (31%)                           | 5.7                                 | 379 (29%)                            | 5.3                                  |
| ≥75 years                                 | 57                                  | 5.6                                 | 67                             | 3.7                             | 58 (12%)                            | 5.6                                 | 115 (9%)                             | 3.5                                  |
| Region                                    |                                     |                                     |                                |                                 |                                     |                                     |                                      |                                      |
| Asia-Pacific                              | 321                                 | 5.7                                 | 319                            | 3.5                             | 341 (69%)                           | 5.7                                 | 237 (18%)                            | 8.9                                  |
| Western regions                           | 155                                 | 6.2                                 | 156                            | 4.6                             | 155 (31%)                           | 6.2                                 | 1090 (82%)                           | 4.7                                  |
| Race Group                                |                                     |                                     |                                |                                 |                                     |                                     |                                      |                                      |
| Asian                                     | 333                                 | 5.7                                 | 325                            | 3.6                             | 353 (71%)                           | 5.7                                 | 188 (14%)                            | 7.4                                  |
| White                                     | 134                                 | 6.5                                 | 141                            | 4.7                             | 134 (27%)                           | 6.5                                 | 1088 (82%)                           | 5.0                                  |
| Black or African American                 | 7                                   | 2.9                                 | 6                              | 2.9                             | 7 (1%)                              | 2.9                                 | 27 (2%)                              | 6.2                                  |
| American Indian or Alaska Native          | 1                                   | 7.4                                 | 0                              | -                               | 1 (0%)                              | 7.4                                 | 2 (0%)                               | 11.9                                 |
| Native Hawaiian or Other Pacific Islander | 0                                   | -                                   | 1                              | 4.0                             | 0                                   | -                                   | 4 (0%)                               | 7.0                                  |
| Other                                     | 1                                   | 3.4                                 | 2                              |                                 | 1 (0%)                              | 3.4                                 | 18 (1%)                              | 3.3                                  |
|                                           |                                     |                                     |                                | 2.5                             |                                     |                                     |                                      |                                      |
| ECOG PS                                   |                                     |                                     |                                |                                 |                                     |                                     |                                      |                                      |
| 0                                         | 304                                 | 6.5                                 | 301                            | 3.7                             | 320 (65%)                           | 6.9                                 | 542 (41%)                            | 8.3                                  |
| ≥1                                        | 172                                 | 5.5                                 | 174                            | 3.7                             | 176 (35%)                           | 5.5                                 | 556 (42%)                            | 5.5                                  |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD.

Percentages are based on total number of subjects in the corresponding safety set within the relevant treatment group. ECOG = Eastern Cooperative Oncology Group; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; PS = performance status; QD = once daily.

a: Duration of treatment (months) = (Date of last dose of study drug - Date of first dose of study drug + 1)/30.4375.

<div style=\"page-break-after: always\"></div>

Table 61: Study 304 Extent of Exposure to Study Treatment including by lenvatinib dose

|                                       | Lenvatinib       | Lenvatinib        | Lenvatinib      | Sorafenib bd     |
|---------------------------------------|------------------|-------------------|-----------------|------------------|
|                                       | 8 mg a (N = 151) | 12 mg a (N = 325) | Total (N = 476) | 400 mg (N = 475) |
| Duration of Treatment b (months)      |                  |                   |                 |                  |
| Mean (SD)                             | 7.6 (6.47)       | 8.5 (7.27)        | 8.2 (7.04)      | 6.0 (6.47)       |
| Median                                | 5.6              | 6.3               | 5.7             | 3.7              |
| Q1, Q3                                | 2.4, 11.0        | 3.2, 12.0         | 2.9, 11.1       | 1.8, 7.4         |
| Min, Max                              | 0.1, 33.7        | 0.0, 35.0         | 0.0, 35.0       | 0.1, 38          |
| Duration of Treatment (months), n (%) |                  |                   |                 |                  |
| 0 -<1                                 | 15 (9.9)         | 24 (7.4)          | 39 (8.2)        | 31 (6.5)         |
| 1 -<2                                 | 15 (9.9)         | 35 (10.8)         | 50 (10.5)       | 124 (26.1)       |
| 2 -<4                                 | 34 (22.5)        | 60 (18.5)         | 94 (19.7)       | 114 (24.0)       |
| 4 -<6                                 | 17 (11.3)        | 42 (12.9)         | 59 (12.4)       | 53 (11.2)        |
| 6 -<8                                 | 10 (6.6)         | 36 (11.1)         | 46 (9.7)        | 47 (9.9)         |
| 8 -<12                                | 29 (19.2)        | 50 (15.4)         | 79 (16.6)       | 45 (9.5)         |
| 12 -<18                               | 19 (12.6)        | 39 (12.0)         | 58 (12.2)       | 28 (5.9)         |
| ≥18                                   | 12 (7.9)         | 39 (12.0)         | 51 (10.7)       | 33 (6.9)         |
| No. of subject months c               | 1141.3           | 2748.9            | 3890.2          | 2869.1           |
| Total Dose (mg) per Subject           |                  |                   |                 |                  |
| Mean                                  | 1609.5           | 2595.2            | 2282.5          | 121396.0         |
| (SD)                                  | (1497.01)        | (2353.30)         | (2167.04)       | (142550.76)      |
| Median                                | 1012.0           | 1812.0            | 1578.0          | 66200.0          |
| Q1                                    | 496.0,           | 768.0,            | 679.0,          | 42000.0,         |
| Q3                                    | 2256.0           | 3648.0            | 3254.0          | 148000.0         |
| Min, Max                              | 24.0, 8208.0     | 48.0, 11964.0     | 24.0, 11964.0   | 1400.0, 916800   |
| Dose Intensity (mg/day/subject)       |                  |                   |                 |                  |
| Mean (SD)                             | 7.0 (1.59)       | 10.5 (6.54)       | 9.4 (5.71)      | 663.8 (173.1)    |
| Median                                | 8.0              | 11.5              | 8.9             | 771.4            |
| Q1, Q3                                | 6.3, 8.0         | 8.7, 12.0         | 7.9, 12.0       | 514.6, 800.0     |
| Min, Max                              | 2.1, 8.0         | 1.7, 120.0        | 1.7, 120.0      | 126.3, 800.0     |
| Percentage of Planned Starting Dose   | Received d       |                   |                 |                  |
| Mean (SD)                             | 87.7(19.84)      | 87.5 (54.53)      | 87.5 (46.40)    | 83.0 (21.64)     |
| Median                                | 100.0            | 96.0              | 98.2            | 96.4             |
| Q1, Q3                                | 78.6, 100.0      | 72.7, 100.0       | 73.5, 100.0     | 64.3, 100.0      |
| Min, Max                              | 25.8, 100.0      | 14.4, 1000.0 e    | 14.4, 1000.0 e  | 15.8, 100.0      |
| <60%                                  | 21 (13.9)        | 38 (11.7)         | 59 (12.4)       | 106 (22.3)       |
| 60% -<70%                             | 8 (5.3)          | 34 (10.5)         | 42 (8.8)        | 24 (5.1)         |
| 70% -<80%                             | 9 (6.0)          | 36 (11.1)         | 45 (9.5)        | 36 (7.6)         |
| 80% -<90%                             | 10 (6.6)         | 31 (9.5)          | 41 (8.6)        | 30 (6.3)         |
| 90% -<100%                            | 26 (17.2)        | 65 (20.0)         | 91 (19.1)       | 118 (24.8)       |
| 100%                                  | 77 (51.0)        | 118 (36.3)        | 195 (41.0)      | 161 (33.9)       |
| >100%                                 | 0 (0.0)          | 3 (0.9)           | 3 (0.6)         | 0 (0.0)          |

Percentages are based on the total number of subjects within the relevant treatment group in the Safety Analysis Set. Dose Intensity = Total dose received during the study/(Date of last dose of study drug -Date of first dose of study drug + 1). Max = maximum; Min = minimum; Q1, Q3 = first quartile, third quartile; SD = standard deviation.

a: 8 mg and 12 mg were the starting doses of lenvatinib based on the subjects' body weight (&lt;60 kg, ≥60 kg) at Baseline b: Duration of treatment (months) = (Date of last dose of study drug -Date of first dose of study drug + 1) ÷ 30.4375.

c: Number of subject-months = Sum of all months that all subjects received study drug based on treatment duration.

d: Defined as the actual dose received as a percentage of planned starting dose (without interruption or reduction). Calculated as cumulative total dose divided by (planned starting daily dose × treatment duration in days).

e: One lenvatinib-treated subject mistakenly took a single 120-mg dose rather than 12 mg on Day 1.

## Adverse events

Table 62: Overview of Treatment-emergent Adverse Events - Study 304 Safety Analysis Set

|                               | Lenvatinib       | Lenvatinib        | Lenvatinib      | Sorafenib   |
|-------------------------------|------------------|-------------------|-----------------|-------------|
|                               | 8 mg a (N = 151) | 12 mg a (N = 325) | Total (N = 476) | (N = 475)   |
| Subject with Any TEAE         | 151 (100.0)      | 319 (98.2)        | 470 (98.7)      | 472 (99.4)  |
| Subject with Any Related TEAE | 143 (94.7)       | 304 (93.5)        | 447 (93.9)      | 452 (95.2)  |

<div style=\"page-break-after: always\"></div>

| Number of Subjects with TEAE with Worst CTCAE Grade b of         |            |              |              |            |
|------------------------------------------------------------------|------------|--------------|--------------|------------|
| ≥3                                                               | 100 (66.2) | 257 ( 79.1 ) | 357 ( 75.0 ) | 316 (66.5) |
| 3                                                                | 74 (49.0)  | 186 (57.2)   | 260 (54.6)   | 248 (52.2) |
| 4                                                                | 12 (7.9)   | 24 (7.4)     | 36 (7.6)     | 32 (6.7)   |
| 5                                                                | 14 (9.3)   | 47 (14.5)    | 61 ( 12.8 )  | 36 (7.6)   |
| Number of Subjects with Related TEAE with Worst CTCAE Grade b of |            |              |              |            |
| ≥3                                                               | 70 (46.4)  | 200 ( 61.5 ) | 270 ( 56.7 ) | 231 (48.6) |
| 3                                                                | 61 (40.4)  | 178 ( 54.8 ) | 239 (50.2)   | 209 (44.0) |
| 4                                                                | 6 (4.0)    | 14 (4.3)     | 20 (4.2)     | 18 (3.8)   |
| 5                                                                | 3 (2.0)    | 8 (2.5)      | 11 (2.3)     | 4 (0.8)    |
| Number of Subjects with Any Serious AE c                         | 58 (38.4)  | 147 (45.2)   | 205 ( 43.1 ) | 144 (30.3) |
| Number of Subjects with Any Fatal SAE d                          | 14 (9.3)   | 47 (14.5)    | 61 ( 12.8 )  | 36 (7.6)   |
| Number of Subjects with Nonfatal SAEs                            | 54 (35.8)  | 135 (41.5)   | 189 ( 39.7 ) | 128 (26.9) |
| Number of Subjects with c                                        |            |              |              |            |
| TEAEs Leading to Study Drug Withdrawal                           | 33 (21.9)  | 61 (18.8)    | 94 ( 19.7 )  | 69 (14.5)  |
| TEAEs Leading to Study Drug Dose Reduction                       | 43 (28.5)  | 141 ( 43.4 ) | 184 (38.7)   | 185 (38.9) |
| TEAEs Leading to Study Drug Interruption                         | 72 (47.7)  | 176 (54.2)   | 248 ( 52.1 ) | 193 (40.6) |
| TEAEs Leading to Study Drug Dose Reduction or Interruption       | 81 (53.6)  | 213 ( 65.5 ) | 294 (61.8)   | 264 (55.6) |

Data cutoff date: 13 Nov 2016. Percentages are based on the total number of subjects within the relevant treatment group in the Safety Analysis Set. For each row category, subjects with 2 or more TEAEs in that category were counted only once.

Related TEAEs include TEAEs that were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality. AE = adverse event; CTCAE = Common Terminology Criteria for AEs; TEAE = treatmentemergent AE.

a: 8 mg and 12 mg were the lenvatinib starting doses based on the subjects' body weight (&lt;60 kg, ≥60 kg) at Baseline.

b: Adverse events were graded using CTCAE version 4.0.

c: Subjects may be counted in more than 1 subcategory.

d:

Category includes 70 subjects who had a TEAE ongoing at the time of death due to disease progression or whose cause of death was unknown.

Exposure  was  1.5-times  longer  with  lenvatinib  than  with  sorafenib.  Therefore,  TEAEs  have  also  been adjusted  by  treatment  duration.  As  shown  in  the  table  below  the  rate  of  TEAE  episodes  adjusted  for treatment duration was 18.89 episodes/SY and 19.73 episodes/SY for the lenvatinib and sorafenib arms, respectively.

Table 63: Overview of Treatment-emergent Adverse Events Adjusted by Treatment Duration - Study 304 Safety Set

|                                                                                    | Lenvatinib                                              | Lenvatinib                                                | Lenvatinib                                              | Sorafenib                                         |
|------------------------------------------------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------|
|                                                                                    | 8 mg a (N = 151) Total Duration= 95.1 years n (AE Rate) | 12 mg a (N = 325) Total Duration= 229.1 years n (AE Rate) | Total (N = 476) Total Duration= 324.2 years n (AE Rate) | (N = 475) Total Duration= 239.1 years n (AE Rate) |
| Any TEAE Episodes Adjusted by SY Related TEAE Episodes Adjusted by SY              | 1737(18.26) 974 (10.24)                                 | 4387 (19.15) 2572 (11.23)                                 | 6124 (18.89) 3546 (10.94)                               | 4718 (19.73) 2865 (11.98)                         |
| Grade 3, 4 or 5 TEAE Episodes Adjusted by SY Related Grade 3, 4 or 5 TEAE Episodes | 278 (2.92) 126                                          | 745 (3.25) 391 (1.71)                                     | 1023 (3.16) 517 (1.59)                                  | 795 (3.33) 430                                    |
| Adjusted by SY Any Serious AE Episodes Adjusted by SY b                            | (1.32)                                                  |                                                           |                                                         | (1.80)                                            |
| Fatal SAE Episodes Adjusted by SY:                                                 | 113 (1.19) 14 (0.15)                                    | 296 (1.29) 47 (0.21)                                      | 409 (1.26) 61 (0.19)                                    | 232 (0.97) (0.15)                                 |
| Fatal SAE not Related to PD                                                        |                                                         | 15 (0.07)                                                 | 19 (0.06)                                               | 36 8 (0.03)                                       |
| Fatal SAE Related to PD c                                                          | 4 (0.04)                                                | 32 (0.14)                                                 | 42 (0.13)                                               | 28                                                |
|                                                                                    | 10 (0.11)                                               |                                                           |                                                         | (0.12)                                            |
| Nonfatal SAE Episodes Adjusted by SY                                               | 108 (1.14)                                              | 271                                                       | 379                                                     | 207 (0.87)                                        |
|                                                                                    |                                                         | (1.18)                                                    | (1.17)                                                  |                                                   |

Data cutoff date: 13 Nov 2016. Related TEAEs include TEAEs that were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality. Adverse events were graded using CTCAE version 4.0. An AE episode was based on MedDRA LLT. A single episode was defined from onset through resolution or, if ongoing, to the end of reporting period. Subjects with fatal SAEs may also have reported nonfatal SAEs.

Total Duration = sum of treatment time (in years) for all subjects in each treatment group (including dose interruption). AE Rate (episode/subject-year) = total occurrence of AE episode (n) divided by total duration in each treatment group. AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; LLT = low level term; MedDRA = Medical Dictionary for Regulatory Activities; PD = disease progression; SAE = serious adverse events; SY = subject-year; TEAE = treatment-emergent adverse event.

a: 8 mg and 12 mg were the lenvatinib starting doses based on the subjects' body weight (&lt;60 kg, ≥60 kg) at Baseline.

b: Fatal AE episodes are counted only once per subject, if more than 1 fatal AE was reported for the same subject.

c: Includes all subjects who had a TEAE ongoing at the time of death due to disease progression.

<div style=\"page-break-after: always\"></div>

Common AEs Table 64: TEAEs Occurring in ≥10% of Subjects in the HCC Safety Sets by MedDRA SOC and PT - HCC Randomized, All HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Sets

|                                                                       | Subject Incidence                   | Subject Incidence              | Subject Incidence                   | Subject Incidence                         |
|-----------------------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|-------------------------------------------|
|                                                                       | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set |
| MedDRA System Organ Class Preferred Term                              | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                 |
| Subjects with Any TEAEs                                               | 470 (98.7)                          | 472 (99.4)                     | 490 (98.8)                          | 1316 (99.2)                               |
| Endocrine disorders                                                   | 84 (17.6)                           | 12 (2.5)                       | 86 (17.3)                           | 193 (14.5)                                |
| Hypothyroidism                                                        | 78 (16.4)                           | 8 (1.7)                        | 79 (15.9)                           | 162 (12.2)                                |
| Gastrointestinal disorders                                            | 371 (77.9)                          | 357 (75.2)                     | 390 (78.6)                          | 1137 (85.7)                               |
| Diarrhoea                                                             | 184 (38.7)                          | 220 (46.3)                     | 189 (38.1)                          | 684 (51.5)                                |
| Nausea                                                                | 93 (19.5)                           | 68 (14.3)                      | 103 (20.8)                          | 568 (42.8)                                |
| Abdominal pain                                                        | 81 (17.0)                           | 87 (18.3)                      | 85 (17.1)                           | 281 (21.2)                                |
| Vomiting                                                              | 77 (16.2)                           | 36 (7.6)                       | 82 (16.5)                           | 443 (33.4)                                |
| Constipation                                                          | 76 (16.0)                           | 52 (10.9)                      | 84 (16.9)                           | 360 (27.1)                                |
| Ascites                                                               | 68 (14.3)                           | 44 (9.3)                       | 71 (14.3)                           | 11 (0.8)                                  |
| Abdominal pain upper                                                  | 58 (12.2)                           | 40 (8.4)                       | 59 (11.9)                           | 195 (14.7)                                |
| Stomatitis                                                            | 45 (9.5)                            | 56 (11.8)                      | 50 (10.1)                           | 371 (28.0)                                |
| General disorders and administration site                             | 284 (59.7)                          | 243 (51.2)                     | 300 (60.5)                          | 1009 (76.0)                               |
| Fatigue                                                               | 141 (29.6)                          | 119 (25.1)                     | 152 (30.6)                          | 631 (47.6)                                |
| conditions                                                            | 69 (14.5)                           | 63 (13.3)                      | 71 (14.3)                           | 164 (12.4)                                |
| Pyrexia                                                               | 66 (13.9)                           | 33 (6.9)                       | 72 (14.5)                           | 220 (16.6)                                |
| Oedema peripheral                                                     |                                     |                                | 54 (10.9)                           | 212 (16.0)                                |
| Asthenia                                                              | 54 (11.3)                           | 48 (10.1)                      | 320 (64.5)                          | 742 (55.9)                                |
| Investigations                                                        | 304 (63.9)                          | 255 (53.7)                     |                                     |                                           |
| Weight decreased                                                      | 147 (30.9)                          | 106 (22.3) 58 (12.2)           | 151 (30.4)                          | 451 (34.0)                                |
| Platelet count decreased Blood bilirubin increased                    | 87 (18.3) 71 (14.9)                 | 63 (13.3)                      | 90 (18.1) 71 (14.3)                 | 62 (4.7) 34 (2.6)                         |
|                                                                       | 65 (13.7)                           | 80 (16.8)                      | 68 (13.7)                           | 100 (7.5)                                 |
| Aspartate aminotransferase increased                                  |                                     |                                |                                     | 106 (8.0)                                 |
| Alanine aminotransferase increased Metabolism and nutrition disorders | 53 (11.1) 220 (46.2)                | 52 (10.9) 196 (41.3)           | 55 (11.1) 235 (47.4)                | 818 (61.6)                                |
| Decreased appetite Musculoskeletal and connective tissue              | 162 (34.0) 180 (37.8)               | 127 (26.7) 132 (27.8)          | 173 (34.9) 190 (38.3)               | 583 (43.9) 829                            |
| disorders Back pain                                                   |                                     | 31 (6.5)                       | 53 (10.7)                           | (62.5) 240 (18.1)                         |
| Nervous system                                                        | 50 (10.5) 163 (34.2)                | 106 (22.3)                     | 172 (34.7)                          | 768 (57.9)                                |
| disorders Headache                                                    | 46 (9.7)                            |                                | 51 (10.3)                           |                                           |
| Renal and                                                             |                                     | 38 (8.0)                       |                                     | 420 (31.7)                                |
| urinary disorders                                                     | 151 (31.7)                          | 84 (17.7)                      | 162 (32.7)                          | 588 (44.3)                                |
| Proteinuria                                                           | 117 (24.6)                          | 54 (11.4)                      | 128 (25.8)                          | 463 (34.9)                                |
| Respiratory, thoracic and mediastinal disorders                       | 213 (44.7)                          | 148 (31.2)                     | 225 (45.4)                          | 858 (64.7)                                |
| Dysphonia                                                             | 113 (23.7)                          | 57 (12.0)                      | 121 (24.4)                          | 412 (31.0)                                |
| Skin and subcutaneous tissue disorders                                | 237 (49.8)                          | 353 (74.3)                     | 257 (51.8)                          | 744 (56.1) 259                            |
| PPE                                                                   | 128 (26.9)                          | 249 (52.4)                     | 144 (29.0)                          | (19.5)                                    |
| Rash                                                                  | 46 (9.7)                            | 76 (16.0)                      | 51 (10.3)                           | 186 (14.0)                                |
| Alopecia                                                              | 14 (2.9)                            | 119 (25.1)                     |                                     | 106 (8.0)                                 |
| Vascular disorders                                                    | 214 (45.0)                          | 152 (32.0)                     | 16 (3.2) 231 (46.6)                 | 854 (64.4)                                |
| Hypertension                                                          | 201 (42.2)                          | 144 (30.3)                     | 218                                 | 775 (58.4)                                |
|                                                                       |                                     |                                | (44.0)                              |                                           |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib  Monotherapy  Safety  Set:  01  Sep  2016  (for  ongoing  studies).  In  the  Non-HCC  Lenvatinib  Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Display is in decreasing order of AE rate of PTs in the lenvatinib group of the HCC Randomized Safety Set. Adverse event terms were coded using MedDRA version 19.1. Subject  Incidence:  Subjects  with  2  or  more  TEAEs  reported  in  the  same  SOC  or  PT  were  counted  only  once. Percentages are based on the total number of subjects in the corresponding safety set within the relevant treatment group. Treatment Exposure-adjusted Rate: AE episode is based on MedDRA LLT. A single episode is defined from onset through  resolution  or,  if  ongoing,  to  the  end  of  reporting  period.  (*)  PPE:  Palmar-plantar  erythrodysaesthesia syndrome AE = adverse event; HCC = hepatocellular carcinoma; PPE = Palmar-plantar erythrodysaesthesia syndrome;

<div style=\"page-break-after: always\"></div>

ISS = Integrated Summary of Safety; LLT = low level term; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; QD = once daily; SOC = system organ class.

Table 65: TEAEs Occurring in ≥ 10% of Subjects in Either Treatment Arm of study 304, by PT

| Preferred Term                              | Lenvatinib (N = 476)   | Sorafenib (N = 475)   |
|---------------------------------------------|------------------------|-----------------------|
| Subjects with Any TEAEs                     | 470 (98.7)             | 472 (99.4)            |
| Hypertension                                | 201 ( 42.2 )           | 144 (30.3)            |
| Diarrhoea                                   | 184 (38.7)             | 220 ( 46.3 )          |
| Decreased appetite                          | 162 ( 34.0 )           | 127 (26.7)            |
| Weight decreased                            | 147 ( 30.9 )           | 106 (22.3)            |
| Fatigue                                     | 141 (29.6)             | 119 (25.1)            |
| Palmar-plantar erythrodysaesthesia syndrome | 128 (26.9)             | 249 ( 52.4 )          |
| Proteinuria                                 | 117 ( 24.6 )           | 54 (11.4)             |
| Dysphonia                                   | 113 ( 23.7 )           | 57 (12.0)             |
| Nausea                                      | 93 ( 19.5 )            | 68 (14.3)             |
| Platelet count decreased                    | 87 ( 18.3 )            | 58 (12.2)             |
| Abdominal pain                              | 81 (17.0)              | 87 (18.3)             |
| Hypothyroidism                              | 78 ( 16.4 )            | 8 (1.7)               |
| Vomiting                                    | 77 ( 16.2 )            | 36 (7.6)              |
| Constipation                                | 76 ( 16.0 )            | 52 (10.9)             |
| Blood bilirubin increased                   | 71 (14.9)              | 63 (13.3)             |
| Pyrexia                                     | 69 (14.5)              | 63 (13.3)             |
| Ascites                                     | 68 ( 14.3 )            | 44 (9.3)              |
| Oedema peripheral                           | 66 ( 13.9 )            | 33 (6.9)              |
| Aspartate aminotransferase increased        | 65 (13.7)              | 80 (16.8)             |
| Abdominal pain upper                        | 58 (12.2)              | 40 (8.4)              |
| Asthenia                                    | 54 (11.3)              | 48 (10.1)             |
| Alanine aminotransferase increased          | 53 (11.1)              | 52 (10.9)             |
| Back pain                                   | 50 ( 10.5 )            | 31 (6.5)              |
| Rash                                        | 46 (9.7)               | 76 ( 16.0 )           |
| Stomatitis                                  | 45 (9.5)               | 56 (11.8)             |
| Alopecia                                    | 14 (2.9)               | 119 ( 25.1 )          |

Data cutoff date: 13 Nov 2016. Percentages are based on the total number of subjects within the relevant treatment group in the Safety Analysis Set. Display is in decreasing order of frequency of TEAEs in the lenvatinib total group. Subjects with 2 or more TEAEs in the same preferred term were counted only once. Adverse Event terms were coded using MedDRA version 19.1. MedDRA = Medical Dictionary for Regulatory Activities; TEAE = treatment-emergent adverse event. a: 8 mg and 12 mg were the lenvatinib starting doses based on the subjects' body weight (&lt;60 kg, ≥60 kg) at Baseline.

## Severe (Grade 3 and 4) TEAEs

A summary of CTCAE grade 3 or 4 TEAEs occurring in ≥ 1% of subjects in any group of the safety sets is presented in the Table 66 below.

Grade 3 or higher TEAEs occurred in 357 subjects (75%) in the lenvatinib arm and 316 subjects (66.5%) in the sorafenib arm.

Adjusted by treatment duration, the rate of Grade ≥ 3 TEAEs in the lenvatinib and sorafenib arms was 3.16 and 3.33 episodes/SY, respectively.

There were higher incidences of Grade 3 WBC (2.4% vs 0.2%) and neutrophil (2.6% vs 0.2%) decreased counts in the All HCC than in the Non-HCC Safety Set.

<div style=\"page-break-after: always\"></div>

Table 66: Grade 3 or 4 TEAEs That Occurred in ≥1% of Subjects in any Group in the HCC Safety Sets Adjusted by Treatment Exposure, by Preferred Term

|                                                   | HCC Randomized Safety Set (Study 304)                                  | HCC Randomized Safety Set (Study 304)                                  | HCC Randomized Safety Set (Study 304)                       | HCC Randomized Safety Set (Study 304)   | All HCC Lenvatinib Safety Set                                        | All HCC Lenvatinib Safety Set                                        | All HCC Lenvatinib Safety Set                                        | Non-HCC Monotherapy Safety Set                                |
|---------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------|
|                                                   | Lenvatinib 8 or 12 mg (N=476) Total Exposure = 324.2 years n (AE Rate) | Lenvatinib 8 or 12 mg (N=476) Total Exposure = 324.2 years n (AE Rate) | Sorafenib 800 mg (N=475) Total Exposure = 239.1 years n (AE | Rate)                                   | Lenvatinib 8 or 12 mg (N=496) Total Exposure = 340 years n (AE Rate) | Lenvatinib 8 or 12 mg (N=496) Total Exposure = 340 years n (AE Rate) | Lenvatinib 8 or 12 mg (N=496) Total Exposure = 340 years n (AE Rate) | Lenvatinib (N=1327) Total Exposure = 1244.7 years n (AE Rate) |
| Preferred Term                                    | Grade 3                                                                | Grade 4                                                                | Grade 3                                                     | Grade 4                                 | Grade 3                                                              | Grade 4                                                              | Grade 3                                                              | Grade 4                                                       |
| Subjects with Any Grade 3 or 4 TEAEs Hypertension | 887 (2.74) 124                                                         | 64 (0.20) 0                                                            | 704 (2.94) 74                                               | 53 (0.22) 0                             | 935 (2.75) 138                                                       | 64 (0.19) 0                                                          | 2874 (2.31) 509 (0.41)                                               | 198 (0.16) 6 (<0.01)                                          |
| Weight decreased                                  | (0.38) 37 (0.11)                                                       | 0                                                                      | (0.31) 14 (0.06)                                            | 0                                       | (0.41) 38 (0.11)                                                     | 0                                                                    | 93 (0.07)                                                            | 0                                                             |
| Hepatic encephalopathy                            | 29 (0.09)                                                              | 2 (<0.01)                                                              | 8 (0.03)                                                    | 0                                       | 33 (0.10)                                                            | 2 (<0.01)                                                            | 0                                                                    | 0                                                             |
| Platelet count decreased                          | 29 (0.09)                                                              | 0                                                                      | 14 (0.06)                                                   | 2                                       | 35 (0.10)                                                            | 0                                                                    | 5                                                                    | 0                                                             |
| Proteinuria                                       | 28 (0.09 )                                                             | 0                                                                      | 8 (0.03)                                                    | (<0.01) 0                               | 33 (0.10)                                                            | 0                                                                    | (<0.01) 140 (0.11)                                                   | 1 (<0.01)                                                     |
| Blood bilirubin increased                         | 27 (0.08)                                                              | 7 (0.02)                                                               | 22 (0.09)                                                   | 2 (<0.01)                               | 27 (0.08)                                                            | 7 (0.02)                                                             | 4 (<0.01)                                                            | 0                                                             |
| Decreased appetite                                | 24 (0.07)                                                              | 0                                                                      | 6 (0.03)                                                    | 0                                       | 24 (0.07)                                                            | 0                                                                    | 50 (0.04)                                                            | 0                                                             |
| Diarrhoea                                         | 24 (0.07)                                                              | 0                                                                      | 24 (0.10)                                                   | 0                                       | 25 (0.07)                                                            | 0                                                                    | 117 (0.09)                                                           | 0                                                             |
| Aspartate aminotransferase increased              | 22 (0.07)                                                              | 3 (<0.01)                                                              | 36 (0.15)                                                   | 6 (0.03)                                | 22 (0.06)                                                            | 3 (<0.01)                                                            | 11 (<0.01)                                                           | 1 (<0.01)                                                     |
| Gamma- glutamyltransferase increased              | 21 (0.06)                                                              | 6 (0.02)                                                               | 16 (0.07)                                                   | 4 (0.02)                                | 21 (0.06)                                                            | 6 (0.02)                                                             | 9 (<0.01)                                                            | 0                                                             |
| Hyponatraemia                                     | 20 (0.06)                                                              | 3 (<0.01)                                                              | 8 (0.03)                                                    | 1 (<0.01)                               | 21 (0.06)                                                            | 3 (<0.01)                                                            | 41 (0.03)                                                            | 9 (<0.01)                                                     |
| Ascites                                           | 18 (0.06)                                                              | 0                                                                      | 15 (0.06)                                                   | 0                                       | 18 (0.05)                                                            | 0                                                                    | 5 (<0.01)                                                            | 0                                                             |
| Fatigue                                           | 18 (0.06)                                                              | 0                                                                      | 17 (0.07)                                                   | 0                                       | 18 (0.05)                                                            | 0                                                                    | 137 (0.11)                                                           | 2 (<0.01)                                                     |
| Neutrophil count decreased                        | 18 (0.06)                                                              | 3 (<0.01)                                                              | 8 (0.03)                                                    | 3 (0.01)                                | 19 (0.06)                                                            | 3 (<0.01)                                                            | 2 (<0.01)                                                            | 0                                                             |
| Anaemia                                           | 17 (0.05)                                                              | 0                                                                      | 17                                                          | 0                                       | 17 (0.05)                                                            | 0                                                                    | 30 (0.02)                                                            | 0                                                             |
| Alanine aminotransferase increased                | 16 (0.05)                                                              | 0                                                                      | (0.07) 12 (0.05)                                            | 4 (0.02)                                | 16 (0.05)                                                            | 0                                                                    | 15 (0.01)                                                            | 0                                                             |
| Asthenia                                          | 15 (0.05)                                                              | 0                                                                      | 11 (0.05)                                                   | 0                                       | 15 (0.04)                                                            | 0                                                                    | 65 (0.05)                                                            | 1 (<0.01)                                                     |
| Palmar-plantar erythrodysaesthesia syndrome       | 15 (0.05)                                                              | 0                                                                      | 63 (0.26)                                                   | 0                                       | 16 (0.05)                                                            | 0                                                                    | 28 (0.02)                                                            | 0                                                             |
| Lymphocyte count decreased                        | 13 (0.04)                                                              | 1 (<0.01)                                                              | 6 (0.03)                                                    | 0                                       | 13 (0.04)                                                            | 1 (<0.01)                                                            | 9 (<0.01)                                                            | 1 (<0.01)                                                     |
| White blood cell count decreased                  | 13 (0.04)                                                              | 0                                                                      | 10 (0.04)                                                   | 1 (<0.01)                               | 13 (0.04)                                                            | 0                                                                    | 4 (<0.01)                                                            | 0                                                             |
| Blood alkaline phosphatase                        | 11 (0.03)                                                              | 0                                                                      | 7 (0.03)                                                    | 0                                       | 11 (0.03)                                                            | 0                                                                    | 9 (<0.01)                                                            | 0                                                             |
| increased                                         | 10 (0.03)                                                              | 4 (0.01)                                                               |                                                             |                                         |                                                                      |                                                                      |                                                                      |                                                               |
| Lipase increased                                  |                                                                        |                                                                        | 8 (0.03)                                                    | 3 (0.01)                                | 10 (0.03)                                                            | 4 (0.01)                                                             | 23 (0.02)                                                            | 6 (<0.01)                                                     |
| Abdominal pain upper                              | 9 (0.03)                                                               | 0                                                                      | 6 (0.03)                                                    | 0                                       | 9 (0.03)                                                             | 0                                                                    | 9 (<0.01)                                                            | 0                                                             |
| Thrombocytopenia                                  | 9 (0.03)                                                               | 1 (<0.01)                                                              | 6 (0.03)                                                    | 0                                       | 18 (0.05)                                                            | 1 (<0.01)                                                            | 20 (0.02)                                                            | 4 (<0.01)                                                     |

<div style=\"page-break-after: always\"></div>

| Abdominal pain                  | 8 (0.02)   | 0         | 14 (0.06 )   | 0         | 8 (0.02)   | 0         | 40 (0.03)   | 3 (<0.01)   |
|---------------------------------|------------|-----------|--------------|-----------|------------|-----------|-------------|-------------|
| Dyspnoea                        | 8 (0.02)   | 0         | 3 (0.01)     | 0         | 8 (0.02)   | 0         | 38 (0.03)   | 2 (<0.01)   |
| Hepatic function abnormal       | 8 (0.02)   | 0         | 9 (0.04)     | 0         | 8 (0.02)   | 0         | 7 (<0.01)   | 0           |
| Neutropenia                     | 7 (0.02)   | 0         | 0            | 0         | 7 (0.02)   | 0         | 15 (0.01)   | 1 (<0.01)   |
| Oesophageal varices haemorrhage | 7 (0.02)   | 1 (<0.01) | 4 (0.02)     | 0         | 7 (0.02)   | 1 (<0.01) | 0           | 0           |
| Hyperkalaemia                   | 6 (0.02)   | 0         | 1 (<0.01)    | 1 (<0.01) | 6 (0.02)   | 0         | 8 (<0.01)   | 2 (<0.01)   |
| Vomiting                        | 6 (0.02)   | 0         | 5 (0.02)     | 0         | 6 (0.02)   | 0         | 36 (0.03)   | 1 (<0.01)   |
| Electrocardiogram QT prolonged  | 5 (0.02)   | 0         | 7 (0.03)     | 0         | 5 (0.01)   | 0         | 14 (0.01)   | 0           |
| Hyperbilirubinaemia             | 5 (0.02)   | 1 (<0.01) | 1 (<0.01)    | 0         | 5 (0.01)   | 1 (<0.01) | 4 (<0.01)   | 0           |
| Jaundice cholestatic            | 5 (0.02)   | 3 (<0.01) | 2 (<0.01)    | 1 (<0.01) | 5 (0.01)   | 3 (<0.01) | 0           | 0           |
| Cancer pain                     | 4 (0.01)   | 0         | 6 (0.03)     | 0         | 5 (0.01)   | 0         | 11 (<0.01)  | 0           |
| Hepatic failure                 | 4 (0.01)   | 1 (<0.01) | 9 (0.04)     | 1 (<0.01) | 4 (0.01)   | 1 (<0.01) | 1 (<0.01)   | 0           |
| Hypokalaemia                    | 4 (0.01)   | 1 (<0.01) | 13 (0.05)    | 0         | 4 (0.01)   | 1 (<0.01) | 22 (0.02)   | 7 (<0.01)   |
| Back pain                       | 1 (<0.01)  | 0         | 5 (0.02)     | 0         | 1 (<0.01)  | 0         | 18 (0.01)   | 0           |
| Jaundice                        | 1 (<0.01)  | 0         | 5 (0.02)     | 0         | 1 (<0.01)  | 0         | 1 (<0.01)   | 0           |

Data  cutoff  date  for  HCC  Randomized  and  All  HCC  Lenvatinib  Safety  Sets:  13  Nov  2016.  Data  cutoff  date  for  Non-HCC  Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies).  In  the  Non-HCC  Lenvatinib  Monotherapy  Safety  Set,  85%  of  subjects received a starting dose of 24 mg QD. Display is in decreasing order of Grade 3 AE rate in the lenvatinib group of the HCC Randomized Safety Set. AE episode is based on MedDRA LLT. A single episode is defined from onset through resolution or, if ongoing, to the end of reporting period. Adverse Event terms were coded using MedDRA version 19.1. Total Exposure (SY) = sum of treatment duration (in years) for all subjects in each treatment group (including dose interruption). AE Rate (episode/SY) = total occurrence of TEAE episodes (n) divided by the total exposure (SY) for the specified treatment group. AE = adverse event; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; LLT = low level term; MedDRA = Medical Dictionary for Regulatory Activities; QD = once daily; SY = subject year; TEAE = treatment-emergent adverse event.

<div style=\"page-break-after: always\"></div>

Table 67: TEAEs that Occurred in at Least 10% of Subjects in Either Treatment Arm by System Organ Class, Overall Incidence and Grade 3 and Above - Study 304

|                                                                          | Lenvatinib (N = 476) n (%)   | Lenvatinib (N = 476) n (%)   | Lenvatinib (N = 476) n (%)   | Lenvatinib (N = 476) n (%)   | Lenvatinib (N = 476) n (%)   | Sorafenib (N = 475) n (%)   | Sorafenib (N = 475) n (%)   | Sorafenib (N = 475) n (%)   | Sorafenib (N = 475) n (%)   | Sorafenib (N = 475) n (%)   |
|--------------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| System Organ Class                                                       | Any Grade                    | Grade 3                      | Grade 4                      | Grade 5                      | Grade ≥3                     | Any Grade                   | Grade 3                     | Grade 4                     | Grade 5                     | Grad e ≥3                   |
| Gastrointestinal disorders                                               | 371 (77.9)                   | 70 (14.7)                    | 1 (0.2)                      | 4 (0.8)                      | 75 (15.8)                    | 357 (75.2)                  | 70 (14.7)                   | 4 (0.8)                     | 4 (0.8)                     | 78 (16.4)                   |
| Investigations                                                           | 304 (63.9)                   | 127 (26.7)                   | 23 (4.8)                     | 0 (0.0)                      | 150 ( 31.5 )                 | 255 (53.7)                  | 99 (20.8)                   | 22 (4.6)                    | 0 (0.0)                     | 121 (25.5)                  |
| General disorders and administration site conditions                     | 284 (59.7)                   | 40 (8.4)                     | 1 (0.2)                      | 7 (1.5)                      | 48 (10.1)                    | 243 (51.2)                  | 33 (6.9)                    | 0 (0.0)                     | 4 (0.8)                     | 37 (7.8)                    |
| Skin and subcutaneous tissue disorders                                   | 237 (49.8)                   | 17 (3.6)                     | 0 (0.0)                      | 0 (0.0)                      | 17 (3.6)                     | 353 (74.3)                  | 64 (13.5)                   | 0 (0.0)                     | 0 (0.0)                     | 64 ( 13.5 )                 |
| Metabolism and nutrition disorders                                       | 220 (46.2)                   | 56 (11.8)                    | 8 (1.7)                      | 1 (0.2)                      | 65 ( 13.7 )                  | 196 (41.3)                  | 33 (6.9)                    | 5 (1.1)                     | 0 (0.0)                     | 38 (8.0)                    |
| Vascular disorders                                                       | 214 (45.0)                   | 114 (23.9)                   | 1 (0.2)                      | 1 (0.2)                      | 116 ( 24.4 )                 | 152 (32.0)                  | 72 (15.2)                   | 1 (0.2)                     | 0 (0.0)                     | 73 (15.4)                   |
| Respiratory, thoracic and mediastinal disorders                          | 213 (44.7)                   | 17 (3.6)                     | 0 (0.0)                      | 8 (1.7)                      | 25 (5.3)                     | 148 (31.2)                  | 12 (2.5)                    | 0 (0.0)                     | 4 (0.8)                     | 16 (3.4)                    |
| Musculoskeletal and connective tissue disorders                          | 180 (37.8)                   | 18 (3.8)                     | 0 (0.0)                      | 0 (0.0)                      | 18 (3.8)                     | 132 (27.8)                  | 14 (2.9)                    | 0 (0.0)                     | 0 (0.0)                     | 14 (2.9)                    |
| Nervous system disorders                                                 | 163 (34.2)                   | 34 (7.1)                     | 4 (0.8)                      | 9 (1.9)                      | 47 ( 9.9 )                   | 106 (22.3)                  | 14 (2.9)                    | 5 (1.1)                     | 1 (0.2)                     | 20 (4.2)                    |
| Renal and urinary disorders                                              | 151 (31.7)                   | 36 (7.6)                     | 1 (0.2)                      | 1 (0.2)                      | 38 ( 8.0 )                   | 84 (17.7)                   | 12 (2.5)                    | 1 (0.2)                     | 2 (0.4)                     | 15 (3.2)                    |
| Infections and infestations                                              | 144 (30.3)                   | 28 (5.9)                     | 5 (1.1)                      | 7 (1.5)                      | 40 (8.4)                     | 134 (28.2)                  | 22 (4.6)                    | 3 (0.6)                     | 2 (0.4)                     | 27 (5.7)                    |
| Hepatobiliary disorders                                                  | 85 (17.9)                    | 34 (7.1)                     | 4 (0.8)                      | 16 (3.4)                     | 54 (11.3)                    | 54 (11.4)                   | 32 (6.7)                    | 2 (0.4)                     | 3 (0.6)                     | 37 (7.8)                    |
| Endocrine disorders                                                      | 84 (17.6)                    | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 12 (2.5)                    | 1 (0.2)                     | 0 (0.0)                     | 0 (0.0)                     | 1 (0.2)                     |
| Blood and lymphatic system disorders                                     | 84 (17.6)                    | 34 (7.1)                     | 2 (0.4)                      | 1 (0.2)                      | 37 (7.8)                     | 78 (16.4)                   | 25 (5.3)                    | 1 (0.2)                     | 0 (0.0)                     | 26 (5.5)                    |
| Psychiatric disorders                                                    | 56 (11.8)                    | 5 (1.1)                      | 1 (0.2)                      | 0 (0.0)                      | 6 (1.3)                      | 46 (9.7)                    | 1 (0.2)                     | 0 (0.0)                     | 0 (0.0)                     | 1 (0.2)                     |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | 51 (10.7)                    | 12 (2.5)                     | 3 (0.6)                      | 13 (2.7)                     | 28 (5.9)                     | 57 (12.0)                   | 16 (3.4)                    | 0 (0.0)                     | 16 (3.4)                    | 32 (6.7)                    |

Data cutoff date: 13 Nov 2016. Percentages are based on the total number of subjects within the relevant treatment group in the Safety Analysis Set. Display is in decreasing order of frequency of TEAEs in the 'Any Grade' column for the lenvatinib arm. Subjects with 2 or more TEAEs in the same System-Organ Class were counted only once.Adverse Event terms were coded using MedDRA version 19.1.Adverse events were graded using CTCAE version 4.0.

CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; TEAE = treatment-emergent adverse event.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

Table 68: SAEs (Fatal and Nonfatal) Occurring in ≥ 1% in any Group in the Safety Sets.

|                                       | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|---------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
| Preferred Term                        | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Subjects with Any SAEs                | 205 (43.1)                          | 144 (30.3)                     | 210 (42.3)                          | 713 (53.7)                                  |
| Hepatic encephalopathy                | 21 (4.4)                            | 3 (0.6)                        | 23 ( 4.6 )                          | 0                                           |
| Hepatic failure                       | 14 (2.9)                            | 8 (1.7)                        | 14 ( 2.8 )                          | 4 (0.3)                                     |
| Ascites                               | 12 (2.5)                            | 11 (2.3)                       | 12 (2.4)                            | 2 (0.2)                                     |
| Decreased appetite                    | 11 (2.3)                            | 2 (0.4)                        | 11 ( 2.2 )                          | 17 (1.3)                                    |
| Malignant neoplasm progression        | 10 (2.1)                            | 14 (2.9)                       | 10 (2.0)                            | 12 (0.9)                                    |
| Diarrhoea                             | 8 ( 1.7 )                           | 2 (0.4)                        | 8 (1.6)                             | 18 (1.4)                                    |
| Asthenia                              | 7 ( 1.5 )                           | 1 (0.2)                        | 7 (1.4)                             | 18 (1.4)                                    |
| Blood bilirubin increased             | 7 (1.5)                             | 1 (0.2)                        | 7 ( 1.4 )                           | 1 (0.1)                                     |
| Jaundice cholestatic                  | 7 (1.5)                             | 3 (0.6)                        | 7 ( 1.4 )                           | 0                                           |
| Oesophageal varices haemorrhage       | 7 ( 1.5 )                           | 5 (1.1)                        | 7 (1.4)                             | 0                                           |
| Sepsis                                | 7 ( 1.5 )                           | 3 (0.6)                        | 7 (1.4)                             | 16 (1.2)                                    |
| Abdominal pain                        | 6 (1.3)                             | 10 (2.1)                       | 6 (1.2)                             | 33 ( 2.5 )                                  |
| Pyrexia                               | 6 (1.3)                             | 5 (1.1)                        | 6 (1.2)                             | 13 (1.0)                                    |
| Vomiting                              | 6 ( 1.3 )                           | 0 (0.0)                        | 6 (1.2)                             | 30 ( 2.3 )                                  |
| Dyspnoea                              | 5 ( 1.1 )                           | 2 (0.4)                        | 5 (1.0)                             | 29 ( 2.2 )                                  |
| General physical health deterioration | 5 ( 1.1 )                           | 3 (0.6)                        | 5 (1.0)                             | 24 ( 1.8 )                                  |
| Pneumonia                             | 5 (1.1)                             | 4 (0.8)                        | 5 (1.0)                             | 48 ( 3.6 )                                  |
| Upper gastrointestinal haemorrhage    | 5 (1.1)                             | 2 (0.4)                        | 5 ( 1.0 )                           | 0                                           |
| Back pain                             | 2 (0.4)                             | 5 (1.1)                        | 2 (0.4)                             | 11 (0.8)                                    |
| Pathological fracture                 | 2 (0.4)                             | 5 (1.1)                        | 2 (0.4)                             | 5 (0.4)                                     |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Serious AEs include any AEs that met the criteria for seriousness, whether fatal or nonfatal. Display is in decreasing order of AE rate of preferred terms in the Lenvatinib group of the HCC Randomized Safety Set. Adverse event terms were coded using MedDRA version 19.1. Subject Incidence: Subjects with 2 or more TEAEs reported in the same PT term were counted only once. Percentages are based on the total number of subjects in the corresponding safety set within the relevant treatment group. AE Rate (episode/SY) = total occurrence of TEAE episodes (n) divided by the total exposure (SY) for the specified treatment group. AE = adverse event; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; LLT = low level term; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; QD = once daily; SAE = serious adverse event; SY = subject year; TEAE = treatment-emergent adverse event.

The SAEs reported were generally of comparable types to those in the Non-HCC Lenvatinib Monotherapy Safety Set, exception for hepatic-related SAEs.

Adjusted by treatment duration, the overall rate of SAEs was 1.26 episodes/SY for the lenvatinib arm and 0.97 episodes/SY for the sorafenib arm.

<div style=\"page-break-after: always\"></div>

Table 69: Serious Treatment-Emergent Adverse Event Episodes Adjusted by Treatment Duration by Preferred Term and Region, Safety Analysis Set

|                                  | Asia-Pacific                                                   | Asia-Pacific                                                      | Asia-Pacific                                                      | Asia-Pacific                                               | Western Regions                                              | Western Regions                                                  | Western Regions                                                   | Western Regions                                           |
|----------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------|
|                                  | Lenvatinib 8mga (N = 130) Total Duration= 85.7years n(AE Rate) | Lenvatinib 12mga (N = 191) Total Duration= 134.9years n (AE Rate) | Lenvatinib Total (N = 321) Total Duration= 220.5years n (AE Rate) | Sorafenib (N = 319) Total Duration= 150.2years n (AE Rate) | Lenvatinib 8mga (N =21) Total Duration= 9.5years n (AE Rate) | Lenvatinib 12mga (N = 134) Total Duration= 94.2years n (AE Rate) | Lenvatinib Total (N = 155) Total Duration= 103.6years n (AE Rate) | Sorafenib (N = 156) Total Duration= 88.8years n (AE Rate) |
| All Serious TEAE Episodes        | 96 (1.12)                                                      | 161 (1.19)                                                        | 257 (1.17)                                                        | 154 (1.03)                                                 | 17 (1.80)                                                    | 135 (1.43)                                                       | 152 (1.47)                                                        | 78 (0.88)                                                 |
| Hepatic encephalopathy           | 6 (0.07)                                                       | 7 (0.05)                                                          | 13 (0.06)                                                         | 3 (0.02)                                                   | 0 (0.0)                                                      | 18 (0.19)                                                        | 18 (0.17)                                                         | 1 (0.01)                                                  |
| Ascites                          | 1 (0.01)                                                       | 10 (0.07)                                                         | 11 (0.05)                                                         | 11 (0.07)                                                  | 0 (0.0)                                                      | 3 (0.03)                                                         | 3 (0.03)                                                          | 2 (0.02)                                                  |
| Decreased appetite               | 4 (0.05)                                                       | 6 (0.04)                                                          | 10 (0.05)                                                         | 2 (0.01)                                                   | 1 (0.11)                                                     | 1 (0.01)                                                         | 2 (0.02)                                                          | 0 (0.0)                                                   |
| Hepatic failure                  | 5 (0.06)                                                       | 4 (0.03)                                                          | 9 (0.04)                                                          | 4 (0.03)                                                   | 0 (0.0)                                                      | 5 (0.05)                                                         | 5 (0.05)                                                          | 4 (0.05)                                                  |
| Abdominal pain upper             | 8 (0.09)                                                       | 0 (0.0)                                                           | 8 (0.04)                                                          | 0 (0.0)                                                    | 0 (0.0)                                                      | 0 (0.0)                                                          | 0 (0.0)                                                           | 0 (0.0)                                                   |
| Oesophagealvariceshaemorrhage    | 1 (0.01)                                                       | 6 (0.04)                                                          | 7 (0.03)                                                          | 5 (0.03)                                                   | 0 (0.0)                                                      | 1 (0.01)                                                         | 1 (<0.01)                                                         | 1 (0.01)                                                  |
| Diarrhoea                        | 1 (0.01)                                                       | 5 (0.04)                                                          | 6 (0.03)                                                          | 0 (0.0)                                                    | 0 (0.0)                                                      | 2 (0.02)                                                         | 2 (0.02)                                                          | 2 (0.02)                                                  |
| Jaundice cholestatic             | 4 (0.05)                                                       | 2 (0.01)                                                          | 6 (0.03)                                                          | 3 (0.02)                                                   | 0 (0.0)                                                      | 1 (0.01)                                                         | 1 (<0.01)                                                         | 0 (0.0)                                                   |
| Malignant neoplasmprogression    | 1 (0.01)                                                       | 5 (0.04)                                                          | 6 (0.03)                                                          | 11 (0.07)                                                  | 1 (0.11)                                                     | 3 (0.03)                                                         | 4 (0.04)                                                          | 3 (0.03)                                                  |
| Blood bilirubinincreased         | 2 (0.02)                                                       | 3 (0.02)                                                          | 5 (0.02)                                                          | 1 (<0.01)                                                  | 0 (0.0)                                                      | 2 (0.02)                                                         | 2 (0.02)                                                          | 0 (0.0)                                                   |
| Pneumonia                        | 3 (0.04)                                                       | 2 (0.01)                                                          | 5 (0.02)                                                          | 3 (0.02)                                                   | 0 (0.0)                                                      | 0 (0.0)                                                          | 0 (0.0)                                                           | 1 (0.01)                                                  |
| Pyrexia                          | 3 (0.04)                                                       | 2 (0.01)                                                          | 5 (0.02)                                                          | 6 (0.04)                                                   | 0 (0.0)                                                      | 1 (0.01)                                                         | 1 (<0.01)                                                         | 0 (0.0)                                                   |
| Uppergastrointestinalhaemorrhage | 1 (0.01)                                                       | 4 (0.03)                                                          | 5 (0.02)                                                          | 3 (0.02)                                                   | 0 (0.0)                                                      | 0 (0.0)                                                          | 0 (0.0)                                                           | 0 (0.0)                                                   |
| Asthenia                         | 1 (0.01)                                                       | 3 (0.02)                                                          | 4 (0.02)                                                          | 0 (0.0)                                                    | 0 (0.0)                                                      | 3 (0.03)                                                         | 3 (0.03)                                                          | 1 (0.01)                                                  |

## Deaths

## Table 70: Summary of All Deaths - HCC Randomized, All HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Sets

|                                                    | HCC Randomized Safety Set           | HCC Randomized Safety Set      | AII HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|----------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
|                                                    | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| All Deaths                                         | 350 (73.5)                          | 350 (73.7)                     | 363 (73.2)                          | 861 (64.9)                                  |
| Due to progressive disease                         | 274 (57.6)                          | 284 (59.8)                     | 274 (55.2)                          | 605 (45.6)                                  |
| Not due to progressive disease                     | 32 (6.7)                            | 17 (3.6)                       | 32 (6.5)                            | 56 (4.2)                                    |
| Unknown                                            | 44 (9.2)                            | 49 (10.3)                      | 57 (11.5)                           | 200 (15.1)                                  |
| Deaths on Treatment or within 30 Days of Last Dose | 63 (13.2)                           | 38 (8.0)                       | 64 (12.9)                           | 185 (13.9)                                  |
| Due to progressive disease                         | 44 (9.2)                            | 30 (6.3)                       | 44 (8.9)                            | 93 (7.0)                                    |
| Not due to progressive disease                     | 17 (3.6)                            | 6 (1.3)                        | 17 (3.4)                            | 44 (3.3)                                    |
| Unknowna                                           | 2 (0.4)                             | 2 (0.4)                        | 3 (0.6)                             | 48 (3.6)                                    |

a: If causes for deaths were not collected, the deaths were counted in the category of Unknown.

<div style=\"page-break-after: always\"></div>

Table 71: Fatal Adverse Events Occurring in ≥ 2 Subjects in any HCC Safety Sets - all sets

| Term with any Fatal AEs               | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|---------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
| Preferred                             | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Subjects                              | 61 (12.8)                           | 36 (7.6)                       | 62 (12.5)                           | 130 (9.8)                                   |
| Hepatic failure                       | 10 (2.1)                            | 2 (0.4)                        | 10 (2.0)                            | 4 (0.3)                                     |
| Malignant neoplasm progression        | 10 (2.1)                            | 14 (2.9)                       | 10 (2.0)                            | 12 (0.9)                                    |
| Sepsis                                | 5 (1.1)                             | 1 (0.2)                        | 5 (1.0)                             | 6 (0.5)                                     |
| Cerebral haemorrhage                  | 3 (0.6)                             | 0                              | 3 (0.6)                             | 0                                           |
| Respiratory failure                   | 3 (0.6)                             | 3 (0.6)                        | 3 (0.6)                             | 4 (0.3)                                     |
| Cerebrovascular accident              | 2 (0.4)                             | 0                              | 2 (0.4)                             | 3 (0.2)                                     |
| Coma hepatic                          | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| General physical health deterioration | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 16 (1.2)                                    |
| Hepatic encephalopathy                | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| Multiple organ dysfunction syndrome   | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 2 (0.2)                                     |
| Pneumonia aspiration                  | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| Portal vein thrombosis                | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| Upper gastrointestinal haemorrhage    | 2 (0.4)                             | 2 (0.4)                        | 2 (0.4)                             | 0                                           |
| Renal impairment                      | 1 (0.2)                             | 2 (0.4)                        | 1 (0.2)                             | 0                                           |
| Sudden death                          | 1 (0.2)                             | 2 (0.4)                        | 1 (0.2)                             | 1 (0.1)                                     |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Display is in decreasing order of AE rate of PTs in the lenvatinib group of the HCC Randomized Safety Set. Adverse event terms were coded using MedDRA version 19.1.

Subject Incidence: Subjects with 2 or more TEAEs reported in the same PT term were counted only once. Percentages are based on the total number of subjects in the corresponding safety set within the relevant treatment group. AE Rate (episode/SY) = total occurrence of TEAE episodes (n) divided by the total exposure (SY) for the specified treatment group. AE = adverse event; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; LLT = low level term; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; QD = once daily; SY = subject year; TEAE = treatment-emergent adverse event.

Adjusted for treatment duration, the overall rate of fatal AE episodes was 0.19 episodes/SY in the lenvatinib and 0.15 episodes/SY in the sorafenib arm. The rate of fatal AE episodes was higher in the lenvatinib arm compared with the sorafenib arm for hepatic failure sepsis and cerebral haemorrhage.

The rate of fatal AEs that were not related to PD was 0.06 and 0.03 episodes/SY in the lenvatinib and sorafenib arms, respectively.

<div style=\"page-break-after: always\"></div>

Table 72 : Duration-adjusted Fatal Treatment-emergent Adverse Events, by CMQ for Hepatic Failure and Sepsis - Study 304 (Safety Analysis Set)

|                         | Lenvatinib                                             | Lenvatinib                                               | Lenvatinib                                                            | Sorafenib                         |
|-------------------------|--------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------|
|                         | 8 mga (N = 151) Total Duration= 95.1 years n (AE Rate) | 12 mga (N = 325) Total Duration= 229.1 years n (AE Rate) | Total (N = 476) Total Duration=Total Duration= 324.2years n (AE Rate) | (N = 475) 239.1 years n (AE Rate) |
| HepaticFailure          |                                                        |                                                          |                                                                       |                                   |
| Hepatic failure         | 4 (0.04)                                               | 6 (0.03)                                                 | 10 (0.03)                                                             | 2 (<0.01)                         |
| Acutehepaticfailure     | 0 (0.0)                                                | 1 (<0.01)                                                | 1 (<0.01)                                                             | 0 (0.0)                           |
| Chronic hepatic failure | 0 (0.0)                                                | 1 (<0.01)                                                | 1 (<0.01)                                                             | 0 (0.0)                           |
| Total                   | 4 (0.04)                                               | 8 (0.03)                                                 | 12 (0.04)                                                             | 2 (<0.01)                         |
| Sepsis                  |                                                        |                                                          |                                                                       |                                   |
| Sepsis                  | 1 (0.01)                                               | 4 (0.02)                                                 | 5 (0.02)                                                              | 1 (<0.01)                         |
| Escherichia sepsis      | 1 (0.01)                                               | 0 (0.0)                                                  | 1 (<0.01)                                                             | 0 (0.0)                           |
| Septic shock            | 0 (0.0)                                                | 0 (0.0)                                                  | 0 (0.0)                                                               | 1 (<0.01)                         |
| Total                   | 2 (0.02)                                               | 4 (0.02)                                                 | 6 (0.02)                                                              | 2 (<0.01)                         |

Table 73: Characterization of Fatal Adverse Events Not Related to Disease Progression - Safety Analysis Set

| Characterization of Cause of Death          | ReportedCauseofDeath                                                                               | No. of Subjects   |
|---------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------|
| Lenvatinib                                  |                                                                                                    | n=19              |
| Hemorrhagic events                          | Cerebral hemorrhage (n=2) Cerebral hemorrhage, upper GI hemorrhage (n=1) Upper GI hemorrhage (n=1) | 4                 |
| Arterial thromboembolic events              | Cerebrovascular accident (n=2) Myocardial infarction (n=1)                                         | 3                 |
| Infectious complications                    | Pneumonia aspiration (n=2) Sepsis (n=1)                                                            | 3                 |
| Hepatic failure (with underlying infection) | Hepatic failure and sepsis (n=1) Hepatic failure and bacterial peritonitis (n=1)                   | 2                 |
| Hepatic failure                             | Hepatic failure (n=2)                                                                              | 2                 |
| Venous thrombotic events                    | Pulmonary embolism (n=1) Pulmonary infarction (n=1)                                                | 2                 |
| Other                                       | Organ failure, unknown (n=1) Circulatory collapse (n=1) Bile duct obstruction (n=1) a              | 3                 |
| Sorafenib                                   |                                                                                                    | n=8               |
| Infectious complications                    | Sepsis (n=2)                                                                                       | 2                 |
| Other                                       | Sudden death, cause unknown (n=2)                                                                  | 2                 |
| Arterial thromboembolic events              | Ischaemic stroke (n=1)                                                                             | 1                 |
| Hemorrhagic events                          | Upper GI haemorrhage (n=1)                                                                         | 1                 |
| Injuryb                                     | Traumatic haematoma and subarachnoid haemorrhage (n=1)                                             | 1                 |
| Respiratory events                          | Respiratory failure (n=1)                                                                          | 1                 |

a: Subject experienced acute pancreatitis 2 days prior to death.

b: Subject was hit by a car.

In Study 304, 12 subjects in the lenvatinib and 6 subjects in the sorafenib arm had a Grade 5 AE that was considered treatment related by the investigator. These included:

- hepatic failure - 4 vs. 1

<div style=\"page-break-after: always\"></div>

- respiratory failure - 2 vs. 1
- cerebral haemorrhage - 3 vs. 1

The occurrence of fatal AEs by treatment arm was analysed based on Kaplan-Meier methodology. The fatal AE-free rate was similar between the 2 treatment arms until Month 7. The sorafenib curve flattens at an earlier time point than the lenvatinib. This is attributed to the fact that ~70% sorafenib patients have discontinued treatment by Month 7 (3 rd quartile for treatment duration 7.4 months vs. 11.1 months for lenvatinib). Fatal AEs are captured up to 30 days after last study drug dose. Beyond that, any death only counts as an event for the OS analysis.

Figure 19 Kaplan-Meier Curves with 95% Hall-Wellner Confidence Bands for Time to Fatal Treatmentemergent Adverse Events - Safety Analysis Set

<!-- image -->

Subjects who did not have a fatal AE were censored at the earliest of 1) treatment end date + 30 days, 2) last date known to be alive (if subject did not die during the study), 3) date of death not caused by a fatal AE, 4) study cut-off date. + censored observations

## Adverse Events of Special Interest

The clinically significant events include hepatotoxicity, arterial TE, cardiac dysfunction, GI perforation and fistula  formation,  hemorrhage,  hypertension,  hypocalcemia,  hypothyroidism,  PPE  syndrome,  PRES, proteinuria, QT prolongation, and renal events.

<div style=\"page-break-after: always\"></div>

Table 74: Overall Incidence of Clinically Significant Treatment-emergent Adverse Events Identified by SMQ or CMQ Search Criteria, Overall and Severe Incidence - Safety Analysis Set

|                                                  | Lenvatinib (N=476) n (%) Grade   | Lenvatinib (N=476) n (%) Grade   | Lenvatinib (N=476) n (%) Grade   | Lenvatinib (N=476) n (%) Grade   | Lenvatinib (N=476) n (%) Grade   | Sorafenib (N =475) n (%)   | Sorafenib (N =475) n (%)   | Sorafenib (N =475) n (%)   | Sorafenib (N =475) n (%)   | Sorafenib (N =475) n (%)   |
|--------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| SMQ or CMQ Preferred Term                        |                                  | 3                                | 4                                | 5                                |                                  | Any                        | 3                          | Grade 4                    | 5                          | &3                         |
| Subjects with any Clinically Significant TEAEs   | Any 414 (87.0)                   |                                  |                                  |                                  | Y3                               | 405 (85.3)                 |                            |                            |                            |                            |
| Subjects with any TEAE in the CSE category of: a |                                  |                                  |                                  |                                  |                                  |                            |                            |                            |                            |                            |
| Hepatotoxicity                                   | 227 (47.7)                       | 89 (18.7)                        | 18 (3.8)                         | 17 (3.6)                         | 124 (26.1)                       | 198 (41.7)                 | 91 (19.2)                  | 16 (3.4)                   | 4 (0.8)                    | 111 (23.4)                 |
| Hypertension                                     | 212 (44.5)                       | 112 (23.5)                       | 0 (0.0)                          | 0 (0.0)                          | 112 (23.5)                       | 147 (30.9)                 | 69 (14.5)                  | 0 (0.0)                    | 0 (0.0)                    | 69 (14.5)                  |
| Palmar-Plantar erythrodysesthesia                | 133 (27.9)                       | 14 (2.9)                         | 0 (0.0)                          | 0 (0.0)                          | 14 (2.9)                         | 249 (52.4)                 | 54 (11.4)                  | 0 (0.0)                    | 0 (0.0)                    | 54 (11.4)                  |
| Proteinuria                                      | 125 (26.3)                       | 28 (5.9)                         | 0 (0.0)                          | 0 (0.0)                          | 28 (5.9)                         | 58 (12.2)                  | 8 (1.7)                    | 0 (0.0)                    | 0 (0.0)                    | 8 (1.7)                    |
| Hemorrhage                                       | 117 (24.6)                       | 16 (3.4)                         | 1 (0.2)                          | 7 (1.5)                          | 24 (5.0)                         | 76 (16.0)                  | 14 (2.9)                   | 3 (0.6)                    | 5 (1.1)                    | 22 (4.6)                   |
| Hypothyroidism                                   | 100 (21.0)                       | 0 (0.0)                          | 0 (0.0)                          | 0 (0.0)                          | 0 (0.0)                          | 12 (2.5)                   | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    |
| Renal Events                                     | 34 (7.1)                         | 7 (1.5)                          | 1 (0.2)                          | 1 (0.2)                          | 9 (1.9)                          | 19 (4.0)                   | 3 (0.6)                    | 1 (0.2)                    | 2 (0.4)                    | 6 (1.3)                    |
| QT Prolongation                                  | 33 (6.9)                         | 5 (1.1)                          | 0 (0.0)                          | 0 (0.0)                          | 5 (1.1)                          | 24 (5.1)                   | 5 (1.1)                    | 0 (0.0)                    | 0 (0.0)                    | 5 (1.1)                    |
| Arterial TE                                      | 11 (2.3)                         | 5 (1.1)                          | 1 (0.2)                          | 3 (0.6)                          | 9 (1.9)                          | 8 (1.7)                    | 1 (0.2)                    | 3 (0.6)                    | 1 (0.2)                    | 5 (1.1)                    |
| GI Perforation/Fistula Formation                 | 9 (1.9)                          | 4 (0.8)                          | 0 (0.0)                          | 1 (0.2)                          | 5 (1.1)                          | 5 (1.1)                    | 4 (0.8)                    | 1 (0.2)                    | 0 (0.0)                    | 5 (1.1)                    |
| Hypocalcemia                                     | 5 (1.1)                          | 2 (0.4)                          | 0 (0.0)                          | 0 (0.0)                          | 2 (0.4)                          | 8 (1.7)                    | 1 (0.2)                    | 0 (0.0)                    | 0 (0.0)                    | 1 (0.2)                    |
| Cardiac Dysfunction                              | 3 (0.6)                          | 1 (0.2)                          | 0 (0.0)                          | 1 (0.2)                          | 2 (0.4)                          | 1 (0.2)                    | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    |
| Posterior Reversible Encephalopathy Syndrome     | 1 (0.2)                          | 0 (0.0)                          | 0 (0.0)                          | 0 (0.0)                          | 0 (0.0)                          | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    | 0 (0.0)                    |

## Hepatotoxicity

The overall AE profile for hepatotoxicity is presented in the table below.

Table 75: Clinically Significant TE Hepatotoxicity AEs in ≥3  Subjects, study 304

| CMQ Preferred Term                     | Lenvatinib             | Lenvatinib              | Lenvatinib            | Sorafenib       |
|----------------------------------------|------------------------|-------------------------|-----------------------|-----------------|
|                                        | 8 mg a (N = 151) n (%) | 12 mg a (N = 325) n (%) | Total (N = 476) n (%) | (N = 475) n (%) |
| Subjects with any Hepatotoxicity TEAEs | 67 (44.4)              | 160 (49.2)              | 227 (47.7)            | 198 (41.7)      |
| Blood bilirubin increased              | 23 (15.2)              | 48 (14.8)               | 71 ( 14.9 )           | 63 ( 13.3 )     |
| Ascites                                | 21 (13.9)              | 47 (14.5)               | 68 (14.3)             | 44 (9.3)        |
| Aspartate aminotransferase increased   | 21 (13.9)              | 44 (13.5)               | 65 (13.7)             | 80 (16.8)       |
| Alanine aminotransferase increased     | 17 (11.3)              | 36 (11.1)               | 53 (11.1)             | 52 (10.9)       |
| Hypoalbuminaemia                       | 17 (11.3)              | 27 (8.3)                | 44 (9.2)              | 38 (8.0)        |
| Hepatic encephalopathy                 | 6 (4.0)                | 32 ( 9.8 )              | 38 ( 8.0 )            | 9 (1.9)         |
| Gamma-glutamyltransferase increased    | 9 (6.0)                | 28 (8.6)                | 37 (7.8)              | 26 (5.5)        |
| Blood alkaline phosphatase increased   | 7 (4.6)                | 25 (7.7)                | 32 (6.7)              | 29 (6.1)        |
| Hepatic failure                        | 5 (3.3)                | 10 (3.1)                | 15 (3.2)              | 12 (2.5)        |
| Hepatic function abnormal              | 2 (1.3)                | 10 (3.1)                | 12 (2.5)              | 13 (2.7)        |
| Hyperbilirubinaemia                    | 1 (0.7)                | 10 (3.1)                | 11 (2.3)              | 6 (1.3)         |
| Hyperammonaemia                        | 5 (3.3)                | 4 (1.2)                 | 9 (1.9)               | 3 (0.6)         |
| Jaundice cholestatic                   | 5 (3.3)                | 4 (1.2)                 | 9 (1.9)               | 3 (0.6)         |
| Hepatic pain                           | 3 (2.0)                | 5 (1.5)                 | 8 (1.7)               | 3 (0.6)         |
| Jaundice                               | 0 (0.0)                | 6 (1.8)                 | 6 (1.3)               | 7 (1.5)         |
| Urine bilirubin increased              | 2 (1.3)                | 3 (0.9)                 | 5 (1.1)               | 2 (0.4)         |
| Hepatic cirrhosis                      | 0 (0.0)                | 4 (1.2)                 | 4 ( 0.8 )             | 0 (0.0)         |
| Coma hepatic                           | 1 (0.7)                | 2 (0.6)                 | 3 (0.6)               | 1 (0.2)         |
| Oedema due to hepatic disease          | 1 (0.7)                | 2 (0.6)                 | 3 (0.6)               | 0 (0.0)         |
| Varices oesophageal                    | 1 (0.7)                | 1 (0.3)                 | 2 (0.4)               | 6 (1.3)         |
| Portal hypertensive gastropathy        | 0 (0.0)                | 1 (0.3)                 | 1 (0.2)               | 4 (0.8)         |

Percentages are based on the total number of subjects within the relevant treatment group in the Safety Analysis Set. Display is in decreasing order of CSE frequency in the lenvatinib total group followed by decreasing order of frequency in the sorafenib arm, then alphabetically. Subjects with 2 or more clinically significant TEAEs in the same preferred term were counted only once. Adverse event terms were coded using MedDRA version 19.1. CMQ = customized MedDRA query; CSE = clinical significant (adverse) event; MedDRA = Medical Dictionary for Regulatory Activities; TEAE = treatment-emergent adverse event. a: 8 mg and 12 mg were the lenvatinib starting doses based on the subjects' body weight (&lt;60 kg, ≥60 kg) at Baseline.

<div style=\"page-break-after: always\"></div>

Table 76: Overview of Hepatotoxicity - All monotherapy Safety Sets

|                                                       | HCC Randomized Safety Set     | HCC Randomized Safety Set   | All HCC Lenvatinib Safety Set   | Non-HCC Lenvatinib Monotherapy   |
|-------------------------------------------------------|-------------------------------|-----------------------------|---------------------------------|----------------------------------|
| For Hepatotoxicity per CMQ, Subjects with at least 1: | Lenvatinib 8 or 12 mg (N=476) | Sorafenib 800 mg (N=475)    | Lenvatinib 8 or 12 mg (N=496)   | Safety Set Lenvatinib (N=1327)   |
|                                                       | SY=324.2                      | SY=239.1                    | SY=340.0                        | SY=1544.7                        |
| TEAE, n (%)                                           | 227 (47.7)                    | 198 (41.7)                  | 236 (47.6)                      | 309 (23.3)                       |
| TEAE, no. of episodes (episodes/SY)                   | 635 (1.96)                    | 481 (2.01)                  | 659 (1.94)                      | 619 (0.50)                       |
| TEAEs with maximum CTCAE Grade of,a n (%)             |                               |                             |                                 |                                  |
| 1                                                     | 43 (9.0)                      | 39 (8.2)                    | 47 (9.5)                        | 111 (8.4)                        |
| 2                                                     | 60 (12.6)                     | 48 (10.1)                   | 62 (12.5)                       | 122 (9.2)                        |
| ≥3                                                    | 124 (26.1)                    | 111 (23.4)                  | 127 (25.6)                      | 76 (5.7)                         |
| 3                                                     | 89 (18.7)                     | 91 (19.2)                   | 92 (18.5)                       | 67 (5.0)                         |
| 4                                                     | 18 (3.8)                      | 16 (3.4)                    | 18 (3.6)                        | 4 (0.3)                          |
| 5                                                     | 17 (3.6)                      | 4 (0.8)                     | 17 (3.4)                        | 5 (0.4)                          |
| SAE, n (%)                                            | 71 (14.9)                     | 34 (7.2)                    | 73 (14.7)                       | 19 (1.4)                         |
| SAE, no. of episodes (episodes/SY)                    | 97 (0.30)                     | 40 (0.17)                   | 100 (0.29)                      | 25 (0.02)                        |
| TEAE leading to treatment discontinuation, n (%)      | 26 (5.5)                      | 14 (2.9)                    | 27 (5.4)                        | 11 (0.8)                         |
| TEAE leading to study drug modification,b n (%)       |                               |                             |                                 |                                  |
| Dose Reduction                                        | 35 (7.4)                      | 20 (4.2)                    | 36 (7.3)                        | 25 (1.9)                         |
| Dose Interruption                                     | 58 (12.2)                     | 45 (9.5)                    | 58 (11.7)                       | 50 (3.8)                         |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Serious AEs include any events that met the criteria for seriousness, whether fatal or nonfatal. For each row category, a subject with 2 or more AEs in that category was counted only once. AE Rate (episode/SY) = total occurrence of TEAE episodes (n) divided by the total exposure (SY) for the specified treatment group. AE = adverse event; CMQ = customized MedDRA query; CTCAE = Common Terminology Criteria for Adverse

Events; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; MedDRA = Medical Dictionary for Regulatory Activities; QD = once daily; SAE = serious adverse event; SY = subject year; TEAE = treatment emergent adverse event.

a: If a subject had more than 1 TEAE, the subject was only counted once at the maximum grade.

b: Study drug modification includes dose reduction or interruption. A subject could be counted in both categories if the subject had TEAEs leading to both dose interruption and dose reduction.

## Hepatic Encephalopathy

In the HCC Randomized Safety Set, 40 subjects (8.4%) in the lenvatinib and 13 subjects (2.7%) in the sorafenib arm had an event of hepatic encephalopathy per CMQ (including PTs of hepatic encephalopathy, encephalopathy, metabolic encephalopathy and coma hepatic). The event was Grade ≥3 in 26 subjects in the lenvatinib and 9 in the sorafenib arm; 4 subjects in the lenvatinib arm had a Grade 5 event. Hepatic encephalopathy was considered by the investigator as related to study drug in 18 lenvatinib and 4 sorafenib-treated subjects.

Hepatic encephalopathy was associated with PD for 13 subjects in the lenvatinib arm (12 received a starting dose of 12 mg and 1 received 8 mg) and 6 subjects in the sorafenib arm. The 13 lenvatinibtreated subjects include Subject 19011002 who had a fatal AE of hepatic coma that was not recorded as PD and a fatal AE of portal vein thrombosis that was considered PD by the investigator. An additional 5 lenvatinib-treated subjects (4 starting on 12 mg and 1 on 8 mg) had hepatic encephalopathy 7 days before or after discontinuation of study drug due to PD (radiologic or clinical).

Hepatic encephalopathy resulted in dose modification (interruption/reduction) in 21 subjects in the lenvatinib and 4 subjects in the sorafenib arm; 8 and 1 patient, respectively, discontinued treatment.

The percentage of subjects with cirrhosis at Baseline per the IIR was higher in subjects with hepatic encephalopathy than in the overall population. Lenvatinib-treated subjects who developed hepatic encephalopathy, particularly within 30 days of starting study drug, had worse baseline liver disease than subjects in the lenvatinib arm overall and sorafenib-treated subjects who developed hepatic encephalopathy. Baseline characteristics included higher mean/median ammonia concentration, greater frequency of MPVI, greater proportion of subjects with a CP score ≥6 (including 2 subjects with the score

<div style=\"page-break-after: always\"></div>

of 7), greater liver tumour burden (measured by sums of the diameters) and cirrhosis. Most subjects had either Grade 0 or Grade 1 baseline AST, ALT and ALP levels and no correlation with the occurrence of hepatic encephalopathy was seen. No significant relationship between lenvatinib exposure and hepatic encephalopathy was detected within the exposure range of Study 304. Hepatic encephalopathy occurred more frequently in subjects aged 75 years and older.

## Hepatic Failure

In the HCC Randomized Safety Set, 17 subjects (3.6%) in the lenvatinib and 12 subjects (2.5%) in the sorafenib arm had an event of hepatic failure per CMQ (including the PTs of hepatic failure, acute hepatic failure and chronic hepatic failure). Grade 5 hepatic failure per CMQ was reported in 12 lenvatinib- and 2 sorafenib-treated subjects. Hepatic failure was considered by the investigator as related to study drug in 6 lenvatinib- and 3 sorafenib-treated subjects. For 9 subjects in the lenvatinib arm (6 starting on 12 mg and 3 on 8 mg) and 6 subjects in the sorafenib arm, the hepatic failure was also associated with PD by the investigator. Hepatic failure resulted in dose modification (interruption/reduction) in 3 lenvatinib- and in 2 sorafenib-treated subjects. Review of baseline characteristics showed that lenvatinib-treated subjects with hepatic failure had worse baseline liver disease than the overall lenvatinib population and the sorafenib -treated subjects with hepatic failure. Baseline characteristics for subjects with hepatic failure included CP score of 6 or 7, greater frequency of MPVI, alpha-fetoprotein concentration ≥200 ng/mL, higher mean/median ammonia concentration and the presence of cirrhosis, per the independent imaging review. Baseline AST, ALT and ALP concentrations were either Grade 0 or 1 for most subjects who had hepatic failure and no correlation with hepatic failure was seen.

Table 77: Summary of the Presence of Cirrhosis per Independent Imaging Review at Baseline for Subjects with Hepatic Failure and Hepatic Encephalopathy per CMQ - HCC Randomized Safety Set

|                                               | Lenvatinib                   | Lenvatinib                      | Lenvatinib            | Sorafenib                    | Sorafenib                      | Sorafenib             |
|-----------------------------------------------|------------------------------|---------------------------------|-----------------------|------------------------------|--------------------------------|-----------------------|
|                                               | Asia- Pacific (N =321) n (%) | Western regions (N = 155) n (%) | Total (N = 476) n (%) | Asia- Pacific (N =319) n (%) | Western regions (N =156) n (%) | Total (N = 475) n (%) |
| SubjectswithanyTEAEofHepaticFailure           | 9                            | 8                               | 17                    | 4                            | 8                              | 12                    |
| Presenceof CirrhosisatBaseline                | 7 (77.8)                     | 7 (87.5)                        | 14 (82.4)             | 3 (75.0)                     | 8 (100.0)                      | 11 (91.7)             |
| SubjectswithanyTEAEsofHepaticEncephalopatlhy° | 19                           | 21                              | 40                    | 8                            | 5                              | 13                    |
| Presenceof CinrrhosisatBaseline               | 17 (89.5)                    | 21 (100.0)                      | 38 (95.0)             | 7 (87.5)                     | 4 (80.0)                       | 11 (84.6)             |

a: The clinically significant event of 'hepatic failure' per CMQ comprises the preferred terms acute hepatic failure, chronic hepatic failure, and hepatic failure.

b: Presence of cirrhosis at Baseline assessed by post-hoc independent imaging review or was present on the CRF as part of the subject's medical or clinical history.

c: The clinically significant event of 'hepatic encephalopathy' per CMQ comprises the preferred terms of hepatic encephalopathy, metabolic encephalopathy, encephalopathy, and coma hepatic.

Table 78: Summary of Baseline Characteristics for Subjects Who Had Hepatic Failure per CMQ - Safety Analysis Set

<div style=\"page-break-after: always\"></div>

|                                          | Lenvatinib              | Lenvatinib           | Sorafenib               | Sorafenib            |
|------------------------------------------|-------------------------|----------------------|-------------------------|----------------------|
|                                          | Subjects with HF (N=17) | All Subjects (N=476) | Subjects with HF (N=12) | All Subjects (N=475) |
| Baseline Child-Pugh Score, n(%)          |                         |                      |                         |                      |
| 5                                        | 9 (52.9)                | 366 (76.9)           | 10 (83.3)               | 356 (74.9)           |
| 6                                        | 6 (35.3)                | 107 (22.5)           | 2 (16.7)                | 114 (24.0)           |
| 7                                        | 2 (11.8)                | 3 (0.6)              | 0 (0.0)                 | 4 (0.8)              |
| 8                                        | 0 (0.0)                 | 0 (0.0)              | 0 (0.0)                 | 1 (0.2)              |
| Baseline MPVI, n(%)                      |                         |                      |                         |                      |
| Yes                                      | 7 (41.2)                | 109 (22.9)           | 4 (33.3)                | 90 (18.9)            |
| No                                       | 10 (58.8)               | 367 (77.1)           | 8 (66.7)                | 385 (81.1)           |
| Baseline Alpha-fetoprotein Level, n(%)   |                         |                      |                         |                      |
| <200 ng                                  | 7 (41.2)                | 254 (53.4)           | 4 (33.3)                | 285 (60.0)           |
| >=200 ng/mL                              | 10 (58.8)               | 221 (46.4)           | 8 (66.7)                | 187 (39.4)           |
| Baseline Alpha-fetoprotein level (ng/mL) |                         |                      |                         |                      |
| N                                        | 16                      | 469                  | 12                      | 462                  |
| Mean (SD)                                | 29984.9(58505.38)       | 17565.5(105357.7)    | 10632.0(30251.10)       | 16714.6(94889.03)    |
| Median                                   | 5102.3                  | 133.1                | 481.6                   | 71.4                 |
| Q1. Q3                                   | 38.2, 34554.1           | 8.0, 3573.3          | 16.5, 1907.7            | 5.6,1081.8           |
| Min, Max                                 | 3.1, 227840             | 0.1, 1567470         | 2.5, 105641             | 0.1,1446396          |
| Baseline Ammonia level (μg/dL)           |                         |                      |                         |                      |
| N                                        | 16                      | 454                  | 11                      | 452                  |
| Mean (SD)                                | 50.0(33.76)             | 38.2(30.01)          | 41.0(14.60)             | 36.7(32.92)          |
| Median                                   | 38.9                    | 31.8                 | 37.9                    | 30.0                 |
| Q1, Q3                                   | 22.1, 78.5              | 22.0, 45.0           | 26.3,48.2               | 21.0, 42.7           |
| Min, Max                                 | 9.0, 124.9              | 4.0, 246.0           | 25.0,72.0               | 4.0, 473.0           |

## Deaths:

Table 79: Grade 5 Hepatic-Related Adverse Events that Occurred in the HCC Safety Sets - HCC Randomized, All HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Sets

|                           | HCC Randomized Safety Set           | HCC Randomized Safety Set      | AIIHCC Lenvatinib Safety Set        | Non-HCC Lenvatinib Monotherapy Safety Set   |
|---------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
| Preferred Term            | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
|                           | 17 (3.6)                            | 4 (0.8)                        | 17 (3.4)                            | 4 (0.3)                                     |
| Hepatic failure           | 10 (2.1)                            | 2 (0.4)                        | 10 (2.0)                            | 4 (0.3)                                     |
| Coma hepatic              | 2 (0.4)                             | 0 (0.0)                        | 2 (0.4)                             | 0 (0.0)                                     |
| Hepatic encephalopathy    | 2 (0.4)                             | 0 (0.0)                        | 2 (0.4)                             | 0 (0.0)                                     |
| Acute hepatic failure     | 1 (0.2)                             | 0 (0.0)                        | 1 (0.2)                             | 0 (0.0)                                     |
| Chronic hepatic failure   | 1 (0.2)                             | 0 (0.0)                        | 1 (0.2)                             | 0 (0.0)                                     |
| Hepatic cirrhosis         | 1 (0.2)                             | 0 (0.0)                        | 1 (0.2)                             | 0 (0.0)                                     |
| Ascites                   | 0 (0.0)                             | 1 (0.2)                        | 0 (0.0)                             | 0 (0.0)                                     |
| Hepatic function abnormal | 0 (0.0)                             | 1 (0.2)                        | 0 (0.0)                             | 0 (0.0)                                     |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016.

Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies).

In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD.

Display is in decreasing order of AE rate in the lenvatinib group of the HCC Randomized Safety Set.

Subjects with 2 or more AEs in the same preferred term were counted only once.

Percentages based on total number of subjects in the corresponding safety set within the relevant treatment group. Adverse event terms were coded using MedDRA version 19.1.

In both arms of study 304 the majority (17/21) of Grade 5 hepatic AEs were related to PD, per investigator assessment and three of the 4 remaining subjects had other relevant AEs or precipitating

<div style=\"page-break-after: always\"></div>

factors that could have triggered the Grade 5 hepatic event. These included i) hepatic haemorrhage, ii) lung infection and sepsis, and iii) bacterial peritonitis and previous AE of gastroenteritis.

Hepatic-related deaths are not unusual in this patient population with advanced HCC, underlying cirrhosis, and hepatitis. In the Non-HCC Lenvatinib Monotherapy Safety Set, 0.3% of subjects had Grade 5 hepatic failure by PT.

Discontinuations : Twenty six of 227 subjects (11.5%) who had a hepatotoxicity event (any grade),in the lenvatinib arm and 14 of 198 subjects (7.1%) in the sorafenib arm discontinued treatment for the event. The median time to first onset was 6.4 weeks in the lenvatinib arm and 4.4 weeks in the sorafenib arm of study 304.

The  incidence  of  hepatotoxicity  per  CMQ  was  evaluated  by  age,  sex,  race,  ECOC  PS,  baseline  renal function, baseline hepatic function, and region.

Comparison with the Non-HCC safety set: As expected, the incidence of hepatotoxicity events per CMQ was  higher  in  the  All  HCC  Lenvatinib  Safety  Set  (47.6%;  1.94  episodes/SY)  than  in  the  Non-HCC Lenvatinib Monotherapy Safety Set (23.3%; 0.50 episodes/SY).

## Pancreatitis

The evaluation of pancreatitis includes both an analysis of the CMQ of pancreatitis based on AE reports and an analysis of laboratory values for serum amylase and lipase.

Events were Grade ≥3 for 14 subjects (2.9%) in the lenvatinib arm and 12 subjects (2.5%) in the sorafenib arm. There was 1 death in the lenvatinib arm and none in the sorafenib arm: Subject 19061007 in the lenvatinib arm had an SAE of acute pancreatitis, which resulted in discontinuation of study drug, and ultimately death (however, 3 additional Grade 5 AEs were reported for this subject: bile duct obstruction, hepatic failure, and multiple organ dysfunction syndrome; all due to PD and not related to treatment, as reported by the investigator).

Grade 3 or 4 increased lipase was observed at a similar incidence in the All HCC Lenvatinib Safety Set (6.4%) and the Non-HCC Lenvatinib Monotherapy Safety Set (6.6%). Grade 3 or 4 increased amylase was observed at a lower incidence in the All HCC Lenvatinib Safety Set (1.1%) than the Non-HCC Lenvatinib Monotherapy Safety Set (3.6%).

Results were generally similar in the lenvatinib arm of the HCC Randomized Safety Set, the All HCC Lenvatinib Safety Set, and the Non-HCC Lenvatinib Monotherapy Safety Set.

There were no additional events of pancreatitis per CMQ in All HCC Lenvatinib Safety Set. The incidence of pancreatitis per CMQ was 3.8% in the All HCC Lenvatinib Safety Set and 5.0% in the Non-HCC Lenvatinib Monotherapy Safety Set.

## Arterial Thromboembolic Events (Arterial TE events)

In the HCC Randomized Safety Set, the incidence of arterial TE events per CMQ was comparable in the lenvatinib and sorafenib arms: 2.3% (11/476) and 1.7% (8/475), respectively, and 0.04 episodes/SY in each arm when adjusted by treatment exposure. The most frequently reported arterial TE events were MI (lenvatinib, 4 [0.8%]; sorafenib, 1 [0.2%]) and cerebral infarction (lenvatinib, 3 [0.6%]; sorafenib, 0). Most were SAEs (10 in the lenvatinib and 6 in the sorafenib arm). There were 3 deaths due to arterial TE events in the lenvatinib arm: 2 subjects with cerebrovascular accident and 1 subject with MI. All 3 subjects had relevant medical history and comorbidities and were at increased risk. There are no changes to the previously reported safety profile of lenvatinib regarding arterial TE events.

## Haemorrhage

In the HCC Randomized Safety Set, the incidence of haemorrhage events per SMQ was higher in the

<div style=\"page-break-after: always\"></div>

lenvatinib than sorafenib arm: 24.6% (117/476) and 16.0% (76/475), respectively, 0.54 and 0.43 episodes/SY adjusted by treatment exposure. Grade 1 and 2 events contributed to the difference in incidence (93 subjects [19.5%] in the lenvatinib arm and 54 subjects [11.4%] in the sorafenib arm). The incidence of Grade ≥3 events was similar between treatment arms: 24 subjects (5.0%) in the lenvatinib arm and 22 subjects (4.6%) in the sorafenib arm.

The most frequently reported haemorrhage events in the lenvatinib and sorafenib arms, respectively, were epistaxis (34 subjects [7.1%; 0.10 episodes/SY]; 15 [3.2%; 0.07 episodes/SY]), haematuria (25 subjects [5.3%; 0.10 episodes/SY]; 10 [2.1%; 0.05 episodes/SY]) and gingival bleeding (18 subjects [3.8%; 0.06 episodes/SY]; 9 [1.9%; 0.05 episodes/SY]).

Incidence of serious haemorrhage events was similar in the lenvatinib and sorafenib arms: 25 subjects (5.3%; 0.09 episodes/SY) and 21 subjects (4.4%; 0.12 episodes/SY), respectively. The most frequently reported serious events were: oesophageal varices haemorrhage (7 subjects [1.5%; 0.02 episodes/SY]; 5 [1.1%; 0.03 episodes/SY]) and upper GI haemorrhage (5 subjects [1.1%; 0.02 episodes/SY]; 2 [0.4%; 0.01 episodes/SY]). These SAEs are consistent with complications of underlying liver disease, including coagulopathy, varices, and portal hypertension.

There were 8 (1.7%) Grade 5 haemorrhage events in the lenvatinib arm and 5 (1.1%) in the sorafenib arm. The 8 Grade 5 TEAEs comprised 3 subjects with cerebral haemorrhage and relevant risk factors (Subject 14071003 - history of hypertension; 24041001 - history of cerebrovascular malformation surgery and cerebral haemorrhage and 24111035 - AEs of BP increase and aortic dissection), 2 subjects with upper GI haemorrhage (Subjects 24041001 and 24111029), and 1 subject each with disseminated intravascular coagulation (Subject 12141007), intestinal haemorrhage (Subject 19011014) and tumour haemorrhage (Subject 44031005).

In the sorafenib arm, the 5 Grade 5 TEAEs were 2 subjects with upper GI haemorrhage (Subjects 24021011 and 24111045), and 1 subject each with traumatic hematoma (Subject 14141005), tumour haemorrhage (Subject 15041006), and oesophageal varices haemorrhage (Subject 24031002).

For subjects who had a CSE of haemorrhage per SMQ, the median time to first onset was 11.9 weeks in the lenvatinib arm and 7.2 weeks in the sorafenib arm. There are no changes to the previously reported safety profile of lenvatinib regarding haemorrhage.

## Hypothyroidism (Based on Adverse Event Data)

In the HCC Randomized Safety Set, hypothyroidism events per CMQ were observed at a higher frequency in the lenvatinib compared to the sorafenib arm: 21.0% (100/476) and 2.5% (12/475), respectively and 0.32 and 0.05 episodes/SY adjusted by treatment exposure.

Hypothyroidism was the most frequently reported PT: 78 subjects (16.4%; 0.24 episodes/SY) in the lenvatinib arm and 8 subjects (1.7%; 0.03 episodes/SY) in the sorafenib arm. Blood TSH increased was reported for 23 subjects (4.8%; 0.07 episodes/SY) in the lenvatinib and 4 subjects (0.8%; 0.02 episodes/SY) in the sorafenib arm. The median time to first onset of hypothyroidism was 8.1 weeks in the lenvatinib and 13.8 weeks in the sorafenib arm.

There were no Grade ≥3 TEAEs of hypothyroidism, no SAEs, no treatment discontinuations; 1 subject in the lenvatinib arm had a TEAE leading to dose interruption and only 1 subject in the sorafenib arm had a TEAE leading to dose reduction. Overall, 66 subjects (13.9%) in the lenvatinib arm and 23 subjects (4.8%) in the sorafenib arm of the HCC Randomized Safety Set took at least 1 concomitant medication for hypothyroidism. This demonstrates that hypothyroidism could be well managed.

By subgroup, the PT of increased blood TSH occurred at a higher incidence in subjects who were male, Asian, and from the Asia-Pacific region. No other meaningful subgroup differences were observed for this CSE.

<div style=\"page-break-after: always\"></div>

There was a higher incidence of hypothyroidism per CMQ in subjects with HCC (22.0% [0.34 episodes/SY] in the All HCC Lenvatinib Safety Set) than the Non-HCC Lenvatinib Monotherapy Safety Set (18.3%; 0.23 episodes/SY). Many subjects in the Non-HCC Lenvatinib Monotherapy Safety Set had thyroid cancer, which confounded the analysis of hypothyroidism. In subjects with an intact thyroid, the PT of hypothyroidism occurred at more than twice the rate compared to subjects with thyroid cancer due to a direct effect on the thyroid. Thyroid dysfunction is a known class effect of TKIs due to their antiangiogenic effect on the thyroid blood vessels. There is no change to the previously reported safety profile of lenvatinib regarding hypothyroidism.

## Renal Events (Based on Adverse Event Data)

In the HCC Randomized Safety Set, renal events per CMQ were observed at a higher frequency in the lenvatinib compared to the sorafenib arm: 7.1% (34/476) and 4.0% (19/475), respectively; 0.14 and 0.08 episodes/SY, when adjusted by treatment exposure. Grade 1 and 2 events were the greatest contributor to the difference in the overall incidence (25 subjects [5.2%] in the lenvatinib arm and 13 subjects [2.8%] in the sorafenib arm). Events were Grade ≥3 for 9 subjects (1.9%) in the lenvatinib and 6 subjects (1.3%) in the sorafenib arm.

The most frequently reported renal events in the lenvatinib and sorafenib arms, respectively were: blood creatinine increased (10 subjects [2.1%; 0.06 episodes/SY]; 4 [0.8%; 0.02 episodes/SY]), acute kidney injury (9 subjects [1.9%; 0.03 episodes/SY]; 5 [1.1%; 0.02 episodes/SY]) and renal impairment (5 subjects [1.1%; 0.02 episodes/SY]; 6 [1.3%; 0.03 episodes/SY]). The median time to first onset was 14.3 weeks in the lenvatinib and 10.4 weeks in the sorafenib arm.

In the HCC Randomized safety Set, 7 subjects (1.5%; 0.02 episodes/SY) reported SAEs of renal event per CMQ in the lenvatinib arm and 4 subjects (0.8%; 0.02 episodes/SY) in the sorafenib arm. The most frequently reported serious renal event was acute kidney injury (lenvatinib, 3 subjects [0.6%; &lt;0.01 episodes/SY]; sorafenib, 2 [0.4%; &lt;0.01 episodes/SY]).

There was 1 (0.2%) Grade 5 renal event in the lenvatinib arm and 2 (0.4%) in the sorafenib arm. All 3 deaths were due to renal impairment.

There was a low incidence of discontinuations due to renal toxicity: 2 subjects (0.4%) in the lenvatinib arm and 3 subjects (0.6%) in the sorafenib arm.

Results were similar in the lenvatinib arm of the HCC Randomized Safety Set and the All HCC Lenvatinib Safety Set (1 additional Grade 3 event of blood creatinine increased that was not a SAE and did not result in treatment modification). The overall incidence of renal events per SMQ was 7.1% (0.14 episodes/SY) in the All HCC Lenvatinib Safety Set and 9.8% (0.16 episodes/SY) in the Non-HCC Lenvatinib Monotherapy Safety Set. There are no changes to the previously reported safety profile of lenvatinib, regarding renal events.

## Cardiac Dysfunction (Based on Adverse Event Data)

In the HCC Randomized Safety Set, the frequency of cardiac dysfunction events per CMQ was low in both the lenvatinib and sorafenib arms: 0.6% (3/476) and 0.2% (1/475), respectively (both &lt;0.01 episodes/SY).  Events were Grade ≥3 for 2 subjects in the lenvatinib arm (1 Grade 3, 1 Grade 5cardiopulmonary failure) and none in the sorafenib arm. One subject (0.2%) in each arm had an SAE. No AEs resulted in treatment discontinuation or modification. The median time to first onset was 36.3 weeks in the lenvatinib and 26.7 weeks in the sorafenib arm.

There were no additional cardiac events per CMQ in the All HCC Lenvatinib Safety Set. The overall incidence of cardiac events per CMQ was lower in the All HCC Lenvatinib Safety Set (0.6%; &lt;0.01 episodes/SY) than in the Non-HCC Lenvatinib Monotherapy Safety Set (4.7%; 0.06 episodes/SY). The potential to cause cardiac dysfunction is a known effect of lenvatinib and heart failure is noted in the

<div style=\"page-break-after: always\"></div>

product information. There are no changes to the previously reported safety profile of lenvatinib regarding cardiac events.

## Gastrointestinal Perforation and Fistula Formation

In the HCC Randomized Safety Set, the incidence of GI perforation and fistula formation was slightly higher in the lenvatinib than sorafenib arm: 1.9% (9/476) and 1.1% (5/475); 0.03 and 0.02 episodes/SY respectively when adjusted by treatment exposure. The most frequent event was (spontaneous) bacterial peritonitis (6 subjects [1.3%; 0.02 episodes/SY]; 1 [0.2%; &lt;0.01 episodes/SY]).

Events were Grade ≥3 for 5 subjects (1.1%) in each arm. Three subjects (0.6%) in the lenvatinib and 2 (0.4%) in the sorafenib arm had an SAE, mainly peritonitis bacterial (lenvatinib, 2 subjects [0.4%; &lt;0.01 episodes/SY]; sorafenib, 0). In the lenvatinib arm, 1 subject (32051003) had a Grade 5 event. One subject (0.2%) in the sorafenib arm discontinued due to an AE.

The median time to onset was 32.3 weeks in the lenvatinib arm and 7.0 weeks in the sorafenib arm of the HCC Randomized Safety Set.

By subgroup analysis, no events occurred in subjects who were ≥75 years of age or female. No other meaningful differences (difference of ≥10% or at least double) were observed in the subgroup analyses for this CSE. None of these differences were observed for the Non-HCC Lenvatinib Monotherapy Safety Set.

There were no additional events of GI perforation and fistula formation events per SMQ in the All HCC Lenvatinib Safety Set. The overall incidence of GI perforation and fistula formation events per SMQ was 1.8% (0.03 episodes/SY) in the All HCC Lenvatinib Safety Set and 2.9% (0.04 episodes/SY) in the NonHCC Lenvatinib Monotherapy Safety Set.

There were no reports of bacterial peritonitis in the Non-HCC population; cirrhosis is a well-recognized risk factor for the development of spontaneous bacterial peritonitis SBP).

## Hypertension (Based on Adverse Event Data)

For AEs, the severity definition also includes the use of antihypertensive medications (NCI CTCAE version 4.03).

In the HCC Randomized Safety Set, hypertension was present at Baseline in 49.8% of subjects in the lenvatinib and 51.4% in the sorafenib arm; 72.9% and 67.8% took concomitant antihypertensive agents. Hypertension events were more frequent in the lenvatinib than sorafenib arm: 44.5% (212/476) and 30.9% (147/475), respectively; 0.83 and 0.71 episodes/SY, when adjusted by treatment exposure.

Grade 3 hypertension events occurred in 112 subjects (23.5%) in the lenvatinib and 69 subjects (14.5%) in the sorafenib arm. No Grade 4 or Grade 5 hypertension events or SAEs were reported. The median time to first onset was 3.7 weeks in the lenvatinib and 2.1 weeks in the sorafenib arm.

One subject (0.2%) in the lenvatinib arm discontinued due to an AE. Hypertension events resulted in dose reduction for 16 subjects (3.4%) in the lenvatinib and 10 (2.1%) in the sorafenib arm, and dose interruption for 17 (3.6%) and 8 (1.7%) subjects, respectively.

By subgroup, the overall incidence and the incidence of severe (Grade ≥3) TEAEs for this CSE, was higher in the oldest age group. Incidence was also higher in females.

The overall incidence of hypertension events per SMQ was lower in subjects with HCC (46.2% [0.84 episodes/SY] in the All HCC Lenvatinib Safety Set) than in the Non-HCC Lenvatinib Monotherapy Safety Set (60.9%; 1.08 episodes/SY). Subjects with HCC received a lower lenvatinib starting dose (8 or 12 mg/day) compared with the Non-HCC Lenvatinib Monotherapy Safety Set (85% started on 24 mg QD) and hypertension is a known dose-related effect of VEGF/VEGFR-targeted therapies. There are no

<div style=\"page-break-after: always\"></div>

changes to the previously reported safety profile of lenvatinib regarding hypertension.

## Hypocalcaemia (Based on Adverse Event Data)

In the HCC Randomized Safety Set, the incidence of hypocalcaemia events per CMQ was comparable in the lenvatinib and sorafenib arms: 1.1% (5/476) and 1.7% (8/475), respectively; 0.02 episodes/SY and 0.03 episodes/SY, when adjusted by treatment exposure. Grade 3 hypocalcaemia events occurred in 2 subjects (0.4%) in the lenvatinib and 1 subject (0.2%) in the sorafenib arm. No Grade 4 or 5 hypocalcaemia events and no discontinuations due to AEs were reported in arm. One SAE of hypocalcaemia was reported in the lenvatinib arm. The median time to first onset was 31.7 weeks in the lenvatinib and 13.0 weeks in the sorafenib arm.

The overall incidence of hypocalcaemia events per CMQ was lower in the All HCC Lenvatinib Safety Set (1.4% [0.03 episodes/SY]) than in the Non- HCC Lenvatinib Monotherapy Safety Set (8.3%; 0.12 episodes/SY). There are no changes to the previously reported safety profile of lenvatinib regarding events of hypocalcaemia.

## Palmar-plantar Erythrodysaesthesia Syndrome

In the HCC Randomized Safety Set, PPE events per CMQ occurred at a lower incidence in the lenvatinib than sorafenib arm: 27.9% (133/476) and 52.4% (249/475), respectively. All cases were Grades ≤3; events were Grade 3 for 14 subjects (2.9%) in the lenvatinib and 54 subjects (11.4%) in the sorafenib arm. There were no SAEs or discontinuations due to AEs in the lenvatinib arm and 3 (0.6%) subjects each with SAEs or discontinuations in the sorafenib arm. The median time to first onset was 5.3 weeks in the lenvatinib and 2.0 weeks in the sorafenib arm.

By subgroup, the overall incidence of TEAEs for this CSE tended to be lower in the oldest subjects. The incidence in Asian was higher than in White subjects.

The overall incidence of PPE was higher in the All HCC Lenvatinib Safety Set (30.0%) than the Non-HCC Lenvatinib Monotherapy Safety Set (20.9%). The proportion of Asian subjects was higher in the All HCC Lenvatinib Safety Set than in the Non-HCC Lenvatinib Monotherapy Safety Set (71.2% vs 14.2%). The incidence of PPE syndrome has also been observed to be higher with other TKIs in Asians compared with non-Asians (Ueda, et al., 2013). PPE is a known toxicity of lenvatinib and is known to occur at a higher incidence with sorafenib. There are no changes to the previously reported safety profile of lenvatinib regarding PPE.

## Proteinuria (Based on Adverse Event Data)

In the HCC Randomized Safety Set, proteinuria-SMQ events were observed at a higher frequency in the lenvatinib than sorafenib arm: 26.3% (125/476) and 12.2% (58/475), respectively. Grade 3 proteinuria occurred in 28 subjects (5.9%) in the lenvatinib and 8 subjects (1.7%) in the sorafenib arm. No Grade 4 or Grade 5 proteinuria events were reported in either arm. Three subjects (0.6%) in the lenvatinib and none in the sorafenib arm reported SAEs of proteinuria. The median time to first onset was 6.1 weeks in the lenvatinib and 4.1 weeks in the sorafenib arm. There were few discontinuations due to proteinuria (0.6% [3/476] of subjects in the lenvatinib arm).

By subgroup, the incidence of TEAEs and of severe (Grade ≥3) TEAEs for this CSE tended to be higher in the 2 older age groups compared with the youngest subjects and in Asian compared with White subjects.

The overall incidence of proteinuria events per SMQ was lower in subjects with HCC (27.4% in the All HCC Lenvatinib Safety Set) than in the Non-HCC Lenvatinib Monotherapy Safety Set (35.5%), again probably due to the lower starting dose of lenvatinib in HCC. Proteinuria is a known dose-related effect of VEGF/VEGFR targeted therapies. There are no changes to the previously reported safety profile of lenvatinib regarding proteinuria.

<div style=\"page-break-after: always\"></div>

## QT Prolongation (Reported as an Adverse Event)

In the HCC Randomized Safety Set, the incidence of QT prolongation events per SMQ was comparable in the lenvatinib and sorafenib arms: 6.9% (33/476) and 5.1% (24/475); 0.14 and 0.20 episodes/SY when adjusted by treatment exposure. Grade 3 QT prolongation occurred in 5 subjects (1.1%) in each arm. No Grade 4 or 5 QT prolongation events, SAEs or treatment discontinuations were reported in either treatment arm. The median time to first onset was 31.1 weeks in the lenvatinib and 14.0 weeks in the sorafenib arm.

By subgroup, the overall incidence of TEAEs tended to be higher in females than in males; however, there were no Grade ≥3 events in females.

The overall incidence of QT prolongation events was 6.7% (0.13 episodes/SY) in the All HCC Lenvatinib and 4.3% (0.07 episodes/SY) in the Non-HCC Lenvatinib Monotherapy Safety Set. There are no changes to the previously reported safety profile of lenvatinib regarding QT prolongation.

## Other Risks

These were based on the company core risk management plan and regional (including the EU) risk management plans. These comprise: GI toxicity, hypokalaemia, pancreatitis, impaired wound healing, interstitial lung disease, abnormal pregnancy and excretion of lenvatinib in milk, male and female fertility, venous TE events, and non-GI fistula. Per the applicant there were no changes to the previously reported safety profile of lenvatinib regarding these risks.

## Venous Thromboembolic Events

In the HCC Randomized Safety Set, the incidence of venous TE events per CMQ was higher in the lenvatinib than sorafenib arm: 3.8% (18/476) and 1.9% (9/475); 0.06 and 0.04 episodes /SY, adjusted by treatment exposure. The most frequently reported venous TE event was portal vein thrombosis: lenvatinib, 9 subjects (1.9%; 0.03 episodes/SY); sorafenib, 3 (0.6%; 0.01 episodes/SY). Events were Grade ≥3 for 10 subjects (2.1%) in the lenvatinib and 6 subjects (1.3%) in the sorafenib arm. There were 4 (0.8%) Grade 5 events in the lenvatinib and none in the sorafenib arm. There were 10 (2.1%) SAEs in the lenvatinib and 3 (0.6%) in the sorafenib arm. The median time to first onset was 7.4 weeks in the lenvatinib and 8.1 weeks in the sorafenib arm.

By subgroup, the incidence of venous TE events was higher in White than in Asian subjects and in the Western than in the Asia-Pacific region. In the All HCC Lenvatinib Safety Set, the PT of portal vein thrombosis occurred at a higher incidence in Western than Asia- Pacific subjects; this difference was not observed for the Non-HCC Lenvatinib Monotherapy Safety Set. In addition, in the All HCC Lenvatinib Safety Set, the PT of pulmonary embolism only occurred in males and at a higher incidence in White subjects and those from the Western region; these differences were similarly observed for the Non-HCC Lenvatinib Monotherapy Safety Set.

The incidence of venous TE events per CMQ was 3.6% (0.06 episodes/SY) in the All HCC Lenvatinib Safety Set and 5.9% (0.07 episodes/SY) in the Non-HCC Lenvatinib Monotherapy Safety Set.

## Laboratory findings

## Haematology

Hemoglobin:

In study 304 an increase in the median haemoglobin concentration from Baseline was observed in the lenvatinib arm as early as day 15 and was generally maintained throughout treatment. In the sorafenib arm, median hemoglobin values also increased on Day 15 but then tended to return to baseline levels or slightly below thereafter. Median increases from Baseline in hemoglobin values were consistently higher

<div style=\"page-break-after: always\"></div>

in the Non-HCC Lenvatinib Monotherapy Safety Set. See also the table below for the incidence of AEs of grade 3 and 4. TEAE anaemia (7.1% lenvatinib vs 9.1% sorafenib)

## Platelets:

In the HCC Randomized Safety Set, a decrease from Baseline in median platelet values occurred in the lenvatinib arm, which was generally maintained throughout treatment (57.0% and 48.8% of lenvatiniband sorafenib-treated subjects, respectively, experienced a worsening shift from

Baseline  for  platelet  count  decreased,  likely  due  to  the  confounding  effect  of  chronic  liver  disease). Median  platelet  values  also  decreased  in  the  sorafenib  arm  and  there  were  no  consistent  differences between the 2 treatment arms over time. Baseline platelet values were higher, and median decreases from Baseline were consistently greater, in the Non-HCC Lenvatinib Monotherapy Safety Set. Overall, the frequency of Grade 3 and 4 events of thrombocytopenia and platelet count decreased was lower than the frequency  of  Grade  3  and  4  platelet  count  decreased  laboratory  values  but  the  incidence  of  AEs (laboratory values) grade 3 and 4 of count decreased was higher in the all HCC lenvatinib safety set than in the non-HCC safety set (see table below Table 15)

There were no SAEs of either thrombocytopenia or platelet count decreased in either lenvatinib treatment arm;  SAEs  of  platelet  count  decreased  were  reported  in  2  subjects  in  the  sorafenib  arm,  one  subject leading to treatment discontinuation.

## White blood cells and neutrophils:

In the HCC Randomized Safety Set, decreases from Baseline in median values for neutrophils and leukocytes occurred over time in the lenvatinib arm; these changes were consistently greater than in the sorafenib arm, in which values fluctuated slightly around the median baseline value throughout treatment. In both treatment arms, neutrophil and leukocyte values recovered to Baseline levels following treatment discontinuation. From Cycle 4 onwards median decreases in neutrophil and leukocyte values were consistently greater in the All HCC Lenvatinib Safety Set than in the Non-HCC Lenvatinib Monotherapy Safety Set that was otherwise similar to the HCC safety set.

A summary of the number and percentage of subjects with least one Grade 3 or 4 postbaseline value for decreased WBC parameters is presented in the table below.

During study 304, a higher percentage (at least twice) of subjects in the lenvatinib arm had a Grade 3 or 4 postbaseline value compared with the sorafenib arm for neutrophil count decreased (7.5% vs 3.4%) and WBC decreased (5.8% vs 3.0%). There was no difference between treatment arms for lymphocyte count decreased. For WBC count decreased, and neutrophil count decreased, the incidence of Grade 3 and 4 abnormalities was higher in the All HCC Lenvatinib Safety Set than in the Non-HCC Lenvatinib Monotherapy Safety Set.

Adverse events data: In the HCC Randomized Safety Set, the following TEAEs occurred at a higher incidence (more than double) in the lenvatinib arm than the sorafenib arm, respectively: decreased WBC count (9.7% vs 4.8%), decreased neutrophil count (8.4% vs 2.3%), and neutropenia (3.8%  vs 1.5%). The incidence and rate of decreased lymphocyte count, leukopenia, and lymphopenia did not differ between treatment arms. The decreases in WBC and neutrophil counts occurred at comparable incidences through the entire treatment period. There were no SAEs of decreased WBC count or neutropenia and no discontinuations due to these AEs. There was only 1 SAE of decreased neutrophil count and 1 discontinuation due to this event (lenvatinib arm of HCC Randomized Safety Set). There were no infections associated with Grade 3 or 4 events of decreased neutrophil count and thus no clinical consequences linked to this observation of a higher incidence of decreased WBC and neutrophil counts, and neutropenia in the lenvatinib arm.

For  platelet  count  decreased,  WBC  count  decreased,  and  neutrophil  count  decreased,  the  incidence  of

<div style=\"page-break-after: always\"></div>

Grade  3  and  4  abnormalities  was  higher  in  the  All  HCC  Lenvatinib  Safety  Set  than  in  the  Non-HCC Lenvatinib Monotherapy Safety Set.

Table 80: Treatment-emergent Laboratory grade 3 or 4 AE for haematology - all safety sets

|                                               | HCC Randomized Safety              | Set                             | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|-----------------------------------------------|------------------------------------|---------------------------------|-------------------------------------|---------------------------------------------|
| Hematology Parameter Worst Postbaseline Grade | Sorafenib 8 or 12 mg (N=476) n (%) | Lenvatinib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Hemoglobin decreased                          |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 469                                | 471                             | 489                                 | 1243                                        |
| Grade 3, n (%)                                | 20 (4.3)                           | 24 (5.1)                        | 21 (4.3)                            | 22 (1.8)                                    |
| Grade 4, n (%)                                | 0                                  | 0                               | 0                                   | 0                                           |
| Hemoglobin increased                          |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 469                                | 471                             | 489                                 | 1243                                        |
| Grade 3, n (%)                                | 1 (0.2)                            | 0                               | 1 (0.2)                             | 4 (0.3)                                     |
| Grade 4, n (%)                                | 0                                  | 0                               | 0                                   | 0                                           |
| Platelet count decreased                      |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 467                                | 471                             | 487                                 | 1238                                        |
| Grade 3, n (%)                                | 40 (8.6)                           | 31 (6.6)                        | 48 ( 9.9 )                          | 22 (1.8)                                    |
| Grade 4, n (%)                                | 6 (1.3)                            | 6 (1.3)                         | 6 (1.2)                             | 5 (0.4)                                     |
| White blood cells increased                   |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 469                                | 471                             | 489                                 | 1242                                        |
| Grade 3, n (%)                                | 0                                  | 0                               | 0                                   | 0                                           |
| Grade 4, n (%)                                | 0                                  | 0                               | 0                                   | 0                                           |
| White blood cells decreased                   |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 469                                | 471                             | 489                                 | 1242                                        |
| Grade 3, n (%)                                | 25 (5.3)                           | 12 (2.5)                        | 25 ( 5.1 )                          | 9 (0.7)                                     |
| Grade 4, n (%)                                | 2 (0.4)                            | 2 (0.4)                         | 2 (0.4)                             | 1 (0.1)                                     |
| Neutrophil count decreased                    |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 467                                | 467                             | 487                                 | 1217                                        |
| Grade 3, n (%)                                | 28 (6.0)                           | 9 (1.9)                         | 28 ( 5.7 )                          | 16 (1.3)                                    |
| Grade 4, n (%)                                | 7 (1.5)                            | 7 (1.5)                         | 7 (1.4)                             | 5 (0.4)                                     |
| Lymphocyte count decreased                    |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 467                                | 466                             | 487                                 | 1149                                        |
| Grade 3, n (%)                                | 39 (8.4)                           | 46 (9.9)                        | 39 (8.0)                            | 134 (11.7)                                  |
| Grade 4, n (%)                                | 4 (0.9)                            | 5 (1.1)                         | 4 (0.8)                             | 10 (0.9)                                    |
| Lymphocyte count increased                    |                                    |                                 |                                     |                                             |
| Study Overall, n a                            | 467                                | 466                             | 487                                 | 1149                                        |
| Grade 3, n (%)                                | 0                                  | 0                               | 0                                   | 3 (0.3)                                     |
| Grade 4, n (%)                                | 0                                  | 0                               | 0                                   | 0                                           |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Subjects are counted only once for each row. Laboratory results were graded using CTCAE version 4.03. CTCAE = Common Terminology Criteria for Adverse Events, HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; QD = once daily.

a: Indicates the number of subjects with nonmissing baseline and postbaseline data; this number is used to calculate percentages within each laboratory test.

## ALT, AST, ALP, bilirubin, and GGT

Shifts in CTCAE grade from Baseline to the worst postbaseline grade for liver parameters were presented and treatment-emergent laboratory results with CTCAE Grade 3 or 4 were summarized. Most changes were Grade 3. In the HCC Randomized Safety Set, there were Grade 3 or 4 increases in blood bilirubin (13.2% with lenvatinib vs 9.5% with sorafenib), ALT (7.9% vs 9.3%), AST (12.1% vs 17.9%), GGT (31.4% vs 37.7%), and ALP (6.6% vs 5.3%).

<div style=\"page-break-after: always\"></div>

Application of the Hy's Law criteria to the HCC population was considered problematic due to the combination of underlying cirrhosis, other aetiologies, hepatitis and HCC; therefore, evaluation of hepatotoxicity was performed through evaluation of reported AEs rather than laboratory criteria.

The incidence of Grade ≥3 postbaseline values was higher in the All HCC Lenvatinib Safety Set than in the Non-HCC Lenvatinib Monotherapy Safety Set for AST, ALT, ALP, GGT and bilirubin, consistent with a diagnosis of HCC.

Application of Hy's Law criteria to the HCC population is problematic due to the combination of underlying cirrhosis, hepatitis, HCC, and other underlying aetiologies; therefore, the evaluation of hepatotoxicity is performed through evaluation of reported AEs rather than laboratory criteria.

ALT and AST: Sorafenib induced a higher increase of AST values than sorafenib. Several subjects in both treatment arms has grade 3 ALT/AST values at Baseline.

ALP: An increase is observed in both the lenvatinib and the sorafenib arms and results are similar in the Non-HCC safety set.

GGT: Lenvatinib induced a decrease of GGT, sorafenib a slight increase while little changes were observed in the Non-HCC safety set. Grade 3 and 4 AEs occurred in respectively 19.6% and 0.4% for lenvatinib and 20.8% and 0.8% for sorafenib.

Bilirubin: Median bilirubin values increased slightly in both arms and results are comparable with those observed in the Non-HCC safety set. A slightly higher incidence of Grade 3 or 4 bilirubin increased occurred with lenvatinib (13.2% vs 9.5%).

## Renal Events

In the HCC Randomized Safety Set, 10 subjects (2.1%) in each treatment arm had Grade 3 increases in creatinine, and 1 subject (0.2%) in the sorafenib arm had a Grade 4 increase. More subjects in the lenvatinib (n=83 [17.6%]) than the sorafenib arm (n=33 [7.0%]) had shifts from Grade 0 or 1 to Grade 2 increases in creatinine.

In the sorafenib arm median creatinine values decreased while no change of the median values from baseline were observed for the lenvatinib safety sets that were comparable to those of the Non-HCC.

Increases in creatinine in the All HCC Lenvatinib Safety Set were consistent with those in the lenvatinib arm of the HCC Randomized Safety Set and the Non-HCC Lenvatinib Monotherapy Safety Set, although there were more Grade 2 increases in the HCC than the non-HCC set (17.4 vs. 13.8%).

## Hypocalcaemia

In the HCC Randomized Safety Set, 2 subjects (0.8%) in the lenvatinib and no subjects in the sorafenib arm had a shift from Grade 0 or Grade 1 at Baseline to Grade 3 during treatment. Consistent with the AE data, fewer subjects had decreases in calcium from Grade 0 or 1 to Grade 3 or 4 in the All HCC Lenvatinib Safety Set (0.8%) than in the Non-HCC Lenvatinib Monotherapy Safety Set (2.6%).

## Proteinuria (Based on Urinalysis)

In  the  HCC  Randomized safety Set, a total of 10.9% (51/468) of subjects in the lenvatinib and 3.6% (17/470) of subjects in the sorafenib arm had a shift in urine dipstick protein from a score of negative, absent,  or  trace  at  Baseline  to  +3  during  treatment.  An  additional  3.2%  (15/468)  of  subjects  in  the lenvatinib and 0.9% (4/470) of subjects in the sorafenib arm had a shirt to +4.

Consistent with the AE data, more subjects in the Non-HCC Lenvatinib Monotherapy Safety Set had shifts to +3 or +4 during treatment (13.5% and 5.6%, respectively) compared to the All HCC lenvatinib Safety Set (11.1% and 3.7%, respectively).

<div style=\"page-break-after: always\"></div>

## Thyroid Stimulating Hormone

In the HCC Randomized Safety Set, baseline TSH was ≤ the upper limit of normal (ULN) in 89.6% of subjects in the lenvatinib arm and 90.1% in the sorafenib arm. The worst postbaseline value was &gt;ULN in 69.6% of subjects in the lenvatinib arm and 32.2% in the sorafenib arm.

Thyroid-stimulating  Hormone  at  Baseline  and  Worst  Postbaseline  Value  -  HCC  Randomized,  All  HCC Lenvatinib, and Non-HCC Lenvatinib Monotherapy Safety Sets

## Echocardiogram Data

In  the  HCC  Randomized  Safety  Set,  most  subjects  had  a  normal  LVEF  value  at  Baseline,  with  no postbaseline shift (lenvatinib, 98.8% [242/245]; sorafenib, 97.8% [268/274]). One subject (0.4%) in the lenvatinib arm had a shift from normal at Baseline to moderate dysfunction postbaseline. In the sorafenib arm,  2  subjects  (0.7%)  shifted  from  normal  to  mild  and  1  subject  (0.4%)  to  moderate  dysfunction postbaseline. The maximum decrease from Baseline in mean LVEF was -0.2% in the lenvatinib arm and 0.5% in the sorafenib arm. No TEAEs of 'ejection fraction decreased' were reported in either treatment arm.

Echocardiogram data were consistent in the lenvatinib arm of the HCC Randomized Safety Set and the All HCC  Lenvatinib  Safety  Set.  In  the  Non-HCC  Lenvatinib  Monotherapy  Safety  Set,  there  were  greater changes in LVEF.

## Blood Pressure Data

In the HCC Randomized Safety Set, 15.4% of subjects (72/468) in the lenvatinib and 11.0% of subjects (52/471)  in  the  sorafenib  arm  had  a  shift  from  Grade  0  or  Grade  1  at  Baseline  to  Grade  3  during treatment. Consistent with the higher incidence of hypertension reported as an AE, more subjects in the Non-HCC  Lenvatinib  Monotherapy  Safety  Set  (30.8%)  had  changes  from  Grade  0  or  1  to  Grade  3 hypertension based on vital sign data compared with subjects with HCC (16.0% in the All HCC Lenvatinib Safety Set).

In the HCC Randomized Safety Set, increases in SBP and DBP were observed in both the lenvatinib and sorafenib treatment arms starting on Cycle 1 Day 15. For both arms, the largest change from Baseline occurred on Cycle 2 Day 1. Both DBP and SBP appeared to stabilize by Cycle 3 or Cycle 4, probably due to  the  introduction  of  antihypertensive  medication(s),  dose  reduction  of  study  drug,  or  both.  The maximum increase in median SBP and DBP did not exceed +6.0 mmHg in either arm. QT Prolongation Based on Electrocardiogram Data

In the HCC Randomized Safety Set, 37 subjects (8.1%) in the lenvatinib arm and 20 subjects (4.3%) in the  sorafenib  arm  had  &gt;60  msec  increases  in  QTcF  from  baseline.  Eleven  subjects  (2.4%)  in  each treatment  arm  had  at  least  1  postbaseline  value  of  &gt;500  msec  in  QTcF.  Fewer  subjects  in  the  All Lenvatinib HCC Safety Set compared to the Non-HCC Lenvatinib Monotherapy Safety Set had at least 1 postbaseline QTcF value of &gt;500 msec in (2.3% vs 5.7%).

## Body Weight

In the HCC Randomized Safety Set, decreases in BW were observed in both the lenvatinib and sorafenib arms starting on Cycle 1 Day 15. The maximum decrease from Baseline in median BW was 5.1 kg with lenvatinib (on Cycle 21 Day 1) and 3.5 kg with sorafenib (on Cycle 11 Day 1). Decreases in BW in the lenvatinib arm were consistent with those observed in the Non-HCC Lenvatinib Monotherapy Safety Set.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Subgroup  analyses  were  conducted  in  special  populations  as  described  and  key  observations  were  as follows:

- The incidence of Grade ≥3 TEAEs and SAEs increased with increasing age
- Females had a higher incidence of Grade ≥3 related TEAEs and of TEAEs leading to study drug dose reduction or interruption than did males.
- Asian and White lenvatinib-treated subjects had a similar safety profile.
- Lenvatinib-treated subjects from the Asia-Pacific and Western regions had a similar safety profile
- In Study 304, the overall AE profile for lenvatinib-treated subjects with baseline renal impairment (creatinine  clearance  &lt;60  mL/min)  was  similar  to  those  without  renal  impairment  (creatinine clearance  ≥60  mL/min)  except  for  a  higher  incidence  of  TEAEs  leading  to  study  drug  dose reduction in subjects with renal impairment.
- In  Study  304,  the  incidence  of  Grade  ≥3  TEAEs,  SAEs,  and  TEAEs  leading  to  study  drug discontinuation  was  higher  in  subjects  with  a  baseline  CP  score  of  6  than  of  5  in  both  the lenvatinib and sorafenib arms (HCC ISS Table 10.1.3). Lenvatinib-treated subjects with a baseline CP score of 6 also had a higher incidence of TEAEs leading to dose modifications (interruption, reduction).

Analyses of TAES based on intrinsic and extrinsic factors (subgroups) was performed. These included:

- Baseline demographic characteristics (drug-demographic interactions): age; sex; geographic region (Asia-Pacific; Western regions) and race.
- Baseline disease characteristics (drug-disease interactions): Baseline ECOG PS (score 0, ≥1); hepatic function (CP score 5, 6); and renal function (CrCl &lt;60, ≥60 mL/min). Analyses of baseline hepatic and renal function were performed for the HCC Randomized Safety Set only.
- Region (Western, Asia-Pacific)
- Starting dose (8, 12 mg) for the HCC Randomized Safety Set and region (Western, Asia-Pacific)

If the incidence in one subgroup was ≥ 10% higher or, for incidences less than 10%, if the incidence in one subgroup was at least twice that in another subgroup, that was considered an increase. Where similar between subgroup trends were not observed for the Non-HCC Lenvatinib Safety Set, these TEAEs are in italics.

## Age (&lt;65, 65- &lt;75, and ≥75 years)

Most subjects were &lt;65 years, 30% were 65- &lt;75 years and ~ 13% were ≥75 years. The incidence of Grade ≥3 TEAEs and SAEs was highest in the oldest age group. TEAEs leading to withdrawal of study drug or dose modification also increased with increasing age. The incidence of the following common TEAEs was highest in the oldest age group: decreased appetite, dehydration, arthralgia , asthenia, dizziness , dysphonia , hypertension , hypoalbuminemia , malaise , peripheral oedema, proteinuria and pruritus. Hepatic encephalopathy, occurred at more than twice the incidence in the oldest age group (17.2%) than in the other 2 age groups (7.1% in each); a similar pattern was observed for the exposureadjusted rate, SAEs and fatal AEs.

Serious AEs for which the incidence was higher in the oldest age group than in 1 or both the other age groups in the All HCC Lenvatinib Safety Set were (italics if a similar trend was not observed for the NonHCC Lenvatinib Monotherapy Safety Set): asthenia , hepatic encephalopathy , MI and pneumonia ; similar results were observed for the exposure-adjusted rates except for hypoalbuminemia and malaise, which were also highest in the oldest age group in the Non-HCC Lenvatinib Monotherapy Safety Set.

## Sex

<div style=\"page-break-after: always\"></div>

Across Studies 304 and 202, most subjects were male (&gt;5:1 ratio). There was a higher incidence of Grade ≥3 related TEAEs (67.1% vs. 54.8%) and of TEAEs leading to dose reduction or interruption (71.2% vs. 60.0%) in females than in males. No between-sex differences were observed in the exposureadjusted rates of episodes.

Table 81: Overview of Exposure-adjusted Treatment-emergent Adverse Events by Sex - HCC Randomized, All HCC Lenvatinib, and Non-HCC Monotherapy Safety Sets

|              |                                  |                                   |                                   |                                  | AllHCCLenvatinib SafetySet        | AllHCCLenvatinib SafetySet        | Non-HCCLenvatinib Monotherapy     | Non-HCCLenvatinib Monotherapy     |
|--------------|----------------------------------|-----------------------------------|-----------------------------------|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|              | Lenvatinib8or12mg                | Lenvatinib8or12mg                 | Sorafenib800mg                    | Sorafenib800mg                   | Lenvatinib8or12mg                 | Lenvatinib8or12mg                 | SafetySet                         | SafetySet                         |
| Episodes     | Male (N=403) SY=281.6 n (AERate) | Female (N=73) SY=42.6 n (AE Rate) | Male (N=400) SY=197.0 n (AE Rate) | Female (N=75) SY=42.1 n (AERate) | Male (N=423) SY=297.4 n (AE Rate) | Female (N=73) SY=42.6 n (AE Rate) | Male (N=666) SY=628.7 n (AE Rate) | Female (N=661) SY=616 n (AE Rate) |
| AllTEAEs     | 5133 (18.23)                     | 991 (23.25)                       | 3837(19.48)                       | 881 (20.91)                      | 5500 (18.49)                      | 991 (23.25)                       | 14342 (22.81)                     | 15083 (24.49)                     |
| Grade>3TEAEs | 847 (3.01)                       | 176 (4.13)                        | 646 (3.28)                        | 149 (3.54)                       | 896 (3.01)                        | 176 (4.13)                        | 1454 (2.31)                       | 1750 (2.84)                       |
| Fatal AEs    | 54 (0.19)                        | 7 (0.16)                          | 32 (0.16)                         | 4 (0.09)                         | 55 (0.18)                         | 7 (0.16)                          | 68 (0.11)                         | 62 (0.10)                         |
| NonfatalSAEs | 330 (1.17)                       | 49 (1.15)                         | 172 (0.87)                        | 35 (0.83)                        | 335 (1.13)                        | 49 (1.15)                         | 704 (1.12)                        | 720 (1.17)                        |

For the All HCC Lenvatinib Safety Set, the following common events occurred at a higher incidence in males than in females: dysphonia, increased ALT, insomnia and musculoskeletal pain . The following occurred at a higher incidence in females than in males: alopecia, anaemia , prolonged QT , fatigue and hypertension. Similar findings were observed for the exposure-adjusted episodes of events, except that the difference for hypertension was also observed for the Non-HCC Lenvatinib Monotherapy Safety Set.

The incidence of SAEs of hepatic encephalopathy did not differ between males and females but the SAE of hepatic failure (including fatal events) only occurred in males. The SAEs of cholestatic jaundice and upper GI haemorrhage occurred more frequently in females than in males in the All HCC Lenvatinib Safety Set.

## Race

All subjects in Study 202 and most subjects in Study 304 were Asian (&gt;2:1 ratio). There were 7 Black or African American subjects in the All HCC Lenvatinib Safety Set. The primary comparison is between the White and Asian subjects.

There was a higher incidence of severe (Grade ≥3) TEAEs, severe (Grade ≥3) related TEAEs and of TEAEs leading to study drug dose reduction in White than in Asian subjects. The incidence of fatal AEs was higher in White (17.2%) than in Asian subjects (11.0%) in the All HCC Lenvatinib Safety Set, although, this did not meet the 10% difference criterion. A similar numerical difference was not observed in the Non-HCC Lenvatinib Monotherapy Safety Set (10.1% vs 9.0%, respectively). The exposure-adjusted rates of episodes were numerically higher in White subjects than in Asian subjects for all categories of TEAEs.

For the All HCC Lenvatinib Safety Set, the following common events occurred at a higher incidence in White than in Asian subjects: acute kidney injury, asthenia, fatigue , flatulence, hepatic encephalopathy , increased blood ALP , nausea , somnolence, thrombocytopenia and vomiting . The following occurred at a higher incidence in Asian than in White subjects: abdominal distension , alopecia , decreased neutrophil count, decreased platelet count, decreased WBC count, maculo-papular rash, malaise, PPE syndrome and proteinuria. Similar findings were observed for the exposure-adjusted episodes of events except that an increased AE rate of nausea and of vomiting in White subjects was observed in the Non-HCC Lenvatinib Monotherapy Safety Set.

For the All HCC Lenvatinib Safety Set, the following SAEs occurred at a higher incidence in White than in Asian subjects: abdominal pain, accidental overdose, hepatic encephalopathy , multi organ dysfunction, MI, pneumonia aspiration , portal vein thrombosis , seizure , umbilical hernia and urinary tract infection . The following occurred at a higher incidence in Asian than in White subjects: cancer pain, cholestatic jaundice , oesophageal varices haemorrhage , pneumonia, pyrexia , and upper GI haemorrhage .

<div style=\"page-break-after: always\"></div>

For the All HCC Lenvatinib Safety Set, the following fatal AEs (that occurred in at least 2 subjects in a racial group) occurred at a higher incidence in White subjects than in Asian subjects: general physical health deterioration, hepatic encephalopathy , multi organ dysfunction syndrome, pneumonia aspiration , and portal vein thrombosis . The following occurred at a higher incidence in Asian subjects than in White subjects: respiratory failure and upper GI haemorrhage.

## Baseline ECOG PS score (0 vs. ≥1)

The incidence of TEAEs in the 2 ECOG PS groups in the All HCC Lenvatinib Safety Set was consistent with the known safety profile for lenvatinib, including a higher incidence of fatal AEs (19.2% vs. 9.2%; 0.29 vs. 0.13 episodes/SY) and a lower incidence of TEAEs leading to study drug dose reduction (30.2% vs. 43.4%) in subjects with an ECOG PS score ≥ 1 than in those with a score of 0. No common TEAEs or SAEs occurred at a higher incidence in subjects with an ECOG PS score ≥ 1 than those with a score of 0. The incidence of SAEs of hepatic encephalopathy was higher in subjects with an ECOG PS score of 0 than in those with a score ≥1, whilst the fatal AE of sepsis occurred at a higher incidence in subjects with an ECOG PS score ≥1.

## Baseline renal function (CrCl &lt;60 mL/min vs. ≥60 mL/min)

In general, the incidence of overall TEAEs was similar for subjects split by baseline CrCl. There was a higher incidence of TEAEs leading to study drug dose reduction (48.4% vs. 37.2%) in subjects with renal impairment (CrCl &lt;60 mL/min).

The following common events occurred at a higher incidence in those with lower baseline in both treatment groups: dehydration, dysphonia, hepatic encephalopathy, hypothyroidism, peripheral oedema, and proteinuria; and in the lenvatinib-treated subjects for constipation, decreased appetite, diarrhoea, fatigue and vomiting.

The incidence of Grade ≥3 TEAEs was higher in the subjects with baseline CrCl &lt;60 mL/min compared with CrCl ≥60 mL/min in both treatment groups for the following events: anaemia, decreased lymphocyte count, pneumonia and respiratory failure; and in the lenvatinib-treated subjects for cachexia, dehydration, dyspnoea, hyponatremia, MI, portal vein thrombosis, syncope and upper GI haemorrhage.

The incidence of SAEs was higher in the subjects with lower baseline CrCl in both treatment groups for pneumonia; and in the lenvatinib-treated subjects for hyponatremia, muscular weakness, MI and peripheral oedema.

## Baseline hepatic function

Most subjects (&gt;75%) had a baseline CP score of 5 (N=722), 221 subjects had a score of 6, 7 subjects had a score of 7 and 1 subject had a score of 8. The analysis was limited to subjects with a baseline CP score of 5 or 6.

The incidence of Grade ≥3 TEAEs (86% vs. 71.6%), SAEs (56.1% vs. 38.8%) and TEAEs leading to study drug discontinuation (27.1% vs. 16.9%) was higher in subjects with a baseline CP score of 6 than of 5 in both the lenvatinib and sorafenib arms (% provided for lenvatinib arm). Lenvatinib-treated subjects with a baseline CP score of 6 also had a higher incidence of TEAEs leading to dose modifications (70.1% vs. 59.6%).

The incidence of Grade ≥3 TEAEs was higher in the subjects with baseline CP score of 6 compared with 5 in both treatment groups for: abdominal pain, oesophageal varices haemorrhage, fatigue, general physical health deterioration and hyperkalaemia; and in lenvatinib-treated subjects for anaemia, decreased blood sodium, prolonged QT, headache, hepatic cirrhosis, hepatic encephalopathy, hyperbilirubinemia, hypoalbuminemia, hypokalaemia, increased blood bilirubin, increased blood sodium,

<div style=\"page-break-after: always\"></div>

increased lipase, liver abscess, peripheral oedema, pneumonia aspiration, portal vein thrombosis and upper GI haemorrhage.

The incidence of SAEs was higher in subjects with baseline CP score of 6 compared with 5 in both treatment groups for oesophageal varices haemorrhage and general physical health deterioration; and in the lenvatinib-treated subjects for bile duct obstruction, dyspnoea, headache, hepatic cirrhosis, hepatic encephalopathy, hepatic failure, liver abscess, pneumonia aspiration, portal vein thrombosis, proteinuria, pyrexia, umbilical hernia and upper GI haemorrhage.

## Geographic Region (Asia-Pacific vs. Western)

There were approximately twice as many subjects from the Asia-Pacific compared to the Western region in both HCC safety sets. There was a higher incidence of Grade ≥3 TEAEs (83.2% vs. 71.0%), Grade ≥3 related TEAEs (65.8% vs. 52.3%) and TEAEs leading to dose reduction (46.5% vs. 34.9%) in subjects from the Western region than in those from Asia-Pacific; this trend was in the opposite direction for the Non-HCC Lenvatinib Monotherapy Safety Set.

Table 82: Overview of Treatment-Emergent Adverse Event Episodes Adjusted for Treatment Exposure by Starting dose and Region - Safety Analysis Set

|                     | HCCRandonizedSafetySet                   | HCCRandonizedSafetySet                 | HCCRandonizedSafetySet                    | HCCRandonizedSafetySet                     | HCCRandonizedSafetySet                   | HCCRandonizedSafetySet                      | HCCRandonizedSafetySet                   | HCCRandonizedSafetySet                    |
|---------------------|------------------------------------------|----------------------------------------|-------------------------------------------|--------------------------------------------|------------------------------------------|---------------------------------------------|------------------------------------------|-------------------------------------------|
|                     | Lenvatinib StartingDose8mg               | Lenvatinib StartingDose8mg             | Lenvatinib StartingDose12mg               | Lenvatinib StartingDose12mg                | LenvatinibTotal                          | LenvatinibTotal                             | Sorafenib800mg                           | Sorafenib800mg                            |
| Episodes            | Asia-Pacific (N=130) SY=85.7 n (AE Rate) | Western Region (N=21) SY=9.5 n(AERate) | Asia-Pacific (N=191) SY=134.9 n (AE Rate) | Western Region (N=134) SY=94.2 n (AE Rate) | Asia-Pacific (N=321) SY=220.5 n(AE Rate) | Western Region (N=155) SY=103.6 n (AE Rate) | Asia-Pacific (N=319) SY=150.2 n(AE Rate) | Western Region (N=150) SY=88.8 n(AE Rate) |
| All TEAEs           | 1531 (17.87)                             | 206 (21.79)                            | 2454 (18.19)                              | 1933 (20.52)                               | 3985 (18.07)                             | 2139 (20.64)                                | 2939 (19.56)                             | 1779 (20.02)                              |
| RelatedTEAEs        | 868 (10.13)                              | 106 (11.21)                            | 1486 (11.02)                              | 1086 (11.53)                               | 2354 (10.67)                             | 1192 (11.50)                                | 1778 (11.83)                             | 1087 (12.23)                              |
| Grade≥3TEAEs        | 244 (2.85)                               | 34 (3.60)                              | 409 (3.03)                                | 336 (3.57)                                 | 653 (2.96)                               | 370 (3.57)                                  | 509 (3.39)                               | 286 (3.22)                                |
| RelatedGrade≥3TEAEs | 109 (1.27)                               | 17 (1.80)                              | 223 (1.65)                                | 168 (1.78)                                 | 332 (1.51)                               | 185 (1.79)                                  | 266 (1.77)                               | 164 (1.85)                                |
| A1lSAEs             | 96 (1.12)                                | 17 (1.80)                              | 161 (1.19)                                | 135 (1.43)                                 | 257 (1.17)                               | 152 (1.47)                                  | 154 (1.03)                               | 78 (0.88)                                 |
| Fatal AEs           | 12 (0.14)                                | 2 (0.21)                               | 25 (0.19)                                 | 22 (0.23)                                  | 37 (0.17)                                | 24 (0.23)                                   | 25 (0.17)                                | 11 (0.12)                                 |
| NonfatalSAEs        | 92 (1.07)                                | 16 (1.69)                              | 149 (1.10)                                | 122 (1.30)                                 | 241 (1.09)                               | 138 (1.33)                                  | 134 (0.89)                               | 73 (0.82)                                 |

The incidence of fatal AEs was numerically higher in subjects from the West (15.5%) than from AsiaPacific (11.1%) in the All HCC Lenvatinib Safety Set; a difference was observed in the Non-HCC Lenvatinib Monotherapy Safety Set (10.3% vs 7.6%, respectively). For the exposure-adjusted rates, there was an increase in TEAEs leading to dose reduction interruption in subjects from the Western region compared with those from Asia-Pacific for the All HCC Lenvatinib Safety Set.

More subjects in the Western than in the Asia-Pacific region had cirrhosis at Baseline as assessed by independent imaging review (81.9% vs 71.0%, respectively).

For the All HCC Lenvatinib Safety Set, the following TEAEs occurred at a higher incidence in subjects from Asia-Pacific than from the West: abdominal distension , alopecia, decreased neutrophil count, decreased platelet count, decreased WBC count, PPE syndrome and proteinuria. The following TEAEs occurred at a higher incidence in subjects from the West: arthralgia , asthenia, hepatic encephalopathy , nausea , thrombocytopenia and vomiting . Similar findings were observed for the exposure-adjusted episodes.

The following SAEs occurred at a higher incidence in subjects from Asia-Pacific than from the West: ascites , cancer pain, cholestatic jaundice , decreased appetite, dyspnoea , oesophageal varices haemorrhage , pneumonia, pyrexia , and upper GI haemorrhage . The following SAEs occurred at a higher incidence in subjects from the West: abdominal pain , general physical health deterioration, hepatic encephalopathy , hyponatremia , multi organ dysfunction syndrome, MI, nausea , pneumonia aspiration , portal vein thrombosis , pulmonary embolism, seizure, umbilical hernia , urinary tract infection and vomiting.

<div style=\"page-break-after: always\"></div>

The following fatal AEs occurred at a higher incidence in subjects from Asia-Pacific: respiratory failure , sepsis and upper GI haemorrhage . The following fatal AEs occurred at a higher incidence in subjects from the West: general physical health deterioration, hepatic encephalopathy , multi organ dysfunction syndrome, pneumonia aspiration and portal vein thrombosis.

## Lenvatinib starting dose

Starting dose was based on body weight rather than randomised; therefore, there were different numbers of subjects (325 for the 12-mg vs 151 for the 8-mg) and differences in demographic and baseline disease characteristics between the starting dose groups. A lower proportion of subjects from the Asia Pacific region (58.4% vs. 86.1%) and a higher proportion of males (91.4% vs. 70.2%) received the 12mg compared with the 8mg starting dose. Median duration of treatment was slightly longer in the 12-mg (6.3 months) compared with the 8-mg (5.6 months) starting dose group in Study 304.

The incidence of Grade ≥3 and of related Grade ≥3 TEAEs was higher in the 12mg than the 8mg starting dose group. There were no notable differences in the AE profile when adjusted by treatment duration.

The rates (episodes/ SY) of TEAEs were assessed by starting dose and by region (Asia-Pacific and Western). For the Western region, the episodes of Grade ≥3 TEAEs that only occurred in the 12-mg starting dose group were small (≤10), except for hepatic encephalopathy (20 episodes; AE rate 0.21 episodes/SY) and increased blood bilirubin (13 episodes; AE rate 0.14 episodes/SY). These differences were not observed within the Asia-Pacific region. There was a higher AE rate for hepatic encephalopathy in the 12-mg starting dose compared with the 8-mg starting dose (AE rates, 0.19 episodes/SY vs 0) in the Western region. However, there were 134 subjects in the ≥60 kg group (12 mg) compared with only 21 subjects in the &lt;60 kg group (8-mg) in Western region, making comparison difficult.

## Safety related to drug-drug interactions and other interactions

See section on clinical pharmacology.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

## Adverse Events Leading to Treatment Discontinuation

Table 83: Subject Disposition and Reasons for Discontinuation from Treatment - All Safety Sets

|                                                        | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|--------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
|                                                        | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Treated                                                | 476                                 | 475                            | 496                                 | 1327 a                                      |
| Treatment ongoing at data cutoff date                  | 27 (5.7)                            | 25 (5.3)                       | 27 (5.4)                            | 61 (4.6)                                    |
| Discontinued Treatment                                 | 449 (94.3)                          | 450 (94.7)                     | 469 (94.6)                          | 1236 (93.1)                                 |
| Primary reason(s) for discontinuation from treatment b |                                     |                                |                                     |                                             |
| Disease Progression                                    | 311 (65.3) c                        | 347 ( 73.1 ) c                 | 324 (65.3)                          | 735 (55.4)                                  |
| Clinical Progression                                   | 32 (6.7) d                          | 33 (6.9) d                     | na                                  | Na                                          |
| Adverse event                                          | 63 ( 13.2 )                         | 43 (9.1)                       | 67 (13.5)                           | 277 (20.9)                                  |
| Subject choice                                         | 28 ( 5.9 )                          | 14 (2.9)                       | 28 (5.6)                            | 46 (3.5)                                    |
| Lost to follow-up                                      | 3 (0.6)                             | 1 (0.2)                        | 3 (0.6)                             | 4 (0.3)                                     |
| Administrative                                         | 44 (9.2)                            | 45 (9.5)                       | 47 (9.5)                            | 174 (13.1)                                  |
| Withdrawal of consent from study                       | 9 (1.9)                             | 5 (1.1)                        | 9 (1.8)                             | 31 (2.3)                                    |
| Other                                                  | 3 (0.6) e                           | 7 (1.5)f                       | 38 (7.7) g                          | 143 (10.8)                                  |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Percentages are based on total number of subjects in the corresponding safety set within the relevant treatment group.

CRF = case report form; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; na = not available; QD = once daily.

a: 30 subjects (6 from Study 104, 23 from Study 208, and 1 from Study 209) completed treatment before the data cutoff date and are not included in either the 'Treatment ongoing at data cutoff date' and 'Discontinued treatment' subcategories.

b: Primary reasons for discontinuation from treatment are based on CRF disposition page.

c:

Radiological progression per modified Response Evaluation Criteria for Solid Tumours.

d: Clinical progression was collected under the \"Other\" category in the CRF.

e: Other reasons for discontinuation in the lenvatinib arm: subject required surgery (n=2) and investigator choice (n=1).

f: Other reasons for discontinuation in the sorafenib arm: investigator choice (n=5); need for a prohibited medication (warfarin; 1 subject); and discontinuation to undergo liver transplantation (n=1).

g: Includes subjects from Study 304 with clinical progression.

<div style=\"page-break-after: always\"></div>

TEAEs leading to discontinuation in ≥ 2 subjects in any group in the HCC Safety Sets are summarized by preferred term in the table below.

Table 84: TEAEs leading to Treatment discontinuation in 2 or more patients, all safety sets.

|                                                              | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|--------------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
| Preferred Term                                               | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Subjects with any TEAEs Leading to Treatment Discontinuation | 94 (19.7)                           | 69 (14.5)                      | 100 (20.2)                          | 336 (25.3)                                  |
| Fatigue                                                      | 7 (1.5)                             | 5 (1.1)                        | 7 (1.4)                             | 23 (1.7)                                    |
| Hepatic encephalopathy                                       | 7 (1.5)                             | 0                              | 8 (1.6)                             | 0                                           |
| Blood bilirubin increased                                    | 6 (1.3)                             | 1 (0.2)                        | 6 (1.2)                             | 1 (0.1)                                     |
| Hepatic failure                                              | 5 (1.1)                             | 3 (0.6)                        | 5 (1.0)                             | 1 (0.1)                                     |
| Cerebral haemorrhage                                         | 3 (0.6)                             | 0                              | 3 (0.6)                             | 0                                           |
| Jaundice cholestatic                                         | 3 (0.6)                             | 1 (0.2)                        | 3 (0.6)                             | 0                                           |
| Myocardial infarction                                        | 3 (0.6)                             | 0                              | 3 (0.6)                             | 4 (0.3)                                     |
| Proteinuria                                                  | 3 (0.6)                             | 1 (0.2)                        | 6 (1.2)                             | 22 (1.7)                                    |
| Sepsis                                                       | 3 (0.6)                             | 0                              | 3 (0.6)                             | 8 (0.6)                                     |
| Abdominal pain                                               | 2 (0.4)                             | 5 (1.1)                        | 2 (0.4)                             | 4 (0.3)                                     |
| Abdominal pain upper                                         | 2 (0.4)                             | 0                              | 2 (0.4)                             | 2 (0.2)                                     |
| Bile duct obstruction                                        | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| Cerebrovascular accident                                     | 2 (0.4)                             | 0                              | 2 (0.4)                             | 7 (0.5)                                     |
| ECOG PS worsened                                             | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 0                                           |
| General physical health deterioration                        | 2 (0.4)                             | 4 (0.8)                        | 2 (0.4)                             | 10 (0.8)                                    |
| Malignant neoplasm progression                               | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 2 (0.2)                                     |
| Multiple organ dysfunction syndrome                          | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 0                                           |
| Portal vein thrombosis                                       | 2 (0.4)                             | 0                              | 2 (0.4)                             | 0                                           |
| Upper gastrointestinal haemorrhage                           | 2 (0.4)                             | 1 (0.2)                        | 2 (0.4)                             | 0                                           |
| Ascites                                                      | 1 (0.2)                             | 4 (0.8)                        | 1 (0.2)                             | 1 (0.1)                                     |
| Renal impairment                                             | 1 (0.2)                             | 2 (0.4)                        | 1 (0.2)                             | 0                                           |
| Respiratory failure                                          | 1 (0.2)                             | 2 (0.4)                        | 1 (0.2)                             | 1 (0.1)                                     |
| Sudden death                                                 | 1 (0.2)                             | 2 (0.4)                        | 1 (0.2)                             | 1 (0.1)                                     |
| Tumour rupture                                               | 1 (0.2)                             | 0                              | 2 (0.4)                             | 0                                           |
| Jaundice                                                     | 0                                   | 3 (0.6)                        | 0                                   | 1 (0.1)                                     |
| PPE                                                          | 0                                   | 3 (0.6)                        | 0                                   | 3 (0.2)                                     |
| Diarrhoea                                                    | 0                                   | 2 (0.4)                        | 0                                   | 8 (0.6)                                     |
| Drug eruption                                                | 0                                   | 2 (0.4)                        | 0                                   | 0                                           |
| Gastrointestinal haemorrhage                                 | 0                                   | 2 (0.4)                        | 0                                   | 0                                           |
| Rash maculo-papular                                          | 0                                   | 2 (0.4)                        | 0                                   | 0                                           |
| Tumour pain                                                  | 0                                   | 2 (0.4)                        | 0                                   | 0                                           |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD.

Display is in decreasing order of AE rate in the Lenvatinib group of the HCC Randomized Safety Set. Subjects with 2 or more AEs in the same preferred term were counted only once. Percentages are based on the total number of subjects in the corresponding safety set within the relevant treatment group. Adverse event terms were coded using MedDRA version 19.1. AE = adverse event; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; MedDRA = Medical Dictionary for Regulatory Activities; QD = once daily; TEAE = treatment-emergent adverse event; PPE = Palmar-plantar erythrodysaesthesia syndrome; ECOG PS = Eastern Cooperative Oncology Group Performance Status

## Adverse Events Leading to Treatment Modification

TEAEs leading to treatment modification (interruption or reduction) in ≥2% of subjects in any group in the HCC Safety Sets are summarized by PT in the table below.

<div style=\"page-break-after: always\"></div>

Table 85: TEAEs Leading to Treatment Modification (Interruption or Reduction) in ≥2% in any Safety Sets

|                                                           | HCC Randomized Safety Set           | HCC Randomized Safety Set      | All HCC Lenvatinib Safety Set       | Non-HCC Lenvatinib Monotherapy Safety Set   |
|-----------------------------------------------------------|-------------------------------------|--------------------------------|-------------------------------------|---------------------------------------------|
| Preferred Term                                            | Lenvatinib 8 or 12 mg (N=476) n (%) | Sorafenib 800 mg (N=475) n (%) | Lenvatinib 8 or 12 mg (N=496) n (%) | Lenvatinib (N=1327) n (%)                   |
| Subjects with any TEAEs Leading to Treatment Modification | 294 (61.8)                          | 264 (55.6)                     | 309 (62.3)                          | 958 (72.2)                                  |
| Decreased appetite                                        | 36 ( 7.6 )                          | 15 (3.2)                       | 38 (7.7)                            | 117 (8.8)                                   |
| Diarrhoea                                                 | 36 (7.6)                            | 35 (7.4)                       | 36 (7.3)                            | 198 (14.9)                                  |
| Proteinuria                                               | 33 ( 6.9 )                          | 7 (1.5)                        | 37 (7.5)                            | 209 (15.7)                                  |
| Hypertension                                              | 29 (6.1)                            | 18 (3.8)                       | 29 (5.8)                            | 217 (16.4)                                  |
| Fatigue                                                   | 27 (5.7)                            | 17 (3.6)                       | 29 (5.8)                            | 164 (12.4)                                  |
| Palmar-plantar erythrodysaesthesia syndrome               | 25 (5.3)                            | 88 (18.5)                      | 27 (5.4)                            | 94 (7.1)                                    |
| Platelet count decreased                                  | 22 (4.6)                            | 12 (2.5)                       | 25 ( 5.0 )                          | 16 (1.2)                                    |
| Blood bilirubin increased                                 | 20 (4.2)                            | 14 (2.9)                       | 20 ( 4.0 )                          | 6 (0.5)                                     |
| Hepatic encephalopathy                                    | 20 ( 4.2 )                          | 3 (0.6)                        | 21 ( 4.2 )                          | 0 (0.0)                                     |
| Weight decreased                                          | 20 ( 4.2 )                          | 4 (0.8)                        | 21 (4.2)                            | 112 (8.4)                                   |
| Asthenia                                                  | 16 (3.4)                            | 9 (1.9)                        | 16 (3.2)                            | 80 (6.0)                                    |
| Nausea                                                    | 16 (3.4)                            | 9 (1.9)                        | 17 (3.4)                            | 113 (8.5)                                   |
| Pyrexia                                                   | 12 ( 2.5 )                          | 5 (1.1)                        | 12 ( 2.4 )                          | 15 (1.1)                                    |
| Vomiting                                                  | 12 ( 2.5 )                          | 6 (1.3)                        | 13 (2.6)                            | 92 (6.9)                                    |
| Neutrophil count decreased                                | 11 ( 2.3 )                          | 5 (1.1)                        | 11 ( 2.2 )                          | 5 (0.4)                                     |
| Ascites                                                   | 10 (2.1)                            | 5 (1.1)                        | 10 ( 2.0 )                          | 0 (0.0)                                     |
| Aspartate aminotransferase increased                      | 9 (1.9)                             | 18 (3.8)                       | 9 (1.8)                             | 18 (1.4)                                    |
| Rash                                                      | 2 (0.4)                             | 10 (2.1)                       | 2 (0.4)                             | 13 (1.0)                                    |

Data cutoff date for HCC Randomized and All HCC Lenvatinib Safety Sets: 13 Nov 2016. Data cutoff date for Non-HCC Lenvatinib Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received a starting dose of 24 mg QD. Display is in decreasing order of AE rate in the Lenvatinib group of the HCC Randomized Safety Set. Subjects with 2 or more adverse events in the same preferred term were counted only once. Percentages are based on the total number of subjects in the corresponding safety set within the relevant treatment group. Adverse event terms were coded using MedDRA version 19.1. AE = adverse event; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; MedDRA = Medical Dictionary for Regulatory Activities; QD = once daily; TEAE = treatment-emergent adverse event.

## Post marketing experience

Lenvatinib was first approved on 13 Feb 2015 (International Birth Date [IBD]) in the USA for the 'treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.' Subsequently, lenvatinib has been approved for radiotherapy refractory-DTC in over 50 countries worldwide, including the EU on 28 May 2015. The RCC indication has been approved in over 30 countries worldwide.  Approximately 6,400 new patients have been exposed to lenvatinib from the IBD until the data lock date of the most recent PSUR (12 Feb 2017). The most frequently reported adverse reactions post-marketing are hypertension, proteinuria, diarrhoea, PPE syndrome and decreased appetite. Cumulatively, 2435 patients have been exposed to lenvatinib in clinical trials. Marketing exposure (new patients) is estimated at 2208 patients and 6367 patients cumulatively. The most frequently reported adverse reactions postmarketing are hypertension, proteinuria, diarrhoea, PPE syndrome and decreased appetite. Signals for pancreatitis and cholecystitis were evaluated in the PSUR reporting period and the CCDS was updated to include cholecystitis, pancreatitis, lipase increase and amylase increase in Section 4.8, Undesirable effects. Evaluation of a signal of interstitial lung disease is ongoing.

## 2.5.1. Discussion on clinical safety

Clinical safety data in support of the sought new indication for hepatocellular carcinoma (HCC) patients are  based  primarily  on  results  of  one  pivotal  randomised  study  (study  304).  The  starting  dose  of

<div style=\"page-break-after: always\"></div>

lenvatinib was based on baseline body weight (BW): 12 mg QD for subjects with a BW of ≥60 kg (325 pts) and 8 mg QD for subjects with a BW of &lt;60 kg (151 pts).

The main issues identified are SAEs associated with decreased liver function due to the underlying disease and AEs in special populations.

## Safety findings in study 304

The safety findings in the lenvatinib arm of study 304 were generally consistent with the known safety profile of lenvatinib monotherapy previously observed in DTC and described in the SmPC.

The majority of patients exposed to lenvatinib reported adverse events (AEs). The toxicity of lenvatinib was overall manageable, by dose interruptions and dose reductions.

The increased rate of hepatotoxicity (hepatic failure/ hepatic encephalopathy) with lenvatinib can to some extent  be  attributed  to  imbalances  in  baseline  risk  factors.  However  the  proportions  of  patients  with elevated ALT/ AST was similar in the 2 treatment arms, including at the end of therapy.

The difference between treatment duration and time to progression in the lenvatinib arm was remarkable while medians for the duration of treatment and time to progression were the same in the sorafenib arm. This  could  be  explained  by  differences  in  baseline  characteristics  and  treatment  discontinuation.  The information regarding duration of treatment is provided in the SmPC.

Section 4.8 of the SmPC has been updated to describe the safety profile of lenvatinib based on data from 496 HCC patients in addition to 452 DTC patients thus allowing characterisation of common adverse drug reactions  in  DTC  and  HCC  patients.  The  incidences  of  the  following  ADRs  'leukopenia',  'neutropenia', 'hypothyroidism', 'blood bilirubin  increased',  'hypoalbuminaemia',  'alanine  transferase  increased'  and 'aspartate aminotransferase increased' were found to be increased from 'common' in the DTC patients to 'very common' in the HCC patients.

The  most  frequently  reported  adverse  reactions  (occurring  in  ≥30%  of  patients)  are  hypertension (44.0%),  diarrhoea  (38.1%),  decreased  appetite  (34.9%),  fatigue  (30.6%),  and  weight  decreased (30.4%).

The  most  important  serious  adverse  reactions  were  hepatic  failure  (2.8%),  hepatic  encephalopathy (4.6%), oesophageal varices haemorrhage (1.4%), cerebral haemorrhage (0.6%), arterial thromboembolic  events  (2.0%)  including  myocardial  infarction  (0.8%),  cerebral  infarction  (0.4%)  and cerebrovascular  accident  (0.4%)  and  renal  failure/impairment  events  (1.4%).    There  was  a  higher incidence of decreased neutrophil count in patients with HCC (8.7% on lenvatinib than in other non- HCC tumour types (1.4%)), which was not associated with infection, sepsis or bacterial peritonitis. No new ADR was observed in study 304

When  reviewed  by  region  and  adjusted  for  treatment  duration,  the  highest  rate  of  TEAEs,  Grade  ≥3 TEAEs,  non-fatal  SAEs  and  fatal  AEs  appeared  to  occur  in  the  Western  region  in  lenvatinib  treated patients,  although  most  fatal  AEs  were  attributed  to  PD.  There  were  more  TEAEs  leading  to  dose reduction  in  the  West  compared  to  Asia  Pacific.  More  subjects  in  the  Western  than  in  the  Asia-Pacific region  had  cirrhosis  at  Baseline  as  assessed  by  independent  imaging  review  (81.9%  vs  71.0%, respectively) but not per CRF.

In the Phase 3 HCC trial, hypertension (including hypertension, blood pressure increased, blood pressure diastolic increased and orthostatic hypertension) was reported in 44.5% of lenvatinib-treated patients and Grade 3 hypertension occurred in 23.5%.  The median time to onset was 26 days.  The majority of cases recovered following dose interruption or reduction, which occurred in 3.6% and 3.4% of patients respectively. One subject (0.2%) discontinued lenvatinib due to hypertension.

<div style=\"page-break-after: always\"></div>

Proteinuria was reported in 26.3% of lenvatinib-treated patients and Grade 3 reactions occurred in 5.9%. The median time to onset was 6.1 weeks.  The majority of cases recovered following dose interruption or reduction, which occurred in 6.9% and 2.5% of patients respectively.  Proteinuria led to permanent treatment discontinuation in 0.6% of patients.

Renal failure/impairment event developed in 7.1% of lenvatinib-treated patients. Grade 3 or greater reactions occurred in 1.9% of lenvatinib-treated patients.

Cardiac dysfunction (including congestive cardiac failure, cardiogenic shock, and cardiopulmonary failure) was reported in 0.6% of patients (0.4% were Grade ≥ 3) in the lenvatinib-treated group.

There was 1 event of PRES (Grade 2) in the lenvatinib-treated group.

In the Phase 3 REFLECT trial, the most commonly reported hepatotoxicity adverse reactions were increased blood bilirubin (14.9%), increased aspartate aminotransferase (13.7%), increased alanine aminotransferase (11.1%), hypoalbuminaemia (9.2%), hepatic encephalopathy (8.0%), increased gamma-glutamyltransferase (7.8%) and increased blood alkaline phosphatase (6.7%). The median time to onset of hepatotoxocity adverse reactions was 6.4 weeks.  Hepatotoxicity reactions of ≥ Grade 3 occurred in 26.1% of lenvatinib-treated patients.  Hepatic failure (including fatal events in 12 patients) occurred in 3.6% of patients (all were ≥ Grade 3).  Hepatic encephalopathy (including fatal events in 4 patients) occurred in 8.4% of patients (5.5% were ≥ Grade 3).  There were 17 (3.6%) deaths due to hepatotoxicity events in the lenvatinib arm and 4 (0.8%) deaths in the sorafenib arm.  Hepatotoxicity adverse reactions led to dose interruptions and reductions in 12.2% and 7.4% of lenvatinib-treated patients respectively, and to permanent discontinuation in 5.5%.

Across clinical studies in which 1327 patients received lenvatinib monotherapy in indications other than HCC, hepatic failure (including fatal events) was reported in 4 patients (0.3%), liver injury in 2 patients (0.2%), acute hepatitis in 2 patients (0.2%), and hepatocellular injury in 1 patient (0.1%).

Patients with worse hepatic impairment and/or greater liver tumour burden at baseline had a higher risk of developing hepatic encephalopathy and hepatic failure.  Hepatic encephalopathy also occurred more frequently in patients aged 75 years and older. Approximately half of the events of hepatic failure and one third of the events of the hepatic encephalopathy were reported in patients with disease progression.

Data in HCC patients with moderate hepatic impairment (Child-Pugh B) are very limited and there are currently no data available in HCC patients with severe hepatic impairment (Child-Pugh C).  Since lenvatinib is mainly eliminated by hepatic metabolism, an increase in exposure in patients with moderate to severe hepatic impairment is expected.

Close monitoring of the overall safety is recommended in patients with mild or moderate hepatic impairment.  Liver function tests should be monitored before initiation of treatment, then every 2 weeks for the first 2 months and monthly thereafter during treatment.  Patients with HCC should be monitored for worsening liver function including hepatic encephalopathy (see section 4.4 of the SmPC).

In the Phase 3 REFLECT trial, arterial thromboembolic events were reported in 2.3% of patients treated with lenvatinib.

In the Phase 3 REFLECT trial, haemorrhage was reported in 24.6% of patients and 5.0% were Grade ≥ 3. Grade 3 reactions occurred in 3.4%, Grade 4 reactions in 0.2% and 7 patients (1.5%) had a grade 5 reaction including cerebral haemorrhage, upper gastrointestinal haemorrhage, intestinal haemorrhage and tumour haemorrhage.  The median time to first onset was 11.9 weeks.  A haemorrhage event led to dose interruption or reduction in 3.2% and 0.8% patients respectively and to treatment discontinuation in 1.7% of patients.

<div style=\"page-break-after: always\"></div>

Screening for and subsequent treatment of oesophageal varices in patients with liver cirrhosis should be performed as per standard of care before starting treatment with lenvatinib.

Hypocalcaemia was reported in 1.1% of patients, with grade 3 reactions occurring in 0.4%.  Lenvatinib dose interruption due to hypocalcaemia occurred in one subject (0.2%) and there were no dose reductions or discontinuations.

Events of gastrointestinal perforation or fistula were reported in 1.9% of lenvatinib-treated patients.

QT/QTc interval prolongation was reported in 6.9% of lenvatinib-treated patients.  The incidence of QTcF interval prolongation of greater than 500ms was 2.4%.

In the Phase 3 HCC trial, 89.6% of patients had a baseline TSH level of less than the upper limit of normal.  Elevation of TSH above the upper limit of normal was observed post baseline in 69.6% of lenvatinib-treated patients.

Diarrhoea was reported in 38.7% of patients treated with lenvatinib (4.2% were Grade ≥ 3).

## Special populations

Patients of age ≥75 years were more likely to experience hypertension, proteinuria, decreased appetite, asthenia, dehydration, dizziness and hepatic encephalopathy.  Hepatic encephalopathy occurred at more than twice the incidence in patients aged ≥75 years (17.2%) than in those &lt;75 years (7.1%). Hepatic encephalopathy tended to be associated with adverse disease characteristics at baseline or with the use of concomitant medications.  Arterial thromboembolic events also occurred at an increased incidence in this age group.

Females had a higher incidence of hypertension, fatigue and ECG QT prolongation.  Hepatic failure events were observed in male patients only.

Asian patients had a higher incidence than Caucasian patients of proteinuria, decreased neutrophil count, decreased platelet count, decreased white blood count and PPE syndrome, while Caucasian patients had a higher incidence of fatigue, hepatic encephalopathy, acute kidney injury, anxiety, asthenia, nausea, thrombocytopenia and vomiting.

Patients with a baseline Child Pugh (CP) score of 6 compare to a baseline CP score of 5 had a higher incidence  of  decreased  appetite,  fatigue,  proteinuria,  hepatic  encephalopathy  and  hepatic  failure. Hepatotoxicity events and haemorrhage events also occurred at a higher incidence in CP score 6 patients compared to CP score 5 patients.

Patients with baseline renal impairment had a higher incidence of fatigue, hypothyroidism, dehydration, diarrhoea, decreased appetite, proteinuria and hepatic encephalopathy.  These patients also had a higher incidence of renal reactions and arterial thromboembolic events.

In  496  patients  with  HCC,  dose  modification  (interruption  or  reduction)  and  discontinuation  were  the actions taken for an adverse reaction in 62.3% and 20.2% of patients, respectively.  Adverse reactions that most commonly led to dose modifications (in ≥ 5% of patients) were decreased appetite, diarrhoea, proteinuria,  hypertension,  fatigue,  PPE  and  platelet  count  decreased.    Adverse  reactions  that  most commonly  led  to  discontinuation  of  lenvatinib  were  hepatic  encephalopathy,  fatigue,  blood  bilirubin increased, proteinuria and hepatic failure (see section 4.8 of the SmPC).

A post-marketing Phase IV safety study will be performed to gather further data in the EU population (or relevant  Western  population)  and  to  better  characterise  safety  concern  of  hepatotoxicity  (including hepatic  encephalopathy)  in  real-life  conditions  and  to  accurately  collect  baseline  demographic  and disease-related  characteristics  for  potential  determination  of  risk  factors  contributing  to  incidence  and severity  of  hepatic-related  events  and  mortality.  It  is  recommended  that  both  Child-Pugh  A  and  B

<div style=\"page-break-after: always\"></div>

patients  are  included  to  mirror  expected  clinical  use.  The  MAH  will  ensure  that  a  sufficient  number  of patients with Child-Pugh B is studied (see RMP).

Baseline information of importance includes: Child-Pugh score, ECOG, BCLC, Stage, previous treatments, extrahepatic spread/ vascular invasion, bilirubin, albumin, INR, ascites, encephalopathy, aetiology (HBV, HCV, ETOH, NASH, other), cirrhosis, weight. Child-Pugh score and performance status changes should be collected during the study, as well as dose modifications/discontinuations, weight, concomitant medications.

The MAH should also discuss relevant comparisons (preferably within the study) of the lenvatinib data to allow an assessment of hepatic safety in an EU-population treated with lenvatinib.

The study protocol should be submitted within 3 months of the approval of the new indication.

## PRO analyses

Assessments of HRQoL scores were performed using the generic cancer HRQoL instrument (EORTC QLQC30), the HCC-specific module (EORTC QLQ-HCC18), and the generic HRQoL instrument, EQ-5D. Patients were asked to complete each of the 3 questionnaires at Baseline, on Day 1 of each subsequent cycle, and at the OTV. Due to the open-label nature of the study, results should be interpreted with caution.

## 2.5.2. Conclusions on clinical safety

The incidence and the severity of AEs in lenvatinib group are somewhat higher than the one observed with  sorafenib.  In  particular,  incidence  of  hepatic-related  serious  AEs  and  hepatic-related  deaths, including  lethal  hepatic  failure)  was  higher  in  the  lenvatinib  arm  (n=21)  than  in  sorafenib  arm  (n=2). Hepatic  encephalopathy  was  4  times  more  frequent  in  lenvatinib  arm  and  remained  higher  after adjustment  by  duration  of  exposure  (0.17  rate  in  lenvatinib  arm,  n=55;  0.04  rate  in  sorafenib  arm, n=10), mostly due to cases occurred with the lenvatinib dose of 12mg (0.20 rate, n = 45). Given that patient with better prognosis has been enrolled in the Study 304 comparing with historical trials and that more  vulnerable  patient  population  would  be  exposed  to  lenvatinib  in  real  life  conditions,  further characterisation of safety profile is needed in EU population (Western group represented 1/3 of the trial population).  All  the  episodes  of  hepatic  encephalopathy  with  the  dose  of  12  mg  occurred  in  Western population.

Patients with well-preserved liver function (Child-Pugh A) have been included in the study and uncertainty remains as to the safety profile of lenvatinib in patients with liver impairment, who represent a significant proportion of patients in real life conditions.

The CHMP considers the following measures necessary to address issues related to safety:

A non-interventional post-marketing Phase IV safety study will be performed in the EU (or Western population) to better characterise safety, primarily hepatotoxicity, in real-life conditions and to inform further on contributing factors. The study protocol will be submitted within 3 months of the approval of the new indication (see RMP).

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.6. Risk management plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Hypertension • Proteinuria • Renal failure or impairment • Hypokalaemia • Cardiac failure • Posterior reversible encephalopathy syndrome (PRES) • Hepatotoxicity • Haemorrhagic events • Arterial thromboembolic events (ATEs) • QTc prolongation • Hypocalcaemia • Hypothyroidism • Gastrointestinal perforation and fistula formation • Non-Gastrointestinal fistula formation (any fistula which does not involve the stomach or intestine) |
| Important potential risks    | • Venous thromboembolic events (VTEs) • Abnormal pregnancy outcome, excretion of lenvatinib in milk • Male and female fertility • Bone and teeth abnormalities in the paediatric population • Impaired wound healing • Interstitial Lung Disease (ILD)-like conditions • Potential of lenvatinib for induction/inhibition of CYP-3A4 Mediated Drug Metabolism • Overdose (concomitant everolimus) (RCC)                                          |
| Missing information          | • Use in severe hepatic impairment • Use in severe renal impairment • Use in patients from ethnic origins other than Caucasian or Asian • Long-term use                                                                                                                                                                                                                                                                                          |

## Pharmacovigilance plan

Table 86 On-going and planned additional PhV studies/activities in the pharmacovigilance plan

| Study/activit y Type, title and category (1-3)   | Objectives   | Safety concerns addressed   | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual   |
|--------------------------------------------------|--------------|-----------------------------|-----------------------------|-----------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)                    | Objectives                                                                                                                                                                 | Safety concerns addressed                                                                                                                              | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual   |
|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------|
| Study 109 (Interventional Clinical Study: Category 3)             | A drug-drug interaction (DDI) study to investigate the potential of lenvatinib for CYP3A4 inhibition/induction                                                             | To investigate correctly the potential of lenvatinib for CYP3A4 inhibition/induction, an in vivo study with midazolam as a probe substrate for CYP3A4. | Planned                     | Mar 2018                                                              |
| Study E7080- A001-010 (Interventional Clinical Study: Category 3) | A Multicenter Phase 0 Study In Healthy Subjects As Well As Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma To Assess In Vitro Lenvatinib Protein Binding | In order to define correctly the dose- adjustment in patients with severe hepatic and renal impairment and determine unbound drug concentration        | Planned                     | June 2019                                                             |
| DTC                                                               |                                                                                                                                                                            |                                                                                                                                                        |                             |                                                                       |
| Study 201 (Interventional Clinical Study: Category 3)             | To evaluate the long-term safety of lenvatinib in Medullary and Iodine-131 Refractory, Unresectable DTC, Stratified by Histology                                           | Continue to characterize/ confirm current safety profile of lenvatinib in DTC                                                                          | Completed *                 | Feb 2014                                                              |
| Study 303 (Interventional Clinical Study: Category 3)             | To evaluate long-term safety of lenvatinib in patients with RR-DTC in a randomized, double-blind, placebo-controlled Phase 3 study.                                        | Continue to characterize/ confirm current safety profile of lenvatinib in DTC                                                                          | Completed *                 | Ongoing                                                               |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)        | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                 | Status (planned, started)                  | Date for submissio n of interim or final reports (planned or actual   |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------------------------------------------------------------|
| Study 211 (Interventional Clinical Study: Category 3) | Primary Objective • To determine whether a starting dose of lenvatinib 20 mg or 14 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 6 months [ORR6M]) with an improved safety profile compared to 24 mg QD (based on treatment- emergent adverse events [TEAEs] of Grade 3 or higher in the first 6 months after randomization). Secondary Objectives: • To evaluate PFS • To evaluate PFS2 • To evaluate safety and tolerability • To evaluate PK-PD relationship between exposure and biomarkers /efficacy/safety • To evaluate impact on HR QOL Exploratory Objectives: • To explore OS •To explore TSH, and other serum biomarkers as potential biomarkers for tumour response • To explore DNA sequence variants in genes that may influence | Characterize/ confirm safety profile of lenvatinib in DTC at lower doses, to determine whether a lower dose starting dose of lenvatinib will provide comparable efficacy with an improved safety profile. | First patient in (ICF signed): 12 Mar 2016 | 31 Aug 2020                                                           |
| Assessment report EMA/582721/2018                     | PK, safety, or pharmacodynamics data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                           |                                            | Page 137/151                                                          |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)         | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Safety concerns addressed                                                                                                                             | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual                                                                                                                        |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RCC                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                       |                             |                                                                                                                                                                                            |
| Study 205 (Interventional Clinical Study: Category 3)* | An Open-Label, Multicenter Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF Targeted Treatment                                                                                                                                                                                                                                                                                                                                                                              | To continue to characterize/confir m the current safety profile of lenvatinib either as monotherapy or in combination with everolimus in advanced RCC | Completed *                 | Final report: Dec 2018                                                                                                                                                                     |
| Study 218 (Interventional Clinical Study: Category 3)  | Primary objective: •To assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg (based on treatment-emergent intolerable Grade 2 or any ≥Grade 3 adverse events in the first 24 weeks after randomization). Secondary objectives: •To assess PFS •To assess ORR •To determine the tolerability and safety profile of lenvatinib in combination with | To continue to characterize/confir m the current safety profile of lenvatinib either as monotherapy or in combination with everolimus in advanced RCC | Planned                     | Final protocol and data analysis plan submission: Nov 2016 Study completion: Nov 2020 Periodic interim analyses by independent Data Monitoring Committee Final report submission: Jul 2021 |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                          | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual   |
|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-----------------------------|-----------------------------------------------------------------------|
|                                                  | everolimus •To assess proportion of subjects who discontinued treatment due to toxicity •To assess time to treatment failure •To assess PK profiles of lenvatinib and everolimus during combination therapy and to assess PK and PD drug-drug interactions •To evaluate OS •To evaluate impact on HR QOL •To evaluate PFS2 Exploratory objectives: •To explore blood biomarkers which correlate with efficacy- related endpoints of this study. •To develop exposure/biomarker/ clinical endpoint models (whenever possible, using a mechanism-based approach) for both efficacy and safety data that will allow exploration of alternative dosing regimens with a better efficacy/safety profile than the 18mg/5mg dose. |                                                    |                             |                                                                       |
| Study 221 (Interventional Clinical Study:        | Primary Objective: •To evaluate objective response rate (ORR) of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | To characterize the safety profile of lenvatinib + | Final protocol 13 May       | Final report submission: Q4 2019                                      |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Safety concerns addressed                                                                      |   Status (planned, started) | Date for submissio n of interim or final reports (planned or actual   |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------|
| Category 3)                                      | lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease Secondary Objectives: •To assess safety and tolerability of lenvatinib in combination with everolimus •To evaluate progression- free survival (PFS) •To evaluate overall survival (OS) •To assess the pharmacokinetic (PK) profiles of lenvatinib and everolimus during combination therapy in subjects with nccRCC. Exploratory Objectives: • To explore clinical benefit rate (CBR) • To explore disease control rate (DCR) • To explore duration of response (DOR) •To identify and explore tumour and blood biomarkers that correlate with clinical outcomes, including efficacy •To explore the relationship of population | everolimus in subjects with nccRCC who have not received any chemotherapy for advanced disease |                        2016 |                                                                       |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)        | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Safety concerns addressed                                                                                                    | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual                                                                                                                       |
|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                       | PK derived exposure parameters to biomarker, safety, and efficacy data using a model-based approach                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                              |                             |                                                                                                                                                                                           |
| Study 307 (Interventional Clinical Study: Category 3) | Primary Objective: • To demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression- free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria In Solid Tumours [RECIST 1.1]) as first-line treatment in subjects with advanced renal cell carcinoma (RCC). Secondary Objectives: To compare objective response rate (ORR) and overall survival (OS) of subjects treated with lenvatinib in combination with everolimus or pembrolizumab versus sunitinib. To compare safety and tolerability of treatment with lenvatinib in combination with everolimus or pembrolizumab versus | To continue to characterize/confir m the current safety profile of lenvatinib in combination with everolimus in advanced RCC | Planned                     | The protocol and the data analysis plan for PK/PD should be submitted by: Nov 2016 Periodic interim analyses by independent Data Monitoring Committee Final report submission 15 Jun 2020 |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Safety concerns addressed   | Status (planned, started)   | Date for submissio n of interim or final reports (planned or actual   |
|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------------|
|                                                  | sunitinib, including the assessment of the proportion of subjects who discontinued treatment due to toxicity and time to treatment failure due to toxicity. To compare the impact of treatment on Health- Related Quality of Life (HRQoL) for subjects treated with lenvatinib in combination with everolimus or pembrolizumab versus sunitinib. To assess progression-free survival (PFS) based on investigator assessment per RECIST 1.1, and to assess PFS on next-line therapy (PFS2). To characterize the population pharmacokinetics (PK) of lenvatinib when co- administered with everolimus or pembrolizumab, and of everolimus and pembrolizumab when co- adminstered with lenvatinib. To asses the PK/pharmacodynamic relationship between exposure and efficacy/biomarkers/safety , if possible using a holistic |                             |                             |                                                                       |

<div style=\"page-break-after: always\"></div>

| Study/activit y Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                      | Safety concerns addressed      | Status (planned, started)                   | Date for submissio n of interim or final reports (planned or actual   |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|---------------------------------------------|-----------------------------------------------------------------------|
|                                                  | approach.                                                                                                                                                                                                                                                                                                                                       |                                |                                             |                                                                       |
| HCC                                              |                                                                                                                                                                                                                                                                                                                                                 |                                |                                             |                                                                       |
| Observational Clinical Study: Category 3)        | To characterise hepatic- related toxicity and overall safety profile (SAEs, Grade 3-5 AEs, dose modifications and discontinuations due to AEs) in real-life conditions in the EU (Western population) in HCC patients, including patients with Child-Pugh B. Overall survival data and detailed baseline charateristics will also be collected. | Hepatotoxicity in HCC patients | Pending protocol and feasibility assessment | Protocol to be submitted by 28 Sep 2018                               |

## Risk minimisation measures

Table 87. Summary Table of Risk Minimization Measures

<div style=\"page-break-after: always\"></div>

| Safety Concern                                      | Routine Risk Minimization Measures                                                                                                                          | Additional Risk Minimizatio n Measures   |
|-----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Identified Risks                                    | Identified Risks                                                                                                                                            | Identified Risks                         |
| Hypertension                                        | Sections 4.2, 4.4, 4.8 of the SmPC. Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                             |
| Proteinuria                                         | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| Renal failure or impairment                         | Sections 4.2, 4.4, 4.8 of the SmPC. Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                             |
| Hypokalaemia                                        | Hypokalaemia is listed in Section 4.8 of the SmPC as a very common (≥1/10) adverse reaction                                                                 | None planned                             |
| Cardiac failure                                     | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| Posterior reversible encephalopathy syndrome (PRES) | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| Hepatotoxicity                                      | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| Haemorrhagic events                                 | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| Arterial thromboembolic events (ATEs)               | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |
| QTc prolongation                                    | Sections 4.4, 4.8 of the SmPC                                                                                                                               | None planned                             |
| Hypocalcaemia                                       | Sections 4.4, 4.8 of the SmPC                                                                                                                               | None planned.                            |
| Hypothyroidism                                      | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.       | None planned                             |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                       | Routine Risk Minimization Measures                                                                                                                                                                                                                                      | Additional Risk Minimizatio n Measures   |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Gastrointestinal perforation and fistula formation                                   | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                   | None planned.                            |
| Non- Gastrointestinal fistula formation                                              | Sections 4.4, 4.8 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                   |                                          |
| Potential Risks                                                                      |                                                                                                                                                                                                                                                                         |                                          |
| Venous thromboembolic events (VTEs)                                                  | Pulmonary embolism is listed in Section 4.8. of the SmPC                                                                                                                                                                                                                | None planned.                            |
| Abnormal pregnancy outcome, excretion in breast milk                                 | Sections 4.6 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                        | None planned                             |
| Male and female fertility                                                            | Section 4.6 and 5.3. of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                | None planned                             |
| Bone and teeth abnormalities in the paediatric population                            | Sections 4.2, 5.3 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                   | None planned                             |
| Impaired Wound Healing                                                               | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data.                             | None planned                             |
| Interstitial Lung Disease (ILD)¬like conditions                                      | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data. Prescription only medicine. | None planned                             |
| Potential of lenvatinib for induction/inhibition of CYP-3A4 mediated drug metabolism | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data. Prescription only medicine. | None planned                             |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                    | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Additional Risk Minimizatio n Measures   |
|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Overdose (concomitant everolimus)                                 | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data. Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                               | None planned                             |
| Missing Information                                               | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                          |
| Use in severe hepatic impairment                                  | Sections 4.2 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | None planned                             |
| Use in severe renal impairment                                    | Sections 4.2 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | None planned                             |
| Use in patients from ethnic origins other than Caucasian or Asian | Sections 4.2 of the SmPC Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | None planned                             |
| Long-term use                                                     | AEs such as cardiovascular events may emerge during long-term treatment, and continuous collection of long- term safety data is relevant for all indications. In RCC, no risk minimization measures are recommended at present as the duration of exposure to the combination covers the lifespan of the treated patient population: 72% of total subject-years of exposure were contributed by patients treated for at least 12 months, whilst median survival for mRCC patients treated with the combination is 25.5 months. Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies | None planned                             |

The CHMP endorsed the Risk Management Plan version 10.6.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly. In addition, section 4.2 of the SmPC is being updated to add that the product can be administered as a suspension in water or apple juice. In addition, the labelling is updated to include the unique identifier.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

<div style=\"page-break-after: always\"></div>

In accordance with the EU 'Guidance concerning consultations with target patient groups for the package leaflet; Article 59(3) and 61(1) of Directive 2001/83/EC as amended by Directive 2004/27/EC' and 'Guideline on the readability of the labelling and package leaflet of medicinal products for human use, Revision 1, 12 Jan 2009', the changes made as part of this application are not significant in nature and hence do not require a user consultation. There is no change in layout, and no major change in the patient target group profile, nor any critical changes in terms of the safety information presented.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

HCC is a cancer that usually occurs in the setting of liver cirrhosis, because of chronic infections with hepatitis B virus or hepatitis C virus, alcohol consumption, non-alcoholic steatohepatitis, or diabetes (EASL&amp;EORTC 2012). It is the third-leading cause of cancer-related death, and the global incidence is rising, with approximately 700,000 cases diagnosed worldwide in 2012 alone (Lozano et al. 2010, Torre et al. 2015).

## 3.1.2. Available therapies and unmet medical need

For patients with unresectable HCC eligible for systemic therapy, the oral multikinase inhibitor sorafenib was until recently the only treatment option. The approval was based on the results of a large Phase-3 clinical trial (Study 100554 SHARP) conducted in 602 HCC patients (Llovet et al. 2008). The study demonstrated significantly increased survival under sorafenib (plus BSC) compared to placebo (plus BSC) (HR 0.69; p=0.0005), with a median survival rate for the sorafenib arm of 10.6 months, compared with 7.9 months for the placebo arm. Currently, another oral multikinase inhibitor regorafenib (Stivarga) is indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

## 3.1.3. Main clinical studies

The pivotal study supporting this application is Study 304 (REFLECT), a multi-centre, multi-national, randomized, open-label phase III trial comparing lenvatinib versus sorafenib in patients with unresectable HCC naïve to systemic therapy. A total of 954 subjects (63.9% of screened patients) were randomly assigned in a 1:1 ratio to receive either lenvatinib 12 mg (baseline body weight [BW] ≥ 60 kg) or 8 mg (baseline BW &lt;60 kg) given once daily (QD) orally or sorafenib 400 mg given twice daily (BID) orally. The proposed dosing regimen in patients with HCC is different from that in patients with DTC (24 mg QD) and RCC (18mg QD in combination with everolimus 5mg QD).

## 3.2. Favourable effects

Lenvatinib demonstrated non-inferiority for overall survival compared to sorafenib in the treatment of patients with advanced/ unresectable HCC. The final OS analysis based on 701 events (73.4% in the lenvatinib arm, 73.5% in the sorafenib arm) (cut-off date 13 Nov 2016) shows results within the noninferiority margin for hazard ratio (Lenvatinib vs. Sorafenib) of 1.08 (HR 0.92, 95% CI 0.79-1.06, p=0.00002), with similar median OS of 13.6 months (12.1, 14.9) for lenvatinib vs 12.3 months (10.4, 13.9) for sorafenib. The NI margin was adequately defined and the benefit with sorafenib was at least as good as the historical studies. The median OS results for both arms were consistent in the FAS and PPS,

<div style=\"page-break-after: always\"></div>

by stratification factors in the IxRS and the CRF and across most subgroups. The HR for OS was consistent across most subgroups analysed.

## 3.3. Uncertainties and limitations about favourable effects

In contrast with the population included in the pivotal study, the HCC patient population treated in clinical practice is very heterogeneous in terms of disease burden/presence of comorbidity and includes also patients with ECOG PS &gt;1, Child Pugh B and C, with significant renal impairment, with cardiovascular comorbidities. The MAH will conduct a post authorisation observational study to collect efficacy and safety data in patients in real life conditions (see RMP).

## 3.4. Unfavourable effects

The overall safety profile of lenvatinib was consistent with other VEGFR targeted therapies, with its known safety profile and its toxicity was usually predictable and in general manageable. The most frequently reported TEAEs with lenvatinib were as expected for a VEGF TKI i.e. hypertension, diarrhoea, PPE, decreased appetite and proteinuria. These events could generally be managed with dose interruption or reduction, which occurred in about 60% of patients. The rate of discontinuations due to AEs was reported as 20.2% in the All HCC safety set and as 14.5% in the sorafenib arm. Adverse events leading to dose reductions, interruptions and modifications (reduction and/or interruptions) were reported respectively in 38.7%, 52.1% and 61.8% of patients in lenvatinib arm and in 38.9%, 40.6% and 55.6% of patients in the sorafenib arm.

Grade ≥ 3 TEAEs, SAEs and fatal AEs occurred at higher frequency in the lenvatinib (56.7%) than sorafenib (48.6%) arm. The incidence of Grade 5 adverse events was higher for lenvatinib, particularly hepatic encephalopathy, hepatic failure, sepsis and cerebral haemorrhage.

The incidence of AEs in the all HCC lenvatinib monotherapy safety set was usually lower than in the nonHCC safety set, except for ascites (14.3%), platelet count decreased (18.1%), ALT (11.1%), ASP (13.7%) and bilirubin (14.3%) increased and Palmar-Plantar Erythrodysesthesia syndrome (PPE) (29%). Hepatic related AEs including hepatic encephalopathy and hepatic failure (both with lethal cases) were also observed at a higher rate in this population of subjects with advanced HCC.

## 3.5. Uncertainties and limitations about unfavourable effects

Patients with well-preserved liver function (Child-Pugh A) have been included in the study and uncertainty remains as to the safety profile of lenvatinib in patients with liver impairment, who represent a significant proportion of patients in real life conditions. A post authorisation observational study will be conducted to address this uncertainty (see RMP).

## 3.6. Effects Table

Table88: Effects Table for Lenvatinib in HCC patients (data cut-off: 13 November 2016)

| Effect             | Short Descripti on   | Unit               | Treatment          | Control            | Uncertainties/ Strength of evidence   | References         |
|--------------------|----------------------|--------------------|--------------------|--------------------|---------------------------------------|--------------------|
| Favourable Effects | Favourable Effects   | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                    | Favourable Effects |
| OS (median)        | Gain in              | Mo                 | 13.6               | 12.3               | Non-inferiority of                    | See clinical       |

<div style=\"page-break-after: always\"></div>

| Effect                                  | Short Descripti on   | Unit      | Treatment                               | Control                   | Uncertainties/ Strength of evidence                                                                                                                                                                             | References                  |
|-----------------------------------------|----------------------|-----------|-----------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
|                                         | survival             |           | HR=0.92 95% CI: 0.79-1.06               | HR=0.92 95% CI: 0.79-1.06 | lenvatinib to sorafenib established. Upper limit of two-sided 95% CI of HR was less than non-inferiority margin of 1.08 Results obtained in selected patient population as defined by strict enrolment criteria | efficacy section of this AR |
| Study 304                               | Study 304            | Study 304 | Study 304                               | Study 304                 | Study 304                                                                                                                                                                                                       | Study 304                   |
| Effect                                  | Short Descriptio n   | Unit      | Treatment lenvatinib 8 or 12 mg 476 pts | Control sorafenib 475 pts | Uncertainties/ Strength of evidence                                                                                                                                                                             | References                  |
| Unfavourable Effects                    |                      |           |                                         |                           |                                                                                                                                                                                                                 |                             |
| At least 1 AE                           | all grades           |           | 98.7%                                   | 99.4%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Related AEs                             | grade 3 -5           |           | 56.7%                                   | 48.6%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Serious AE                              | Serious              | % Pts     | 43.1%                                   | 30.3%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Fatal AE                                | Fatal                |           | 12.8%                                   | 7.6%                      | Randomised data from open-label trial                                                                                                                                                                           |                             |
| AE leading to dose discontinuation      | Discontinu ation     |           | 19.7%                                   | 14.5%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| hypertension                            | all grades           | % Pts     | 42.2%                                   | 30.3%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Weight decreased                        | all grades           | % Pts     | 30.9%                                   | 22.3%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Diarrhoea                               | all grades           | % Pts     | 38.7%                                   | 46.3%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Fatigue                                 | all grades           | % Pts     | 29.6%                                   | 25.1%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| PPE syndrome                            | all grades           | % Pts     | 26.9%                                   | 52.4%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| proteinuria                             | all grades           | % Pts     | 24.6%                                   | 11.4%                     | Randomised data from open-label trial                                                                                                                                                                           |                             |
| Hepatic encephalopathy and coma hepatic | Serious              | % Pts     | 4.4% (21/476)                           | 0.6% (3/475)              | Low numbers and patients'                                                                                                                                                                                       |                             |
| Hepatic encephalopathy and coma hepatic | death                | % Pts     | 0.8% (4/476)                            | 0% (0/475)                | underlying condition result in uncertainties                                                                                                                                                                    |                             |
| Hepatic failure                         | Serious death        | % Pts     | (14/476) 2.1% (10/476)                  | (8/475) 0.4%              | underlying condition result in uncertainties                                                                                                                                                                    |                             |
| Hepatic encephalopathy and coma hepatic |                      | % Pts     |                                         | (2/475)                   | underlying condition result in uncertainties                                                                                                                                                                    |                             |

Abbreviations:

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Advanced hepatocellular carcinoma (HCC) not amenable for surgery, is a highly invalidating and life threatening condition with an overall poor prognosis. Currently there are two systematic therapy options

<div style=\"page-break-after: always\"></div>

registered in Europe for this patient population, namely sorafenib approved initially for palliative systemic treatment regardless of the line of therapy and regorafenib, recently approved as second-line therapy after prior sorafenib.

Lenvatinib demonstrated efficacy in the treatment of HCC and was non-inferior to sorafenib in terms of overall survival. On subgroup analysis, the OS trend favoured sorafenib in the Western region. This may be due to different aetiologies for HCC in the West, with more alcohol and less hepatitis C induced cirrhosis, leading to an increased propensity to develop hepatic encephalopathy.

In some patients, underlying liver function maybe too poor to tolerate treatment with lenvatinib and, despite observed efficacy, subsequent liver damage negatively affects prognosis. The risk of hepatic failure/ encephalopathy should be further analysed in real-life setting given that lenvatinib will be also used in more vulnerable non-selected population. Due to inclusion criteria used in the pivotal study, more homogenous patient population with better prognosis has been enrolled. Therefore, uncertainties remain as to efficacy and safety in more heterogeneous and less fit patient population in real life conditions.

Data in EU population (or relevant Western population) were obtained in one third of patients enrolled in the study. Only patients with well-preserved liver function have been included and more data needs to be collected in a real-life setting. An observational clinical trial (PASS category 3 study in the RMP) aims to further characterise safety (mainly hepatic-related events) and to collect OS data. Accurate reporting of baseline disease-related, other baseline characteristics and AEs in this study would allow further correlative analysis of risk factor for hepatic-related toxicity.

## 3.7.2. Balance of benefits and risks

Although patients with advanced-stage HCC and intermediate-stage who progress after locoregional therapy are currently treated with sorafenib, lenvatinib is considered as a possible treatment option based on the results of the Study 304. Non-inferiority in terms of OS is supported by results of surrogate endpoints (PFS, TTP, ORR).

## 3.8. Conclusions

The overall B/R of Lenvima as monotherapy is positive for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy (see Section 5.1)'.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.4                 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data              | Type II | I and IIIB         |
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication to include treatment of adult patients with advanced or unresectable

<div style=\"page-break-after: always\"></div>

hepatocellular carcinoma (HCC) who have received no prior systemic therapy; consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are being updated and the package leaflet is updated accordingly. In addition, section 4.2 of the SmPC is being updated to add that the product can be administered as a suspension in water or apple juice. In addition, the labelling is updated to include the unique identifier. The RMP was updated (version 10.6). The Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The group of variations leads to amendments to the Summary of Product Characteristics, Package Leaflet and to the Risk Management Plan (RMP).